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DISCLAIMER
The use of company or product name(s) is for identification only and does not imply endorsement by the
Agency for Toxic Substances and Disease Registry.
This information is distributed solely for the purpose of pre dissemination public comment under
applicable information quality guidelines.  It has not been formally disseminated by the Agency for Toxic
Substances and Disease Registry.  It does not represent and should not be construed to represent any
agency determination or policy.
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Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333
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v 
FOREWORD 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for 
Toxic Substances and Disease Registry (A TSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necesslll)'. 
The A TSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews 
the key literature that describes a substance's toxicologic properties. Other pertinent literature is also 
presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; more comprehensive sources of specialty information are referenced. 
The focus of the profiles is on health and toxicologic information. Each toxicological profile begins 
with a public health statement that describes, in nontechnical language, a substance's relevant toxicological 
properties. Following the public health statement is information concerning levels ofsignificant human 
exposure and, where known, significant health effects. The adequacy of information to determine a 
substance's health effects is described in a health effects summlll)'. Data needs that are ofsignificance to 
protection ofpublic health are identified by A TSDR and EPA. 
Each profile includes the following: 
(A) The examination, summlll)', and interpretation ofavailable toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels ofsignificant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
(B) 	 A determination ofwhether adequate information on the health effects ofeach substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health ofacute, subacute, and chronic health effects; and 
(C) 	 Where appropriate, identification oftoxicologic testing needed to identifY the types or levels of 
exposure that may present significant risk ofadverse health effects in humans. 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members ofthe public. We pIan to 
revise these documents in response to public comments and as additional data become available. 
Therefore, we encourage comments that will make the toxicological profile series ofthe greatest use. 
Comments should be sent to: 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine 
1600 Clifton Road, N.E. 
Mail Stop F-62 
Atlanta, Georgia 30333 
VI 
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
I 04(i)(1) directs the Administrator ofATSDR to " ...effectuate and implement the health related 
authorities" of the statute. This inCludes the preparation of toxicological profiles for hazardous substances 
most commonly found at facilities on the CERCLA National Priorities List and that pose the most 
significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of 
CERCLA, as amended, directs the Administrator ofA TSDR to prepare a toxicological profile for each 
substance on the list. In addition, A TSDR has the authority to prepare toxicological profiles for substances 
not found at sites on the National Priorities List, in an effort to " ...establish and maintain inventory of 
literature, research, and studies on the health effects oftoxic substances" under CERCLA Section 
I 04(i)(1 XB), to respond to requests for consultation under section 104(iX 4), and as otherwise necessary to 
support the site-specific response actions conducted by ATSDR. 
This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and is being made available for public review. Final responsibility for the contents 
and views expressed in this toxicological profile resides with ATSDR. 
Howard Frumkin, M.D., Dr. P.H. VThomas R. Frieden, M.D., M.P.H. 
Director, National Center for Environmental Administrator, Agency for Toxic Substances and 
Health/Agency for Toxic Substances and Disease Disease Registry 
Registry 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided.  Other case studies of interest include Reproductive and Developmental
***DRAFT FOR PUBLIC COMMENT***
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Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide
Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-
1998 • Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-
4976 • FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review.  The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review.  Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
A peer review panel was assembled for phosphate ester flame retardants.  The panel consisted of the 
following members:
1. Sam Kacew, Ph.D., Associate Director of Toxicology, University of Ottawa, McLaughlin Center for
Population Health, Ottawa, ON, Canada
2. Richard K. Miller, Ph.D., Professor of Environmental Medicine, University of Rochester School of
Medicine and Dentistry, Department of Obstetrics and Gynecology, Rochester, NY
3. Michael Pereira, Ph.D., Professor, Division of Hematology and Oncology, College of Medicine and 
Public Health, Ohio State University, Columbus, OH
These experts collectively have knowledge of phosphate ester flame retardants' physical and chemical
properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
content.  The responsibility for the content of this profile lies with the ATSDR.
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1PHOSPHATE ESTER FLAME RETARDANTS
1. PUBLIC HEALTH STATEMENT
 
This public health statement tells you about phosphate ester flame retardants and the effects of
exposure to them.
This profile discusses the following phosphate ester flame retardants:  tris(2-chloroethyl)
phosphate (TCEP), tributyl phosphate (TnBP), tris(2-butoxyethyl) phosphate (TBEP), 
tris(1,3-dichloro-2-propyl) phosphate (TDCP), triphenyl phosphate (TPP), tris(2-chloro-
isopropyl) phosphate (TCPP), and triisobutyl phosphate (TiBP).
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for
long-term federal clean-up activities.  Phosphate ester flame retardants have been found in at
least 8 of the 1,699 current or former NPL sites.  Although the total number of NPL sites
evaluated for these substances is not known, the possibility exists that the number of sites at
which phosphate ester flame retardants are found may increase in the future as more sites are 
evaluated.  This information is important because these sites may be sources of exposure and 
exposure to these substances may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a
container, such as a drum or bottle, it enters the environment.  Such a release does not always
lead to exposure.  You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact.
If you are exposed to phosphate ester flame retardants, many factors will determine whether you 
will be harmed.  These factors include the dose (how much), the duration (how long), and how
you come in contact with them.  You must also consider any other chemicals you are exposed to 
and your age, sex, diet, family traits, lifestyle, and state of health.
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PHOSPHATE ESTER FLAME RETARDANTS	 2
1.  PUBLIC HEALTH STATEMENT
1.1	 WHAT ARE PHOSPHATE ESTER FLAME RETARDANTS?
Description Phosphate ester flame retardants are human-made chemicals added
to consumer and industrial products for the purpose of reducing 
flammability.
Phosphate ester flame retardants are composed of a group of
chemicals with similar properties but slightly different structures.
Phosphate esters are typically liquids at room temperature; however,
some are solids.
Uses Phosphate esters are flame retardants, plasticizers, hydraulic fluids,
solvents, extraction agents, antifoam agents, and coatings for
electronic devices.
For more information on the physical and chemical properties of phosphate esters and their
production, disposal and use, see Chapters 4 and 5.
1.2	 WHAT HAPPENS TO PHOSPHATE ESTER FLAME RETARDANTS WHEN THEY
ENTER THE ENVIRONMENT?
Sources Phosphate ester flame retardants are released to the environment
from industrial sources and disposal of consumer products containing 
flame retardants.
Breakdown
• Air
• Water and soil
Phosphate ester flame retardants can change chemical composition
in the environment.
There is no information available that suggests the selected 
phosphate ester flame retardants undergo transformation or
degradation in the atmosphere.  Particulate-phase phosphate esters
are subject to wet and dry deposition, while semi-volatile phosphate 
esters have the potential to hydrolyze to diesters, monoesters, and 
phosphoric acid.
Generally, most phosphate esters are poorly soluble in water and 
adsorb strongly to soils.  These compounds are considered emerging
pollutants due to their prevalence and persistence in the environment.
Phosphate esters are subject to biodegradation in aquatic and 
terrestrial environments.
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PHOSPHATE ESTER FLAME RETARDANTS 3
1.  PUBLIC HEALTH STATEMENT
1.3 HOW MIGHT I BE EXPOSED TO PHOSPHATE ESTER FLAME RETARDANTS?
Routes of exposure Humans can be exposed by a combination of oral, inhalation, and 
dermal routes.
Food—primary source 
of exposure
Ingesting contaminated food:  Most foods have been found to contain 
trace amounts of phosphate ester flame retardants due to their wide 
use in plastics and presence in the environment.  
Air Breathing contaminated outdoor air: Hydraulic fluid is the primary
source of phosphate esters in outdoor air.
Breathing contaminated indoor air:  Indoor air can contain phosphate 
ester flame retardants from certain plastics, adhesives, foams, or
electronics.
Water and soil Drinking water contaminated with phosphate esters due to leaching 
from plastics or industrial waste water discharge.
By skin contact with contaminated soil: Hydraulic fluid spills or
industrial waste water used for agriculture can result in the presence 
of phosphate esters in soil.
Children Young children may be at a higher risk of exposure since they are 
more likely to put phosphate ester flame retardant treated materials in 
their mouths.
1.4 HOW CAN PHOSPHATE ESTER FLAME RETARDANTS ENTER AND LEAVE MY 
BODY?
Enter the body
• Humans
• Animals
There is virtually no information about the entrance of these 
substances into the body. However, TDCP had been found in human 
tissues and body fluids, so we know that this substance can enter the 
body possibly by inhaling aerosols or dusts or ingesting contaminated 
food or water.
Oral – Studies found that TDCP, TCEP, and TnBP can easily pass
from the stomach and intestines to the blood stream.
Dermal – Less amounts entered the body through the skin of rats and
only very small amounts through the skin of pigs. 
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4PHOSPHATE ESTER FLAME RETARDANTS
1.  PUBLIC HEALTH STATEMENT
Leave the body
• Humans
• Animals
There is no information on how these chemicals leave your body, but
based on studies in animals, phosphate ester flame retardants may 
be broken down in the body and the breakdown product may be 
eliminated in the urine.  However, there are no studies in humans to 
prove that this actually happens.
Neither phosphate ester flame retardants nor their breakdown 
products seemed to accumulate in the body. Most breakdown 
products were eliminated in the urine in 2–3 days. 
1.5 HOW CAN PHOSPHATE ESTER FLAME RETARDANTS AFFECT MY HEALTH?
This section looks at animal and human studies concerning potential health effects.
Workers Long-term exposure of workers to TDCP or TPP was not associated 
with adverse health effects.  No information was available regarding
exposure to other phosphate ester flame retardants.
General population Almost no information is available regarding health effects in 
members of the general population exposed to the phosphate ester
flame retardants discussed in this profile.
There have been a few cases of allergic reactions to consumer
products that contain TPP, but a study that examined several
hundred people exposed to plastics and glues that contained TPP did 
not find any allergic reactions. 
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5PHOSPHATE ESTER FLAME RETARDANTS
1.  PUBLIC HEALTH STATEMENT
Laboratory animals One way to learn about the effects of phosphate ester flame 
retardants is to see how they affect test animals.  Almost all studies in 
animals have administered these substances orally and generally at
levels much higher than what can be expected from environmental
exposures.
TCEP given to rats for 16 weeks or longer caused brain lesions.  
When given for 2 years, it also caused lesions in the kidneys.  TCEP 
also decreased the fertility of mice that were exposed for 18 weeks
before mating.
TnBP induced lesions in the urinary bladder of rats when given for
10 weeks or longer.
TBEP caused liver lesions in rats after the rats ate food that
contained TBEP for 18 weeks.  
Rats that ate food containing TDCP for 2 years developed lesions in 
the kidneys and liver.  
The few studies that examined the effects of TPP, TiBP, and TCPP in
animals did not report significant adverse health effects.
Cancer There is not enough information available to determine with certainty
whether or not phosphate ester flame retardants produce cancer in 
humans.
A study of workers employed in the manufacture of TDCP did not find 
significant associations between exposure to TDCP and cancer. No 
information was available regarding the carcinogenic potential of the 
other phosphate esters to humans.
Rats that received oral doses of TCEP for 2 years developed kidney
tumors.  Feeding mice a diet that contained TCEP for 18 months
induced tumors in the kidney, liver, and stomach, and also induced 
leukemia.  Long-term administration of TnBP to rats and mice 
induced tumors in the urinary bladder and the liver, respectively.  
Feeding rats with a diet that contained TDCP for 2 years produced 
tumors in the liver, kidneys, testes, and adrenal gland.
Neither the EPA nor the Department of Health and Human Services
(DHHS) has classified the carcinogenic potential of the phosphate 
esters discussed in this profile.  The International Agency for
Research on Cancer (IARC) determined that TCEP is not classifiable 
as to its carcinogenicity to humans.
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PHOSPHATE ESTER FLAME RETARDANTS 6
1.  PUBLIC HEALTH STATEMENT
1.6 HOW CAN PHOSPHATE ESTER FLAME RETARDANTS AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age. 
Effects in humans There are no studies that examined the health effects of the 
phosphate ester flame retardants discussed in this profile on 
pregnant women or on their embryo or fetus.
There are no studies that examined the health effects in children of
the phosphate ester flame retardants discussed in this document.
Laboratory animals In general, exposure of rodents during gestation to TCEP, TnBP, 
TBEP, TDCP, TPP, or TCPP did not result in adverse effects to the 
fetuses or newborn animals.
However, continuous exposure of two generations of mice to TCEP
reduced the number of male pups born alive in the third generation.  
A similar study with TnBP in rats found that pups born to exposed rats
had lower body weight during the first weeks of life than pups born to 
untreated rats. 
Exposure of the fetus There is no information regarding transfer of phosphate ester flame 
retardants to the fetus across the placenta in pregnant women.
Human breast milk No studies have been conducted to determine whether phosphate
ester flame retardants can be detected in human breast milk from
women exposed at work or from the general population.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PHOSPHATE ESTER
FLAME RETARDANTS?
Food Avoid food that is generally high in phosphate ester content as
indicated by the current market basket for the U.S. Total Diet study.
Air Avoid installation or use of materials that are known to contain 
phosphate ester-based flame retardants in indoor environments to 
minimize exposure to them via air and particulate matter.
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PHOSPHATE ESTER FLAME RETARDANTS	 7
1.  PUBLIC HEALTH STATEMENT
1.8	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
PHOSPHATE ESTER FLAME RETARDANTS?
Detecting exposure Phosphate ester flame retardants can be measured in blood and 
urine, but this is not a routine test that can be performed in a doctor’s
office.  You should, however, see a physician if you believe that you 
have been exposed to high levels of these substances.
No studies have been conducted to measure these chemicals in
blood samples from groups of people representative of the U.S.
general population.
Measuring exposure The presence of phosphate ester flame retardants in your blood may
indicate that you have been exposed to these substances and some 
amount entered your bloodstream.
The presence of phosphate ester flame retardants in your blood does
not necessarily indicate that adverse health effects will occur.
Additional studies are needed to help to determine the health effects
associated with exposure to these substances.
1.9	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law.  The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal
agencies that develop regulations for toxic substances.  Recommendations provide valuable
guidelines to protect public health, but cannot be enforced by law. The Agency for Toxic
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety
and Health (NIOSH) are two federal organizations that develop recommendations for toxic
substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels.  These are levels
of a toxic substance in air, water, soil, or food that do not exceed a critical value.  This critical
value is usually based on levels that affect animals; they are then adjusted to levels that will help 
protect humans.  Sometimes these not-to-exceed levels differ among federal organizations
because they used different exposure times (an 8-hour workday or a 24-hour day), different
animal studies, or other factors.
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1.  PUBLIC HEALTH STATEMENT
Recommendations and regulations are also updated periodically as more information becomes
available.  For the most current information, check with the federal agency or organization that
provides it.
Some regulations and recommendations for phosphate ester flame retardants include the
following:
Levels in workplace air
set by OSHA
OSHA set a legal limit of 3 and 5 mg/m3 for TPP and TnBP,
respectively, in air averaged over an 8-hour work day.
Food The EPA has permitted TnBP, TBEP, and TPP for use in nonfood 
pesticide products.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics.  These
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances.
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9PHOSPHATE ESTER FLAME RETARDANTS
1.  PUBLIC HEALTH STATEMENT
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You 
may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information 
and technical assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at 
cdcinfo@cdc.gov, or by writing to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road NE
Mailstop F-62
Atlanta, GA 30333
Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS)
 
5285 Port Royal Road
 
Springfield, VA 22161
 
Phone: 1-800-553-6847 or 1-703-605-6000
 
Web site:  http://www.ntis.gov/
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11PHOSPHATE ESTER FLAME RETARDANTS
2. RELEVANCE TO PUBLIC HEALTH
2.1	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PHOSPHATE ESTER 
FLAME RETARDANTS IN THE UNITED STATES
Phosphate esters are a class of anthropogenic organic compounds found in the environment due to their
release from commercial and industrial products. They are pervasive throughout the world due to their
extensive industrial and commercial use since the 1940s.  Phosphate esters represent an important class of
commercial additives used as flame retardants, plasticizers, hydraulic fluids, solvents, extraction agents, 
antifoam agents, adhesives, and coatings for electronic devices. 
Human exposure to phosphate ester flame retardants can occur via ingestion of food and water, and 
through contact with water, air, or soil containing phosphate esters.  The most likely route of exposure to 
the general population is through ingestion of food and water containing phosphate esters or inhalation of
vapors or particulates released from flame retardant materials. The dermal route can account for exposure
if contact with flame-retarded textiles occurs.  Oral exposure could occur in young children from
dissolution of phosphate ester treated materials since children are more likely to suck on these materials.  
The ranges of expected exposure through food are generally 0.5–20 ng/kg/day for adults and 0.1– 
40 ng/kg/day for children under 2 years of age.  These estimated intakes are significantly lower than the
doses administered to laboratory animals.  Workers in industries that manufacture phosphate esters or 
products containing phosphate esters are subject to a greater exposure risk than the general population.
Concentrations of phosphate esters in ambient outdoor air are not well known, as few studies address this
subject. The presence of phosphate esters in outdoor air likely originates from hydraulic fluid
volatilization and diffusion of plasticizers.  Concentrations were in the low μg/m3 range when detected 
near airports and low ng/m3 range outside of office buildings.  Indoor air is well documented to contain a
wide array of phosphate esters at concentrations in the µg/m3 range.  Concentrations measured indoors
typically range from ng/m3 to µg/m3.
Surface water is the most likely place to find anthropogenic phosphate ester flame retardants.  
Concentrations of 0.5 µg/L are commonplace in rivers, lakes, and groundwater, but effluent and waste
water have been documented to contain up to 15 µg/L of select phosphate esters, predominantly tributyl 
phosphate (TnBP) or triphenyl phosphate (TPP).  Tris-(2-chloroethyl)-phosphate (TCEP) has also been 
***DRAFT FOR PUBLIC COMMENT***
    
 
   
 
 
 
 
 
 
  
 
  
   
 
    
 
  
   
 
   
  
  
  
    
  
    
  
  
 
 
 
 
   
   
   
 
  
 
  
  
   
  
12PHOSPHATE ESTER FLAME RETARDANTS
2. RELEVANCE TO PUBLIC HEALTH
found in water in above average concentrations.  Groundwater is less likely to contain phosphate esters 
due to their potential to adsorb to soils and sediments.  For a more complete discussion of phosphate ester
flame retardants found in the environment, see Chapter 6.
2.2 SUMMARY OF HEALTH EFFECTS 
Very limited information was located in the database available for review regarding adverse health effects 
in humans exposed to the phosphate ester flame retardants covered in this profile.  Studies of subjects 
occupationally exposed to tris(1,3-dichloro-2-propyl) phosphate (TDCP) found no apparent medical
conditions related to exposure.  The time-weighted average exposure concentration was estimated to have 
been ≤0.4–0.5 μg/m3. Examination of the mortality experience in 289 workers employed in the
manufacture of TDCP also found no significant association between exposure and any specific cause of
death.  Examinations conducted over the years of small groups of operators in a TPP production plant did 
not reveal any usual frequency of symptoms, or physical or laboratory findings as compared to unexposed 
groups.  The estimated weighted average concentration of TPP vapor mist and dust was 3.5 mg/m3. A
few individual cases of allergic dermal reactions to TPP have been reported.  However, a much bigger
study of 343 patients seen at a dermatology clinic reported that no individuals showed allergic reactions to
TPP.  No studies were located regarding immunological effects or on effects on human reproduction.  In 
addition, no studies were available in pregnant women or children.
The great majority of the studies in animals have been conducted by the oral route of exposure.  However, 
two 3-week studies in rabbits exposed to TPP and tributoxyethyl phosphate (TBEP) by skin application 
evaluated hematology and clinical chemistry parameters and gross and microscopic morphology of tissues 
and found virtually no toxicity with daily dermal doses of up to 1,000 mg/kg/day of each substance.  The
only significant effect observed was slight edema, atonia, and desquamation at the application site of
rabbits applied the lowest dose of 10 mg TBEP/kg/day.  In rabbits treated with 1,000 mg TBEP/kg/day, 
microscopic examination of the treated sites showed squamous cell hyperplasia, hyperkeratosis, erosions-
ulcers, acute-subacute inflammation, and congestion and hemorrhage, in various combinations.
The information available from oral studies does not support treating these chemicals as a class for
purposes of risk assessment based on the different toxicities exhibited by each one of them.  For TCEP,
TnBP, TBEP, and TDCP, there was sufficient information to identify sensitive end points; this was not 
the case for TPP, triisobutyl phosphate (TiBP), or tri-(2-chloroisopropyl) phosphate (TCPP).  Because of
the structural similarity of some of these compounds, particularly TPP, to the potent neurotoxicant, tri-
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2. RELEVANCE TO PUBLIC HEALTH
ortho cresyl phosphate (TOCP), it was thought that they might also induce organophosphate-induced 
delayed neurotoxicity (OPIDN).  However, studies have shown that not to be the case for the alkyl
substituted phosphate ester flame retardants discussed in this profile.  Studies have also shown that TPP
has only a fraction of the potency of TOCP for inducing OPIDN.
TCEP induced brain lesions in rats in 16-week (175 mg/kg/day) and 2-year (88 mg/kg/day) studies; 
females appeared more sensitive than males.  In the 16-week studies, the lesions were located in the
hippocampus and thalamus, whereas dosing for 2 years involved primarily the brain stem and cerebral
cortex.  Cerebral ischemia and/or convulsive activity are potential mechanisms by which these lesions
might occur.  No such lesions were reported in studies with the other phosphate esters discussed in this 
profile.  Decreased conduction velocity was reported in rats treated with 411 mg TnBP/kg/day for
14 days, and this was accompanied by morphological alterations in the nerve.  Acute high doses of TBEP
induced abnormal gait, piloerection, and tremors in rats.  Several studies measured red blood cell
cholinesterase activity and only in a study in rats dosed with TBEP was there a statistically significant
decrease (although the magnitude was not specified) after 9 weeks of treatment, but not after 18 weeks of 
treatment.  No clinical signs were associated with the decrease in cholinesterase activity in that study. 
The kidney and urinary tract from rats were targets for some of the subject phosphate ester flame 
retardants of this profile. Administration of TCEP to rats for 16 weeks resulted in increases in absolute
and relative kidney weight without inducing histological alterations in doses of up to 350 mg/kg/day.  
However, treatment for 2 years with 88 mg/kg/day induced renal tubule epithelial hyperplasia in male and 
female rats.  Effects were also reported in mice, but at higher dose levels.  The kidney was also a sensitive 
target for TDCP in rats.  Relatively low dietary doses of 20 mg/kg/day significantly increased the
incidence of hyperplasia of the convoluted tubular epithelium in male rats; females appeared slightly less 
sensitive.  For TnBP, the urinary bladder of rats was the most sensitive target in intermediate- and 
chronic-duration oral studies.  Urinary bladder hyperplasia was found to be reversible during a 10-week
period in a control diet that followed a 10-week exposure period.  Interestingly, doses of TnBP that
induced nearly 100% incidence of urinary bladder hyperplasia following intermediate-duration exposure
induced a much lower incidence of this lesion in a 2-year study.  This appeared to be due to the fact that
in the 2-year study, rats with malignant bladder tumors usually did not have any remaining uninvolved 
epithelium to evaluate for the presence or absence of hyperplasia.  The latter suggested that urinary
bladder hyperplasia may be a precursor of bladder tumors.  
***DRAFT FOR PUBLIC COMMENT***
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The liver was also a target for some of the phosphate ester flame retardants discussed in this document, 
although effects in some cases were limited to changes in organ weight.  TCEP induced increases in liver
weight without histological alterations in rats dosed with up to 350 mg TCEP/kg/day for 16 weeks.  
Extending the treatment for 2 years with doses of up to 88 mg TCEP/kg/day also resulted in only 
increases in organ weight.  Similar findings were reported in rats dosed with TnBP in acute- and 
intermediate-duration studies and in intermediate- and chronic-duration studies in mice.  TBEP induced 
histological alterations in the liver of rats in a 2-year study and the same was reported in rats dosed with 
TBEP for 18 weeks.  In the single study available with TiBP, rats treated with up to 404 mg TiBP/kg/day 
for 13 weeks did not show gross or microscopic alterations in the liver.
For the most part, standard toxicity studies did not report morphological alterations in the reproductive
organs of rats and mice.  Of the phosphate esters subject of this profile, TCEP, TnBP, TPP, and TDCP
were also tested for effects on fertility.  TCEP in doses ≥350mg/kg/day significantly reduced fertility in 
mice in a continuous breeding protocol study.  Cross-mating experiments conducted to determine the
affected sex showed that both sexes were adversely affected, but the males were relatively more sensitive, 
as all sperm end points examined (concentration, motility, and percent abnormal) were affected.  In a
2-generation reproductive toxicity study in rats dosed with 217 mg TnBP/kg/day, there were no 
significant reproductive effects in either the F0 or F1 generations, including mating and fertility, or on 
gross and microscopic appearance of the reproductive organs.  TDCP was tested for its effects on fertility
in male rabbits by dosing the rabbits with up to 200 mg TDCP/kg/day by gavage for 12 weeks and then 
mating the males with untreated females.  Fertility was not affected and examination of sperm from the
cauda epididymides for motility, morphology, and concentration did not show significant alterations. 
Fertility indices (number pregnant, corpora lutea, implantations, implantation efficiency, resorptions)
were not affected in male or female rats dosed with up to 690 mg TPP/kg/day for 91 days before mating.
Studies in which animals have been exposed to various phosphate ester flame retardants only during
pregnancy suggest that developmental end points are not particularly sensitive to these substances.  Doses 
of TCEP that produced maternal toxicity in rats and mice did not affect fetal parameters.  However, in a
continuous breeding protocol study in mice, the lowest dose tested (175 mg TCEP/kg/day) significantly
decreased the number of live male F2 pups per litter.  Studies conducted with TnBP also showed lack of
developmental toxicity for this chemical even in the presence of frank maternal toxicity.  However, in a
2-generation reproductive study in mice, exposure to TnBP produced a significant reduction in F1 and 
F2 pup weight per litter during postnatal days 0–21.  Significant reductions in maternal body weight also 
occurred at this level, which may have contributed to the decrease in pup weight.  Studies in rats exposed 
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15PHOSPHATE ESTER FLAME RETARDANTS
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to TBEP or TDCP during pregnancy also reported no developmental effects at dose levels that
significantly reduced weight gain in the dams.  TPP was not a developmental toxicant in a study in which 
both male and female rats were dosed for 91 days before mating, and females continued being treated 
through gestation.  A gestational exposure study with TCPP in rats also reported no significant
developmental toxicity under the conditions of the study.
Very limited information is available regarding the effects of the phosphate esters covered in this profile 
on the immune system.  Gross and microscopic examinations of the thymus, spleen, and lymph nodes
conducted in many of the toxicity studies available did not reveal significant treatment-related alterations.  
Parameters of immunocompetence were evaluated only in one study in rats dosed with up to 711 mg
TPP/kg/day for 120 days. The only effects noted were increases in the levels of α- and β-globulins at
6 months, which suggested increased hepatic activity.  Assessment of the humoral response to the
T-lymphocyte-dependent antigen sheep red blood cell (SRBC) did not indicate alterations in 
immunocompetence due to treatment with TPP.
TCEP, TnBP, and TDCP have been tested for carcinogenicity in long-term oral bioassays.  Doses of 
88 mg TCEP/kg/day significantly increased the incidence of renal tubule adenoma or carcinoma in male 
Fischer-344 rats and renal tubule adenomas in female Fischer-344 rats.  Based on these findings, NTP
concluded that there was clear evidence of carcinogenic activity for male and female Fischer-344/N rats.
TCEP (350 mg/kg/day) also induced a nonsignificant increase in the incidence of a rare renal tubule 
neoplasm in male B6C3F1 mice, which led NTP to conclude that there was equivocal evidence of 
carcinogenic activity for male mice.  TCEP increased, although not significantly, the incidence of tumors 
of the Harderian gland in female B6C3F1 mice; based on this, NTP concluded that there was equivocal
evidence of carcinogenic activity for female mice.  In a dietary study in ddY mice, TCEP increased the
incidences of renal (1,333 mg/kg/day) and liver (267 mg/kg/day) tumors in male mice and forestomach 
tumors (1,333 mg/kg/day) and leukemia (267 mg/kg/day) in female mice.  In dermal assays, TCEP
showed no significant carcinogenic, initiating, or promoting activity on the skin of female Swiss mice.  
IARC evaluated TCEP and concluded that the chemical is not classifiable as to its carcinogenicity to 
humans.
TnBP significantly increased the incidence of combined papillomas, squamous cell carcinomas, and 
transitional cell carcinomas in the urinary bladder of male Sprague-Dawley rats at 143 mg/kg/day and of
hepatocellular adenomas in male CD-1 mice at 585 mg/kg/day.  TDCP significantly increased the
incidence of neoplastic nodules in the liver of male and female Sprague-Dawley rats and the incidence of 
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hepatocellular carcinomas in male rats dosed with 20 mg/kg/day.  Doses of ≥20 mg TDCP/kg/day also 
increased the incidence of renal cortical tumors in male and female rats and interstitial cell tumors in the
testes in males; the incidence of adrenocortical adenomas was also significantly increased in females 
dosed with 80 mg TDCP/kg/day.
The EPA has not evaluated the carcinogenicity of the phosphate ester flame retardants discussed in this
profile.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for phosphate ester
flame retardants.  An MRL is defined as an estimate of daily human exposure to a substance that is likely
to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of
exposure.  MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
Although some human data were available in two reports of occupational exposure to TDCP (Stauffer 
Chemical Co. 1983) and in a report of occupational exposure to TPP (Sutton et al. 1960), the data were 
inadequate for derivation of inhalation MRLs.  
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Stauffer Chemical Co. (1983) conducted a retrospective cohort study to examine the mortality experience 
of 289 workers employed in the manufacture of TDCP.  Exposure levels were <8 ppb.  The overall
mortality of the cohort was 75% of that expected in a comparable population of U.S. males.  There were
three deaths attributed to lung cancer, which was higher than the 0.8 expected.  However, one case was
found to have not been exposed to TDCP, a second case worked only 2 years before onset of the disease, 
and all three cases were cigarette smokers.  The investigators concluded that there was insufficient
evidence to establish a causal relationship between lung cancer and TDCP.  ATSDR does not derive
MRLs based on death or cancer; therefore, even if the exposure concentration of 8 ppb had been 
considered a reliable no-observed-adverse-effect level (NOAEL), an inhalation MRL based on this
limited survey would have not been derived.
Stauffer Chem Co. (1983) also conducted a morbidity survey to identify adverse health effects among
workers occupationally exposed to TDCP.  The survey was based on an analysis of the physical
examination reports of 93 exposed and 31 non-exposed workers examined in 1981 and found no apparent
medical conditions related to exposure to TDCP.  Time-weighted average breathing zone sampling
conducted in 1978 and 1979 showed that the concentration in the process area or in other areas was ≤7– 
8 ppb (0.4–0.5 µg/m3).  The evaluation included tests for respiratory and cardiovascular functions, 
urinalyses and evaluation of hematology and clinical chemistry parameters.  Limitations of the survey
noted by the investigators included the fact that the number of non-exposed workers was only one third 
that of the exposed workers.  Secondly, since payroll records were unavailable prior to 1975, some
workers classified as non-exposed could have been exposed prior to 1975.  Thirdly, since a higher
percentage of exposed workers were employed before 1975 than non-exposed, and some of the exposed 
workers could have had potentially a long duration of exposure, the maximum effect of any harmful
exposure should be observed among the exposed workers.  These limitations, plus the lack of control for
confounding, render the study inadequate for MRL derivation.
Sutton et al. (1960) reported that red blood cell cholinesterase activity was significantly reduced (18%) in 
a small group (n=6) of regular operators in a TPP production plant compared to unexposed subjects. 
They also noted that the variability both within and between individuals was great enough so that the
small depressions in cholinesterase activity were not sufficient to identify individuals with TPP exposure.
Health evaluations of this group and of others (the total number of workers examined was not specified)
conducted over the years did not reveal any unusual frequency of symptoms, or physical or laboratory
findings as compared to unexposed groups.  Sutton et al. (1960) estimated that workers may have been 
exposed to a weighted average concentration of TPP vapor mist and dust of 3.5 mg/m3. The lack of
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information regarding the total number of workers that participated in the health surveys, lack of detailed 
presentation of the results of the surveys, and uncertainty regarding the estimation of exposure levels 
make this report unsuitable for MRL derivation. 
Toxicity information from animal studies available in the literature reviewed was limited to acute high-
dose experiments aimed primarily at determining lethal concentrations, and is therefore inadequate for
MRL derivation. 
Oral MRLs
No studies were located on health effects in humans exposed orally to the phosphate ester flame 
retardants discussed in this profile.  Therefore, the discussion of derivation of MRLs for these compounds
is based purely on results from animal studies. As previously mentioned, the information available from
oral studies does not support treating these chemicals as a class for purposes of risk assessment based on 
the different toxicities exhibited by each one of them.
TCEP. An acute-duration oral MRL for TCEP was not derived due to inadequacies of the database.  The
few studies available did not identify a target for TCEP toxicity.  The lowest lowest-observed-adverse-
effect level (LOAEL) in the studies available was 200 mg TCEP/kg/day for death of 7/30 pregnant Wistar
rats (0/23 in the control group) in a developmental study in which the rats were exposed to TCEP by 
gavage on gestational days (Gd) 7–15 (Kawashima et al. 1983a).  That dose level, however, did not
produce developmental effects, including neurobehavioral evaluations in the pups.  Other information 
available include LD50 data (Eldefrawi et al. 1977; Smyth et al. 1951), data from a developmental study of
CD-1 mice in which the single dose level tested on Gd 6–13, 940 mg TCEP/kg/day, significantly reduced 
weight gain in the dams between Gd 6 and postnatal day (Pnd) 3, but produced no developmental effects 
in the progeny (Hardin et al. 1987), and a dose-range finding study in which CD-1 mice treated by gavage 
with doses of up to 1,000 mg TCEP/kg/day for 14 days did not show clinical signs or significant 
alterations in body weight or water consumption (NTP 1991b).  Adverse neurological effects were 
reported in two studies.  Female Fischer-344 rats administered a single gavage dose of 275 mg TCEP/kg 
(only dose level tested) suffered seizures within 60–90 minutes of dosing (Tilson et al. 1990).  This
treatment resulted in mild impairment in the acquisition of a reference memory task in a water maze, and 
in performing a repeated acquisition task in a water maze.  In a 16-day gavage study, B6C3F1 mice given 
350 or 700 mg TCEP/kg/day exhibited ataxia and convulsive movements during the first 3 days of dosing
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(NTP 1991a).  These studies do not identify a clear target for TCEP, and the studies that provide
information other than lethal doses are unsuitable for dose-response assessments.
•	 An MRL of 0.6 mg/kg/day was derived for intermediate-duration oral exposure (15–364 days) to 
TCEP based on necrosis of hippocampal neurons in female rats.
Although a limited number of intermediate-duration oral studies with TCEP were available for review, 
the data were sufficient for derivation of an intermediate-duration oral MRL.  NTP (1991a) conducted 
studies in rats and mice administered TCEP by gavage 5 days/week for 16 days or 16 weeks, Anonymous
(1977) conducted a 3-month dietary study in rats, and NTP (1991b) conducted a reproductive study in 
mice using a continuous breeding protocol; dosing was by daily gavage.  The hippocampus from female
rats was a target for TCEP toxicity in the 16-week gavage study in rats (NTP 1991a).  Necrosis of neurons
of the hippocampus was seen in 10/10 females and in 2/10 males treated with TCEP at 350 mg/kg/day 
and in 8/10 females treated with 175 mg/kg/day; no lesions were seen at ≤88 mg/kg/day.  The affected 
neurons were mainly in the dorsomedial portion of the pyramidal row of the hippocampus.  The more
severe lesions showed mineral deposits in the affected areas.  Females dosed with 350 mg/kg/day also 
showed neuronal necrosis in the thalamus.  No brain lesions were seen in mice treated with up to 700 mg
TCEP/kg/day for 16 weeks.  It is worth noting that the unpublished 3-month dietary study in male and 
female rats administered up to 506 and 586 mg TCEP/kg/day, respectively, does not mention the
occurrence of brain lesions, but it is unclear in the report available whether the brain was examined 
microscopically (Anonymous 1977).  
In the NTP (1991a) study, treatment of rats and mice with TCEP also produced dose-related increases in 
absolute and relative liver and kidney weight in female rats dosed by gavage for 16 days or 16 weeks, in 
both cases without histological alterations; changes >10% relative to controls were generally achieved in
the highest-dose groups.  Mice dosed by gavage with 700 mg TCEP/kg/day for 16 weeks showed 
enlargement of the nuclei of epithelial cells in the renal tubules.  In the absence of histopathology, the
weight changes in the liver and kidneys from rats in the intermediate-duration studies could be considered 
not adverse; however, results from a chronic-duration study suggest that in the kidneys, but not the liver, a
progression into more severe effects takes place.  Based on the latter observation, the increase in absolute 
kidney weight in rats in the 16-week gavage studies is considered a minimal LOAEL (175 mg/kg/day);
the corresponding NOAEL is 88 mg/kg/day.
In the reproductive study using a continuous breeding protocol, mice were dosed by gavage with 0, 175, 
350, or 700 mg TCEP/kg/day (NTP 1991b).  Treatment with ≥350 mg TCEP/kg/day significantly 
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decreased the number of F1 litters produced by the parental generation.  Only 2 out of 18 pairs delivered a
third litter in the high-dose group versus 37/38 in the controls, and 13 out of 18 pairs delivered a fifth 
litter in the mid-dose group.  Treatment with TCEP also induced significant and dose-related reductions in
the number of live pups per litter at ≥350 mg TCEP/kg/day and in the number of live F2 male pups/litter
at ≥175 mg TCEP/kg/day (dose-related).  Based on the effect on F2 pups, a serious developmental
LOAEL of 175 mg TCEP/kg/day was identified in this study; a developmental NOAEL was not defined. 
Data sets for necrosis of hippocampal neurons and changes in absolute kidney weight in female rats 
reported in the NTP (1991a) study and decreased number of live F2 pups reported in the NTP (1991b)
study were analyzed using the benchmark dose (BMD) approach to determine the point of departure for
MRL derivation.  Models in the EPA Benchmark Software (BMDS version 2.1) were fit to the three data 
sets.  In each data set, adequate model fit is judged by three criteria:  goodness-of-fit (p>0.1), visual
inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to 
the predefined BMR.  The data set for changes in absolute kidney weight in female rats in the NTP
(1991a) proved not suitable for benchmark modeling even after dropping the two highest doses (out of
five dose levels tested).  Of the two data sets remaining, the best fit for the incidence of necrosis in 
hippocampal neurons in female rats (NTP 1991a) was obtained with the log-logistic model (BMD10 
143.41 mg/kg/day; BMDL10 85.07 mg/kg/day), whereas the linear model provided the best fit for the
decrease in live male F2 pups in the continuous breeding protocol study (BMD10 242.19 mg/kg/day;
BMDL10 167.83 mg/kg/day) (NTP 1991b).  The lower BMDL10 of 85.07 mg/kg/day is more health 
protective and was selected as the point of departure for MRL derivation.  Multiplying the BMDL10 of
85.07 mg/kg/day by 5/7, to adjust for continuous exposure, results in a duration-adjusted BMDL10 of
60.76 mg/kg/day.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for 
human variability) to the duration-adjusted BMDL10 of 60.76 mg/kg/day results in an intermediate-
duration oral MRL of 0.6 mg/kg/day for TCEP. A detailed description of the NTP (1991a) study and of
the MRL derivation is presented in Appendix A.
If the changes in absolute kidney weight in female rats in the NTP (1991a) study had been used as a basis 
for MRL derivation using a NOAEL/LOAEL approach, the NOAEL would have been 88 mg
TCEP/kg/day (<10% increase in kidney weight).  The next highest dose, 175 mg/kg/day, induced a 16%
increase in absolute kidney weight.  Applying an uncertainty factor of 100 (10 for animal to human 
extrapolation and 10 for human variability) to the duration-adjusted NOAEL of 62.85 mg/kg/day 
(88 mg/kg/day x 5/7) would have resulted in an MRL of 0.6 mg/kg/day for TCEP, which is identical to 
the MRL based on brain lesions in female rats derived using the BMD approach.
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•	 An MRL of 0.3 mg/kg/day was been derived for chronic-duration oral exposure (365 days and 
longer) to TCEP based on renal tubule lesions in female rats.
The chronic-duration database for TCEP was limited to the NTP (1991a) 2-year bioassay in rats and mice. 
Fischer-344 rats were treated by gavage 5 days/week with 0, 44, or 88 mg TCEP/kg/day and B6C3F1 
mice were dosed similarly with 0, 175, or 350 mg TCEP/kg/day.  Animals were monitored for clinical
signs, body weight gain, hematology and clinical chemistry parameters (week 66 and at termination), and 
gross and microscopic changes in tissues and organs at week 66 and at termination.  Nonneoplastic effects
in mice were limited to an increased incidence of karyomegaly of the cells in the proximal convoluted 
tubules of the inner cortex and outer stripe of the outer medulla at ≥175 mg TCEP/kg/day.  In rats, one of
the principal nonneoplastic alterations attributed to administration of the test chemical was a significant
increase in renal tubule epithelial hyperplasia in the convoluted tubules of the cortex in high-dose males 
and females; the respective incidences were 0/50, 2/50, and 24/50, and 0/50, 3/50, and 16/50.  In addition 
to the kidney lesions, high-dose female rats showed degenerative lesions in the brain.  The degenerative 
lesions were located in the cerebral cortex and brain stem, involved both the gray and white matter, and 
were focally distributed.  Specifically, the lesions were in the thalamus, hypothalamus, basal ganglia, and 
frontal and parietal cortex.  Other affected structures included the cingulate cortex, olfactory cortex, 
superior colliculus, hippocampus, geniculate body, globus pallidus, ventral pallidum, and amygdaloid 
nuclear region.  The lesions varied in severity from minimal to marked, and often involved extensive 
areas.  Active lesions were characterized by degeneration and necrosis with hemorrhage, while resolving
lesions exhibited loss of neurons and neuropil, proliferation of glial cells, capillary hyperplasia, 
hypertrophy of the tunica media of small vessels, and hemosiderin-laden macrophages.  Brain lesions 
were already observed at the 66-month interim sacrifice.  Incidences of lesions in specific areas ranged 
from 24 to 38%.  However, the reporting of the data (no individual animal data) in the NTP (1991a) study
did not allow the determination of whether individual animals had more than one lesion type.  The lesion 
with the highest incidence was cerebrum gliosis with an incidence of 19/50 (38%); the incidences in the 
control and low-dose groups were 0/50 and 0/49, respectively.  
The incidences of cerebrum gliosis in female rats and of renal epithelial hyperplasia in both male and 
female rats reported in the NTP (1991a) study were analyzed using the BMD approach for MRL
derivation.  Models in the EPA BMDS (version 2.1) were fit to the three data sets.  The best fit for the
incidence of renal tubule hyperplasia in male rats was obtained with the log-logistic model, which 
identified a BMD10 and BMDL10 of 54.80 and 43.58 mg TCEP/kg/day, respectively.  The gamma model
provided the best fit for the incidence of renal lesions in female rats; a BMD10 and BMDL10 of 53.09 and 
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36.09 mg TCEP/kg/day, respectively, were identified.  The data set for incidences of cerebrum gliosis in 
female rats was best fitted with the log-logistic model, which defined a BMD10 and BMDL10 of 80.04 and 
59.86 mg TCEP/kg/day, respectively.  The BMDL10 of 36.09 mg TCEP/kg/day for renal tubular lesions in 
female rats is selected as the point of departure for MRL derivation on the basis of being more health 
protective.  The slightly higher BMDL10 obtained with the male rat data set does not seem to indicate that 
female rats are more sensitive than males.  Multiplying the BMDL10 of 36.09 mg/kg/day by 5/7, to adjust
for continuous exposure, results in a duration-adjusted BMDL10 of 25.78 mg/kg/day.  Applying an 
uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability) to the
duration-adjusted BMDL10 of 25.78 mg/kg/day yields a chronic-duration oral MRL of 0.3 mg/kg/day for
TCEP.  A detailed description of the NTP (1991a) study and of the MRL derivation can be found in 
Appendix A.
TnBP
•	 An MRL of 1.1 mg/kg/day was derived for acute-duration oral exposure (14 days or less) to
TnBP based on reduced body weight gain in pregnant rats.
Few acute-duration oral studies were available for review.  One study conducted hematological and 
clinical chemistry tests and histological examinations of the brain, heart, kidneys, liver, lungs, spleen, 
ovaries, and testes from Sprague-Dawley rats following a 14-day gavage regime with 0, 137, or 411 mg
TnBP/kg/day (Laham et al. 1984b).  Significant findings in high-dose rats included decreased hemoglobin 
in females, increased absolute and relative liver weight in males and females, increased serum potassium
in females, decreased absolute and relative spleen weight, and degenerative changes in the testes.  
Decreased nerve conduction velocity accompanied by morphological alterations in the sciatic nerve was 
also reported in Sprague-Dawley rats dosed with 411 mg TnBP/kg/day for 14 days; the NOAEL was
274 mg TnBP/kg/day (Laham et al. 1983).  In a developmental study, pregnant Wistar rats were exposed 
to 0, 62.5, 125, 250, or 500 mg TnBP/kg/day on Gd 7–17; sacrifices were conducted on Gd 20 (Noda et
al. 1994).  Rats exposed to 500 mg/kg/day showed piloerection, wetting of abdominal hair with urine, and 
salivation during the treatment, but these signs disappeared after the last treatment.  Final maternal weight
was reduced 6–9% in the two highest dose groups.  Adjusted body weight gain (body weight gain minus
gravid uterus weight) from Gd 0 to 20 was reduced 13% at 125 mg/kg/day, 39% at 250 mg/kg/day, and 
63% at 500 mg/kg/day.  Food consumption was also reduced starting on Gd 7.  Liver weight was 
increased 6% at 500 mg/kg/day and kidney weight was not significantly affected.  Spleen weight was
reduced 11% at 500 mg/kg/day.  Gravid uterus weight was not affected.  All pregnant rats had living
fetuses on Gd 20. There was no significant difference between the groups in the number of corpora lutea, 
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implants or living fetuses, incidence of dead or resorbed fetuses, sex ratio, or body weight of the living
fetuses.  There was only one malformation that occurred in the groups exposed to 125 mg/kg/day in 
which there were conjoined twins.  No visceral anomalies attributed to treatment with TnBP were 
reported.  Based on a significant reduction in maternal body weight gain at ≥125 mg/kg/day, a maternal
NOAEL and LOAEL of 62.5 and 125 mg/kg/day, respectively, were defined in this study; the highest
dose tested, 500 mg/kg/day, was a developmental NOAEL.  Since the Noda et al. (1994) study identified 
the most sensitive end point, it was selected as the principal study for the derivation of an acute-duration 
oral MRL for TnBP.  
Data from Noda et al. (1994) were analyzed using the BMD approach for MRL derivation.  BMD models
in the EPA BMDS (version 2.1) (linear, polynomial, power, and Hill models) were fit to the maternal
body weight gain data to determine potential points of departure for the MRL (details of the modeling are
presented in Appendix A). In the absence of a clear criteria as to what level of change in weight gain 
during pregnancy should be considered adverse, the benchmark response (BMR) was defined as a change
in mean body weight gain equal to one standard deviation from the control mean (EPA 2000).  The linear
model provided the best fit. The corresponding BMD1SD was 130.32 mg/kg/day; the corresponding
BMDL1SD was 111.47 mg/kg/day.  Applying an uncertainty factor of 100 (10 for animal to human 
extrapolation and 10 for human variability) to the BMDL1SD results in an acute-duration oral MRL of
1.1 mg/kg/day for TnBP. 
•	 An MRL of 0.02 mg/kg/day was derived for intermediate-duration oral exposure (15–364 days)
to TnBP based on urinary bladder lesions in male rats.
Intermediate-duration oral studies with TnBP identified the urinary bladder as the most sensitive target for
TnBP toxicity.  Increased incidence of urothelial hyperplasia was reported in male Sprague-Dawley rats 
(females not tested) dosed via the diet with approximately 33 mg TnBP/kg/day for 10 weeks (Arnold et
al. 1997), male Sprague-Dawley rats dosed with 68.1 mg TnBP/kg/day in the diet for 90 days (FMC
1985a), and in male and female F0 and F1 Sprague-Dawley rats dosed with 51 mg TnBP/kg/day in the diet 
for 10 weeks in a 2-generation reproductive study (Tyl et al. 1997).  The NOAELs were in the range of 9– 
15 mg TnBP/kg/day.  An additional study that also reported urothelial hyperplasia in rats used somewhat
higher doses (200, or 333 mg/kg/day for 18 weeks) (Laham et al. 1985a).  Mice appeared to be less 
sensitive than rats as evidenced by a NOAEL and LOAEL of 95 and 382 mg/kg/day, respectively, for
urinary bladder hyperplasia in male mice (Auletta 1991).  Arnold et al. (1997) also demonstrated that
hyperplastic effects were reversible upon cessation of treatment and that acidification of the urine with
ammonium chloride did not completely inhibit the proliferative changes, but the hyperplastic changes 
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were milder when TnBP was coadministered with ammonium chloride.  Also consistently reported in 
intermediate-duration oral studies with TnBP were increases in liver weight, generally with histological 
alterations observed only at the highest dose levels (FMC 1985a; Laham et al. 1985a; Oishi et al. 1982;
Tyl et al. 1997).  In a 2-generation reproductive study in rats dosed through the diet with up to 217 mg
TnBP/kg/day, fertility indices were not significantly affected, but that dose level significantly decreased 
F1 and F2 pup weight during the preweaning periods (Tyl et al. 1997).  In a 13-week gavage study, 
excessive salivation occurred frequently in rats after dosing with 100 mg TnBP/kg/day, and almost all the
time in rats dosed with 325 mg TnBP/kg/day (Healy et al. 1995).  In that study, neither motor activity nor
functional observational battery (FOB) results obtained during the study were affected by treatment with 
up to 325 mg TnBP/kg/day.  In addition, histological evaluations of unspecified nervous tissues were
unremarkable (Healy et al. 1995).  
As indicated above, urothelial hyperplasia was the most sensitive end point in the intermediate-duration 
studies with TnBP and will serve as the basis for the derivation of an intermediate-duration oral MRL for
TnBP.  Of the four studies that described the lesion in rats, only the studies by Arnold et al. (1997), FMC
(1985a), and Tyl et al. (1997) are considered for further analysis on the basis that they identified a
NOAEL; the lowest dose used by Laham et al. (1985a) induced hyperplasia in 100% of the rats.  The data 
are summarized in Table 2-1, which also includes the data set from the 2-year study of Auletta et al. 
(1998a).  The data set from Tyl et al. (1997) corresponds to incidences in the parental generation (F0).  
Incidences in F1 females were virtually the same as in F0 females, whereas incidences in mid-dose
F1 males were slightly lower than in F0 males.  
Incidence data for urothelial hyperplasia in male rats from the Arnold et al. (1997) study, for urothelial
hyperplasia in F0 males and females from the Tyl et al. (1997), and for urothelial hyperplasia in male rats 
from the FMC (1985a) study were analyzed using the BMD approach for MRL derivation (further details 
of the modeling are presented in Appendix A).  Models in the EPA Benchmark Dose Software (BMDS
version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull models)
were fit to urothelial hyperplasia data to determine potential points of departure for the MRL.  Comparing
across data sets, and using the established criteria for model selection, the BMDL10 of 1.96 mg/kg/day
obtained with the Multistage model for the incidence data reported by Arnold et al. (1997) is selected as 
point of departure for the MRL.  Applying an uncertainty factor of 100 (10 for animal to human 
extrapolation and 10 for human variability) to the BMDL10 yields an intermediate-duration oral MRL of
0.02 mg/kg/day for TnBP.
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Table 2-1.  Incidence of Urinary Bladder Hyperplasia Induced by Tributyl 

Phosphate in Four Studies in Rats
 
NOAEL LOAEL BMDL10 
Arnold et al. (1997)–10 weeks
Dose (mg/kg/day) 0 9 33 143 1.96
Incidence 0/10 0/10 8/10 10/10
FMC (1985a)–13 weeks
Dose (mg/kg/day) 012 0.6 2.8 13.8 68.1 360
Males 0/10 0/10 0/10 0/10 10/10 10/10 2.60
Tyl et al. (1997)–10 weeks
Dose (mg/kg/day) 0 15 51 217
Males 0/30 1/29 22/29 30/30 13.77
Females 0/30 2/29 21/30 30/30 10.50
Auletta et al. (1998a)–2 years
Dose (mg/kg/day) 0 9 33 143
Males 3/50 3/50 12/49 17/49 23.51
Females 1/50 1/50 5/49 29/49 19.85
BMDL10 = The 95% lower confidence limit on the dose associated with a 10% extra risk; LOAEL = lowest-observed­
adverse-effect level; NOAEL = no-observed-adverse-effect level
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•	 The intermediate-duration oral MRL of 0.02 mg/kg/day for TnBP was adopted as chronic-
duration (365 days or longer) oral MRL for TnBP.  
Only two chronic-duration oral studies were located for TnBP, one in Sprague-Dawley rats (Auletta et al. 
1998a) and one in CD-1mice (Auletta et al. 1998b).  As in the intermediate-duration studies, the urinary
bladder from rats was the most sensitive target for TnBP toxicity.  Rats were dosed via the diet for
2 years, whereas mice were treated for 18 months.  Male rats received doses of 0, 9, 33, or 143 mg
TnBP/kg/day, whereas females received doses of 0, 12, 42, or 182 mg TnBP/kg/day.  The doses for male
and female mice were 0, 28.9, 169, or 585 mg/kg/day and 0, 24.1, 206, or 711 mg/kg/day, respectively.  
At termination, the incidences of trace to severe urinary bladder hyperplasia in male rats were 3/50, 3/50, 
12/49, and 17/49 with increasing doses.  The corresponding incidences in female rats were 1/50, 1/50, 
5/49, and 29/49.  Urinary bladder hyperplasia was not observed in mice.  Based on these findings, the
increased incidence of urothelial hyperplasia in rats was used to determine the point of departure for
derivation of a chronic-duration oral MRL for TnBP.  
Incidence data for urinary bladder hyperplasia in male and female rats exposed to TnBP (Auletta et al. 
1998a) were analyzed using the BMD approach for MRL derivation.  Models in the EPA BMDS
(version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull 
models) were fit to the urinary bladder lesion data to determine potential points of departure for the MRL.  
Comparing across models showed that the Gamma model provided the best fit for the incidence data in 
male rats, whereas the Multistage 1-degree polynomial provided the best fit for the incidence data in 
female rats. This analysis yielded respective BMDL10 values of 23.51 and 19.85 mg TnBP/kg/day.  As
seen in Table 2-1, these values are higher than the BMDL10 values obtained in the analyses of the
incidences of urinary bladder hyperplasia reported in the intermediate-duration studies (Arnold et al. 
1997; Tyl et al. 1997).  As the data show, the incidences of urinary bladder hyperplasia at comparable
high doses are higher in the intermediate-duration studies than in the chronic-duration study.  A likely
explanation for this phenomenon is provided in the chronic study by the observation that rats with 
malignant bladder tumors usually did not have any remaining uninvolved epithelium to evaluate for the
presence or absence of hyperplasia (Auletta et al. 1998a).  Whether urinary bladder hyperplasia is a
potential precursor of urinary bladder tumors is not known for certain, but the data are suggestive.  The
lower incidence of the lesion in the chronic-duration study may be indicating that the hyperplasia
transformed into neoplasia.  As shown in Table 2-1, dose levels that did not increase the incidence of
urothelial hyperplasia in the intermediate-duration studies (NOAELs ranged from 9 to 15 mg/kg/day) also 
did not increase the incidence of urinary bladder hyperplasia in the chronic-duration study (NOAEL was
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9 mg/kg/day) and did not increase the incidence of neoplastic lesions; thus, the NOAEL from
intermediate-duration studies would also be protective for chronic exposure.  Therefore the intermediate-
duration oral MRL of 0.02 mg/kg/day based on a BMDL10 of 1.96 mg/kg/day is adopted also as chronic-
duration oral MRL for TnBP.  
TBEP
•	 An MRL of 4.8 mg/kg/day was derived for acute-duration oral exposure (14 days or less) to
TBEP based on reduced body weight gain in pregnant rats.
Three acute-duration oral studies were located in the literature reviewed.  In a gestational exposure study
rats were administered 0, 250, 500, or 1,500 mg TBEP/kg/day on Gd 6–15 (Monsanto Co. 1985b).  The
highest dose tested induced overt toxicity in the dams, including wet haircoat matting or staining with
urine, and brown material or blood on the face, neck, thorax, and/or anogenital area; this was observed in 
approximately half of the high-dose rats.  Following dosing on Gd 6, two high-dose rats were ataxic, had 
reduced righting reflex, and/or were lethargic.  Terminal body weight of high-dose dams (unadjusted for
uterine content) was significantly reduced, but only by 6% relative to controls.  In high-dose dams, weight
gain was significantly reduced from Gd 6 on, and during treatment (Gd 6–15), weight gain was reduced 
35%.  Food consumption data were not provided. The maternal NOAEL in the study was 500 mg/kg/day 
and the developmental NOAEL was 1,500 mg/kg/day based on no evidence of fetotoxicity or
teratogenicity.  A single gavage dose study in Sprague-Dawley rats measured caudal nerve conduction 
velocity 3 weeks following exposure and also performed microscopic examination of the sciatic nerve 
(Laham et al. 1985b).  During the week after dosing, females dosed with ≥1,750 mg/kg showed slight
tremors and piloerection, whereas those treated with 3,200 mg/kg exhibited tremors and abnormal gait;
males appeared to be somewhat less sensitive.  Examination of the sciatic nerve showed nerve 
degeneration in females dosed with ≥2,000 mg/kg.  The NOAEL for males and females was 3,200 and 
1,500 mg/kg, respectively.  In an additional acute-duration study, Sprague-Dawley rats (10/sex/dose)
were treated with up to 100 mg TBEP/kg/day by gavage in corn oil for 14 days (Komsta et al. 1989).  End 
points monitored included clinical signs, body weight, hematology and clinical chemistry at termination, 
organ weights (brain, heart, liver, kidneys, and spleen), microsomal liver enzyme activities, and gross and 
microscopic morphology of all major tissues and organs.  The results did not show any significant
differences between the treated and control groups for any of the parameters evaluated.  However, 
because no adverse effects were reported, the Komsta et al. (1989) study is not a suitable basis for an 
MRL.  The developmental study is a well-conducted study and the maternal changes in weight gain 
during the treatment period were used to determine the point of departure for MRL derivation.
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Data from Monsanto Co. (1985b) were analyzed using the BMD approach for MRL derivation.  BMD
models in the EPA BMDS (version 2.1) (linear, polynomial, power, and Hill models) were fit to the
maternal body weight gain data to determine potential points of departure for the MRL.  The multistage 
3-degree polynomial model provided the best fit (details of the modeling are presented in Appendix A).  
In the absence of a clear criteria as to what level of change in weight gain during pregnancy should be
considered adverse, the BMR was defined as a change in mean body weight gain equal to one standard 
deviation from the control mean (EPA 2000).  The corresponding BMD1SD was 824.97 mg/kg/day; the
corresponding BMDL1SD was 477.25 mg/kg/day.  Applying an uncertainty factor of 100 (10 for animal to 
human extrapolation and 10 for human variability) to the BMDL1SD results in an acute-duration oral MRL
of 4.8 mg/kg/day for TBEP. 
•	 An MRL of 0.2 mg/kg/day was derived for intermediate-duration oral exposure (15–365 days) to 
TBEP based on hepatocyte hypertrophy in male rats.
Only one intermediate-duration oral study was located for TBEP.  In that study, groups of Sprague-
Dawley rats (20/sex/group) were fed a diet containing 0, 300, 3,000, or 10,000 ppm TBEP for
approximately 18 weeks (Reyna and Thacke 1987a).  This corresponds to doses of approximately 0, 17.3, 
173, or 578 mg/kg/day for males and 0, 21, 209, or 698 for females using food intake and body weight
data from the study.  End points monitored included clinical signs, body weight, food consumption, 
clinical chemistry and hematology (weeks 9 and 18), organ weights (brain, liver, kidneys, testes with 
epididymides), and gross and microscopic examination of all the major organs and tissues of controls and 
high-dose rats plus target tissues defined by the high-dose group and gross lesions from all necropsied 
animals.  A detailed description of the study is provided in Appendix A.  There were no treatment-related 
mortalities or adverse clinical signs throughout the study.  Body weight was not significantly affected by
treatment with the TBEP.  Food consumption was lower in high-dose males and females and mid-dose
males during the first week of the study, but was comparable to controls for the remainder of the study.  
The most sensitive organ was the liver.  Absolute and relative liver weight was increased in high-dose
males and females, but not significantly.  Histopathology was restricted to the liver of males and consisted
of increased incidence of periportal hepatocellular hypertrophy (0/10, 0/10, 3/10, 7/10 with increasing
TBEP doses) and periportal vacuolization (1/10, 2/10, 6/10, 7/10).  In the same study, although presented 
separately, the investigators measured tail nerve conduction velocity at the end of the treatment period 
(Reyna and Thacke 1987b).  Following these measurements, the sciatic, tibial, and plantar nerves were 
processed for light microscopy.  A significant reduction in nerve conduction velocity was measured only
in high-dose females.  Since both the absolute and relative refractory periods were decreased (the opposite
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of what would be expected in the case of a reduction in conduction velocity), the effect was not seen in 
males, and morphology of the nerves was unremarkable, the decrease in conduction velocity in females
appeared questionable.
Although the increased incidences of periportal hepatocyte hypertrophy and vacuolization may represent
adaptive responses of the cell and not necessarily an adverse effect, the lack of chronic data makes it
impossible to predict whether these changes may progress into more severe lesions under a longer
exposure regime.  Incidence data for periportal hepatocyte hypertrophy and vacuolization in male rats
exposed to TBEP (Reyna and Thacke 1987a) were analyzed using the BMD approach for MRL derivation 
(further details of the modeling are presented in Appendix A).  Models in the EPA BMDS (version 2.1)
(gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull models) were fit to 
the hepatocyte hypertrophy and hepatocyte vacuolization reported in male rats to determine the point of
departure for the MRL.  Comparing across models using using established criteria for model selection, the
best fit for the hepatocyte hypertrophy data was provided by the Log logistic model; the BMD10 and 
BMDL10 were 80.62 and 21.92 mg TBEP/kg/day, respectively.  The best fit for the incidence of
hepatocyte vacuolization was provided by the Log logistic model, which estimated a BMD10 and BMDL10 
of 22.02 and 8.88 mg TBEP/kg/day, respectively.  Since hypertrophy is a more valid physiological end 
point than vacuolization, the BMDL10 of 21.92 mg/kg/day is selected as the point of departure for the
intermediate-duration MRL.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation 
and 10 for human variability) to the BMDL10 results in an intermediate-duration oral MRL of
0.2 mg/kg/day for TBEP.  
No chronic-duration oral studies with TBEP were located; therefore, a chronic-duration oral MRL was
not derived for this compound. 
TDCP. An acute-duration oral MRL was not derived for TDCP due to an insufficient database.  Other
than lethal dose studies, only one study, a developmental study in rats, was available for review for TDCP
(Stauffer Chemical Co. 1981b).  Pregnant rats were treated by gavage with 0, 25, 100, or 400 mg
TDCP/kg/day on Gd 6–15; sacrifices were conducted on Gd 19.  Compound-related clinical signs were 
observed during treatment mainly in the high-dose group consisting of urine stains, hunched appearance, 
and salivation in almost all rats in this group, and alopecia in approximately half of the rats in the group.  
Final body weight of the high-dose group was significantly lower (16%) than in controls.  During Gd 6– 
11, body weight gain of the mid-dose group was approximately 29% lower than controls and rats in the
high-dose group lost weight.  During the posttreatment days, weight gain was comparable among all
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groups.  Food consumption during treatment days was significantly lower in the mid- and high-dose rats, 
but posttreatment values were comparable among groups.  There was no significant effect on the numbers
of corpora lutea or implantations.  A statistically higher incidence of resorptions was found in high-dose
rats, but the number per litter was not significantly affected.  Fetal viability was significantly decreased in 
high-dose rats.  Mean fetal weight and length were significantly lower in high-dose rats.  Decreased 
skeletal development (incomplete ossification of various bones) was noted in high-dose fetuses.  This 
single study gives a very limited picture regarding the acute toxicity of TDCP since it provides virtually
no information on maternal effects other than body weight changes.  Acute-duration oral MRLs were
derived for TnBP and TBEP based on effects on maternal body weight in gestational exposure studies
(Monsanto Co. 1985b; Noda et al. 1994), but in both cases, there was additional information regarding the
chemical from studies that evaluated gross and microscopic morphology of a number of organs and 
tissues and conducted hematological and clinical chemistry tests (Komsta et al. 1989; Laham et al. 
1984b).  
•	 An MRL of 0.05 mg/kg/day has been derived for intermediate-duration oral exposure (15– 
364 days) to TDCP based on increased absolute kidney weight in male rats.
Limited intermediate-duration studies were available.  In a study in male rabbits, the animals were 
administered doses of 0, 2, 20, or 200 mg TDCP/kg/day by gavage for 12 weeks (Anonymous 1977).  
During the last week of treatment, male fertility was tested by mating the males with untreated females.  
Fertility was assessed by sacrificing the females at mid-gestation and evaluating their uteri. After the
mating period, the males were sacrificed and sperm from the cauda epididymides were analyzed for
motility, morphology, and concentration.  Blood was also collected for hematology and clinical chemistry
tests.  The pituitary, liver, kidneys, and reproductive tract were processed for microscopic examination.  
The treatment-related effects appeared to be a significant increase in relative liver weight (23%) and in 
absolute kidney weight (14%).  Neither gross necropsy nor microscopic examinations revealed significant
alterations in the organs examined.  The fact that only a small number of organs were examined and no 
adverse effects were reported other than possibly minimal LOAELs for changes in liver and kidney
weights, and the lack of information in female animals, limit the usefulness of the study for risk
assessment.  In the 2-year bioassay in rats conducted by Stauffer Chemical Co. (1981a), hematology and 
clinical chemistry tests, as well as urine analyses were conducted after 3 and 6 months of treatment; 
however, no gross or microscopic examination of the tissues was conducted at these times.  Body weights
were reduced in males and females 5–7% relative to controls at the 3- and 6-month time points.  Body
weight was reduced 12% in high-dose males on week 50.  Hematology tests showed significant
reductions in hemoglobin and hematocrit in high-dose males both at 3 and 6 months and of hemoglobin in 
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females at 6 months.  High-dose males also showed a reduction in red blood cell count at 6 months.  At
12 months, there were significant reductions in hemoglobin in high-dose males (10.6%) and females 
(7.5%) and in red cell counts in high-dose males (10.7%).  None of these alterations were observed after
24 months of treatment with TDCP.  Prothrombin times and partial thromboplastin times showed 
considerable variability from interval to interval and no consistent pattern of differences between treated 
and control rats were apparent during the study.  Serum alkaline phosphatase levels were lower than 
controls in high-dose rats both at the 3- and 6-month intervals.  Blood urea nitrogen (BUN) values in 
treated rats were not significantly different than in controls.  Other clinical chemistry tests showed no 
consistent dose-related differences between controls and treated rats that could be attributed to treatment
with TDCP.  The most significant observations at 12 months were dose-related increases in absolute 
kidney and liver weights which achieved significance at the highest dose level; these changes in organ 
weights were not accompanied by histopathology.  Changes in kidney weight were more marked than 
those in liver weight, 48% increase in high-dose males and 39% increase in high-dose females relative to 
controls.  At the lowest dose, kidney weight was increased 12% in males relative to controls.  In mid-dose
males, absolute thyroid and liver weight were increased by 14 and 12%, respectively; the corresponding
increases in high-dose males were 25 and 26%.  Since the kidney was the most sensitive end point in rats 
exposed to TDCP for 24 months in the same study, it would appear that the increase in kidney weight
observed at 12 months is a continuum of the same spectrum of health effects used to derive the chronic-
duration MRL (see below) and may in fact be a precursor to the renal tubule hyperplasia seen in rats
exposed to TDCP for 24 months.  Since the hematological changes observed during the first year of the
study are of questionable toxicological significance, it is appropriate to use the changes in absolute kidney 
weight at the 12-month time point as the basis for derivation of an intermediate-duration oral MRL for
TDCP. 
Although ATSDR typically defines intermediate duration to be from 15 to 364 days, using a 1-year
(365 days) study, which is 1 day longer, is not a significantly different time frame.  In addition, using a
365-day end point is protective of intermediate-duration exposure.  
Data from Stauffer Chemical Co. (1981a) were analyzed using the BMD approach for MRL derivation.  
BMD models in the EPA BMDS (version 2.1) (linear, polynomial, power, and Hill models) were fit to the
absolute kidney weight male and female datasets to determine potential points of departure for the MRL. 
In the absence of a clear criteria as to what level of change in kidney weight should be considered 
adverse, the BMR was defined as a change in mean kidney weight equal to one standard deviation from
the control mean (EPA 2000).  Based on the criteria for model selection, the Hill model provided the best
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fit for the male data set, whereas the Linear model provided the best fit for the female data set.  The
corresponding BMDL1SD values were 4.69 and 13.49 mg/kg/day.  In order to be health protective, the
male BMDL1SD of 4.69 mg/kg/day is preferred as point of departure over the female BMDL1SD of
13.49 mg/kg/day.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for 
human variability) to the BMDL1SD of 4.69 mg/kg/day yields an intermediate-duration oral MRL of
0.05 mg/kg/day for TDCP.  Details of the modeling are presented in Appendix A.
•	 An MRL of 0.02 mg/kg/day has been derived for chronic-duration oral exposure (365 days and 
longer) to TDCP based on renal tubule hyperplasia in male rats.
A chronic-duration study with TDCP was available for review.  In that study, groups of male and female
Sprague-Dawley rats (60/sex/dose) were fed a diet that provided 0, 5, 20, or 80 mg TDCP/kg/day for
24 months (Stauffer Chemical Co. 1981a).  End points monitored included lethality, clinical signs, body
weight, food consumption, hematology, clinical chemistry and urinalysis (periodically throughout the
study), gross necropsy, and histopathology at termination and at 12 months (10 rats/sex/dose).  The most
sensitive organs affected by treatment with TDCP appeared to be the liver and kidneys.  At termination, 
gross observations revealed masses, nodules, and raised areas in the liver of high-dose rats; enlargement
of the kidney in mid- and high-dose males and high-dose females plus higher incidence of discolorations, 
surface irregularities, masses, nodules, and cysts in treated rats than in controls; and higher incidence of
small seminal vesicles and testicular enlargement, masses, nodules, flaccidity, and discolorations in mid-
and high-dose males.  Nonneoplastic lesions that were significantly increased in treated rats were 
foci/areas of hepatocellular alterations (high-dose males and females), dilation of liver sinusoids (high-
dose males and females), hyperplasia of convoluted tubular epithelium of the kidney (high-dose males 
and females, mid-dose males), and chronic nephropathy (high-dose males and females).  None of these 
alterations were seen at the 12-month interim sacrifice.  Hyperplasia of the renal convoluted tubular
epithelium was the most sensitive effect and occurred with incidences of 2/45, 10/49, 28/48, and 24/46 in 
males as the doses increased; the corresponding incidences in females were 0/49, 1/48, 3/48, and 22/50. 
Based on the incidences of the lesion in males, a LOAEL of 20 mg TDCP/kg/day was defined; the
NOAEL was 5 mg/kg/day. Examination of these incidences shows that males were clearly more sensitive 
than females.  Therefore, the data set for hyperplasia of the renal convoluted tubular epithelium in males 
served as the basis for determining the point of departure for MRL derivation. A detailed description of
the study and modeling of the data is provided in Appendix A.
Incidence data for renal tubule epithelial hyperplasia in male rats exposed to TDCP (Stauffer Chemical
Co. 1981a) were analyzed using the BMD approach for MRL derivation.  Models in the EPA BMDS
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(version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull
models) were fit to the renal tubular epithelial hyperplasia data in male rats to determine potential points
of departure for the MRL. Since an adequate fit to the data set could not be obtained with any of the
models, the high-dose was dropped, in accordance with EPA (2000) guidance. Comparing across models, 
the Multistage 1-degree polynomial model provided the best fit to the renal epithelial hyperplasia data
after dropping the highest dose.  From this model, the predicted dose associated with a 10% extra risk
(BMD10) was 2.60 mg TDCP/kg/day; the lower 95% confidence limit on this dose (BMDL10) was 
1.94 mg TDCP/kg/day.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 
10 for human variability) to the BMDL10 of 1.94 mg/kg/day yields a chronic-duration oral MRL of
0.02 mg/kg/day for TDCP.
TPP. No MRLs were derived for TPP due to inadequacies of the database available for review;
specifically, no toxicity was reported.  Information regarding acute exposure to TPP was limited to lethal
dose studies aimed mainly at determining LD50 values.  Information regarding intermediate-duration 
exposure was limited to an early study by Sutton et al. (1960) who treated rats with up to 416 mg
TPP/kg/day via the diet for 35 days and reported no hematological effects or alterations in body weight or
in the weight of the liver and kidneys; no further end points were evaluated.  In a 4-month dietary study, 
doses of 345 mg TPP/kg/day reduced weight gain of rats by 11%, but doses of up to 711 mg TPP/kg/day 
had no significant effect on the results of a battery of behavioral tests administered at monthly intervals
during treatment (Sobotka et al. 1986).  In a study in which male and female rats received doses of up to 
690 mg TPP/kg/day for 90 days before mating and during gestation, there were no significant effects on 
reproductive parameters or on fetal parameters assessed on Gd 20 (Welsh et al. 1987).  Indices of
immunocompetence, including the humoral response to immunization with SRBC were also not
significantly affected in rats exposed to up to 711 mg TPP/kg/day for 120 days (Hinton et al. 1996).  No 
chronic-duration studies with TPP were located in the literature available for review.
TiBP. No MRLs were derived for TiBP due to lack of adequate information.  Only one study with TiBP
was available for review.  In that study, male and female rats received doses of up to 346 and 404 mg 
TiBP/kg/day, respectively, for 13 weeks in the diet (Naylor and Ribelin 1990).  End points evaluated 
included clinical signs, body weight, food consumption, hematology and clinical chemistry, selected
organ weights, and gross and microscopic evaluation of all major organs and tissues.  The only reported 
effects were a statistically significant decrease in neutrophil count in high-dose males and an increase in 
mean corpuscular hemoglobin (MCH) in high-dose males and in mean corpuscular hemoglobin 
concentration (MCHC) in mid- (68 mg/kg/day) and high-dose males.  Clinical chemistry tests also 
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showed a statistically significant increase in serum cholesterol in high-dose males.  In the absence of any
other significant alterations, the toxicological significance of the reported effects is unknown and not
suitable for MRL derivation.
TCPP. No MRLs were derived for TCPP due to lack of adequate information.  Only one study was
available for review (Kawasaki et al. 1982).  That study determined a 96-hour LD50 of 1,500 mg TCPP/kg 
in female rats and reported that exposure to up to 1,000 mg TCPP/kg/day by gavage for 7 days had no 
significant effect on the relative weights of the brain, heart, lungs, liver, spleen, kidneys, or adrenals.  In 
another experiment, exposure of pregnant rats to up to 893 mg TCPP/kg/day by gavage on Gd 0–20, 
followed by sacrifice on Gd 20, did not result in fetotoxicity or teratogenicity.  Some dams were allowed
to give birth and their offspring were monitored for 4 weeks after weaning.  Neonatal growth and viability
during this period was comparable among groups.  The information available is not suitable for MRL
derivation.
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3. HEALTH EFFECTS
 
3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of phosphate ester
flame retardants.  It contains descriptions and evaluations of toxicological studies and epidemiological
investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic
data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to produce significant dysfunction or
death, or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
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major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
This profile discusses the following phosphate ester flame retardants: tris(2-chloroethyl) phosphate
(TCEP), tributyl phosphate (TnBP), tris(2-butoxyethyl) phosphate (TBEP), tris(1,3-dichloro-2-propyl)
phosphate (TDCP), triphenyl phosphate (TPP), tris(2-chloroisopropyl) phosphate (TCPP), and triisobutyl
phosphate (TiBP).  
Although the industrial properties of the selected phosphate ester flame retardants have been known for
many decades, there is relatively little information on their adverse health effects in the peer-review
literature.  In contrast, a significant amount of studies performed or sponsored by industry remain 
unpublished, although many of them can be obtained from the EPA.  ATSDR has made an effort to 
include all of the relevant information in this profile for the chemicals mentioned above.  However, it is
important to note that the quality of the microfiche that contain the unpublished studies varied greatly;
some are unreadable and others could not be used due to being “sanitized” by the manufacturer, thus 
making it impossible to determine the identity of the chemical being tested.
3.2.1 Inhalation Exposure 
No studies were located regarding adverse health effects in the general population due to inhalation 
exposure to the subject phosphate ester flame retardants of this profile and very limited information was 
located regarding people occupationally exposed to these substances.  
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Data in animals were limited to brief summaries of exposures to high concentrations of the chemicals 
(vapors, aerosols, dusts) aimed primarily to estimate lethal concentrations. Therefore, only this 
information is presented in Section 3.2.1.
3.2.1.1 Death 
No reports of death in humans following inhalation exposure to the subject phosphate ester flame 
retardants were located in the literature reviewed.  See Section 3.2.1.7, Cancer, for information regarding
cancer mortality among workers exposed to TDCP.    
An LC50 of >5,000 mg/m
3 was estimated in rats exposed for 4 hours to an aerosol of TCEP (Anonymous
1977).  All rats survived through the exposure and the observation period of 14 days, and gross necropsy
did not reveal compound-related effects.  FMC (1976) reported that the lowest LC50 following a 1-hour
exposure of rats to vapors of TnBP was 28,000 mg/m3.  Studies conducted by Eastman Kodak Co. (1968)
reported that one out of three rats died following exposure to TnBP at a concentration of 41,382 mg/m3; 
no deaths or clinical signs of toxicity occurred at 10.89 mg/m3. MacKellar (1976) reported an LC50 of
<200,000 mg/m3 for TnBP in rats, as exposure to 200,000 mg/m3 of TnBP killed 100% of the rats. 
An LC50 of >9,800 mg/m
3 was reported for rats exposed for 1 hour to an aerosol of TDCP (Stauffer
Chemical Co. 1981b).  All rats survived through the exposure and 14-day observation period, and gross
necropsy did not reveal compound-related effects.  Exposure of rats for 4 hours to an aerosol of TBEP at a 
nominal concentration of 5,000 mg/m3 resulted in the death of 4/5 males and 3/3 females at the end of a 
14-day observation period (Mobil Oil Corporation 1981).  Clinical signs of toxicity included lethargy, 
brown discharge from the mouth, and labored breathing.
An LC50 >200,000 mg/m
3 was described for TPP in rats in a summary of an acute inhalation study (FMC
1982).  Rats were exposed for 1 hour to dusts of TPP and were observed for 14 days.  All rats survived 
through the exposure and observation period, and gross necropsy did not reveal compound-related effects.  
Exposure of rats to up to 83,350 mg/m3 of vapors of TiBP for 6 hours induced gasping; prostration;
yellow hair, ears, and feet; and red eyes during exposure, but no deaths occurred (Eastman Kodak Co. 
1990).  However, all rats exposed to this concentration died 48 hours following the exposure.
Additional information regarding LC50 values and lethal concentrations of the selected phosphate ester
flame retardants can be found in IPCS (1991a, 1991b, 1998, 2000b).
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3. HEALTH EFFECTS
Lethal exposure concentrations and LC50 values are presented in Table 3-1 and plotted in Figure 3-1. 
3.2.1.2 Systemic Effects
Respiratory Effects. Stauffer Chem Co. (1983) conducted a morbidity survey to identify adverse
health effects among workers occupationally exposed to TDCP.  The survey was based on an analysis of
the physical examination reports of 93 exposed and 31 non-exposed workers examined in 1981.  The
evaluation included a self administered 175 item questionnaire, clinical studies including pulmonary
function tests, a chest x-rays and electrocardiograms (EKG), and laboratory test including urinalyses, 
hematology and clinical chemistry parameters.  Time-weighted average breathing zone sampling
conducted in 1978 and 1979 showed that the concentration in the process area or in other areas was ≤7– 
8 ppb (0.4–0.5 μg/m3).  Analysis of alcohol consumption habits showed that there were significantly more
non drinkers among non-exposed individuals and a higher daily alcohol consumption among exposed 
workers than non-exposed.  There were no significant differences between the groups regarding smoking
habits.  In general, prevalence rates for positive responses to the questionnaire tended to be higher among
non-exposed workers.  From the respiratory section of the questionnaire, the main focus of the survey, 
exposed workers showed a 2-fold excess for bringing up phlegm first thing in the morning and for having
a stuffy nose or post-nasal drip in the summer.  Results from the chest x-rays showed no significant
differences between exposed and non-exposed workers.  Results from the pulmonary tests showed a six 
times greater percentage of abnormal pulmonary tests in non-exposed workers than in exposed workers;
the impairment occurred primarily in FEV1. Based on these findings, the investigators concluded that it
was apparent that workers exposed to TDCP were not at increased risk for respiratory conditions.  
Limitations of the survey (which also apply to other end points mentioned below) noted by the
investigators included the fact that the number of non-exposed workers was only one third that of of the
exposed workers.  Secondly, since payroll records were unavailable prior to 1975, some of the workers 
classified as non-exposed could have been exposed prior to 1975.  Thirdly, since a higher percentage of
exposed workers were employed before 1975 than non-exposed, and some of the exposed workers could
have had potentially a long duration of exposure, the maximum effect of any harmful exposure should be
observed among the exposed workers.
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
ACUTE EXPOSURE 
Death 
1 Rat 4 hr 5000 (LC50 is greater than Anonymous 1977
(NS) 5000 mg/m3) 115-96-8 
2 Rat 6 hr 41382 (1/3 deaths) Eastman Kodak Co. 1968
 
(NS) (NS)
 126-73-8 
3 Rat 6 hr 83350 (3/3 deaths 48 hours Eastman Kodak Co. 1990 
(NS) (NS) after exposure) 126-71-6 
4 Rat 1 hr 28000 (LC50) FMC 1976 
(Wistar) (NS) 126-73-8 
5 Rat 1 hr 200000 (LC50 was greater than FMC 1982 
(Wistar) (NS) 200000 mg/m3) 115-86-6 
Rat 1 hr6 200000 (LC50 is less than MacKeller 1976 
(NS) (NS) 200000 mg/m3) 126-73-8 
7 Rat 4 hr 5000 (7/8 deaths in 14 days) Mobil Oil Corporation 1981
(Sprague- (NS) 78-51-3Dawley) 
8 Rat 1 hr 9800 (1-hr LC50 is greater Stauffer Chemical Co. 1981b
 
(Sprague- (NS)
 than 9800 mg/m3) 13674-87-8Dawley) 
hr = hour(s); LC50 = lethal concentration, 50% kill; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; NS = not specified 
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Figure 3-1  Levels of Significant Exposure to Selected Phosphate Esters - Inhalation
Acute (≤14 days)
c-Cat
d-Dog
r-Rat
p-Pig
q-Cow
 -Humans
k-Monkey
m-Mouse
h-Rabbit
a-Sheep
f-Ferret
j-Pigeon
e-Gerbil
s-Hamster
g-Guinea Pig
n-Mink
o-Other
  Cancer Effect Level-Animals
  LOAEL, More Serious-Animals
  LOAEL, Less Serious-Animals
  NOAEL - Animals
  Cancer Effect Level-Humans
  LOAEL, More Serious-Humans
  LOAEL, Less Serious-Humans
  NOAEL - Humans
  LD50/LC50
  Minimal Risk Level
   for effects
   other than
   Cancer
TPP TnBP
TnBP
TnBP
TiBP
TCEP TBEP
TDCP
P
H
O
S
P
H
A
TE
 E
S
TE
R
 FLA
M
E
 R
E
TA
R
D
A
N
TS
3.  H
E
A
LTH
 E
FFE
C
TS
40
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
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Sutton et al. (1960) reported the results of health evaluations of men engaged in the manufacture and use 
of TPP.  The workers could have been exposed to up to 29 mg/m3 TPP mist and vapor or dust for short
period of time, but the investigators estimated a weighted average exposure concentration of 3.5 mg/m3. 
Although the total number of men evaluated was not indicated, review of medical records and chest x-ray 
tests did not reveal respiratory alterations attributable to exposure to TPP.  Review of the medical records, 
illnesses, and examinations of 11 plant operators found no cases of respiratory tract irritation. 
Cardiovascular Effects. In the survey conducted by Stauffer Chem Co. (1983), workers exposed to 
TDCP had twice as many abnormal EKG tracings as non-exposed workers.  The principal abnormalities
observed were sinus bradycardia, sinus arrhythmias, left axis deviation and incomplete right bundle
branch block.  However, from the health questionnaire information, a lower percentage of these workers
had a history of heart trouble than non-exposed workers, but a higher percent had a history of “other” 
chest trouble.  In addition, exposed workers had a lower prevalence of diseases of the circulatory system.  
The review of medical evaluations of workers exposed to TTP conducted by Sutton et al. (1960) did not
reveal electrocardiographic alterations attributable to occupational exposure to TPP. 
Hematological Effects. Hematology tests (complete blood counts with differentials) carried out in 
the morbidy survey conducted by Stauffer Chem Co. (1983) showed no statitistically significant
differences between workers exposed to TDCP and non-exposed workers.  Health evaluations of workers 
exposed to TPP that included hematology tests (hemoglobin, cell volume, white blood cell count, and 
differential) did not show deviations from the normal range attributable to exposure to TPP (Sutton et al. 
1960). 
Hepatic Effects. Results of the liver function tests performed on the workers studied by Stauffer
Chem Co. (1983) showed that workers exposed to TDCP had a higher percentage of abnormal total
bilirubin and total protein values than non-exposed workers.  However, non-exposed workers had higher
serum aspartate aminotransferase (AST) and alkaline phosphatase values.  Health evaluations conducted 
in workers exposed to TPP did not reveal alterations in liver function as assessed by the cephalin 
cholesterol flocculation test (Sutton et al. 1960).
Renal Effects. In the morbidity survey conducted by Stauffer Chem Co. (1983), there was a 
considerably greater percentage of workers exposed to TDCP with abnormal BUN values than non-
exposed workers, 14.1 versus 0.0%; creatinine values were similar for both groups.  The results also 
showed that a greater percentage of non-exposed workers (25.8%) had abnormal urine results
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42PHOSPHATE ESTER FLAME RETARDANTS
3. HEALTH EFFECTS
(unspecified) than exposed workers (6.7%).  Examination of the urine of workers exposed to TPP did not
reveal any abnormalities that could be attributed to exposure to the chemical (Sutton et al. 1960).
Dermal Effects. A higher prevalence of dermatitis was reported among TDCP workers compared 
with non-exposed workers in the morbidity survey conducted by Stauffer Chem Co. (1983); no further
details were provided.  No cases of dermatitis were observed among 11 workers exposed to TPP that were
evaluated by Sutton et al. (1960).
3.2.1.3 Immunological and Lymphoreticular Effects
No information was located regarding immunological and lymphoreticular effects in humans or animals
following inhalation exposure to the phosphate ester flame retardants discussed in this profile.
3.2.1.4 Neurological Effects
Examination of 32 men who were assigned to jobs in which they occasionally handled bags of TPP and 
had a mean length of exposure of 7.4 years revealed no cases of neurological disease (Sutton et al. 1960).  
Examination of 11 of the men with the highest exposure who were working regularly at the time of the
evaluations showed no evidence of neurological disease (Sutton et al. 1960).  However, red blood cell
cholinesterase activity was significantly reduced (18%) in this group of workers compared to unexposed 
subjects.  Yet, Sutton et al. (1960) noted that the variability both within and between individuals was
great enough so that the small depressions in cholinesterase activity were not sufficient to identify 
individuals with TPP exposure.
No studies were located regarding the following effects:
3.2.1.5 Reproductive Effects
3.2.1.6 Developmental Effects
3.2.1.7 Cancer
Stauffer Chemical Co. (1983) conducted a retrospective cohort study to examine the mortality experience 
of 289 workers employed in the manufacture of TDCP.  The study period was established as January 
1956 through December 1980.  The cohort included active, terminated, retired, and deceased employees.  
Full-shift, time weighted average breathing zone sampling conducted from December, 1978 to May, 1979 
showed that exposure levels were <8 ppb.  Of the total cohort, only 42 workers had been employed 
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≥15 years.  The overall mortality of the cohort was 75% of that expected in a comparable population of
U.S. males, which probably reflected the healthy worker effect.  There were three deaths attributed to 
lung cancer, which was higher than the 0.8 expected.  However, based on the fact that one case was found 
to have not been exposed to TDCP, a second case worked only 2 years before onset of the disease, and all
three cases were cigarette smokers, the investigators conluded that there was insufficient evidence to 
establish a causal relationship between lung cancer and TDCP.  Considering the small size of the cohort, 
the investigators recommended continued surveillance of the group.  Without providing further details, 
Stauffer Chem Co. (1983) stated that in the morbidity survey conducted among TDCP workers, there was
an excess of benign neoplasms, primarily lipomas, relative to non-exposed workers.
3.2.2 Oral Exposure
3.2.2.1 Death 
No reports of deaths of humans following oral exposure to the phosphate ester flame retardants subject of
this profile were located in the reviewed literature.
Oral LD50 values between 46.4 and 100 mg/kg and between 46.4 and 1,000 mg/kg were reported for 
TCEP in male and female rats, respectively (Anonymous 1977).  Other LD50 values reported for TCEP in 
rats were 1,230 and 1,410 mg/kg (Eldefrawi et al. 1977; Smyth et al. 1951).  In a gestational exposure
study, 7/30 rats dosed with 200 mg TCEP/kg/day died during the study; no deaths occurred in a group 
treated with 100 mg/kg/day (Kawashima et al. 1983a).  In a 16-week duration study in which rats were 
treated with TCEP by gavage 5 days/week, 5/10 males and 3/10 females died on week 16 (NTP 1991a).  
LD50 values and/or lethal doses ranging from 1,400 to 3,200 mg/kg were reported for TnBP in rats (Dow
Chemical Co. 1956; Eastman Kodak Co. 1968; EI Dupont Denemours 1953a; Johannsen et al. 1977;
Stauffer Chemical Co. 1973; Union Carbide Corp 1943).  MacKellar (1976) reported that all rats
(unspecified number) treated once with 20,000 mg TnBP/kg died.  Eastman Kodak Co. (1968) also
reported an LD50 between 400 and 800 mg/kg for TnBP in mice.  In a gestational exposure study, all five
pregnant rats dosed with 800 mg TnBP/kg/day died after five or six treatments (Noda et al. 1994).  These 
rats showed marked reduction in body weight and food consumption, piloerection, wetting of abdominal
hair with urine, and salivation.  In a 13-week gavage study, 7/24 rats died at unspecified times before the
end of the study (Healy et al. 1995).  Gross examination of these rats showed a pale, frothy material in the
trachea and/or lungs, suggesting that deaths may have been due to aspiration of saliva.  
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Oral LD50 values of 13,278 and 5,383 mg/kg were reported for TBEP in male and female rats, 
respectively (Mobil Oil Corporation 1976a).  Clinical signs of toxicity observed included ataxia, labored 
breathing, red stains on the nose or eyes, rough coat, soft feces, urine stains, depression, prostration, and 
tremors.  Gross necropsy of animals that died during the study revealed reddened intestines and/or 
reddened stomach linings.  Without providing any details, Eldefrawi et al. (1977) reported an estimated
oral LD50 of 2,830 mg/kg for TDCP in rats. 
An oral LD50 of 10,800 mg/kg was described in rats administered TPP by capsule and observed for
14 days (Johannsen et al. 1977).  Without providing further details, EF Houghton and Co. (1996) and 
FMC (1982) reported LD50 values >6,400 and >20,000 mg/kg, respectively, for TPP in rats.  Oral LD50 
values >3,200 and >6400 mg/kg were described for TiBP in rats and mice, respectively (Eastman Kodak
Co. 1990).  Mortality in rats occurred between 2.5 hours and 2 days following administration of TiBP and 
clinical signs of toxicity included ataxia, jerking, and white foam at the mouth.  Mortality in mice
occurred between 2 and 3 hours following administration of TiBP, and clinical signs of toxicity included 
ataxia.  In a study conducted by Monsanto Co. (1989a, 1989b), a single dose of 5,000 mg/kg killed only 
1/10 rats within a 14-day observation period.  Clinical signs of toxicity observed 24 hours after dosing
included dry rales, hypoactivity, and red nasal discharge.
Oral LD50 values of 2,000 and 1,260 mg/kg were reported for TCPP in male and female rats, respectively
(Anonymous 1977).  Spasm, salivation, ataxia, and spasmodic jumping were noticed in the rats.
Kawasaki et al. (1982) reported a 96-hour oral LD50 of 1,500 mg/kg for TCPP in female rats.  Tremors 
and wheezing were evident 30 minutes after dosing in rats that died.  Rats that did not die after 5 hours
did not do so later.  In rats dosed once with 200, 500, or 2,000 mg TCPP/kg, all five high-dose females 
died (Stropp 1996).  There were no other mortalities at any other dose level.  Clinical signs observed in 
high-dose females included apathy, spasms, blood-crusted snout, and lateral position.  No clinical signs of
toxicity were observed in either sex at 200 or 500 mg/kg, and body weight was not affected.  At necropsy, 
reddened lungs were observed in animals that died during the study; however, no surviving animals
showed pathological changes upon sacrifice.
Additional information regarding LD50 values and lethal doses of phosphate ester flame retardants can be
found in IPCS (1991a, 1991b, 1998, 2000b).
Oral LD50 values and oral lethal doses for the selected phosphate ester flame retardants are presented in 
Tables 3-2, 3-3, 3-4, 3-5, and 3-6 and plotted in Figures 3-2, 3-3, 3-4, 3-5, and 3-6.
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
ACUTE EXPOSURE 
Death 
1 Rat once 46.4 M (LD50 is between 46.4 Anonymous 1977
(Sprague- (NS) and 100 mg/kg) 115-96-8Dawley) 
46.4 F (LD50 is between 46.4 
and 1000 mg/kg) 
2 Rat once 1230 (LD50) Eldefrawi et al. 1977
 
(albino) (G)
 115-96-8 
3 Rat 9 d 200 F (7/30 pregnant rats died, Kawashima et al. 1983aGd 7-15(Wistar) 
1 x/d 0/23 in controls) 115-96-8 
(GO) 
4 Rat once 1410 (LD50) Smyth et al. 1951

(albino) (G)
 115-96-8 
Systemic 
5 Mouse 8 d Only one dose levelBd Wt 940 F (12% reduced weight Hardin et al. 1987Gd 6-13(CD-1) was used.gain between Gd 6 and1 x/d 115-96-8 Pnd 3)
(G) 
6 Mouse 14 d Bd Wt 1000 NTP 1991b1 x/d(CD-1) 115-96-8(GO) 
Neurological 
7 Rat once 275 F (convulsions; loss of Tilson et al. 1990 
(Fischer- 344) (GO) hippocampal cells) 115-96-8 
10
175 300
67
200
65
940
13
350
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
8 Mouse 3 d 175	 300 (ataxia, convulsions) NTP 1991a1 x/d(B6C3F1) 115-96-8(GO) 
Developmental 
9 Rat 9 d 200 F Kawashima et al. 1983a NOAEL is for standard 
(Wistar) Gd 7-15 developmental indices.
1 x/d	 115-96-8 
(GO) 
Mouse 8 d10 940 F	 Hardin et al. 1987 NOAEL is for Gd 6-13(CD-1)	 developmental indices
1 x/d	 115-96-8 in a preliminary assay. 
(G) 
INTERMEDIATE EXPOSURE 
Death 
11 Rat 16 wk 350 (5/10 males and 3/10 NTP 1991a5 d/wk(Fischer- 344) 
1 x/d	 females died on week 115-96-8
 16)

(GO) 
103
586
586
586
586
586
586
586
586
586
586
192
506
586
586
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Systemic 
Rat 3 mo12 Resp 586 F Anonymous 1977 NOAELs are for tissue 
(Sprague- ad lib or organ115-96-8Dawley) (F)	 histopathology. Other 
refers to urinary 
bladder. 
Cardio 586 F 
Gastro 586 F 
Hemato 586 F 
Musc/skel 586 F 
Hepatic 586 F 
Renal 586 F 
Endocr 586 F 
Dermal 586 F 
Ocular 586 F 
Bd Wt 192 M 506 M (13% reduction in final
 
body weight)
 
Metab 586 F
 
Other 586 F
 
12
350
350
350
350
88
175
88
175
350
350
350
350
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
13 Rat 16 wk NTP 1991a	 NOAELs are for organResp 3505 d/wk(Fischer- 344)	 or tissue 
1 x/d	 115-96-8 histopathology. Other 
(GO) refers to urinary 
bladder. 
Cardio 350 
Gastro 350 
Musc/skel 350 
Hepatic 88 175	 (>10% increase in
 
absolute liver weight)
 
Renal 88 F 175 F	 (>10% increased
 
absolute and relative
 
kidney weight)
 
Endocr 350
 
Dermal 350
 
Bd Wt 350
 
Other 350
 
3350
350
350
350
350
88
175
350
350
350
350
14 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Rat 16 d Resp 350 NTP 1991a NOAELs are for organ5 d/wk(Fischer- 344) or tissue 
1x/d 115-96-8 histopathology. Other 
(GO) refers to urinary 
bladder. 
Cardio 350 
Gastro 350 
Musc/skel 350 
Hepatic 350 
Renal 88 M 175 M (increased absolute and
 
relative kidney weight)
 
Endocr 350
 
Dermal 350
 
Bd Wt 350
 
Other 350
 
17
700
700
700
700
700
350
700
700
700
700
700
15 
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Mouse 16 wk Resp 700 NTP 1991a NOAELs are for organ 
(B6C3F1) 5 d/wk or tissue 
1 x/d	 115-96-8 histopathology. Other 
(GO) refers to urinary 
bladder. 
Cardio 700 
Gastro 700 
Musc/skel 700 
Hepatic 700 
Renal 350 M 700	 (nuclear enlargement of
 
epithelial cells in renal
 
tubules)
 
Endocr 700
 
Dermal 700
 
Bd Wt 700
 
Other 700
 
8700
700
700
700
700
700
700
700
700
700
104
586
15
350
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ 
Duration/ 
a FrequencyKey to	 Species (Route)Figure (Strain) System 
Resp 
Cardio 
Gastro 
Musc/skel 
Hepatic 
Renal 
Endocr 
Dermal 
Bd Wt 
Other 
16 d 
5 d/wk 
1 x/d 
(GO) 
3 mo 
ad lib 
(F) 
16 d 
5 d/wk 
1 x/d 
(GO) 
LOAEL 
ReferenceNOAEL Less Serious Serious 
(mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
NTP 1991a	 NOAELs are for organ700 
or tissue115-96-8 histopathology. Other 
refers to urinary 
bladder. 
700
 
700
 
700
 
700
 
700
 
700
 
700
 
700
 
700
 
586 F Anonymous 1977	 NOAEL is for lymphoid 
tissues histopathology.115-96-8 
350 NTP 1991a	 NOAEL is for
 
histopathology of
115-96-8 lymphoreticular organs 
and tissues. 
16	 Mouse 
(B6C3F1) 
Immuno/ Lymphoret 
17 Rat 
(Sprague-
Dawley) 
18	 Rat 
(Fischer- 344) 
6350
18
700
9
700
105
586
14
88
175
7
350
140
700
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Rat 16 d19 350 NTP 1991a NOAELs is for 
(Fischer- 344) 5 d/wk lymphoreticular tissues
1 x/d	 115-96-8 histopathology. 
(GO) 
20 Mouse	 16 wk NTP 1991a The NOAEL is for7005 d/wk(B6C3F1)	 histopathology of
1 x/d	 115-96-8 lymphoreticular organs. 
(GO) 
21 Mouse	 16 d NTP 1991a NOAEL is for 
(B6C3F1) 5 d/wk 
700 
histopathology of
1 x/d	 115-96-8 lymphoreticular organs. 
(GO) 
Neurological 
22 Rat	 3 mo 586 F Anonymous 1977 NOAEL is for brain ad lib(Sprague-	 histopathology.115-96-8Dawley) (F) 
23 Rat 16 wk b 88 F	 175 F (necrosis of hippocampal NTP 1991a5 d/wk(Fischer- 344) 
1 x/d neurons) 115-96-8
 
(GO)
 
24 Rat	 16 d NTP 1991a	 NOAEL is for brain3505 d/wk(Fischer- 344)	 histopathology.
1 x/d 115-96-8
 
(GO)
 
25 Mouse	 16 d NTP 1991a	 NOAEL is for brain700
(B6C3F1) 1 x/d	 histopathology.115-96-8(GO) 
19
700
106
506
586
16
350
5
350
11
700
20
700
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 Frequency ReferenceKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
26 Mouse 16 wk 700 NTP 1991a5 d/wk(B6C3F1) 
1 x/d 115-96-8 
(GO) 
Reproductive 
27 Rat 3 mo 506 M Anonymous 1977ad lib(Sprague- 115-96-8Dawley) (F) 586 F 
28 Rat 16 wk 350 NTP 1991a5 d/wk(Fischer- 344) 
1 x/d 115-96-8 
(GO) 
29 Rat 16 d 350 NTP 1991a5 d/wk(Fischer- 344) 
1 x/d 115-96-8 
(GO) 
30 Mouse 16 d 700 NTP 1991a5 d/wk(B6C3F1) 
1 x/d 115-96-8 
(GO) 
31 Mouse 16 wk 700 NTP 1991a5 d/wk(B6C3F1) 
1 x/d 115-96-8 
(GO) 
Comments 
The NOAEL is for 
histopathology of the 
brain. 
NOAELs are for brain 
histopathology of 
reproductive organs. 
NOAEL is for 
histopathology of 
reproductive organs. 
NOAEL is for 
reproductive organs 
histopathology. 
NOAEL is for 
histopathology of 
reproductive organs. 
The NOAEL is for 
histopathology of 
reproductive organs. 
91
175
350
92
175
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
32 Mouse 18 wk 175 350 (decreased number of F1 NTP 1991b1 x/d(CD-1) litters) 115-96-8(GO) 
Developmental 
33 Mouse 18 wk 175 (decreased number of NTP 1991b1 x/d(CD-1) live male F2 pups per 115-96-8(GO) litter) 
21
88
88
88
88
88
88
44
88
88
88
88
88
88
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 Frequency	 ReferenceKey to Species	 NOAEL Less Serious Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
CHRONIC EXPOSURE 
Systemic 
Rat 104 wk34 Resp 88 NTP 1991a NOAELs are for organ5 d/wk(Fischer- 344)	 or tissue 
1x/d	 115-96-8 histopathology. Other 
(GO) refers to urinary 
bladder. 
Cardio 88
 
Gastro 88
 
Hemato 88
 
Musc/skel 88
 
Hepatic 88
 
c 
Renal 44 88	 (renal tubule epithelium
 
hyperplasia)
 
Endocr 88
 
Dermal 88
 
Ocular 88
 
Bd Wt 88
 
Other 88
 
26
350
350
350
350
350
350
175
350
350
350
350
350
213
267
1333
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
35 Mouse 104 wk	 NTP 1991a NOAELs are for organResp 350
(B6C3F1) 5 d/wk	 or tissue 
1 x/d	 115-96-8 histopathology. Other 
(GO) refers to urinary 
bladder. 
Cardio 350 
Gastro 350 
Hemato 350 
Musc/skel 350 
Hepatic 350 
Renal 175	 (nuclear enlargement in
 
tubule cells)
 
Endocr 350
 
Dermal 350
 
Ocular 350
 
Bd Wt 350
 
Other 350
 
36 Mouse 18 mo Bd Wt 267	 1333 (32% reduction in final Takada et al. 1989ad libitum(albino) body weight) 115-96-8(F) 
22
88
27
350
23
44
88
28
350
24
88
29
350
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 Frequency	 ReferenceKey to	 Species NOAEL Less Serious Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Immuno/ Lymphoret 
Rat	 104 wk37 88 NTP 1991a The NOAEL is for 
(Fischer- 344) 5 d/wk histopathology of
1x/d	 115-96-8 lymphoreticular organs 
(GO) and tissues. 
Mouse	 104 wk
 
5 d/wk
 
38 350	 NTP 1991a The NOAEL is for 
(B6C3F1)	 histopathology of
1 x/d	 115-96-8 lymphoreticular tissues. 
(GO) 
Neurological 
39 Rat 104 wk 44 F	 88 F (degenerative lesions in NTP 1991a5 d/wk(Fischer- 344) cerebral cortex and brain 
stem)1x/d	 
115-96-8 
(GO) 
40	 Mouse 104 wk NTP 1991a	 The NOAEL is for3505 d/wk(B6C3F1)	 histopathology of the115-96-81 x/d brain. 
(GO) 
Reproductive 
41	 Rat 104 wk 88 NTP 1991a The NOAEL is for 
(Fischer- 344) 5 d/wk histopathology of
1x/d	 115-96-8 reproductive organs. 
(GO) 
42	 Mouse 104 wk 350 NTP 1991a The NOAEL is for 5 d/wk(B6C3F1)	 histopathology of the
1 x/d	 115-96-8 reproductive organs. 
(GO) 
25
88
139
350
350
212
267
267
Table 3-2 Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 FrequencyKey to Species	 NOAEL Less Serious Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Cancer 
43 Rat 104 wk 88 (CEL:renal tubule NTP 1991a5 d/wk(Fischer- 344) 
1x/d	 adenomas) 115-96-8 
(GO) 
44 Mouse 104 wk	 Carcinogenic activity350 M (CEL: renal adenoma NTP 1991a5 d/wk(B6C3F1)	 was considered 
1x/d	 and adenocarcinoma) 115-96-8 equivocal by NTP. 
(GO) 
350 F	 (CEL: harderian gland 
tumors) 
45 Mouse 18 mo 267 M (CEL:hepatocellular Takada et al. 1989ad libitum(albino) adenoma/carcinoma) 115-96-8(F) 
267 F	 (CEL: leukemia) 
a The number corresponds to entries in Figure 3-2. 
b Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.6 mg/kg/day; the MRL was derived by adjusting the BMDL10 of 85.07 mg/kg/day for continuous exposure 
(85.07 mg/kg/day 5/7) and dividing by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability). 
c Used to derive a chronic-duration MRL of 0.3 mg/kg/day; the MRL was derived by adjusting the BMDL10 of 36.09 mg/kg/day for continuous exposure (36.09 x 5/7) and dividing by 
an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = 
gastrointestinal; Gd = gestation day; (GO) = gavage in oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = 
month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; pnd = post-natal day; Resp = respiratory; wk = week(s); x = time(s) 
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Figure 3-2  Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral
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Figure 3-2  Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2  Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2  Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2  Levels of Significant Exposure to Tris(2-chloroethyl) Phosphate (TCEP) - Oral (Continued)
Chronic (≥365 days)
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*Doses represent the lowest dose tested per study that produced a tumorigenic
response and do not imply the existence of a threshold for the cancer endpoint.
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral 
***D
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T***
Exposure/ LOAEL 
Duration/ 
a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg) (mg/kg) (mg/kg) 
ACUTE EXPOSURE 
Death 
1 Rat once 2000 (2/2 died)
(NS) (GO) 
2 Rat once 1600 (LD50 is 1600-3200
(NS) (NS) mg/kg) 
3 Rat once 2250 (lethal dose)
(NS) (NS) 
4 Rat once 1400 (14-day LD50)
(Sprague- (GO)
 
Dawley)
 
5 Rat once 20000 (all rats died)
(NS) (NS) 
6 Rat 11 d 800 F (5/5 dead pregnant ratsGd 7-17(Wistar) after 5 or 6 treatments)1 x/d
 
(GO)
 
7 Rat once 3160 M (LD50)
(Sprague- (G)
 
Dawley)
 
8 Rat once 3200 (LD50)
(NS) (G) 
Reference 
Chemical Form Comments 
Dow Chemical Co. 1956 
126-73-8 
Eastman Kodak Co. 1968 
126-73-8 
EI Dupont Denemours 1953a, 
1953b 
126-73-8 
Johannsen et al. 1977 
126-73-8 
MacKeller 1976 
126-73-8 
Noda et al. 1994 
126-73-8 
Stauffer Chemical Co. 1973 
126-73-8 
Union Carbide Corp 1943 
126-73-8 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
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T***
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain) System (mg/kg) (mg/kg)	 (mg/kg) Chemical Form Comments 
9 Mouse once 400 (LD50 is 400-800 mg/kg) Eastman Kodak Co. 1968 
(NS) (NS) 126-73-8 
Systemic 
10 Rat 14 d Bd Wt 411	 Laham et al. 19831x/d(Sprague- 126-73-8Dawley) (G) 
11 Rat 14 d	 Laham et al. 1984b NOAELs are for organResp 4111 x/d(Sprague-	 weight and126-73-8Dawley) (G)	 histopathology. 
Cardio 411
 
Hemato 137 F 411 F (decreased hemoglobin)
 
Hepatic 137 411 (increased absolute and
 
relative liver weight) 
Renal 411
 
Bd Wt 411
 
Metab 137 F (increased serum
 
potassium) 
12 Rat 11 d Bd Wt 100 F	 200 F (37% reduced adjusted Noda et al. 1994Gd 7-17(Wistar) 
1 x/d	 body weight gain on Gd 126-73-8
 0-20)

(GO) 
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411
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38
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411
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56
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411
Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
LOAEL 
a 
Key to Species 
Figure (Strain) 
13 Rat 
(Wistar) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
Hepatic 
Renal
 
Bd Wt
 
NOAEL 
(mg/kg/day) 
500 F 
500 F 
b 
62.5 F 
137 F 
325 
274 
411 
137 M 
Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
125 F	 (13% reduced adjusted
 
body weight gain on Gd
 
0-20)
 
411 F	 (decreased absolute and
 
relative spleen weight)
 
1000	 (decreased motor activity 
11 hours postdosing) 
411	 (decreased nerve
 
conduction velocity)
 
411 M (degenerative changes in
 
seminiferous tubules)
 
11 d 
Gd 7-17 
1 x/d 
(GO) 
14 d 
1 x/d 
(G) 
once 
(GO) 
14 d 
1x/d 
(G) 
14 d 
1 x/d 
(G) 
14 d 
1 x/d 
(G) 
Reference 
Chemical Form 
Noda et al. 1994 
126-73-8 
Laham et al. 1984b 
126-73-8 
Healy et al. 1995 
126-73-8 
Laham et al. 1983 
126-73-8 
Laham et al. 1984b 
126-73-8 
Laham et al. 1984b 
126-73-8 
Comments 
Liver and kidneys 
NOAEL are for organ 
weight. 
NOAEL is for weight 
and histopathology of 
the brain. 
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Immuno/ Lymphoret 
14 Rat 
(Sprague-
Dawley) 
Neurological 
15 
16 
17 
Rat 
(Sprague-
Dawley) 
Rat 
(Sprague-
Dawley) 
Rat 
(Sprague-
Dawley) 
Reproductive 
18 Rat 
(Sprague-
Dawley) 
45
400
49
500
52
325
36
143
143
33
143
9 33
39
182
Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ LOAEL
 
Duration/
 
a
 Frequency	 ReferenceKey to Species	 NOAEL Less Serious Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Developmental 
19 Rat 11 d Noda et al. 1994 NOAEL is for standard400 F
(Wistar)	 Gd 7-17 developmental indices.
1 x/d	 126-73-8 
(GO) 
Rat	 11 d
 
Gd 7-17
 
20 500 F	 Noda et al. 1994 NOAEL is for standard 
(Wistar)	 developmental indices.
1 x/d	 126-73-8 
(GO) 
INTERMEDIATE EXPOSURE 
Death 
21 Rat 13 wk 325 (7/24 deaths before end Healy et al. 19951x/d(Sprague- of the study) 126-73-8Dawley)	 (GO) 
Systemic 
22 Rat 10 wk Gastro 143 M Arnold et al. 1997 NOAELs are for 
(Sprague- ad lib histopathology of126-73-8Dawley)	 (F) stomach and kidneys. 
Renal 143 M 
Bd Wt 33 M 143 M (final body weight
 
reduced more than 10%
 
relative to controls)
 
c,d
Other 9 M 33 M (urothelial hyperplasia) 
23 Rat 12 mo Hemato 182 F	 Auletta et al. 1998aad lib(Sprague- 126-73-8Dawley)	 (F) 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral (continued) 
***D
R
A
FT FO
R
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U
B
LIC
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M
M
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N
T***
Exposure/ LOAEL
 
Duration/
 
a
 Frequency ReferenceKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
24 Rat 90 d FMC 1985a NOAELs are for organResp 423 F
(Sprague- ad lib histopathology.126-73-8Dawley) (F) 
Cardio 423 F 
Gastro 423 F 
Hemato 68.1 M 360 M (increased activated
 
partial thromboplastin
 
time)
 
Musc/skel 423 F 
Hepatic 13.8 M 68.1 M (increased absolute and
 
relative liver weight)
 
Renal 423 F
 
Endocr 423 F
 
Dermal 423 F
 
Ocular 423 F
 
Bd Wt 68.1 M 360 M (14% reduction in final
 
body weight) 
Metab 68.1 M 360 M (increased serum
 
calcium)
 
Other 13.8 M 68.1 M (urinary bladder epithelial
 
cell hyperplasia)
 
P
H
O
S
P
H
A
TE
 E
S
TE
R
 FLA
M
E
 R
E
TA
R
D
A
N
TS
3.  H
E
A
LTH
 E
FFE
C
TS
 
68
53
100
325
60
333
333
333
333
200
333
333
333
200
333
333
200
Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
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R
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U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
25 Rat 13 wk Bd Wt 100 325 (final body weight	 Healy et al. 19951x/d(Sprague- reduced 15-20%)	 126-73-8Dawley) (GO) 
26 Rat 18 wk Laham et al. 1985a NOAELs are for organResp 333
(Sprague- 5 d/wk	 histopathology.
1 x/d	 126-73-8Dawley) 
(G) 
Cardio 333
 
Gastro 333
 
Hemato 333
 
Hepatic 200 F 333 F (increase absolute and
 
relative liver weight) 
Renal 333
 
Endocr 333
 
Bd Wt 200 M 333 M (14% reduction in final
 
body weight) 
Metab 333 
Other 200	 (epithelial hyperplasia of
 
the urinary bladder)
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
27 Rat	 10 wk 
ad lib(Wistar) 
(F) 
28 Rat	 9 wk 
ad lib(Wistar) 
(F) 
LOAEL 
ReferenceNOAEL Less Serious	 Serious 
System (mg/kg/day) (mg/kg/day)	 (mg/kg/day) Chemical Form Comments 
Hemato 460 M (increased coagulation Oishi et al. 1980 
time) 126-73-8 
Renal	 460 M (increased BUN) 
Bd Wt 460 M (17% reduction in final 783 M (31% reduction in final 
body weight) body weight) 
Hemato 460 M	 Oishi et al. 1982 
126-73-8 
Hepatic 460 M (increase in absolute and 
relative liver weight; 
slight histopathology) 
Renal	 460 M (increased BUN) 
Bd Wt 460 M (11% decrease in final 
body weight) 
Metab 460 M 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
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R
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U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ LOAEL
 
Duration/
 
a
 Frequency	 ReferenceKey to Species	 NOAEL Less Serious Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Rat 70-110 d Hepatic 51 F 217 F (hepatic centrilobular	 Tyl et al. 1997Gd 1-20(Sprague-
Ld 1-20	 hypertrophy in F0 126-73-8Dawley) females)ad lib 
(F) 
Renal 51 M 217 M (renal pelvic epithelial
 
hyperplasia in F1 males)
 
Bd Wt 51 217	 (greater than 10%
 
reduction in body weight
 
in F0 generation)
 
Other 15 51	 (bladder hyperplasia in
 
F0 generation)
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral (continued) 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
30 Mouse 13 wk Resp 1776 F Auletta 1991ad lib(CD-1) 126-73-8(F) 
Cardio 1776 F
 
Gastro 1776 F
 
Hemato 382 M 1478 M (increased platelet
 
counts) 
Musc/skel 1776 F
 
Hepatic 95 M 382 M (hepatocyte hypertrophy)
 
Renal 1776 F
 
Endocr 1776 F
 
Ocular 1776 F
 
Bd Wt 1776 F
 
Metab 382 M 1478 M (increased serum
 
calcium) 
Other 95 M 382 M (urinary bladder epithelial
 
hyperplasia)
 
31 Mouse 12 mo Hemato 711 F Auletta et al. 1998bad lib(CD-1) 126-73-8(F) 
Immuno/ Lymphoret 
32 Rat 90 d FMC 1985a NOAEL is for lymphoid423 Fad lib(Sprague- organs histopathology.126-73-8Dawley) (F) 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
FT FO
R
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U
B
LIC
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M
M
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N
T***
Exposure/ LOAEL
 
Duration/
 
a
 
Key to	 Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
33	 Rat 18 wk 333 Laham et al. 1985a NOAEL is for spleen 
(Sprague- 5 d/wk histopathology.
1 x/d	 126-73-8Dawley) 
(G) 
34	 Rat 9 wk Oishi et al. 1982 NOAEL is for spleen460 Mad lib(Wistar)	 histopathology.126-73-8(F) 
35 Mouse	 13 wk 1776 F Auletta 1991 NOAEL is for lymphoidad lib(CD-1)	 tissues histopathology.126-73-8(F) 
Neurological 
36 Rat 90 d FMC 1985a	 NOAEL is for423 Fad lib(Sprague-	 histopathology of126-73-8Dawley) (F)	 central and peripheral 
nervous tissues. 
37	 Rat 13 wk 32.5 100 (excessive salivation)	 Healy et al. 19951x/d(Sprague- 126-73-8Dawley) (GO) 
38	 Rat 18 wk 333 Laham et al. 1985a NOAEL is for clinical 5 d/wk(Sprague-	 signs and brain
1 x/d	 126-73-8Dawley)	 histopathology. 
(G) 
39	 Mouse 13 wk 1776 F Auletta 1991 NOAEL is for 
(CD-1) ad lib histopathology of the126-73-8(F)	 brain and spinal cord. 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
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LIC
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M
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T***
a 
Key to Species 
Figure (Strain) 
Reproductive 
40 Rat 
(Sprague-
Dawley) 
41	 Rat 
(Sprague-
Dawley) 
42	 Rat 
(Sprague-
Dawley) 
43	 Mouse 
(CD-1) 
Developmental 
44 Rat 
(Sprague-
Dawley) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
90 d 
ad lib 
(F) 
18 wk 
5 d/wk 
1 x/d 
(G) 
70-110 d 
Gd 1-20 
Ld 1-20 
ad lib 
(F) 
13 wk 
ad lib 
(F) 
70-110 d 
Gd 1-20 
Ld 1-20 
ad lib 
(F) 
NOAEL 
System (mg/kg/day) 
360 M 
423 F 
333 
217 
1478 M 
1776 F 
51 
LOAEL 
Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
217	 (reduced F1 and F2 pup 
weight during 
preweaning period) 
Reference 
Chemical Form 
FMC 1985a 
126-73-8 
Laham et al. 1985a 
126-73-8 
Tyl et al. 1997 
126-73-8 
Auletta 1991 
126-73-8 
Tyl et al. 1997 
126-73-8 
Comments 
NOAEL is for 
histopathology of 
reproductive organs. 
NOAEL is weight and 
histopathology of 
ovaries or testes. 
NOAEL is for 
reproductive indices in 
2-generation study. 
NOAEL is for 
histopathology of 
reproductive organs. 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
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T***
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
CHRONIC EXPOSURE 
Systemic 
45 Rat 2 yr 
ad lib(Sprague-
Dawley) (F) 
LOAEL 
ReferenceNOAEL Less Serious Serious
 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments
 
Resp 182 F Auletta et al. 1998a	 NOAELs are for tissue 
or organ126-73-8 histopathology. 
Cardio 182 F 
Gastro 182 F 
Hemato 182 F 
Musc/skel 182 F 
Hepatic 182 F 
Renal 182 F 
Endocr 182 F 
Dermal 182 F 
Ocular 182 F 
Bd Wt 12 F 42 F (12% reduction in final 182 F (20% reduction in final 
body weight)	 body weight) 
Other 9 M 33 M (urinary bladder 
hyperplasia) 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
46 Mouse	 18 mo 
ad lib(CD-1) 
(F) 
Immuno/ Lymphoret 
47 Rat 2 yr 
ad lib(Sprague-
Dawley) (F) 
48 Mouse	 18 mo 
ad lib(CD-1) 
(F) 
System 
Resp 
Cardio 
Gastro 
Hemato 
Musc/skel 
Hepatic 
Renal 
Endocr 
Dermal 
Ocular 
Bd Wt 
Other 
LOAEL 
ReferenceNOAEL Less Serious Serious 
(mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
711 Auletta et al. 1998b	 NOAELs are for organ 
or tissue126-73-8 histopathology. 
711 F
 
711 F
 
711 F
 
711
 
28.9 M 169 M (increased absolute and
 
relative liver weight)
 
711
 
711 F
 
711 F
 
711
 
711 F
 
711
 
182 F Auletta et al. 1998a	 The NOAEL is for
 
histopathology of
126-73-8 lymphoreticular organs. 
Auletta et al. 1998b NOAEL is for lymphoid711 F 
organs histopathology.126-73-8 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral	 (continued) 
***D
R
A
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T***
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Neurological 
49 Rat 2 yr 182 F Auletta et al. 1998a The NOAEL is for 
(Sprague- ad lib histopathology of126-73-8Dawley) (F)	 central or peripheral 
nervous system. 
50 Mouse	 18 mo 711 F Auletta et al. 1998b NOAEL is for nervous ad lib(CD-1)	 system tissues126-73-8(F)	 histopathology. 
Reproductive 
51 Rat 2 yr 143 M	 Auletta et al. 1998a The NOAEL is for ad lib(Sprague-	 histopathology of the126-73-8Dawley) (F)	 reproductive organs.182 F 
52 Mouse	 18 mo 585 M	 Auletta et al. 1998b NOAELs are for ad lib(CD-1)	 histopathology of126-73-8(F)	 reproductive organs.711 F 
Cancer 
53 Rat 2 yr 143 M (CEL: urinary bladder Auletta et al. 1998aad lib(Sprague- papillomas and 126-73-8Dawley) (F) carcinomas) 
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Table 3-3 Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral (continued) 
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Mouse 18 mo 585 M (CEL: hepatocellular Auletta et al. 1998bad lib(CD-1) adenomas) 126-73-8(F) 
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T***
a The number corresponds to entries in Figure 3-3. 
b Used to derive an acute-duration oral MRL of 1.1 mg/kg/day; the MRL was derived by dividing the BMDL1SD of 111.47 mg/kg/day by an uncertainty factor of 100 (10 for animal to 
human extrapolation and 10 for human variability). 
c Used to derive an intermediate-duration oral MRL of 0.02 mg/kg/day; the MRL was derived by dividing the BMDL10 of 1.96 mg/kg/day by an uncertainty factor of 100 (10 for animal 
to human extrapolation and 10 for human variability). 
d ATSDR adopted the intermediate-duration oral MRL also as chronic-duration oral MRL for TnBP. 
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; 
Gastro = gastrointestinal; Gd = gestation day; (GO) = gavage in oil; Hemato = hematological; Ld = lactation day; LD50 = lethal dose, 50% kill; LOAEL = 
lowest-observed-adverse-effect level; M = male; Metab = metabolic; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; 
Resp = respiratory; wk = week(s); x = time(s); yr = year(s) 
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Figure 3-3  Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral
Acute (≤14 days)
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Figure 3-3  Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-3  Levels of Significant Exposure to Tri-n-butyl Phosphate (TnBP) - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-3  Levels of Significant Exposure to Tri-n-butyl Phosphate (TNBP) - Oral (Continued)
Chronic (365 days)
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*Doses represent the lowest dose tested per study that produced a tumorigenic
response and do not imply the existence of a threshold for the cancer endpoint.
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Table 3-4 Levels of Significant Exposure to Tris(2-butoxyethyl) Phosphate (TBEP) - Oral 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
ACUTE EXPOSURE 
Death 
1 Rat Once 13278 M (LD50) Mobil Oil Corporation 1979a

(Fischer- 344) (G)
 78-51-3 
5383 F (LD50) 
Systemic 
2 Rat 14 d Komsta et al. 1989 NOAELs are for organResp 100
(Sprague- 1 x/d	 weight and78-51-3Dawley) (GO)	 histopathology. 
Cardio 100
 
Gastro 100
 
Hemato 100
 
Musc/skel 100
 
Hepatic 100
 
Renal 100
 
Endocr 100
 
Dermal 100
 
Bd Wt 100
 
Metab 100
 
3 Rat 10 d	 b Bd Wt 500 F	 1500 F (weight gain reduced Monsanto Co. 1985bGd 6-15(CD)	 
1 x/d 35% during Gd 6-15) 78-51-3
 
(GO)
 
Immuno/ Lymphoret 
4 Rat 14 d Komsta et al. 1989 NOAEL is for lymphoid100
(Sprague- 1 x/d	 organ weights and78-51-3Dawley) (GO)	 histopathology. 
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Table 3-4 Levels of Significant Exposure to Tris(2-butoxyethyl) Phosphate (TBEP) - Oral	 (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Neurological 
5 Rat 14 d 100 Komsta et al. 1989 NOAEL is for weight 
(Sprague- 1 x/d and histopathology of78-51-3Dawley) (GO)	 the brain. 
6 Rat	 once 1500 F 1750 F (slight tremors and 3200 F (abnormal gait, tremors) Laham et al. 1985b 
(Sprague- (G) piloerection) 78-51-3Dawley) 
Reproductive 
7 Rat	 14 d 100 Komsta et al. 1989 NOAEL is for weight1 x/d(Sprague-	 and histopathology of78-51-3Dawley) (GO)	 the testes and ovaries. 
Developmental 
8 Rat 10 d 1500 F Monsanto Co. 1985b NOAEL is for standard 
(CD) Gd 6-15 developmental indices.
1 x/d	 78-51-3 
(GO) 
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Table 3-4 Levels of Significant Exposure to Tris(2-butoxyethyl) Phosphate (TBEP) - Oral (continued) 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
P
H
O
S
P
H
A
TE
 E
S
TE
R
 FLA
M
E
 R
E
TA
R
D
A
N
TS
3.  H
E
A
LTH
 E
FFE
C
TS
85
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
INTERMEDIATE EXPOSURE 
Systemic 
9 Rat 18 wk Reyna and Thake 1987a NOAELs are for tissueResp 698 F
(Sprague- ad lib histopathology.78-51-3Dawley) (F) 
Cardio 698 F 
Gastro 698 F 
Hemato 173 M 578 M (increased platelet
 
counts)
 
Musc/skel 698 F 
c 
Hepatic 17.3 M 173 M (periportal hepatocelllar
 
hypertrophy)
 
Renal 698 F
 
Endocr 698 F
 
Dermal 698 F
 
Ocular 698 F
 
Bd Wt 698 F
 
Metab 698 F
 
Other 698 F
 
Immuno/ Lymphoret 
10 Rat 18 wk Reyna and Thake 1987a NOAEL is for lymphoid698 Fad lib(Sprague- tissues histopathology.78-51-3Dawley) (F) 
Neurological 
11 Rat 18 wk Reyna and Thake 1987a NOAEL is for brain and698 M
(Sprague- ad lib sciatic nerve78-51-3Dawley) (F) histopathology. 
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Table 3-4 Levels of Significant Exposure to Tris(2-butoxyethyl) Phosphate (TBEP) - Oral (continued) 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
P
H
O
S
P
H
A
TE
 E
S
TE
R
 FLA
M
E
 R
E
TA
R
D
A
N
TS
3.  H
E
A
LTH
 E
FFE
C
TS
86
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
12 Rat 18 wk 209 F 698 F (reduced conduction Reyna and Thake 1987bad lib(Sprague- velocity in tail nerve) 78-51-3Dawley) (F) 
Reproductive 
13 Rat 18 wk 578 M Reyna and Thake 1987a NOAEL is for 
(Sprague- ad lib histopathology of78-51-3Dawley) (F) reproductive organs.698 F 
a The number corresponds to entries in Figure 3-4. 
b Used to derive and acute-duration oral MRL of 4.8 mg/kg/day; the MRL was derived by dividing the BMDL1SD of 477.25 mg/kg/day by an uncertainty factor of 100 (10 for animal to 
human extrapolation and 10 for human variability). 
c Used to derive an intermediate-duration oral MRL of 0.2 mg/kg/day; the MRL was derived by dividing the BMDL10 of 21.92 mg/kg/day by an uncertainty factor of 100 (10 for animal 
to human extrapolation and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestation 
day; (GO) = gavage in oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab =  metabolic; Musc/skel = 
musculoskeletal; NOAEL = no-observed-adverse-effect level; Resp = respiratory; wk = week(s); x = time(s) 
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Figure 3-4  Levels of Significant Exposure to Tris(2-butoxyethyl) Phosphate (TBEP) - Oral
Acute (≤14 days)
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Figure 3-4  Levels of Significant Exposure to Tris(2-butoxyethyl) Phosphate (TBEP) - Oral (Continued)
Intermediate (15-364 days)
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Table 3-5 Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
ACUTE EXPOSURE 
Death 
1 Rat once 2830 (LD50) Eldefrawi et al. 1977
 
(albino) (G)
 13674-87-8 
Systemic 
2 Rat 10 d Bd Wt 25 F 100 F (29% decreased weight Stauffer Chemical Co. 1981bGd 6-15(Sprague-
1 x/d gain on Gd 6-11) 13674-87-8Dawley)
 
(GO)
 
Developmental 
3 Rat 10 d 100 F 400 F (reduced fetal viability) Stauffer Chemical Co. 1981bGd 6-15(Sprague-
1 x/d 13674-87-8Dawley)
 
(GO)
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Table 3-5 Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
INTERMEDIATE EXPOSURE 
Systemic 
4 Rat 12 mo Resp 80 Stauffer Chemical Co. 1981aad lib(Sprague- 13674-87-8Dawley) (F) 
Cardio 80 
Gastro 80 
Hemato 20 M 80 M (10.6% reduction in
 
hemoglobin and red cell
 
count at 12 months)
 
Musc/skel 80 
Hepatic 5 M 20 M (12% increase in
 
absolute liver weight)
 
b 
Renal 5 M (12% increase in
 
absolute kidney weight)
 
Endocr 5 M 20 M (14% increase in
 
absolute thyroid weight)
 
Dermal 80 
Ocular 80 
Bd Wt 20 M 80 M (12% reduction in body
 
weight on week 50)
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Table 3-5 Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP)  - Oral (continued) 
Exposure/ 
Duration/ 
a FrequencyKey to	 Species (Route)Figure (Strain) 
LOAEL 
Comments 
Other is for urinary 
bladder histopathology. 
NOAEL is for lymphoid 
tissues histopathology. 
NOAEL is for 
histopathology of the 
brain and spinal cord. 
NOAEL is for 
histopathology of the 
reproductive organs. 
NOAEL is for fertility 
parameters. 
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91
System 
Hemato 
Hepatic 
Renal 
Endocr 
Bd Wt 
Other 
NOAEL 
(mg/kg/day) 
200 M 
20 M 
20 M 
200 M 
200 M 
200 M 
80 
80 
80 
200 M 
Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
200 M (23% increase in relative 
liver weight) 
200 M (14% increase in 
absolute kidney weight) 
Reference 
Chemical Form 
Anonymous 1977 
13674-87-8 
Stauffer Chemical Co. 1981a 
13674-87-8 
Stauffer Chemical Co. 1981a 
13674-87-8 
Stauffer Chemical Co. 1981a 
13674-87-8 
Anonymous 1977 
13674-87-8 
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5	 Rabbit 
(New 
Zealand) 
Immuno/ Lymphoret 
6 Rat 
(Sprague-
Dawley) 
Neurological 
7 Rat 
(Sprague-
Dawley) 
Reproductive 
8 Rat 
(Sprague-
Dawley) 
9	 Rabbit 
(New 
Zealand) 
12 wk 
1 x/d 
(GO) 
12 mo 
ad lib 
(F) 
12 mo 
ad lib 
(F) 
12 mo 
ad lib 
(F) 
12 wk 
1 x/d 
(GO) 
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80
80
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20
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Table 3-5 Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain) System (mg/kg/day)	 (mg/kg/day) (mg/kg/day) Chemical Form Comments 
CHRONIC EXPOSURE 
Systemic 
Rat 24 mo10 Resp 80	 Stauffer Chemical Co. 1981aad lib(Sprague- 13674-87-8Dawley) (F) 
Cardio 80 
Gastro 80 
Hemato 20 80	 (reduced hemoglobin,
 
hematocrit, and total
 
erythrocyte count)
 
Musc/skel 80 
Hepatic 20 80	 (foci/areas of
 
hepatocellular
 
alterations;dilation of
 
sinusoids)
 
c 
Renal 5 M 20 M (hyperplasia of
 
convoluted tubular
 
epithelium)
 
Endocr 80 
Dermal 80 
Ocular 20 80	 (accelerated
 
development of
 
sacculation along retinal
 
arterioles)
 
Bd Wt 20 80	 (21-24% reduction in final 
body weight) 
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Table 3-5 Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral (continued) 
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious	 Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Immuno/ Lymphoret 
11 Rat 24 mo 80 Stauffer Chemical Co. 1981a NOAEL is for lymphoid 
(Sprague- ad lib tissues histopathology.13674-87-8Dawley) (F) 
Neurological 
Rat 24 mo12 80	 Stauffer Chemical Co. 1981a NOAEL is for ad lib(Sprague-	 histopathology of the13674-87-8Dawley) (F)	 brain and spinal cord. 
Reproductive 
13 Rat 24 mo 80 Stauffer Chemical Co. 1981a NOAEL is for 
(Sprague- ad lib histopathology of the13674-87-8Dawley) (F)	 reproductive organs. 
Cancer 
14 Rat 24 mo 20 M (CEL: testicular interstitial Stauffer Chemical Co. 1981aad lib(Sprague- cell tumors) 13674-87-8Dawley) (F) 
20	 (CEL: renal cortical 
tumors) 
a The number corresponds to entries in Figure 3-5. 
b Used to derive an intermediate-duration oral MRL of 0.05 mg/kg/day; the MRL was derived by dividing the BMDL1SD of 4.69 mg/kg/day by an uncertainty factor of 100 (10 for 
animal to human extrapolation and 10 for human variability). 
c Used to derive a chronic-duration oral MRL of 0.02 mg/kg/day; the MRL was derived by dividing the BMDL10 of 1.94 mg/kg/day by an uncertainty factor of 100 (10 for animal to 
human extrapolation and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = 
gastrointestinal; Gd = gestation day; (GO) = gavage in oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = 
month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; wk = week(s); x = time(s) 
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Figure 3-5  Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral
Acute (≤14 days)
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Figure 3-5  Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral (Continued)
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Figure 3-5  Levels of Significant Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCP) - Oral (Continued)
Chronic (≥365 days)
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*Doses represent the lowest dose tested per study that produced a tumorigenic
response and do not imply the existence of a threshold for the cancer endpoint.
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Exposure/ LOAEL 
Duration/ 
a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
ACUTE EXPOSURE 
Death 
1 Rat once 2000 M (4-6 hr LD50)
(Sprague- (NS)
 
Dawley)
 1260 F (5-hr LD50) 
2 Rat once 3200 (LD50s between 3200
(NS) (G) and 6400 mg/kg were 
estimated) 
3 Rat once 6400 (LD50 is greater than
(NS) (NS) 6400 mg/kg) 
4 Rat once 20000 (LD50 is greater than
(Wistar) (GW) 20000 mg/kg) 
5 Rat once 10800 (14-day LD50)
(Sprague- (C)
 
Dawley)
 
6 Rat once 1500 F (96-hr LD50)
(Wistar) (GO) 
7 Rat once 5000 (LD50 is greater than
(Sprague- (G) 5000 mg/kg)
Dawley) 
Reference 
Chemical Form Comments 
Anonymous 1977 
13674-84-5 
Eastman Kodak Co. 1990 
126-71-6 
EF Houghton & Co. 1996 
115-86-6 
FMC 1982 
115-86-6 
Johannsen et al. 1977 
115-86-6 
Kawasaki et al. 1982 
13674-84-5 
Monsanto Co. 1989a, 1989b 
126-71-6 
144
500
632
150
6400
115
1000
117
893
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
8 Rat once 500 M (LD50 is greater than 500 Stropp 1996
(Wistar) (GO) mg/kg) 13674-84-5 
632 F (3-6 hr LD50) 
9 Mouse once 6400 (LD50s between 6400 Eastman Kodak Co. 1990 
(NS) (G) and 12800 mg/kg were 126-71-6 
estimated) 
Systemic 
10 Rat 7 d Bd Wt 1000 F Kawasaki et al. 19821 x/d(Wistar) 13674-84-5(GO) 
INTERMEDIATE EXPOSURE 
Systemic 
11 Rat 20 d Bd Wt 893 F Kawasaki et al. 1982Gd 0-20(Wistar) 
ad lib 13674-84-5 
(F) 
94
404
404
404
68
346
404
68
346
404
404
404
404
404
404
404
73
161
345
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Exposure/ LOAEL
 
Duration/
 
a
 Frequency ReferenceKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
12 Rat 13 wk Resp 404 F Naylor and Ribelin 1990 NOAELs are for organ 
(Sprague- ad lib or tissue126-71-6Dawley) (F) histopathology. 
Cardio 404 F 
Gastro 404 F 
Hemato 68 M 346 M (decreased neutrophil
 
count; increased MCH
 
and MCHC)
 
Musc/skel 404 F 
Hepatic 68 M 346 M (increased serum
 
cholesterol)
 
Renal 404 F
 
Endocr 404 F
 
Dermal 404 F
 
Ocular 404 F
 
Bd Wt 404 F
 
Metab 404 F
 
Other 404 F
 
13 Rat 4 mo Bd Wt 161 M 345 M (11% reduced body Sobotka et al. 1986ad lib(Sprague- weight gain) 115-86-6Dawley) (F) 
76
416
416
416
416
74
711
95
404
96
404
72
711
141
893
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Exposure/ LOAEL
 
Duration/
 
a
 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
14 Rat 35 d Hemato 416 M Sutton et al. 1960ad lib(Holtzman) 115-86-6(F) 
Hepatic 416 M 
Renal 416 M 
Bd Wt 416 M 
Immuno/ Lymphoret 
15 Rat 120 d 711 Hinton et al. 1996ad lib(Sprague- 115-86-6Dawley) (F) 
16 Rat 13 wk 404 F Naylor and Ribelin 1990ad lib(Sprague- 126-71-6Dawley) (F) 
Neurological 
17 Rat 13 wk 404 F Naylor and Ribelin 1990ad lib(Sprague- 126-71-6Dawley) (F) 
18 Rat 4 mo 711 M Sobotka et al. 1986ad lib(Sprague- 115-86-6Dawley) (F) 
Reproductive 
19 Rat 20 d 893 F Kawasaki et al. 1982Gd 0-20(Wistar) 
ad lib 13674-84-5 
(F) 
Comments 
Liver and kidney 
NOAELs are for organ 
weight. 
NOAEL is for lymphoid 
tissue histopathology 
and humoral response 
to SRBC immunization. 
NOAEL is for lymphoid 
tissues histopathology. 
NOAEL is for 
histopathology of 
nervous tissues. 
NOAEL is for 
neuromotor function 
tests. 
NOAEL is for number 
of implantations and 
resorptions. 
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Exposure/ LOAEL
 
Duration/
 
a
 FrequencyKey to	 Species NOAEL Less Serious Serious Reference (Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Rat 13 wk20 346 M Naylor and Ribelin 1990 NOAELs are for 
(Sprague- ad lib histopathology of126-71-6Dawley) (F)	 reproductive organs.404 F 
21	 Rat 111 d 690 F Welsh et al. 1987 NOAEL is for 
(Sprague- ad lib reproductive indices.115-86-6Dawley) (F) 
Developmental 
22 Rat 20 d Kawasaki et al. 1982 NOAEL is for standard893 FGd 0-20(Wistar)	 developmental indices.
ad lib	 13674-84-5 
(F) 
23	 Rat 111 d 690 F Welsh et al. 1987 NOAEL is for embryo 
(Sprague- ad lib and fetotoxicity.115-86-6Dawley) (F) 
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd 
= gestation day; (GO) = gavage in oil; (GW) = gavage in water; Hemato = hematological; hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M 
= male; Metab = metabolic; Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Resp = respiratory; wk = week(s); x = time(s) 
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Figure 3-6  Levels of Significant Exposure to TPP, TCPP, And TiBP - Oral
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Figure 3-6  Levels of Significant Exposure to TPP, TCPP, And TiBP - Oral (Continued)
Intermediate (15-364 days)
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104PHOSPHATE ESTER FLAME RETARDANTS
3. HEALTH EFFECTS
3.2.2.2 Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Tables 3-2, 3-3, 3-4, 3-5, and 3-6 and plotted in Figures 3-2, 
3-3, 3-4, 3-5, and 3-6. 
Respiratory Effects. The respiratory tract of animals has been examined in many repeated oral dose 
studies of the phosphate ester flame retardants discussed in this profile and no significant histological
alterations have been reported.  For example, no effects were noted in rats dosed daily with 350 mg
TCEP/kg/day by gavage for up to 16 weeks (NTP 1991a) or in rats receiving dietary doses of up to 
596 mg TCEP/kg/day for 3 months (Anonymous 1977).  Similarly, mice dosed daily with up to 
700 mg TCEP/kg/day for up to 16 weeks showed no alterations in the respiratory tract (NTP 1991a).  No 
respiratory alterations were reported in rats or mice dosed with up to 88 or 350 mg TCEP/kg/day, 
respectively, for 2 years (NTP 1991a).
In studies with TnBP, treatment of rats with up to 411 mg/kg/day for 14 days (Laham et al. 1984b), 
423 mg/kg/day for 90 days (FMC 1985a), 333 mg/kg/day for 18 weeks (Laham et al. 1985a), or
182 mg/kg/day for 2 years (Auletta et al. 1998a) did not result in alterations in the respiratory tract.  
Similar findings were reported in mice dosed with up to 1,776 mg/kg/day for 13 weeks (Auletta et al. 
1991) or 711 mg/kg/day for 18 months (Auletta et al. 1998b).
Rats dosed with up to 100 mg TBEP/kg/day for 14 days (Komsta et al. 1989) or 698 mg TBEP/kg/day for
18 weeks (Reyna and Thacke 1987a) showed no histological alterations in the respiratory tract.  Doses of
up to 404 mg TiBP/kg/day for 13 weeks also had no significant effect on the respiratory tract of rats 
(Naylor and Ribelin 1990).  Administration of up to 80 mg TDCP/kg/day to rats for 2 years did not
induce respiratory tract alterations (Stauffer Chemical Co. 1981a). 
Cardiovascular Effects. Evaluations of the cardiovascular system have been limited to monitoring
the weight and gross and microscopic appearance of the heart of animals.  No significant alterations in 
these parameters were reported in the studies mentioned above. 
Gastrointestinal Effects. No alterations were observed in the gastrointestinal tract of rats dosed 
daily with 350 mg TCEP/kg/day by gavage for up to 16 weeks (NTP 1991a) or in rats receiving dietary
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105PHOSPHATE ESTER FLAME RETARDANTS
3. HEALTH EFFECTS
doses of up to 596 mg TCEP/kg/day for 3 months (Anonymous 1977).  Mice dosed daily with up to 
700 mg TCEP/kg/day for up to 16 weeks showed no alterations in the gastrointestinal tract (NTP 1991a).  
No apparent alterations were reported in rats or mice dosed with up to 88 or 350 mg TCEP/kg/day, 
respectively, for 2 years (NTP 1991a).
Rats dosed with up to 143 mg TnBP/kg/day in the diet for 10 weeks showed no significant alterations in 
the stomach (Arnold et al. 1997).  Similar findings were reported in rats administered up to 423 mg
TnBP/kg/day in the diet for 90 days (FMC 1985a) or 333 mg/kg/day by gavage for 18 weeks (Laham et
al. 1985a).  No alterations in the gastrointestinal tract were reported in mice treated with dietary doses of 
up to 1,776 mg TnBP/kg/day for 13 weeks (Auletta 1991).  Longer-term studies also found a lack of 
significant alterations in the gastrointestinal tract of rats dosed with up to 182 mg TnBP/kg/day (Auletta
et al. 1998a) for 2 years or mice dosed with up to 711 mg TnBP/kg/day for 18 months (Auletta et al. 
1998b).  
TBEP administered to rats by gavage in doses of up to 100 mg/kg/day for 14 days (Komsta et al. 1989) or
in dietary doses of up to 698 mg/kg/day for 18 weeks (Reyna and Thacke 1987a) did not induce gross or
microscopic alterations in the gastrointestinal tract.  TDCP in dietary doses of up to 80 mg/kg/day for
24 months also did not induce these alterations (Stauffer Chemical Co. 1981a).  Administration of doses
of up to 404 mg TiBP/kg/day to rats in the diet for up to 13 weeks did not result in alterations in the
gastrointestinal tract (Naylor and Ribelin 1990).  
Hematological Effects. No significant alteration in hematological parameters were reported in rats 
fed diets that provided up to 586 mg TCEP/kg/day for 3 months (Anonymous 1977) or in rats treated by
gavage with up to 88 mg TCEP/kg/day for 2 years (NTP 1991a).  Similar results were reported in mice 
dosed by gavage with up to 350 mg TCEP/kg/day for 2 years (NTP 1991a).  
More information is available for TnBP.  Laham et al. (1984b) reported a significant decrease in 
hemoglobin in female rats, but not male rats, dosed with 411 mg TnBP/kg/day for 14 days.  At
137 mg/kg/day, females also showed a decrease in mean corpuscular hemoglobin (MCH) and mean 
corpuscular hemoglobin concentration (MCHC), but hemoglobin concentration was not elevated in high-
dose females.  A 90-day dietary study reported a significant increase in activated partial thromboplastin 
time in male rats dosed with 360 mg TnBP/kg/day at termination but not at the midpoint; this effect was
not present in female rats that received doses of up to 423 mg TnBP/kg/day (FMC 1985a).  The NOAEL
in males was 68.1 mg/kg/day.  Oishi et al. (1980) also reported an increase in coagulation time in rats
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3. HEALTH EFFECTS
dosed with 460 mg TnBP/kg/day (lowest dose tested) for 10 weeks.  In a 2-year study in rats dosed via 
the diet with up to 182 mg TnBP/kg/day, interim evaluations conducted at 12 months showed no
significant alterations in hematological parameters (Auletta et al. 1988a).  Similar results were reported in 
an 18-week study in rats dosed with up to 333 mg TnBP/kg/day (Laham et al. 1985a).  Evaluation of
hematological parameters in mice showed an increase in platelet counts in males dosed with 1,478 mg
TnBP/kg/day for 13 weeks (Auletta et al. 1991), but there was no evidence of hematological alterations at
9 months or at termination in mice dosed with up to 711 mg/kg/day in an 18-month study, although it
appears that evaluations were limited to red blood cell and leukocyte total counts only (Auletta et al. 
1988b). 
Data for TDCP indicate that treatment of rabbits by gavage with up to 200 mg TDCP/kg/day for 12 weeks 
did not result in significant alterations in hematological parameters (Anonymous 1977).  In the 2-year
bioassay in rats, hemoglobin, hematocrit, and total erythrocyte values were often significantly lower than 
controls in high-dose rats (80 mg/kg/day), and the differences with the control group were usually more
pronounced in males (Stauffer Chemical Co. 1981a).  Hemoglobin and hematocrit were significantly
reduced in high-dose males both at 3 and 6 months and hemoglobin was reduced in high-dose females at
6 months.  High-dose males also showed a reduction in red blood cell count at 6 months.  At 12 months, 
there were significant reductions in hemoglobin in high-dose males (10.6%) and females (7.5%) and in 
red cell counts in high-dose males (10.7%).  None of these alterations were observed after 24 months of
treatment with TDCP.  At 24 months, prothrombin times and partial thromboplastin times were
significantly elevated in high-dose males; the NOAEL was 20 mg/kg/day.
Two studies were available that provided information for TBEP.  No significant hematological alterations
were reported in rats dosed daily by gavage with up to 100 mg TBEP/kg/day for 14 days (Komsta et al. 
1989).  In an 18-week study, dietary administration of TBEP resulted in statistically significant
hematological changes that included decreased leukocyte counts (lymphocytes) in high-dose males 
(578 mg/kg/day) on week 9, increased platelet counts in high-dose males and females (698 mg/kg/day) on 
weeks 9 and 18, and increased platelet counts in mid-dose males (173 mg/kg/day) only on week 9 (Reyna
and Thacke 1987a).
Even less information is available for the remaining phosphate ester flame retardants discussed in this 
profile.  Decreased neutrophil count and increased MCH and MCHC were reported in male rats treated 
with dietary doses of 346 mg TiBP/kg/day for 13 weeks; the NOAEL was 68 mg/kg/day (Naylor and 
Ribelin 1990).  Sutton et al. (1960) reported that dietary doses of up to 416 mg TPP/kg/day for 35 days 
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107PHOSPHATE ESTER FLAME RETARDANTS
3. HEALTH EFFECTS
did not alter hematological parameters in rats (red blood cell and leukocyte counts, hemoglobin content,
and cell volume). 
Musculoskeletal Effects. No alterations in gross or microscopic morphology of bone or skeletal
muscle have been reported in any of the studies of the phosphate ester flame retardants summarized in 
this profile.  No effects were noted in rats dosed daily with 350 mg TCEP/kg/day by gavage for up to 
16 weeks (NTP 1991a) or in rats receiving dietary doses of up to 596 mg TCEP/kg/day for 3 months
(Anonymous 1977).  Similarly, mice dosed daily with up to 700 mg TCEP/kg/day for up to 16 weeks 
showed no alterations in bone or muscle (NTP 1991a).  No effects were reported in rats or mice dosed 
with up to 88 or 350 mg TCEP/kg/day, respectively, for 2 years (NTP 1991a).
Dietary administration of 423 mg TnBP/kg/day to rats for 90 days (FMC 1985a), 182 mg/kg/day to rats
for 2 years (Auletta et al. 1998a), 1,776 mg TnBP/kg/day to mice for 13 weeks (Auletta 1991), or
711 mg/kg/day to mice for 18 months (Auletta et al. 1998b) did not result in alterations in bone or muscle. 
Similar results were reported in rats treated with 80 mg TDCP/kg/day for 2 years (Stauffer Chemical Co. 
1981a), rats treated with 100 mg TBEP/kg/day for 14 days (Komsta et al. 1989), rats treated with 698 mg
TBEP/kg/day for 18 weeks (Reyna and Thacke 1987a), or rats dosed with 404 mg TiBP/kg/day for
13 weeks (Naylor and Ribelin 1990).
Hepatic Effects. Administration of 350 mg TCEP/kg/day by gavage 5 days/week for 16 days to rats 
resulted in a significant increase (10%) in absolute and relative liver weight in females; doses of 
≥175 mg/kg/day and 350 mg/kg/day produced similar effects in females and males, respectively, after
61 weeks of dosing; however, gross or microscopic examination of the liver did not show lesions (NTP
1991a).  Dietary administration of up to 586 mg TCEP/kg/day for 3 months to rats did not produce
significant changes in liver weight or in gross or microscopic appearance of the liver (Anonymous 1977). 
Mice administered up to 700 mg TCEP/kg/day for 16 days by gavage had no significant changes in liver
weight or in gross or microscopic appearance of the liver, but similar dosing with ≥175mg TCEP/kg/day 
for 16 weeks induced a significant increase in absolute and relative liver weight of females (NTP 1991a);
the NOAEL was 88 mg/kg/day.  No significant gross or microscopic alterations were reported in the liver
in the latter experiment.  In the 2-year bioassay, the liver did not appear to be a particularly sensitive 
target for TCEP.  The only significant effect reported was an increase in absolute and relative liver weight
in rats dosed with 88 mg TCEP/kg/day at week 66 interim sacrifice; the NOAEL was 44 mg/kg/day (NTP
1991a).  Clinical chemistry tests, as well as gross and microscopic examination of the liver, did not reveal
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significant chemical-related alterations.  In mice, doses of up 350 mg TCEP/kg/day had no significant
effect on liver parameters (NTP 1991a).
Treatment of male and female rats with 411 mg TnBP/kg/day by gavage for 14 days resulted in a 
significant increase in absolute and relative liver weight, and gross examination revealed slight liver
enlargement; however, microscopic evaluation of liver tissue did not show significant alterations (Laham
et al. 1984b).  The NOAEL for liver weight was 137 mg/kg/day.  In a developmental study, treatment of
pregnant rats with up to 500 mg TnBP/kg/day on gestation days (Gd) 7–17 resulted in a 6% increase in 
absolute liver weight on Gd 20; no other liver parameter was evaluated in this study (Noda et al. 1994). 
In a 90-day study in rats, consumption of a diet containing 1,000 ppm TnBP (68.1 mg/kg/day for males 
and 80.9 mg/kg/day for females) resulted in a significant increase in absolute and relative liver weight in 
males; the NOAEL was 13.8 mg/kg/day (FMC 1985a).  Increases in serum transaminases were observed 
at the midpoint in the study and at termination mainly in rats that consumed 5,000 ppm TnBP in the diet
(360 and 423 mg/kg/day in males and females, respectively); histological evaluation of the liver did not
reveal lesions.  In a similar study, dosing rats by gavage with 333 mg TnBP/kg/day for 18 weeks induced 
a significant increase in absolute and relative liver weight in females; the NOAEL was 200 mg/kg/day 
(Laham et al. 1985a).  Clinical chemistry tests as well histological examination of the liver were 
unremarkable.  In a 2-generation reproductive study in rats, dietary doses of approximately ≥51mg
TnBP/kg/day for 110 days induced a significant increase in the incidence of hepatic centrilobular
hyperplasia only in parental females (Tyl et al. 1997); the NOAEL was 15 mg/kg/day.  F1 females treated
similarly showed the lesion, but at a higher dose level of 217 mg TnBP/kg/day.  In an intermediate-
duration study in mice, dietary doses of ≥382 mg/kg/day significantly increased the incidence of
centrilobular hepatocyte hypertrophy in males (Auletta et al. 1998b).  Clinical chemistry tests showed 
significantly elevated serum alanine aminotransferase (ALT) and alkaline phosphatase (AP) activities in 
males dosed with 1,478 mg TnBP/kg/day and females dosed with 1,776 mg/kg/day.  The NOAEL for
hepatocyte hyperplasia in males was 95 mg/kg/day.
The liver was not a sensitive target in male or female rats dosed with up to 143 and 182 mg TnBP/kg/day, 
respectively, for 2 years, as judged by a lack of treatment-related gross or microscopic alterations in the
liver at termination (Auletta et al. 1998a).  In a similar 18-month study in mice, nonneoplastic effects
were limited to significant increases in absolute and relative liver weight in males and females at dietary
doses of ≥169 and ≥206 mg TnBP/kg/day, respectively (Auletta et al. 1998b).
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Less information is available for the remaining phosphate ester flame retardants subject of this profile.  
Komsta et al. (1989) conducted liver function tests, measured microsomal enzyme activities, and 
evaluated the gross and microscopic appearance of the liver of rats dosed by gavage with up to 100 mg
TBEP/kg/day for 14 days and reported no significant alterations in any of the parameters examined.  
However, in an 18-week dietary study in rats, treatment of males with ≥173 mg TBEP/kg/day resulted in 
a significant increase in periportal hepatocellular vacuolization (Reyna and Thacke 1987a).  At the next
highest dose level, 578 mg/kg/day, the incidence of periportal hepatocellular hypertrophy was also 
significantly elevated.  This was accompanied by elevations in serum gamma-glutamyl transferase (GGT)
activity on weeks 9 and 18 of the study.  No significant histopathology was reported in female rats.  The
hepatic NOAEL in males was 17.3 mg TBEP/kg/day.
In a 12-week study with TDCP in rabbits, daily gavage doses of up to 200 mg/kg/day had no significant
effect on clinical chemistry tests or on gross or microscopic morphology of the liver (Anonymous 1977).  
In the Stauffer Chemical Co. (1981a) bioassay, absolute liver weight was significantly increased in high-
dose (80 mg/kg/day) males and females (26 and 23.5%, respectively) at the 12 month interval, but there
were no significant histoplogical alterations.  In that study, extending the treatment to 24 months resulted 
in a significantly increased incidence of foci/areas of hepatocellular alterations and of dilated sinusoids in 
high-dose (80 mg/kg/day) males and females (Stauffer Chemical Co. 1981a).  Gross observations 
revealed masses, nodules, and raised areas in the liver of rats in the 80 mg/kg/day groups.  Clinical
chemistry tests showed no consistent alterations throughout the study.
In a 13-week dietary study with TiBP in rats, clinical chemistry tests at termination showed a significant 
increase in serum cholesterol in males dosed with 346 mg/kg/day.  The NOAEL was 68 mg/kg/day; no 
other clinical chemistry parameter was affected (Naylor and Ribelin 1990).  Neither gross nor
microscopic examination of the liver showed treatment-related effects.  The NOAEL in females was 
404 mg/kg/day.  In an early study in rats, Sutton et al. (1960) reported that dietary administration of up to 
approximately 416 mg TPP/kg/day for 35 days had no significant effect on the weight of the liver; no 
other hepatic parameter was evaluated in this study.  
Renal Effects. Treatment of male and female rats with 350 mg TCEP/kg/day by gavage 5 days/week
for 16 days significantly increased the absolute and relative weight of the kidneys in males, whereas 
similar treatment with ≥175 mg TCEP/kg/day for 16 weeks increased absolute and relative kidney weight
in both males and females (NTP 1991a); no kidney histopathology was reported in either case.  In a
3-month dietary study in rats, doses of up to 586 mg TCEP/kg/day did not alter kidney weight or gross or
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microscopic morphology (Anonymous 1977).  Treatment of mice with up to 700 mg TCEP/kg/day by 
gavage for 16 days did not produce alterations in the kidneys, but similar treatment with 700 mg/kg/day 
for 16 weeks significantly reduced absolute and relative kidney weight in males (NTP 1991a).  Light
microscopy showed enlargement of the nuclei of epithelial cells in the renal tubules in all males and 
females treated with 700 mg/kg/day.  These lesions were observed primarily in the proximal convoluted 
tubules of the inner cortex and outer stripe of the outer medulla, and to a lesser extent, in the outer portion 
of the loops of Henle in the outer medulla.  The NOAEL was 350 mg/kg/day.
In the 2-year bioassay in rats, the principal nonneoplastic alterations attributed to administration of TCEP
were seen in the kidneys and consisted of focal hyperplasia of the renal tubule epithelium in high-dose
(88 mg/kg/day) males and females; this occurred in the convoluted tubules of the cortex.  The lesions
were focal or multifocal and were characterized by stratification of the epithelial cells with partial to 
complete obliteration of the tubule lumens.  The NOAEL was 44 mg/kg/day.  In mice, the principal 
nonneoplastic effect associated with administration of TCEP also occurred in the kidneys.  The incidence 
of karyomegaly (nuclear enlargement) of the cells in the proximal convoluted tubules of the inner cortex 
and outer stripe of the outer medulla was significantly increased in mid- (175 mg/kg/day) and high-dose
(350 mg/kg/day) males and females (NTP 1991a).
Daily gavage doses of up to 411 mg TnBP did not induce significant alteration in the weight or
morphology of the kidneys (Laham et al. 1984b).  Similar findings were reported in studies in rats dosed 
with up to 143 mg TnBP/kg/day for 10 weeks (Arnold et al. 1997), 423 mg/kg/day for 90 days (FMC
1985a), or 333 mg/kg/day for 18 weeks (Laham et al. 1985a).  Dose related increases in blood urea 
nitrogen (BUN) were reported in rats dosed via the diet with ≥460mg TnBP/kg/day for 9–10 weeks 
(Oishi et al. 1980, 1982), but histopathologic evaluations apparently were not conducted.  Increased 
incidence of renal pelvic epithelial hyperplasia was reported in F1 males treated with 217 mg
TnBP/kg/day in a 2-generation reproductive study (Tyl et al. 1997); the NOAEL was 51 mg/kg/day.  No 
significant kidney alterations were reported in mice dosed with up to 1,776 mg TnBP/kg/day for 13 weeks 
(Auletta et al. 1991), in mice dosed with up to 711 mg/kg/day for 18 months (Auletta et al. 1998b), or in 
rats dosed with up to 182 mg/kg/day for 2 years (Auletta et al. 1998a).
Dosing of male rabbits by gavage with 200 mg TDCP/kg/day for 12 weeks induced a significant increase
in absolute kidney weight, but did not induce gross or microscopic alterations in the kidneys (Anonymous
1977).  In a 2-year bioassay in rats (0, 5, 20, or 80 mg/kg/day), the kidneys appeared to be the target for
TDCP (Stauffer Chemical Co. 1981a).  At the 12-month interval males and females exhibited dose-related
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increases in absolute kidney weight which achieved statistical significance in the high-dose groups;
effects were more pronounced in males than in females.  Relative to controls, absolute kidney weight
increased 12, 17, and 48% in the low-, mid-, and high-dose males, respectively.  However, no significant
histological alterations were seen at this time point.  Necropsy at 24 months revealed enlargement of the
kidney in mid- and high-dose males and high-dose females, plus higher incidence of discolorations,
surface irregularities, masses, nodules, and cysts in treated rats than in controls.  Light microscopy
revealed a significant increase in the incidence of hyperplasia of the convoluted tubular epithelium in 
males dosed with ≥20 mg TDCP/kg/day.  High-dose females also exhibited this lesion and both high-dose
males and females showed increased incidence of chronic nephropathy.  BUN was significantly elevated 
in some mid- and high-dose rats at 18 and 24 months, which was consistent with the microscopic
evidence of renal pathology.
Dosing of rats with up to 100 mg TBEP/kg/day for 14 days (Komsta et al. 1989) or 698 mg/kg/day for
18 weeks (Reyna and Thacke 1987a) did not induce renal alterations, and neither did administration of up
to 404 mg TiBP/kg/day for 13 weeks (Naylor and Ribelin 1990).  Sutton et al. (1960) reported that a
35-day dietary regime of up to 416 mg TPP/kg/day did not significantly alter the weight of the kidney in 
rats, but histological examinations were not conducted.
Endocrine Effects. Endocrine parameters evaluated in the toxicity studies available generally
consisted of the weight and gross and microscopic morphology of endocrine glands (i.e., thyroid, 
pituitary, adrenals).  For the most part, no significant alterations were reported following oral exposure to 
the phosphate ester flame retardants discussed in this profile.  No effects were noted in rats dosed daily 
with 350 mg TCEP/kg/day by gavage for up to 16 weeks (NTP 1991a) or in rats receiving dietary doses 
of up to 596 mg TCEP/kg/day for 3 months (Anonymous 1977).  Similarly, mice dosed daily with up to 
700 mg TCEP/kg/day for up to 16 weeks showed no alterations in the endocrine glands (NTP 1991a).  No 
alterations in endocrine glands were reported in rats or mice dosed with up to 88 or 350 mg TCEP/kg/day, 
respectively, for 2 years (NTP 1991a).
No significant alteration in endocrine glands were noted in rats dosed with up to 423 mg TnBP/kg/day for
90 days (FMC 1985a) or 182 mg/kg/day for 2 years (Auletta et al. 1998a), or in mice dosed with up to 
1,776 mg/kg/day for 13 weeks (Auletta et al. 1991) or 711 mg/kg/day for 18 months (Auletta et al. 
1998b).  Dosing of rabbits with up to 200 mg TDCP/kg/day for 12 weeks did not produce alterations in 
the pituitary gland (Anonymous 1977).  Significant increases in absolute thyroid weight were reported in 
rats dosed with up to 80 mg TDCP/kg/day for 12 or 24 months, but there were no significant histological 
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alterations (Stauffer Chemical Co. 1981a).  Rats dosed with 100 mg TBEP/kg/day for 14 days (Komsta et
al. 1989) or rats dosed with 698 mg TBEP/kg/day for 18 weeks also showed no histological alterations in 
the thyroid gland (Reyna and Thacke 1987a).  A single study with TiBP reported no significant endocrine
gland alterations in rats dosed with up to 404 mg/kg/day for 13 weeks (Naylor and Ribelin 1990). 
Dermal Effects. Many of the oral toxicity studies described above conducted gross and microscopic 
examinations of the skin and none reported chemical-related alterations.
Ocular Effects. The eyes were examined in many toxicity studies with the phosphate ester flame 
retardants discussed in this profile and, with one exception, no significant alterations were reported.  In 
the 24-month dietary study in rats dosed with 0, 20, or 80 mg TDCP/kg/day conducted by Stauffer
Chemical Co. (1981a), ophthalmological examinations performed at 18 and 24 months revealed 
sacculations along the course of the retinal arterioles in one mid-dose male, four high-dose males, and 
four high-dose females, primarily at 24 months.  Stauffer Chemical Co. (1981a) stated that this type of
lesion is observed occasionally in old untreated rats and that, in this study, there appeared to have been an 
acceleration of this abnormal arteriolar process in some treated animals.
Body Weight Effects. Body weight was monitored in virtually all of the toxicity studies already
described.  Food consumption was not always reported, but when information was provided, it was
usually in absolute terms (i.e., g/day); few studies also provided relative intake (i.e., g/kg body
weight/day.  It should also be noted that differences in food consumption, and consequently in body
weight gain, between gavage and dietary studies may be due, in part, to poor palatability of the feed.  
Body weight was not significantly affected in intermediate- and chronic duration gavage studies in rats 
and mice conducted by NTP (1991a). In the intermediate-duration studies, rats and mice received doses 
of up to 350 and 700 mg TCEP/kg/day for 16 weeks; the corresponding doses in the 2-year study were 
88 and 350 mg TCEP/kg/day.  However, in a 3-month dietary study, male and female rats dosed with 
506 and 586 mg TCEP/kg/day, respectively, had a final body weight 11–18% lower than controls
(Anonymous 1977).  The lower body weight was associated with a significant reduction in food 
consumption by the end of the study.  In a gestational exposure study, Hardin et al. (1987) reported that
pregnant rats dosed with 940 mg TCEP/kg/day on Gd 6–13 experienced a 12% reduction in body weight
gain between Gd 6 and postnatal day 3 relative to controls; food consumption data were not available.
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Administration of up to 411 mg TnBP/kg/day by gavage for 14 days to rats had no significant effect on 
body weight (Laham et al. 1984b), but administration of 125 mg/kg/day to pregnant rats on Gd 7–17
reduced adjusted body weight gain on Gd 0–20 by 13% relative to controls and 200 mg TnBP/kg/day 
reduced the same parameter by 37% (Noda et al. 1994).  Food consumption was also significantly
reduced.  Final body weight was reduced between 10 and 20% relative to controls in rats dosed with 
143 mg TnBP/kg/day in the diet for 10 weeks (Arnold et al. 1997), 217 mg/TnBP/kg/day in the diet for
70-110 days (Tyl et al. 1997), 360–423 mg TnBP/kg/day in the diet for 3 months (FMC 1985a), 460 mg 
TnBP/kg/day in the diet for 9 weeks (Oishi et al. 1980), 325 mg TnBP/kg/day by gavage for 13 weeks 
(Healy et al. 1995), 333 mg TnBP/kg/day by gavage for 18 weeks (Laham et al. 1985a), or 42 mg
TnBP/kg/day in the diet for 2 years (Auletta et al. 1998a); some reduction in food consumption was
reported in all of these studies except in Laham et al. (1985a), who did not provide information in that
regard.  Mice dosed via the diet with up to 1,776 mg TnBP/kg/day for 13 weeks (Auletta et al. 1991) or
711 mg TnBP/kg/day for 18 months (Auletta et al. 1998b) did not experience significant alterations in
body weight compared to controls.
Weight gain was significantly reduced (29%) on Gd 6–11 in pregnant rats dosed with 100 mg
TDCP/kg/day; and on Gd 6–15, rats dosed with 400 mg/kg/day lost weight (Stauffer Chemical Co. 
1981b).  Food consumption during treatment days was significantly reduced relative to controls.  Body
weight gain was not affected in rabbits dosed by gavage with up to 200 mg TDCP/kg/day for 12 weeks 
(Anonymous 1977).  In the 2-year bioassay, final body weight of male and female rats was reduced 21– 
24% relative to controls (Stauffer Chemical Co. 1981a).  There was no consistent pattern of differences 
among groups over time regarding food consumption. 
Studies with TBEP showed no significant alterations in body weight in rats treated with gavage doses of
up to 100 mg/kg/day for 14 days (Komsta et al. 1989) or up to 698 mg/kg/day in the food for 18 weeks 
(Reyna and Thake 1987a).  TiBP also did not alter weight gain in rats in dietary doses of up to 
404 mg/kg/day for 13 weeks (Naylor and Ribelin 1990).  TPP administered to rats in doses of up to 
416 mg/kg/day in the food for 35 days had no significant effect on weight gain (Sutton et al. 1960), but
345 mg TPP/kg/day, also administered in the food, reduced weight gain by 11% (Sobotka et al. 1986);
food consumption was not significantly altered in the latter study.  TCPP administered to rats in gavage
doses of up to 1,000 mg/kg/day for 7 days did not significantly affect weight gain (Kawasaki et al. 1982).  
Metabolic Effects. Alterations in metabolic effects, principally in mean levels of serum electrolytes, 
have been reported in studies with some phosphate ester flame retardants subject of this profile.  The 
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toxicological significance of these effects is unknown.  No significant alterations in serum electrolytes or
glucose were reported in rats dosed with up to 586 mg TCEP/kg/day for 3 months (Anonymous 1977).  
Female rats dosed with ≥137 mg TnBP/kg/day for 14 days showed a dose-related increase in serum
potassium levels, whereas no such effect was seen in males (Laham et al. 1984b); neither glucose nor
other serum electrolytes were affected.  In a 90-day study, male rats treated with 360 mg TnBP/kg/day 
had a significant increase in serum calcium levels at termination (FMC 1985a), but treatment of rats with
up to 333 mg TnBP/kg/day for 18 weeks did not affect serum electrolytes, including calcium (Laham et
al. 1985a).  Neither sodium nor potassium levels were altered in rats dosed with 460 mg TnBP for
9 weeks (Oishi et al. 1982).  Dosing of male and female mice with 1,478 and 1,776 mg TnBP/kg/day, 
respectively, for 13 weeks induced a significant increase in serum calcium at termination; the respective 
NOAELs were 382 and 461 mg/kg/day (Auletta et al. 1991).  No significant alterations in serum
electrolytes were reported in rats dosed with up to 100 mg TBEP/kg/day for 14 days (Komsta et al. 1989), 
698 mg TBEP/kg/day for 18 weeks (Reyna and Thacke 19897a), or 404 mg TiBP/kg/day for 13 weeks 
(Naylor and Ribelin 1990).
Other Systemic Effects. The urinary bladder of rats appears to be a sensitive target for TnBP.  
Treatment of male rats with TnBP in the diet for 10 weeks produced urothelial hyperplasia (Arnold et al. 
1997).  The incidence of simple hyperplasia was significantly increased at ≥33mg TnBP/kg day, whereas 
the incidence of papillary and nodular hyperplasia was significantly increased at 143 mg/kg/day.  
Simultaneous administration of ammonium chloride (to acidify the urine and thus prevent the formation 
of magnesium ammonium phosphate crystals) did not prevent the proliferative changes in the bladder
epithelium, but the hyperplastic effects were milder.  Removing the rats from the experimental diet for
10 weeks after treatment led to healing, but the ulcer repair process was accompanied by submucosal
fibrosis.  The NOAEL was 9 mg TnBP/kg/day.  FMC (1985a) also reported increased incidence of
minimal to moderate hyperplasia of the transitional cell epithelium and males appeared more sensitive 
than females.  The incidence of urinary bladder hyperplasia was significantly increased in males dosed 
with ≥68.1 mg TnBP/kg/day, and the NOAEL was 13.8 mg/kg/day; increased incidence in females 
occurred at 423 mg/kg/day.  Laham et al. (1985a) also reported this lesion in an 18-week gavage study.  
All treated rats (6/6 compared with 0/6 in controls) showed diffuse hyperplasia of the bladder epithelium;
severity appeared greater in males.  The epithelium of treated rats showed a greater frequency of 
prominent nucleoli compared to controls and was thicker than in controls, particularly in males.  The
lowest dose of TnBP in this study was 200 mg/kg/day. Tyl et al. (1997) also reported bladder epithelial in 
male and female rats dosed with ≥51 mg TnBP/kg/day for 70–110 days via the diet; the NOAEL was 
15 mg/kg/day.  In the 2-year study, a significant increase in urinary bladder hyperplasia was seen in males 
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dosed with ≥33 mg TnBP/kg/day; the NOAEL was 9 mg/kg/day.  Rats with benign tumors also had 
hyperplasia present; however, rats with malignant bladder tumors usually did not have any remaining
uninvolved epithelium to evaluate for the presence or absence of hyperplasia.  This led Auletta et al. 
(1991a) to speculate that the bladder hyperplasia and papillomas could represent a progression of a
hyperplastic lesion to neoplasia.  Urinary bladder lesions were not seen in mice or in rats exposed to other
phosphate ester flame retardants subject of this profile.
3.2.2.3 Immunological and Lymphoreticular Effects 
The information available does not suggest that the immunological system of rodents is especially
sensitive to the effects of orally administered phosphate ester flame retardants discussed in this profile,
although it should be mentioned that, for the most part, the testing has been limited to measurements of
the weight of the thymus and spleen and gross and microscopic examinations of these organs and lymph 
nodes.
In studies with TCEP that evaluated the parameters mentioned above, no significant effects were noted in 
rats dosed daily with 350 mg TCEP/kg/day by gavage for up to 16 weeks (NTP 1991a) or in rats
receiving dietary doses of up to 596 mg TCEP/kg/day for 3 months (Anonymous 1977).  Similarly, mice
dosed daily with up to 700 mg TCEP/kg/day for up to 16 weeks showed no alterations in lymphoreticular
tissues (NTP 1991a).  Similar findings were reported in rats or mice dosed with up to 88 or 350 mg
TCEP/kg/day, respectively, for 2 years (NTP 1991a).
TnBP administered by gavage to rats in doses of 411 mg/kg/day for 14 days produced a significant
decrease in absolute and relative spleen weight, but microscopic morphology was unremarkable (Laham
et al. 1984b).  Rats dosed with 423 mg/kg/day for 90 days (FMC 1985a), 333 mg/kg/day for 18 weeks 
(Laham et al. 1985a), or 182 mg/kg/day for 2 years (Auletta et al. 1998a) showed no significant
alterations in lymphoid tissues.  Similar findings were reported in mice dosed with up to 1,776 mg/kg/day 
for 13 weeks (Auletta et al. 1991) or 711 mg/kg/day for 18 months (Auletta et al. 1998b).
The same results were reported for TBEP given to rats by gavage in doses of up to 100 mg/kg/day for
14 days (Komsta et al. 1989) or in the diet in doses of up to 698 mg/kg/day for 18 weeks (Reyna and 
Thake 1987a).  No significant alterations were observed in lymphoreticular organs of rats dosed via the
diet with up to 404 mg TiBP/kg/day for 13 weeks (Naylor and Ribelin 1990) or up to 80 mg
TDCP/kg/day for 12 or 24 months (Stauffer Chemical Co. 1981a).
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Parameters of immunocompetence were evaluated in rats treated with dietary doses of up to 711 mg
TPP/kg/day for 120 days (Hinton et al. 1996).  Beginning on day 60, groups of rats were immunized with 
sheep red blood cells (SRBC).  Secondary and tertiary immunizations were performed at successive 
21-day intervals.  Serum was analyzed for total and relative amount of proteins. At termination, the
weights of the spleen and thymus were measured. Treatment with TPP did not significantly affect the
weight or the microscopic appearance of the thymus or spleen.  Separate evaluations of B- and 
T-lymphocyte regions in lymphoid organs showed no significant effects on distribution and proliferation.  
Total serum protein determination showed no significant effects of TPP, although there was a positive
trend with increasing dose.  At 6 months, all treated male groups had significantly increased β-globulins
and females had increased α-globulins, but no significant differences were seen at termination.  
Assessment of the humoral response to the T-lymphocyte-dependent antigen SRBC did not indicate
alterations in immunocompetence due to treatment with TPP. 
The highest NOAEL values and all LOAEL values from each reliable study for immunological and 
lymphoreticular effects in each species and duration category are recorded in Tables 3-2, 3-3, 3-4, 3-5, 
and 3-6 and plotted in Figures 3-2, 3-3, 3-4, 3-5, and 3-6.
3.2.2.4 Neurological Effects 
Acute-, intermediate-, and chronic-duration exposure of rats to TCEP has produced adverse neurological
effects including morphological and behavioral effects.  Tilson et al. (1990) administered a single dose of
275 mg TCEP/kg by gavage to female rats and reported that the animals suffered seizures within 60– 
90 minutes of dosing, characterized by facial twitching, myoclonic motions of the jaw, forelimb clonus,
and whole body jerks.  Necropsy conducted 7 days after dosing showed severe damage to the CA1 and 
CA3 regions of the hippocampus.  TCEP also produced some necrosis in the lateral and medial thalamic
nuclei.  In a separate experiment, treated rats were trained on a spatial memory task in a water maze 
3 weeks after dosing and were killed 2 days after training for histological evaluation.  The results showed 
that the treated rats were mildly impaired in the acquisition of a reference memory task in the water maze, 
and were consistently impaired in performing a repeated acquisition task in the water maze.  In a 16-day 
study in mice dosed daily by gavage, mice given 350 or 700 mg TCEP/kg/day exhibited ataxia and 
convulsions during the first 3 days of dosing; the NOAEL was 175 mg/kg/day (NTP 1991a).  Neither
gross nor microscopic examination of the brain at termination showed significant alterations, but it was
not specifically indicated whether the hippocampus was examined.
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In a 16-week study, administration of ≥175 mg TCEP/kg/day, 5 days/week to male and female rats
induced ataxia, convulsions, excessive salivation, and gasping in some females and reduced serum
cholinesterase activity by 25–41% (NTP 1991a).  Examination of the hippocampus at termination 
revealed necrosis in 10/10 females and 2/10 males dosed with 350 mg/kg/day (the highest dose tested)
and in 8/10 females dosed with 175 mg/kg/day; the NOAEL for these effects was 88 mg/kg/day.  None of
these effects were observed in rats dosed by gavage with the same doses for 16 days (NTP 1991a).  
Dietary doses of up to 586 mg TCEP/kg/day for 3 months did not induce alterations in the brain and did 
not affect the activity of red blood cell cholinesterase (Anonymous 1977).
In the 2-year NTP (1991a) study (0, 44, or 88 mg/kg/day by gavage 5 days/week), there were no clinical
signs in rats attributable to administration of TCEP, but treatment with TCEP resulted in degenerative
lesions in the brain, mainly in high-dose females.  The degenerative lesions were located in the cerebral
cortex and brain stem, involved both the gray and white matter and were focally distributed.  Specifically, 
the lesions were in the thalamus, hypothalamus, basal ganglia, and frontal and parietal cortex. Other
affected structures included the cingulate cortex, olfactory cortex, superior colliculus, hippocampus, 
geniculate body, globus pallidus, ventral pallidum, and amygdaloid nuclear region.  The lesions varied in 
severity from minimal to marked and often involved extensive areas.  Active lesions were characterized 
by degeneration and necrosis with hemorrhage, while resolving lesions exhibited loss of neurons and 
neuropil, proliferation of glial cells, capillary hyperplasia, hypertrophy of the tunica media of small
vessels, and hemosiderin-laden macrophages.  Mice treated similarly with up to 350 mg TCEP/kg/day did 
not exhibit brain lesions.
Studies with TnBP showed that a single gavage dose of 1,000 mg/kg/day induced a significant reduction 
in motor activity in rats 11 hours postdosing, but that was comparable to controls on days 7 and 
14 postdosing (Healy et al. 1995); the NOAEL was 325 mg/kg/day.  A FOB performed at various time 
points during the 14-day study occasionally revealed differences between high-dose rats and controls
(data not shown), which the investigators attributed to nonspecific toxicity rather than to neurotoxicity.  In 
another acute-duration study, Laham et al. (1983) reported decreased caudal nerve conduction velocity in 
rats dosed with 411 mg TnBP/kg/day 2 days after a 14-day daily dosing.  Two weeks after the last dose, 
light and electron microscopy of the nerve showed retraction of Schwann cell processes surrounding
unmyelinated fibers. The NOAEL was 274 mg/kg/day.  This dosing protocol did not alter brain weight or
the gross or microscopic appearance of the brain, and red blood cell acetylcholinesterase activity was not
significantly reduced (Laham et al. 1984b).  There were no signs of toxicity in any of the 14-day studies.
***DRAFT FOR PUBLIC COMMENT***
    
 
    
 
 
 
 
 
 
  
 
   
 
 
   
  
 
  
   
        
    
 
  
  
 
    
     
   
    
   
  
    
 
     
    
   
 
 
  
    
118PHOSPHATE ESTER FLAME RETARDANTS
3. HEALTH EFFECTS
Dosing male and female rats with up to 360 and 423 mg TnBP/kg/day, respectively, for 90 days had no 
significant effect on the gross or microscopic morphology of the brain, spinal cord, or sciatic nerve, or on 
red blood cell or brain cholinesterase activities measured on day 45 and at termination (FMC 1985a).  In 
another 90-day study in rats treated daily by gavage with TnBP, Healy et al. (1995) reported that
postdosing salivation occurred rarely at 32.5 mg/kg/day, frequently at 100 mg/kg/day, and almost all the
time at 325 mg/kg/day.  An FOB conducted at various times during the dosing period showed no 
significant alterations, and light microscopy of unspecified tissues of the nervous system was 
unremarkable.  In yet another intermediate-duration study, gavage doses of up to 333 mg TnBP/kg/day 
for 18 weeks reduced red blood cell cholinesterase only by 9% in females and had no significant effect on 
brain weight or morphology (Laham et al. 1985a).  Dietary treatment of rats with up to 182 mg
TnBP/kg/day for 2 years (Auletta et al. 1998b) or mice with up to 711 mg/kg/day for 18 months did not
induce clinical signs or produce histopathology in the brain, spinal cord, or sciatic nerve.
Less information is available for other phosphate ester flame retardants.  Female rats administered a
single gavage dose of ≥3,200 mg TBEP/kg showed abnormal gait, piloerection, and tremors during the
first week after dosing; these signs were also seen in some females dosed with 1,750 mg/kg (Laham et al. 
1985b).  Males exhibited similar signs at ≥8,000 mg/kg.  Exposure of rats to up to 100 mg TBEP/kg/day 
by gavage for 14 days did not produce alterations in the weight or histology of the brain (Komsta et al. 
1989).  In the only long-term studies available with TBEP, 18-week dosing of male and female rats with 
up to 578 and 698 mg TBEP/kg/day, respectively, did not produce adverse clinical signs or induce gross 
or microscopic alterations in the brain or sciatic nerve (Reyna and Thacke 1987a), but induced a reduction 
in nerve conduction velocity in females (Reyna and Thake 1987b).  Red blood cell cholinesterase activity
was significantly reduced in all treated groups of females at week 9, but not at week 18; the magnitude of 
the reduction was not provided (Reyna and Thacke 1987a).  
The only information available for TDCP is that from a 24-month bioassay in which rats received dietary
doses of 0, 20, or 80 mg TDCP/kg/day (Stauffer Chemical Co. 1981a).  TDCP did not induce clinical
signs or morphological alterations in the brain or spinal cord. Changes in red blood cell cholinesterase 
measured throughout the study were inconsistent.
Administration of dietary doses of up to 346 and 404 mg TiBP/kg/day to male and female rats, 
respectively, for 13 weeks did not induce clinical signs or produce morphological alterations in the brain, 
spinal cord, or sciatic nerve (Naylor and Ribelin 1990).  A 4-month study with TPP in rats receiving up to 
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711 mg TPP/kg/day via the diet reported no treatment-related effects in a battery of behavioral tests 
administered at various intervals, which included assessment of motility, balance, coordination, and
muscular strength (Sobotka et al. 1986).
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Tables 3-2, 3-3, 3-4, 3-5, and 3-6 and plotted in 
Figures 3-2, 3-3, 3-4, 3-5, and 3-6.
3.2.2.5 Reproductive Effects
No significant alterations were noted in the weight or gross or microscopic appearance of the reproductive 
organs of male or female rats dosed daily with 350 mg TCEP/kg/day by gavage for up to 16 weeks (NTP
1991a) or of rats receiving dietary doses of up to 596 mg TCEP/kg/day for 3 months (Anonymous 1977).  
Similarly, mice dosed daily with up to 700 mg TCEP/kg/day for up to 16 weeks showed no alterations in 
the reproductive organs (NTP 1991a).  No alterations were reported in the reproductive organs of rats or
mice dosed by gavage with up to 88 or 350 mg TCEP/kg/day, respectively, for 2 years (NTP 1991a).
The effects of TCEP on fertility of CD-1 mice were examined in a continuous breeding protocol study
(NTP 1991b).  Pairs of mice were administered TCEP in doses of 0, 175, 350, or 700 mg/kg/day by
gavage in corn oil for 1 week during cohabitation, 14 weeks postmating, and 3 additional weeks.  End
points evaluated included clinical signs, body weight, fertility, litters per pair, live pups per litter, 
proportion of pups born alive, sex ratio, and neonatal pup weight.  The last F1 litter was reared by the dam
until weaning, after which time the F1 rats were treated as were the F0 generation.  The F1 rats were used 
to assess second generation fertility.  Dosing with TCEP significantly reduced the number of litters
produced by mid- and high-dose F0 mice.  Only 2/18 pairs delivered a third litter in the high-dose group 
versus 37/38 in the controls.  The number of pairs that delivered a fifth litter in the mid-dose group was
also significantly reduced.  Cumulative days to litter were also significantly increased in the high-dose
group starting with the second litter.  Cross-mating experiments conducted with controls and high-dose
mice to determine the affected sex showed that both sexes were adversely affected, but the males were 
relatively more sensitive, as all sperm end points examined (concentration, motility, and percent
abnormal) were affected.  Mating of the F1 generation showed no significant effect on pregnancy or
fertility indices.
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Daily administration of 411 mg TnBP/kg/day by gavage for 14 days to male and female rats induced
degenerative changes in about 50% of the seminiferous tubules in one out of four males examined 
(Laham et al. 1984b).  The tubules showed varying degrees of aspermatogenesis; spermatocytes and 
spermatids were the cells most frequently affected. The NOAEL was 137 mg/kg/day.  No significant 
alterations were reported in the ovaries.  No significant gross or microscopic alterations were reported in 
the reproductive organs of male and female rats that received dietary doses of up to 423 mg TnBP/kg/day 
for 90 days (FMC 1985a) or 333 mg/kg/day by daily gavage for 18 weeks (Laham et al. 1985a), or in 
mice dosed with up to 1,776 mg/kg/day in the diet for 90 days (Auletta et al. 1991).  In a 2-generation 
reproductive toxicity study in rats dosed with up to 217 mg TnBP/kg/day, there were no significant
reproductive effects in either the F0 or F1 generations, including mating and fertility, and no effects on 
gross and microscopic appearance of the reproductive organs (Tyl et al. 1997).  In rats dosed for 2 years 
with up to 182 mg TnBP/kg/day (Auletta et al. 1998a) or mice dosed with up to 711 mg TnBP/kg/day for
18 months (Auletta et al. 1998b), examination of the reproductive organs showed no significant gross or
microscopic alterations.
Daily administration of up to 100 mg TBEP/kg/day to rats by gavage for 14 days did not significantly 
affect the weight or gross or microscopic morphology of the testes or ovaries (Komsta et al. 1989).  
Similar findings were reported in rats that consumed doses of up to 698 mg TBEP/kg/day via the diet for
18 weeks (Reyna and Thacke 1987a).  
TDCP was tested for its effects on fertility in male rabbits (Anonymous 1977) by dosing the rabbits by
gavage with up to 200 mg TDCP/kg/day for 12 weeks.  During the last week of treatment, male fertility
was tested by mating the males with untreated females.  Fertility was assessed by sacrificing the females 
at mid-gestation and evaluating their uteri.  After the mating period, the males were sacrificed and sperm
from the cauda epididymides were analyzed for motility, morphology, and concentration.  The results
showed no alterations in mating behavior, fertility, or sperm quantity and quality.  Neither gross necropsy
nor microscopic examinations revealed significant alterations in the reproductive tract.  In the 2-year
bioassay with TDCP, dietary doses of up to 80 mg TDCP/kg/day had no significant effect on the gross or
microscopic morphology of the reproductive organs of males or females (Stauffer Chemical Co. 1981a).
Fertility indices (number pregnant, corpora lutea, implantations, implantation efficiency, resorptions)
were not affected in male or female rats dosed with up to 690 mg TPP/kg/day through the diet for 91 days 
before mating (Welsh et al. 1987).  Feeding rats a diet that provided up to 404 mg TiBP/kg/day for
13 weeks also did not affect the gross or microscopic anatomy of the reproductive organs.  Dietary
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administration of up to 893 mg TCPP/kg/day to rats on Gd 0–20 had no significant effect on the number
of implantations or resorptions (Kawasaki et al. 1982).
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Tables 3-2, 3-3, 3-4, 3-5, and 3-6 and plotted in 
Figures 3-2, 3-3, 3-4, 3-5, and 3-6.
3.2.2.6 Developmental Effects 
The developmental effects of TCEP have been studied in rats and mice.  In rats, administration of up to 
200 mg TCEP/kg/day by gavage in oil on Gd 7–15 did not significantly affect the number of live fetuses, 
sex ratio, or fetal weight measured on Gd 20 (Kawashima et al. 1983a).  In addition, treatment with TCEP
had no significant effect on the incidence of skeletal malformations or on postnatal viability monitored up 
to postnatal week 10.  Behavioral and motor tests conducted on the offspring, including open field 
activity, performance in a water maze, balance, pain reflexes, and hearing reflexes, did not reveal
significant differences between treated and control rats.  Hardin et al. (1987) conducted a preliminary
assay of developmental toxicity of TCEP in mice dosed by gavage with 940 mg TCEP/kg/day (only dose
level tested) on Gd 6–13.  At delivery, the number of live pups was recorded and live pups were weighed 
as a litter.  Neither live pups nor dead pups were systematically examined for malformations.  Dosing
with TCEP had no significant effects on the number of viable litters, number of live pups born per litter, 
percent survival of pups, birth weight, or pup weight gain.  In the continuous breeding protocol study
conducted by NTP (1991b), treatment of the F0 generation with ≥350 mg TCEP/kg/day significantly
reduced the number of live pups per litter.  In addition, the number of F2 male pups per litter born to the
treated F1 generation was significantly lower than in controls in the groups dosed with ≥175mg
TCEP/kg/day, the lowest dose level tested; a developmental NOAEL was not identified in the study.
Studies conducted by Noda et al. (1994) with TnBP showed lack of developmental toxicity for this
chemical even in the presence of frank maternal toxicity.  Treatment of pregnant female rats by gavage on 
Gd 7–17 with up to 500 mg/kg/day resulted in piloerection, wetting of abdominal hair with urine, and 
salivation during the treatment, but these effects disappeared after the last treatment.  Adjusted body
weight gain from Gd 0–20 was reduced 13% at 125 mg/kg/day, 39% at 250 mg/kg/day, and 63% at
500 mg/kg/day.  Gravid uterus weight was not affected.  All pregnant rats had living fetuses on Gd 20.  
There was no significant difference between groups in the number of corpora lutea, implants or living
fetuses, incidence of dead or resorbed fetuses, sex ratio, or body weight of the living fetuses.  There was 
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only one malformation that occurred in the 125 mg/kg/day group in which there were conjoined twins.  
No increases in visceral anomalies were reported.  In a 2-generation reproduction study, the only
significant developmental effect attributed to treatment with TnBP was a reduction in F1 and F2 pup 
weight per litter measured 5 times from postnatal days 0–21 at maternal doses of approximately
217 mg/kg/day; the number of pups per litter was comparable among groups (Tyl et al. 1997).  Significant
reductions in maternal body weight also occurred at this level, which may have contributed to the
decrease in pup weight.
Monsanto (1985b) conducted a gestational exposure study with TBEP.  Pregnant rats were treated with up 
to 1,500 mg TBEP/kg/day by gavage on Gd 6–15 and sacrifices were conducted on Gd 20.  Immediately
after sacrifice, the uterus and ovaries were exposed and the number and location of viable and nonviable
fetuses, early and late resorptions, and number of total implantations and corpora lutea were recorded.  
Fetuses were weighed, sexed, and examined for external malformations and variations.  Fetuses were then 
prepared for visceral and skeletal examinations.  No significant alterations were reported in any of the
developmental parameters evaluated.  Some dams in the 1,500 mg/kg/day group occasionally exhibited 
signs of toxicity after dosing such as ataxia and lethargy, and gained significantly less weight than control
rats. 
A study with TDCP evaluated litter data, and fetal development (visceral abnormalities and skeletal
anomalies) following exposure of pregnant rats to up to 0, 25, 100, or 400 mg TDCP/kg/day on Gd 6–15
(Stauffer Chemical Co. 1978f); sacrifices were conducted on Gd 19. There was no effect on number of
corpora lutea or implantations.  A statistically higher incidence of resorptions was found in rats dosed 
with 400 mg/kg/day, but the number per litter was not statistically increased.  Fetal viability was
significantly decreased in high-dose rats (86.6 vs. 93.3% in controls).  Mean fetal weight and length were
lower in high-dose rats, but the difference with controls was <10%.  Decreased skeletal development
(incomplete ossification of various bones) was noted in high-dose fetuses.  Maternal final body weight of
the high-dose group was significantly lower (16%) than in controls.  During Gd 6–11, body weight gain 
of the mid-dose group was significantly lower (30%) than controls, and high-dose rats lost weight.  A
developmental NOAEL of 100 mg/kg/day was defined in this study; the maternal NOAEL was 
25 mg/kg/day.
Information regarding developmental effects of TPP is available in a study by Welsh et al. (1987).  Male
and female rats were fed a diet containing TPP for 91 days before mating and the females continued in the
experimental diets during gestation and lactation.  Cesarean sections were performed on Gd 20.  The
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investigators estimated that during Gd 0–20, the females consumed up to 690 mg TPP/kg/day.  Treatment
with TPP had no significant effect on fetal parameters (viability, early or late deaths, fetal weight, length 
or distribution) or skeletal anomalies.  Although the incidence of some specific soft-tissue variations
seemed higher in treated rats than in controls, Welsh et al. (1987) stated that because the baseline
incidence in controls was also high and there was no clear dose-response, the significance of the finding
was unclear.  Dietary administration of up to 893 mg TCPP/kg/day to rats on Gd 0–20 had no significant
effects on fetal weight or incidences of external malformations (Kawasaki et al. 1982).  Cervical ribs, 
missing ribs, and delayed ossification of sternebrae were more frequent in the treated groups but the
difference with controls was not significant.  Neonatal growth and viability during the 4 weeks after
weaning was comparable among groups.
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in
each species and duration category are recorded in Tables 3-2, 3-3, 3-4, 3-5, and 3-6 and plotted in 
Figures 3-2, 3-3, 3-4, 3-5, and 3-6.
3.2.2.7 Cancer
Information regarding the carcinogenic potential of TCEP, TnBP, and TDCP was available in the
literature reviewed. 
NTP (1991a) conducted 2-year bioassays in Fischer-344/N rats and B6C3F1 mice.  Rats were dosed by
gavage once per day, 5 days/week for 104 weeks with 0, 44, or 88 mg TCEP/kg/day.  Survival was
reduced in high-dose males and females.  Females that died early frequently had brain lesions, while 
males did not.  Interim sacrifices (10/sex/group) on week 66 revealed an adenoma of the renal tubule in 
one high-dose male; no other neoplastic lesions were reported at this time point.  Treatment with TCEP
resulted in the following significant increased incidences of neoplastic lesions (overall rates):  (1) renal
tubule adenomas (1/50, 5/50, 24/50) renal tubule adenoma or carcinomas (2/50, 5/50, 25/50) in high-dose
males; and renal tubule adenomas (0/50, 2/50, 5/50) in high-dose females (the adenomas occurred in the
cortex and consisted of cells morphologically similar to those in foci of renal tubule epithelial
hyperplasia); (2) benign granular cell tumors of the brain in high-dose males (0/50, 0/50, 3/50); and 
(3) follicular cell adenoma or carcinoma of the thyroid in high-dose females (0/50, 3/50, 4/50).  
Mononuclear cell leukemia was also elevated in treated rats, but the incidences were within the range of 
historical controls.  NTP (1991a) concluded that there was clear evidence of carcinogenic activity for 
male and female rats based on the increased incidence of renal tubule adenomas. 
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Mice were treated in the same manner with doses of 0, 175, or 350 mg TCEP/kg/day (NTP 1991a).  
Survival rate in mice was not significantly affected by treatment with TCEP.  An initial analysis of the
kidneys showed adenomas of the renal tubule in one control male, one high-dose male, and one low-dose
female, and a carcinoma in a second high-dose male.  Because of the rare occurrence of renal tubule 
neoplasms in male B6C3F1 mice, the remaining portions of the kidneys were processed to produce
additional sections per mouse for light microscopy examination.  The results of a combined initial and
second analysis of incidences of renal neoplasms yielded the following results: male adenomas 1/50, 
1/50, 3/50; male adenocarcinoma, 0/50, 0/50, 1/50; and female adenoma, 0/50, 1/49, 0/50.  Based on these
results, NTP (1991a) concluded that there was equivocal evidence of carcinogenic activity for male mice.  
Female mice showed an increased incidence of tumors of the Harderian gland (3/50, 8/50, 7/50, not
significant) which became significant at the high-dose if data for the interim evaluation and termination 
were combined (3/59, 8/60, 10/60).  Based on these results, NTP (1991a) concluded that there was
equivocal carcinogenic activity for female mice.
Takada et al. (1989) also conducted a bioassay with TCEP in ddY mice.  Mice were fed TCEP in the diet
at 0, 0.012, 0.06, 0.3, and 1.5% for 18 months.  Assuming a mean body weight of 0.045 kg and daily food 
consumption of 0.004 kg/day from graphs in the paper, the diet provided approximately 0, 11, 53, 267,
and 1,333 mg TCEP/kg/day.  Treatment with TCEP significantly increased the incidences of renal cell
adenomas and carcinomas in high-dose males (2/50, 0/49, 2/49, 5/47, and 41/50), hepatocellular
adenoma/carcinoma in the two highest male groups (4/50, 5/49, 7/49, 12/47, and 19/50), forestomach 
papillomas/squamous cell carcinomas in high-dose females (0/49, 0/49, 0/50, 1/49, and 7/50), and 
leukemia in the two highest female groups (1/49, 3/49, 6/50, 9/49, and 9/50).
Auletta et al. (1998a; 1998b) examined the carcinogenicity of TnBP in Sprague-Dawley rats and CD-
1 mice.  TnBP was administered in the diet to rats at levels that provided 0, 9, 33, or 143 mg TnBP/kg/day 
to males and 0, 12, 42, or 182 mg TnBP/kg/day to females.  Treatment with TnBP did not affect survival.  
Neoplastic lesions were restricted to the urinary bladder.  The incidence of urinary bladder papillomas
was significantly increased in high-dose males and females; transitional cell carcinomas were also 
significantly increased in males.  The incidences of combined papillomas, squamous cell carcinoma, and 
transitional cell carcinomas was 0/50, 0/50, 2/49, and 30/49 in males and 0/50, 0/50, 0/49, and 2/49 in 
females.  Most of the hyperplastic and neoplastic lesions were not associated with calculi, but when 
calculi were present, they were usually associated with hyperplasia and/or neoplasia.  Rats found to have
papillomas (benign tumors) often had hyperplasia present.  In contrast, rats with malignant bladder tumors
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usually did not have any remaining uninvolved epithelium to evaluate for the presence or absence of
hyperplasia.
In mice, the experimental diets provided doses of 0, 28.9, 169, or 585 mg TnBP/kg/day to males and 0, 
24.1, 206, or 711 mg TnBP/kg/day to females.  Survival was not affected by treatment with TnBP.  
Increased incidence of neoplasms was seen only in the liver of male mice.  The incidences of 
hepatocellular adenomas in males were 3/50, 6/50, 7/50, and 10/50 with increasing doses; the highest
dose level achieved statistical significance.  The incidence of malignant liver tumors was comparable 
between controls and treated males.  In females, there was no significant association between tumor 
incidences and treatment with TnBP.
TDCP was tested only in rats (Stauffer Chemical Co. 1981a).  Male and female Sprague-Dawley rats 
were fed a diet that provided 0, 20, or 80 mg TDCP/kg/day for 2 years.  Mortality was comparable among
groups during the first year of the study, but it increased in high-dose males during the second year and 
was significantly higher than controls at termination. The incidence of neoplastic nodules in the liver of
high-dose males and females was significantly increased (2/45, 7/48, 1/48, 13/46 in males and 1/49, 1/47, 
4/46, 8/50 in females) and the incidence of hepatocellular carcinomas was also increased in high-dose
males (1/45, 2/48, 3/48, 7/46).  In the kidney, both mid- and high-dose males and females had 
significantly increased incidence of renal cortical tumors (1/45, 3/49, 9/48, 22/36 in males; 0/49, 1/48, 
8/48, 25/50 in females).  In the testes, interstitial cell tumors were significantly increased in mid- and 
high-dose males (7/43, 8/48, 23/47, 32/45), whereas adrenocortical adenomas were significantly increased 
in high-dose females (8/48, 5/27, 2/33, 19/49).
3.2.3 Dermal Exposure 
3.2.3.1 Death 
No reports of deaths in humans following dermal exposure to the selected phosphate ester flame 
retardants were located in the reviewed literature.
No deaths occurred among an unspecified number of rabbits applied a dose of 5,000 mg TCEP/kg and 
observed for 14 days (Anonymous 1977).  Application of 10–20 mL TnBP/kg to guinea pigs for 24 hours
under occluded conditions resulted in an estimated dermal LD50 between 9,727 and 19,454 mg/kg
(Eastman Kodak Co. 1968).  Other studies reported dermal LD50 values >3,100, >10,000, and 
>4,640 mg/kg for TnBP in rabbits (Johannsen et al. 1977; MacKellar 1976; Stouffer Chemical Co. 1973).  
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No deaths were reported in rabbits applied a dose of 4,640 mg TDCP/kg to the skin for 24 hours and 
observed for 14 days (Stauffer Chemical Co. 1981b).  Application of 23,700 mg TDCP/kg also did not
cause lethality among rabbits, but induced signs of cholinergic stimulation (Stauffer Chemical Co. 
1981b).  Dermal LD50 values >5,000 and >10,000 mg/kg were estimated for TiBP in guinea pigs and
rabbits, respectively (Eastman Kodak Co. 1990; Monsanto Co. 1989a, 1989b).  Johannsen et al. (1977)
reported that the dermal LD50 for TPP in rabbits was >7,900 mg/kg, whereas FMC (1982) estimated an 
oral LD50 >10,000 mg/kg for TPP in rabbits.  Additional information regarding acute lethal doses or LD50 
values of dermally-applied phosphate ester flame retardants can be found in IPCS (1991a, 1991b, 1998, 
2000b). 
Dermal lethal doses and/or dermal LD50 values are presented in Table 3-7.
3.2.3.2 Systemic Effects
With the exception of dermal and ocular effects, most of the information summarized below is derived 
from two 3-week studies of TBEP and TPP in rabbits (Monsanto Co. 1979, 1985d). 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-7.
Respiratory Effects. The only relevant information is that application of up to 1,000 mg TPP/kg/day 
onto a clipped intact or abraded area of the back of rabbits 5 days/week for 3 weeks did not result in gross
or microscopic alterations in the lungs (Monsanto Co. 1979).
Cardiovascular Effects. A 3-week study reported that daily applications of up to 1,000 mg
TPP/kg/day onto the clipped intact or abraded area of the back of rabbits had no effect on the gross or
microscopic morphology of the heart (Monsanto Co. 1979).
Gastrointestinal Effects. No gross or microscopic alterations were reported in the gastrointestinal
tract of rabbits that received daily applications of up to 1,000 mg TPP/kg/day on a clipped intact or
abraded area on the back 5 days/week for 3 weeks (Monsanto Co. 1979).  
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ACUTE EXPOSURE 
Death 
Gn Pig 24 hr Eastman Kodak Co. 1968
9727 (LD50 is 9727-19454(NS) (NS) mg/kg) 126-73-8mg/kg 
Gn Pig once Eastman Kodak Co. 1990
10000 (the LD50 was greater(NS) (NS) 
mg/kg than 10000 mg/kg) 126-71-6 
Rabbit Anonymous 1977
5000 (LD50 is greater than(New (NS) 
Zealand) mg/kg/day 5000 mg/kg) 115-96-8 
Rabbit once FMC 1982
10000 (LD50 is greater than(NS) (NS) 
mg/kg 10000 mg/kg) 115-86-6 
Rabbit 24 hr Johannsen et al. 1977
7900 B (The LD50 was greater(New than 7900 mg/kg) 115-86-6Zealand) mg/kg 
Rabbit 24 hr Johannsen et al. 1977
3100 B (the LD50 was greater(New than 3100 mg/kg) 126-73-8Zealand) mg/day 
Rabbit MacKeller 1976
10000 (LD50 is greater than(NS) (NS) 
mg/kg 10000 mg/kg) 126-73-8 
Rabbit NS Monsanto Co. 1989a, 1989b
5000 (the LD50 was greater(NS) (NS) 
mg/kg than 5000 mg/kg) 126-71-6 
186 mg/kg
186
167 mg/kg
167
210
mg/kg/day
210
197
mg/kg
197
181
g/kg
181
169
mg/kg
169
215
mg
215
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Rabbit 
(New 
Zealand) 
Rabbit 
(New 
Zealand) 
Rabbit 
(NS) 
Systemic 
Rat 
(NS) 
Gn Pig 
(NS) 
Gn Pig 
(NS) 
Gn Pig 
(Hartley) 
24 h Stauffer Chemical Co. 1973
4640 (LD50 is greater than(NS) 
mg/kg 4640 mg/kg) 126-73-8 
24 h Stauffer Chemical Co. 1981b
4640 (LD50 is greater than(NS) 
mg/kg 4640 mg/kg) 13674-87-8 
once Stauffer Chemical Co. 1981b
23700 (LD50 is greater than(NS) 
mg/kg/day 23700 mg/kg) 13674-87-8 
Akzo Chemical Inc 1991Dermal 750(NS) 126-73-8mg/kg 
24 hr Eastman Kodak Co. 1968Dermal 20 (severe skin irritation)(NS) 126-73-8g/kg 
once Eastman Kodak Co. 1990Dermal 5000 (moderate edema)(NS) 126-71-6mg/kg 
Socma 1990Dermal 0.3 B (NS) 126-73-8mg 
206 mg
206
171
Percent (%)
171
172
Percent (%)
172
201 ml
201
156
ml
156
157
ml
157
200 ml
200
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Rabbit once Ocular 10 Anonymous 1977 (New (NS) 115-96-8mgZealand) 
Rabbit	 Dow Chemical Co. 1956Ocular 100 (moderate immediate(NS) (NS) 
Percent (%)	 pain with slight 126-73-8 
conjunctival irritation) 
Rabbit	 Dow Chemical Co. 1956Dermal 10 (slight hyperemia and(NS) (NS) 
Percent (%)	 moderate necrosis) 126-73-8 
Rabbit 24 hr Dermal	 FMC 1979, 19810.5 B (mild skin irritation)(New (NS) 126-73-8Zealand)	 ml 
Rabbit once	 FMC 1982Dermal 0.5(NS) (NS) 115-86-6ml 
Rabbit once	 FMC 1982Ocular 0.1 (mild eye irritation)(NS) (NS) 115-86-6ml 
Rabbit 4 hr Dermal	 Mobil Oil Corporation 1979b0.5 (mild skin irritation)(New (NS) 126-73-8Zealand)	 ml 
148 ml
148
188 ml
188
191
ml
191
199
mg
199
214
mg/kg
214
Table 3-7 Levels of Significant Exposure to Selected Phosphate Esters - Dermal	 (continued) 
Exposure/ LOAEL
 
Duration/
 
Frequency Reference
Species 
(Route)(Strain) System NOAEL Less Serious	 Serious Chemical Form Comments 
***D
R
A
FT FO
R
 P
U
B
LIC
 C
O
M
M
E
N
T***
P
H
O
S
P
H
A
TE
 E
S
TE
R
 FLA
M
E
 R
E
TA
R
D
A
N
TS
3.  H
E
A
LTH
 E
FFE
C
TS
 
130
Rabbit 4 hr	 Monsanto Co. 1989a, 1989bDermal 0.5 B (slight erythema)(New (NS) 126-71-6Zealand)	 ml 
Rabbit once	 Stauffer Chemical Co. 1973Ocular 0.1(New (NS) 126-73-8mlZealand) 
Rabbit once Ocular	 Union Carbide Corp 19430.02 (necrosis)(NS) (NS) 126-73-8ml 
Immuno/ Lymphoret 
Gn Pig	 Socma 1990Dermal 0.3 B (Hartley) (NS) 126-73-8mg 
Neurological 
Rabbit once	 Stauffer Chemical Co. 1981b
23700 (diarrhea, pupillary(NS) (NS) 
mg/kg	 constriction, depressed 13674-87-8 
RBC cholinesterase) 
126 mg/kg/day 126
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
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INTERMEDIATE EXPOSURE 
Systemic 
Rabbit 3 wk Resp
(New 5 d/wk 
Zealand) 1 x/d 
Cardio 
Gastro 
Hemato 
Musc/skel 
Hepatic 
Renal 
Endocr 
Dermal 
Ocular 
Bd Wt 
Monsanto Co. 1979 NOAELs are for organ1000 B or tissuemg/kg/day 115-86-6 histopathology. 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
1000 B 
mg/kg/day 
mg/kg/day
113 mg/kg/day
113
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
127 mg/kg/day
127
128 mg/kg/day
128
216 mg/kg/day 216
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Metab 1000 B 
mg/kg/day 
Rabbit	 3 wk Monsanto Co. 1985dHemato 1000 B (New	 5 d/wk 
1 x/d mg/kg/day 78-51-3Zealand) 
Hepatic 1000 B 
mg/kg/day 
Renal 1000 B 
mg/kg/day 
Dermal 10 B (slight edema, atonia, 
mg/kg/day desquamation) 
Bd Wt 1000 B 
mg/kg/day 
Immuno/ Lymphoret 
Rabbit 3 wk	 Monsanto Co. 1979 NOAEL is lymphoid1000 B (New 5 d/wk	 tissues histopathology.
1 x/d mg/kg/day	 115-86-6Zealand) 
Neurological 
Rabbit	 3 wk Monsanto Co. 1979 NOAEL is for1000 B (New	 5 d/wk histopathology of
1 x/d mg/kg/day	 115-86-6Zealand)	 central and peripheral 
nervous tissues. 
Rabbit 3 wk	 Monsanto Co. 1985d NOAEL is for brain1000 B (New 5 d/wk	 weight and RBC and
1 x/d mg/kg/day	 78-51-3Zealand)	 brain cholinesterase. 
129 mg/kg/day 129
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Reproductive 
Rabbit 3 wk Monsanto Co. 1979 NOAEL is for1000 B (New 5 d/wk histopathology of themg/kg/day 115-86-6Zealand) 1 x/d reproductive organs. 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; ; F = Female; Gastro = gastrointestinal; Gn Pig = guinea pig; Hemato = hematological; hr = hour(s); 
LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = metabolic; NOAEL = no-observed-adverse-effect level; NS = not specified; Resp = 
respiratory; wk = week(s); x = time(s) 
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Hematological Effects. Hematology tests done on blood collected at termination from rabbits treated 
dermally with up to 1,000 mg TBEP/kg/day 5 days/week for 3 weeks did not reveal any significant
deviation from normal limits (Monsanto Co. 1985d).  Similar results were reported in rabbits exposed to 
TPP (Monsanto Co. 1979).
Musculoskeletal Effects. There were no gross or microscopic alterations in skeletal muscle from
rabbits that received daily application of up to 1,000 mg TPP/kg/day 5 days/week for 3 weeks onto the 
clipped intact and abraded area of the back (Monsanto Co. 1979).
Hepatic Effects. Application of up to 1,000 mg TBEP/kg/day to the unabraded clipped skin of rabbits
5 days/week for 3 weeks did not result in alterations in liver weight, liver function tests, or the gross or
microscopic appearance of the liver (Monsanto Co. 1985d).  The same results were obtained in rabbits
exposed to up to 1,000 mg TPP/kg/day (Monsanto Co. 1979). 
Renal Effects. Application of up to 1,000 mg/kg/day of TBEP or TPP to the clipped skin on the back
of rabbits 5 days/week for 3 weeks did not result in alterations in kidney weight or the gross or
microscopic appearance of the kidney (Monsanto Co. 1985d).  
Endocrine Effects. Application of up to 1,000 mg TPP/kg/day to a clipped intact or abraded area of 
the skin of rabbits 5 days/week for 3 weeks had no significant effect on the gross or morphological
appearance of the adrenal, thyroid, and pituitary (Monsanto Co. 1979).
Dermal Effects. Without providing any further details, IPCS (1991a, 1991b) stated that there have
been reports of skin irritation among subjects occupationally exposed to TnBP.  Several studies provide
information regarding dermal effects of TnBP in animals.  Application of 750 mg TnBP/kg to the skin of
rats did not produce irritation (Akzo Chemical Inc 1991).  In guinea pigs, application of a dose of
20,000 mg TnBP/kg for 24 hours produced severe skin irritation (Eastman Kodak Co. 1968), but
application of 0.3 mg once per week for 3 weeks did not produce skin irritation (SOCMA 1990).  
Application of TnBP as a 10% emulsion for 20 times on the ear and 6 times on the abdomen produced
moderate exfoliation on the ear and slight hyperemia and slight exfoliation on the abdomen (Dow
Chemical Co. 1956).  Similar application of TnBP neat produced slight hyperemia and moderate necrosis
on the ear after the 5th application.  All signs of toxicity were reversed within 2–3 weeks after treatment
(Dow Chemical Co. 1956).  Both FMC (1979, 1981) and Mobil Oil Corporation (1979b) reported that
application of 0.5 mL TnBP for 4–24 hours produced mild skin irritation in rabbits. Moderate edema was 
***DRAFT FOR PUBLIC COMMENT***
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3. HEALTH EFFECTS
reported in guinea pigs that received an application of 5,000 mg TiBP/kg to the skin (Eastman Kodak Co. 
1990) and mild, reversible skin irritation was reported in rabbits applied 0.5 mL TiBP and observed for 7– 
14 days (Monsanto Co. 1989a, 1989b).  Application of 0.5 mL TPP to the clipped, intact, or abraded skin 
of rabbits did not result in the formation of erythema or edema (FMC 1982).
In the 3-week study with TBEP in rabbits (Monsanto Co. 1985d), the undiluted test material was applied 
to the unabraded dorsal skin clipped of hair in doses of 0, 10, 100, or 1,000 mg/kg/day; the area was 
covered for 6 hours after each application.  Gross necropsy showed slight to moderate erythema in the
treated rabbits during the study; the incidence and severity was dose-related during the second and third
week of the study.  Atonia and desquamation were also more pronounced in treated rabbits (incidence and 
severity were dose-related).  Slight fissuring became evident over time in some mid-dose and most high-
dose rabbits.  Eschar formation was also seen in treated rabbits.  Exfoliation also occurred in mid- and 
high-dose animals.  Microscopic evaluation of sites from high-dose rabbits showed squamous cell
hyperplasia, hyperkeratosis, erosions-ulcers, acute-subacute inflammation, and congestion and 
hemorrhage, in various combinations.
In the 3-week study with TPP, there were no treatment-related alterations in the intact or abraded skin of
rabbits applied up to 1,000 mg TPP/kg/day for 3 weeks (Monsanto Co. 1979).
Ocular Effects. Application of 10 mg or 0.1 mL of TCEP into the lower eyelid of rabbits did not
produce significant eye irritation (Anonymous 1977).  Application of neat TnBP to the eye of rabbits
induced slight conjunctival irritation which subsided within 24 hours (Dow Chemical Co. 1956).  Union 
Carbide (1943) reported that application of 0.02 mL TnBP to the eye of rabbits induced necrosis, but a 
report by Stauffer Chemical Co. (1973) indicates that application of 10 mg or 0.1 mL TnBP to the eye of 
rabbits did not induce signs of eye irritation.  There is not enough information in either report to explain 
this apparent discrepancy.  Instillation of 0.1 mL TPP into the eye of rabbits produced mild irritation only
when the eye remained unwashed after application (FMC 1982).  No ocular effects were reported in 
rabbits that received daily skin applications of up to 1,000 mg TPP/kg/day 5 days/week for 3 weeks 
(Monsanto Co. 1979).
Body Weight Effects. Application of up to 1,000 mg/kg/day of TBEP or TPP to a clipped area of
intact or abraded the dorsal skin of rabbits 5 days/week for 3 weeks did not affect food consumption, 
body weight, or body weight gain (Monsanto Co. 1979, 1985d).
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Metabolic Effects. Application of up to 1,000 mg TPP/kg/day to a clipped area of intact or abraded 
dorsal skin of rabbits 5 days/week for 3 weeks had no significant effect on serum levels of glucose, 
calcium, or inorganic phosphorus (Monsanto Co. 1979).
3.2.3.3 Immunological and Lymphoreticular Effects
No studies were located regarding immunological and lymphoreticular effects in humans following
dermal exposure to the selected phosphate ester flame retardants.  
A study in which 0.3 mg TnBP was applied to the skin of guinea pigs once per week for 3 weeks showed 
that under the conditions of the study, TnBP was nonsensitizing (SOCMA 1990).  A 3-week study in 
which rabbits were applied up to 1,000 mg TPP/kg/day 5 days/week to an area of intact or abraded dorsal
skin did not report gross or microscopic changes in the spleen, thymus, or lymph nodes (Monsanto Co.
1979). 
These two values are presented in Table 3-7.
3.2.3.4 Neurological Effects 
No studies were located regarding neurological effects in humans following dermal exposure to the 
subject phosphate ester flame retardants of this profile. 
Application of up to 1,000 mg TEBP/kg/day to the clipped unabraded dorsal skin of rabbits 5 days/week
for 3 weeks did not induce clinical signs nor did it alter the activities of red blood cell (RBC) or brain 
cholinesterase or affect brain weight (Monsanto Co. 1985d).  In the study with TPP, there were no 
alterations in brain weight or in gross and microscopic morphology of the brain, spinal cord, or sciatic
nerve (Monsanto Co. 1979).  However, at termination, there was a dose-related decrease in RBC and 
brain cholinesterase activities, which achieved statistical significance in the high-dose group 
(1,000 mg/kg/day, other groups were 10 and 100 mg/kg/day), but there were no clinical signs of increased 
cholinergic activity. 
The doses of 1,000 mg/kg/day of TBEP and TPP are presented as NOAELs for neurological effects in 
Table 3-7.
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3.2.3.5 Reproductive Effects
No studies were located regarding reproductive effects in humans exposed to the selected phosphate ester
flame retardants by any route of exposure.
The only relevant information regarding reproductive effects in animals is that in a 3-week study in 
rabbits applied up to 1,000 mg TPP/kg/day to the dorsal skin 5 days/week, there were no morphological
alterations in the ovaries, uterus, prostate, or testes (Monsanto Co. 1979).  This value is presented as a 
NOAEL in Table 3-7.
3.2.3.6 Developmental Effects 
No studies were located regarding developmental effects in humans or animals following dermal
exposure to the subject phosphate ester flame retardants of this profile.
3.2.3.7 Cancer
Only information regarding TCEP was located in the literature.  Sala et al. (1982) studied the initiation/ 
promotion properties of TCEP in female Swiss mice.  In the initiation study, mice received a single
application of 71 mg of TCEP to the dorsal clipped skin and then repeated applications of 12-O-tetra-
decanoyl-phorbol-13-acetate (TPA).  In the promotion studies, mice received, for 78 weeks, twice weekly
applications of TCEP (21 mg) in acetone onto the area of dorsal skin after initiation with 7,12-dimethyl-
benz(a)anthracene (DMBA).  TCEP was also tested for complete carcinogenicity by treating the mice 
twice weekly without any initiation treatment.  TCEP was negative as an initiator, promoter, and complete
skin carcinogen.  However, TCEP by itself increased the incidence (not significantly) of lung adenomas
in mice relative to a group initiated with DMBA and promoted with TCEP.  The investigators had no 
explanation for the role of DMBA in decreasing the incidence of lung tumors.
3.3 GENOTOXICITY
For the most part, the phosphate ester flame retardants subject of this profile have provided negative
evidence of mutagenicity in in vitro tests with prokaryotic organisms (i.e., Salmonella typhimurium) and 
mammalian cell systems.  In vivo studies have, for the most part, also provided negative results.  
Tables 3-8 and 3-9 provide a summary of genotoxicity data for these test systems.
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Table 3-8.  Genotoxicity of Phosphate Ester Flame Retardants In Vitro
Results
With Without
Species (test system) Compound End point activation activation Reference
Prokaryotic organisms:
Salmonella TBEP Gene mutation – – Abe and Urano 1994
typhimurium, TA98
S. typhimurium, TA09, TBEP Gene mutation – – Monsanto Co. 1985e
TA100, TA1535, and 
TA1537
S. typhimurium, TCEP Gene mutation – – Föllmann and Wober
TA97a, TA98, TA100, 2006
TA104, TA1535,
TA1537, and TA1538
S. typhimurium, TCEP Gene mutation – No data Haworth et al. 1983
TA1535, TA1537,
TA98, and TA100
S. typhimurium, TA98 TCEP Gene mutation – – Abe and Urano 1994
S. typhimurium, TCEP Gene mutation ± ± Nakamura et al. 1979;
TA100, TA1535, NTP 1991a
TA1537, and TA98
S. typhimurium, TA98, TCEP Gene mutation – – Tennant and Ashby
TA100, TA1535, 1991
TA1537, and/or TA97
S. typhimurium, TCPP Gene mutation – – Föllmann and Wober
TA97a, TA98, TA100, 2006
TA104, TA1535,
TA1537, TA1538
S. typhimurium, TA98 TCPP Gene mutation – – Abe and Urano 1994
S. typhimurium, TA97, TCPP Gene mutation – – Zeiger et al. 1992
TA98, TA100, TA102,
TA104, TA1535,
TA1537, and TA1538
S. typhimurium, strain TDCP Gene mutation + No data NTP 1983
n/a
S. typhimurium, TA100 TDCP Gene mutation + No data Gold et al. 1978
S. typhimurium, TA100 TDCP Gene mutation – – Søderlund et al. 1985
S. typhimurium TDCP Gene mutation + + Mortelmans et al.
TA1535, TA1537, 1986
TA97, TA98, and 
TA100
S. typhimurium, TA100 TDCP Gene mutation ± – Lynn et al. 1981
S. typhimurium, TA100 TDCP Gene mutation ± ± Brusick et al. 1979
S. typhimurium, TDC Gene mutation – – Brusick et al. 1979
TA11535
S. typhimurium, TA100 TDCP Gene mutation – No data Dybing et al. 1983
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Table 3-8.  Genotoxicity of Phosphate Ester Flame Retardants In Vitro
Results
With Without
Species (test system) Compound End point activation activation Reference
S. typhimurium, TA98, TDCP Gene mutation – – Stauffer Chemical Co.
TA100, TA1535, 1981b
TA1537, and TA1538/ 
Saccharomyces
cerevisiae strain D4
S. typhimurium, TA98, TiBP Gene mutation – – Stegeman et al. 1992
TA100, TA1535,
TA1537
S. typhimurium, TA98 TnBP Gene mutation – No data Abe and Urano 1994
S. typhimurium, TA102 TnBP Gene mutation – – Watanabe et al. 1996
and TA2638
Escherichia coli, TnBP Gene mutation – – Watanabe et al. 1996
Wp2/pKM1010 and
WP2 uvrA/pKM101
S. typhimurium, strain TPP Gene mutation – No data NTP 1982
 
n/a
 
S. typhimurium, TA98, TPP Gene mutation – – Zeiger et al. 1987
TA100, TA1535,
TA1537, and/or TA97
Mammalian cells:
Chinese hamster ovary TBEP Forward gene – – Monsanto Co. 1985c
(CHO) cells (HGPRT) mutation
Mouse L5178Y TBEP Gene mutation – – Mobil Oil Corp 1991
Lymphoma cells
Chinese hamster V79 TCEP Cytotoxicity, + – Föllmann and Wober
cells neutral red 2006
uptake assay
Chinese hamster V79 TCEP DNA damage, – – Föllmann and Wober
cells Comet 2006
analysis,
CHO cells TCEP Chromosomal – – Galloway et al. 1987;
aberrations NTP 1991a
CHO cells TCEP Chromosomal ± – Galloway et al. 1987;
aberrations, NTP 1991a
sister
chromatid 
exchange
Chinese hamster V79 TCEP Forward gene – – Sala et al. 1982
 
cells mutation
 
Chinese hamster V79 TCEP Sister + + Sala et al. 1982
 
cells chromatid 
exchange
 
Mouse C3H10T1/2 TCEP Transformation – – Sala et al. 1982
 
cells assay
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Table 3-8.  Genotoxicity of Phosphate Ester Flame Retardants In Vitro
Results
With Without
Species (test system) Compound End point activation activation Reference
Syrian hamster embryo TCEP Transformation + + Sala et al. 1982
cells assay
Chinese hamster V79 TCPP Cytotoxicity, + – Föllmann and Wober
cells neutral red 2006
uptake assay
Chinese hamster V79 TCPP DNA damage, – – Föllmann and Wober
cells Comet 2006
analysis,
Chinese hamster V79 TDCP Gene mutation – No data Søderlund et al. 1985
cells
Syrian hamster cells TDCP Transformation No data + Søderlund et al. 1985
assay
Mouse L5178Y TDCP Gene mutation – – Brusick et al. 1979
Lymphoma cells
Mouse L5178Y TDCP Sister ± ± Brusick et al. 1979
lymphoma cells chromatid 
exchange
Mouse L5178Y TDCP Chromosomal + + Brusick et al. 1979
lymphoma cells aberrations
Mouse BALB/3T3 cells TDCP Transformation – – Brusick et al. 1979
assay
Chinese hamster V79 TDCP Gene mutation – No data Dybing et al. 1983
cells
Mouse L5178Y TDCP Gene mutation ± – Stauffer Chemical Co.
lymphoma cells 1981b
CHO cells TnBP Gene mutation – – Batt et al. 1992
CHO cells TnBP Chromosomal – – Batt et al. 1992
aberrations
+ = positive result; C = negative result; ± = weak or equivocal result; TBEP = tributoxyethyl phosphate; 
TCEP = tris-(2-chloroethyl)-phosphate; TCPP = tri-(2-chloroisopropyl) phosphate; TDCP = tris(1,3 dichloro-2-propyl)
phosphate; TiBP = triisobutyl phosphate; TnBP = tributyl phosphate; TPP = triphenyl phosphate
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Table 3-9 Genotoxicity of Phosphate Ester Flame Retardants In Vivo
Species (test system) Compound End point Results Reference
Chinese hamster TCEP Chromosomal ± Sala et al. 1982
(male/female, aberrations,
2/sex/dose) micronucleus assay
Drosophila TCEP Gene mutation, spot – Vogel and Nivard 
melanogaster test 1993
Mouse (male, Charles TDCP Chromosomal – Brusick et al. 1979
River CD; eight per aberrations, bone 
treatment) marrow cytogenic assay
D. melanogaster TDCP Gene mutation, sex­ – Brusick et al. 1979
(modifed Muller five linked recessive lethal
stock) assay
D. melanogaster TDCP Gene mutation, sex­ – Stauffer Chemical Co.
(males, 25/dose) linked recessive lethal 1981b
assay
Mouse (Male CD-1; TDCP Chromosomal – Stauffer Chemical Co.
6/dose) aberrations, bone 1981b
marrow cytogenic assay
Mouse (male/female TiBP Chromosomal – Flowers and Garrett
CD1; 15/sex/dose) aberrations, 1992
micronucleus assay
Rat (male/female, TnBP Chromosomal – Batt et al. 1992
strain and number not aberrations
reported)
+ = positive result; C = negative result; ± = equivocal result; TCEP = tris-(2-chloroethyl)-phosphate; TDCP = tris(1,3
dichloro-2-propyl) phosphate; TiBP = triisobutyl phosphate; TnBP = tributyl phosphate
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In vitro Exposure Studies. In vitro studies with phosphate ester flame retardants have provided mixed 
results.  In general, TBEP, TCEP, TCPP, TiBP, TnBP, and TPP have been found to be nonmutagenic in 
S. typhimurium with and without metabolic activation (Abe and Urano 1994; Brusick et al. 1979;
Föllmann and Wober 2006; Monsanto Co. 1985e; Segeman et al. 1992; Søderlund et al. 1985; Stauffer 
Chemical Co. 1981b; Tennant and Ashby 1991; Watanabe et al. 1996; Zeiger et al. 1987, 1992).  
Additionally, in a study conducted by Watanabe et al. (1996), TnBP was found to be nonmutagenic in 
Escherichia coli. Studies of TCEP conducted by Nakamura et al. (1979) provided weak evidence of
mutagenicity for this compound. Studies with TDCP have demonstrated mixed results in S. typhimurium, 
probably reflecting differences in methodology. Positive results were determined for an unreported strain 
with metabolic activation (NTP 1983), for strain TA100 with metabolic activation (Gold et al. 1978; Lynn 
et al. 1981), and for strains TA1535, TA1537, TA97, TA98, and TA100 with and without metabolic
activation (Mortelmans et al. 1986).  Conversely, negative results were determined for strain TA100 with 
and without metabolic activation in a study conducted by Søderlund et al. (1985), and equivocal results
were noted in studies conducted with and without metabolic activation by Brusick et al. (1979). 
Studies with mammalian cells in vitro have also provided mixed results.  TBEP was not genotoxic in 
Chinese hamster ovary cells or in mouse L5178Y lymphoma cells in assays conducted with and without
metabolic activation (Mobil Oil Corporation 1991; Monsanto Co. 1985c).  TnBP also produced negative
results in tests for chromosomal aberrations and gene mutation in Chinese hamster ovary cells with and 
without metabolic activation (Batt et al. 1992).  Results for TCEP, TCPP, and TCDP were mixed.  
In a neutral red uptake assay in Chinese hamster V79 cells, Föllmann and Wober (2006) reported positive
results for TCEP and TCPP in the presence of metabolic activation only.  Negative results were also 
reported in this study for TCEP and TCPP in a comet analysis of V79 cells both in the presence and 
absence of metabolic activation. TCEP did not induce chromosomal aberrations in Chinese hamster
ovary cells in tests with and without metabolic activation (Galloway et al. 1987; NTP 1991a).  However, 
in studies conducted by Sala et al. (1982), TCEP was found to be positive for sister chromatid exchange
in Chinese hamster V79 cells as well as in a transformation assay in Syrian hamster embryo cells.  
Although a positive result was obtained in the sister chromatid exchange assay, no clear concentration-
response was evident.  Results from studies conducted by Sala et al. (1982) also showed TCEP to be
negative in a test for forward gene mutation in Chinese hamster V79 cells, and negative in a
transformation assay in mouse C3H10T1/2 cells. Sala et al. (1982) speculated that the negative result
seen in mouse C3H10T1/2 cells in comparison with the positive result in Syrian hamster cells could have 
been due to the high metabolic activity known to occur naturally in hamster cells.
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In vitro studies with TDCP in mammalian cells provided negative results for gene mutation in Chinese
hamster V79 cells, mouse L5178Y lymphoma cells, and mouse BALB/3T3 cells (Brusick et al. 1979;
Dybing et al. 1983; Søderlund et al. 1985).  In a chromosomal aberration study conducted on mouse
L5178Y lymphoma cells, positive results were demonstrated with and without metabolic activation 
(Brusick et al. 1979).  Søderlund et al. (1985) also provided positive results in a gene mutation study in 
Syrian hamster cells in the absence of metabolic activation only.  Equivocal results were obtained in a 
gene mutation assay (Stauffer Chemical Co. 1981b) and in a chromosomal aberration study (Brusick et al. 
1979) in mouse L5178Y lymphoma cells. The classification of equivocal was based on the variability of
the results and on weak positive results.
In vivo Exposure Studies.  The relatively few studies available for review that examined the potential in 
vivo genotoxicity of the phosphate ester flame retardants discussed in this profile were negative 
(Table 3-9).  In a micronucleus assay conducted on Chinese hamsters with TCEP, study results were 
equivocal (Sala et al. 1982).  This result was due to a difference in response between sexes and dose 
variations which made analysis difficult.  TDCP was negative for gene mutations in sex-linked recessive 
studies conducted on Drosophila melanogaster (Brusick et al. 1979; Stauffer Chemical Co. 1981b), as
well as in a gene mutation spot test (Bruisck et al. 1979).  Results for chromosomal aberrations in rats
were negative in a study conducted with TnBP (Batt et al. 1992).  Chromosomal aberration studies were
also negative in CD-1 mice for TDCP (Brusick et al. 1979; Stauffer Chemical Co. 1981b) and TiBP
(Flowers and Garrett 1992).
3.4 TOXICOKINETICS
Almost all of the information regarding toxicokinetics of the subject phosphate ester flame retardants is 
derived from studies with TDCP, TCEP, and TnBP in animals.  TDCP, TCEP, and TnBP were well
absorbed in rats following oral dosing.  Significant amounts of TDCP and TnBP were also absorbed
through rat skin; however, TnBP was poorly absorbed through pig skin.  Oral and dermal absorption of
the remaining phosphate ester flame retardants covered in this profile can be inferred from toxicity
studies, but rates are not available.  None of these substances showed preferential accumulation in 
specific tissues or organs.  Analyses of excreta, mostly from rats, indicated that TDCP, TCEP, and TnBP
undergo extensive metabolism by Phase I and Phase II enzymatic systems and the metabolic products are 
rapidly excreted, principally in the urine.  Species and gender differences in metabolism and excretion 
were reported for TCEP.  Female rats excreted less of a high-dose of TCEP than did males, and mice
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eliminated TCEP faster than did male or female rats.  An in vitro study showed that both liver slices and 
microsomes from humans and male rats metabolized TCEP to the same main metabolites; female liver
microsomes did not appear to metabolize TCEP.  No physiologically based pharmacokinetic (PBPK)
models have been developed for any of the phosphate ester flame retardants covered in this profile. 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
The only relevant information available in humans regarding the phosphate ester flame retardants 
discussed in this profile is that male volunteers who inhaled small particles of TPP at a flow rate of
18 L/second retained a mean of 41% of the inhaled TPP in the lungs (Landhal et al. 1951, 1952).  
Retention increased as particle size and flow rate increased.  No pertinent information was found from
studies in animals.
3.4.1.2 Oral Exposure
No information was located regarding absorption of phosphate ester flame retardants in humans following
oral exposure.  The fact that TDCP was detected in adipose tissue and seminal fluid from members of the
general population (Hudec et al. 1981; LeBel and Williams 1986) suggests that this substance was
absorbed, most likely through consumption of contaminated food or water, the main sources of exposure 
for the general population. 
TDCP. A study in which male Sprague-Dawley rats were administered 0.2, 2, or 20 μmol TDCP/kg 
(0.086, 0.86, or 8.6 mg/kg) showed that better than 90% of the administered dose was absorbed from the
gastrointestinal tract within 24 hours after dosing, regardless of the dose (Nomeir et al. 1981).  
TCEP. Administration of a single gavage dose of 175 mg 14C-TCEP/kg to male and female Fischer-
344 rats resulted in rapid absorption from the stomach (Herr et al. 1991).  Analysis of radioactivity in 
plasma over a 4-hour period showed that unmetabolized TCEP accounted for an average of 43.6% of the
total radioactivity across time points and sexes.  The concentration of TCEP in plasma reached a
maximum early and did not vary significantly from 5 minutes to 4 hours after dosing.  It appeared that at
early time points plasma from female rats had twice as much TCEP than that from males, but because 
only three rats per sex were used, it was not possible to determine whether the difference was statistically
significant.
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TnBP. Analysis of the urine, expired air, and tissues of male and female Sprague-Dawley rats following
gavage administration of single or repeated doses of 10 or 350 mg 14C-TnBP/kg yielded a maximum
combined radioactivity of approximately 90% of the administered dose in females dosed repeatedly with 
350 mg TnBP/kg/day (SOCMA 1992).  Approximately 6% of the administered 14C was found in the
feces, but it is not possible to determine whether this amount correspond to unabsorbed parent compound 
or absorbed material secreted in the bile.  The half-life for the 14C-TnBP-derived radioactivity in blood 
was estimated to be approximately 25 hours for both dosing regimes.  
3.4.1.3 Dermal Exposure 
No studies were located regarding absorption of the selected phosphate ester flame retardants in humans
following dermal exposure.
TDCP. Measurements of 14C-TDCP-derived radioactivity in tissues from male Sprague-Dawley rats 
4 hours after application of the compound in methanol to a shaved area of 4 cm2 in the back showed that
the chemical was readily absorbed through the skin (Nomeir et al. 1981).  The rate of absorption was not
estimated.  
TnBP. Application of 10 or 350 mg 14C-TnBP/kg to a 2 cm2 shaved area of the skin of male and female 
Sprague-Dawley rats for 6 hours followed by washing with soap and water resulted in absorption of at
least 53% (high-dose females) of the applied dose, which was the radioactivity recovered in combined 
urine, feces, expired air, and tissues (SOCMA 1992).
In a study in Yucatan® minipigs, males and females were applied a dose of 10 or 350 mg 14C-TnBP to a
lightly clipped area of the skin for 6 hours after which time the area was washed with soap and water
(SOCMA 1992).  Excreta were collected for up to 168 hours after dosing.  Analysis of urine and feces 
samples showed only ≤4% of the applied dose in excreta.  In low-dose animals, 57–64% of the applied 
dose of 14C was recovered at the dosing site (includes dosed site plus dose wash plus dose wrappings).  In 
high-dose minipigs, 87–92% of the applied 14C was recovered at the dosing site. Compared to rats, 
minipigs absorbed about 10 times less TnBP than rats.
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3.4.1.4 Other Routes of Exposure
TDCP. Hughes et al. (2001) studied the dermal absorption of TDCP in an in vitro preparation of skin 
from adult hairless mice mounted on a flow-through diffusion cell.  14C-TDCP in acetone in 
concentrations of 20, 100, or 200 pmol were applied to the skin and receptor fluid was collected over a 
24-hour period.  At this time, the skin was washed with ethanol to remove unabsorbed TDCP.  For all
doses, the greatest percent of the dose was absorbed between 6 and 12 hours.  The 24-hour cumulative
percent of the dose in the receptor fluid was 57, 45, and 39% for the 20, 100, and 200 pmol solutions, 
respectively.  Washing with ethanol removed 11–25% of the applied radioactivity, whereas 28–35% of
the applied radioactivity remained in the skin.  Analysis of homogenates of the skin and receptor fluid 
showed the presence of parent compound and a minor unknown peak.
TnBP. Marzulli et al. (1965) studied the in vitro dermal absorption of a series of organic phosphates 
using sheets of anterior forearm stratum corneum conjunctum from humans mounted in diffusion cells.
The chemicals comprised TnBP and other organic phosphates with shorter alkyl chain.  TnBP was found 
to penetrate the skin at a maximum steady state rate of 0.18 μg/cm2/minute, which was slower than the 
rates determined for the other organic phosphates tested, indicating that chain length was an important
factor in dermal absorption of organic phosphates.
Intravenous administration of a single dose on 5 mg 14C-TnBP/kg to male or female Sprague-Dawley rats 
showed that 14C declined in plasma during the first 4 hours and then increased to reach a plateau between 
4 and 24 hours; this was followed by a gradual decline of radioactivity in plasma that reached about 5%
of the peak at 96 hours after dosing (SOCMA 1992).  No significant differences were noted between 
males and females.  The investigators suggested that 14C during the first 4 hours may reflect unchanged 
TnBP with a short half-life in blood of approximately 1.3 hours.  The mean terminal half-life of 14C 
estimated from urinary excretion data was approximately 29 hours, suggesting that the TnBP metabolites
rapidly disappear from plasma due to tissue uptake followed by slower excretion into the urine.
3.4.2 Distribution 
3.4.2.1 Inhalation Exposure 
No relevant information was located regarding distribution of the selected phosphate ester flame 
retardants in humans or animals following inhalation exposure.
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3.4.2.2 Oral Exposure
As mentioned previously, TDCP was detected in adipose tissue and seminal fluid from members of the 
general population (Hudec et al. 1981; LeBel and Williams 1986); no further relevant information was
located.
The tissue distribution of an equimolar dose of 14C-labeled TCPP, TCEP, and TDCP was studied in male 
Wistar rats (Minegishi et al. 1988). The rats received a single dose of 50 μmol/kg (~14 mg/kg) by gavage
and sacrifices were conducted at various times during a 7-day period.  Elimination half-lives from blood 
appeared to have two phases.  The first phase ranged from 12 to 14 hours, whereas the second phase
ranged from 42 to 59 hours for the three chemicals.  The average times at which each chemical reached 
the maximum concentration in various tissues were 5.7 hours for TCPP, 6 hours for TCEP, and 9.6 hours
for TDCP.  In general, low tissue/blood ratios were recorded in the brain, heart, muscle, and testes.  
Moderate ratios were obtained in adipose tissue, the spleen, and lung; high ratios were recorded in the
liver and kidneys.  The highest amounts of radioactivity in the liver and kidney were detected during the
first 12 hours after dosing.  Seven days after dosing, for the three flame retardants, the highest amount of 
radioactivity was found in the liver.  The longest elimination half-lives from any tissue corresponded to 
adipose tissue and ranged from 87 hours for TCEP to 103 hours for TCPP.  
TCEP. The distribution of 14C-TCEP into seven brain regions from male and female Fischer-344 rats was 
studied by Herr et al. (1991).  The brain areas analyzed were: cerebellum, brainstem, caudate, 
hypothalamus, cortex, hippocampus, and midbrain.  Two hours after administration of single doses of
175, 350 or 700 mg TCEP/kg, all brain areas had dose-related TCEP-derived radioactivity.  No 
preferential distribution was found across brain regions, sexes, or doses.  Twenty-four hours after dosing, 
all brain areas had similar amounts of radioactivity; at this time, mean brain/blood ratios of 0.3 and 
0.7 were determined for the 175 and 350 mg/kg dose groups, respectively, providing no evidence of
bioaccumulation.  Twenty-four hours after 14 days of dosing with 175 mg TCEP/kg/day, radioactivity 
could be quantified in blood and in all brains areas.  Again, no preferential accumulation was observed in 
any specific brain area.  At this time, the average brain/blood ratio was only 0.4, indicating that no 
accumulation occurred even after repeated dosing.  Analysis of blood and brain tissues 72 hours after a
single dose of TCEP showed brain/blood ratios of approximately 0.5, indicating that no differential
elimination of radioactivity existed among the various brain areas.  Extraction of cortical tissue 2 hours
after a single dose of 14C-TCEP showed that the radioactivity was primarily parent compound.  However, 
when cortical tissues from selected treatment groups were pooled to maximize detection of 14C, a 
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metabolite could be detected, and there was evidence that the parent compound/metabolite ratio was
greater in cortical tissue of female rats than of male rats.  
TnBP. Administration of a single dose of 10 or 350 mg 14C-TnBP/kg or eight consecutive doses of 10 or
350 mg 14C-TnBP/kg/day to male or female Sprague-Dawley rats by gavage in corn oil resulted in only 
≤1% of the administered radioactivity detected in tissues 168 hours after dosing (SOCMA 1992), 
suggesting little or no accumulation of parent compound or metabolites at the time of tissue analysis.  
TDCP. A study in which male Sprague-Dawley rats were administered a single oral dose of 0.2, 2, or
20 μmol TDCP/kg (0.086, 0.86, or 8.6 mg/kg) showed that distribution of radioactivity to tissues, 
determined 24 hours after dosing, was unaffected by the size of the dose and that the liver and kidneys
had the highest concentration of radioactivity (Nomeir et al. 1981).  
3.4.2.3 Dermal Exposure 
No relevant information was found in human studies.
TDCP. Application of 0.86 mg 14C-TDCP/kg to a 4-cm2 shaved area of the skin of rats resulted in 
tissue/blood ratios similar to those estimated in an experiment in which rats were injected TDCP
intravenously (see Section 3.4.2.4 below), suggesting that tissue distribution is independent of the route of
administration (Nomeir et al. 1981).  Four hours after the application, the concentration in tissues, in 
decreasing order was: liver > lung > skin > blood > kidneys > adipose > muscle.
TnBP. Application for 6 hours of 10 or 350 mg 14C-TnBP/kg to a 2-cm2 area of the back of male or
female Sprague-Dawley rats followed by washing with soap and water resulted in ≤1% of the applied 
radioactivity in tissues 168 hours after dosing (SOCMA 1992).
3.4.2.4 Other Routes of Exposure
TDCP. The distribution of 14C-TDCP-derived radioactivity was studied in male Sprague-Dawley rats 
administered a single intravenous injection of 14C-TDCP (Lynn et al. 1981).  Tissue samples (all major
tissues and organs) were collected at five time intervals up to 120 hours after dosing.  TDCP disappeared 
rapidly from plasma with a half-life of <5 minutes.  This was paralleled by a rapid rise in the
concentration of the major metabolite of TDCP, bis(1,3-dichloro-2-propyl) phosphate (BDCP, see
Section 3.4.3).  After 2 hours, the concentration of BDCP declined with a half-life of approximately 4– 
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6 hours.  In most tissues, the concentrations of TDCP were initially (at 5 minutes) high, but declined 
considerably by 30 minutes; 8 hours after dosing, TDCP was detected only in fat tissue.  No TDCP was
detected in any tissues studied ≥24 hours after dosing.  BDCP was also quantified in each of the tissues 
studied.  The highest concentration of the metabolite was observed in the lung, liver, blood, and kidneys.  
BDCP could be detected in tissues within 5 minutes of dosing and up to 24 hours later, but not in 
quantifiable amounts 5 days after dosing.  The highest concentrations of radiolabel were measured in the 
kidneys, lung, and liver.  Five minutes after dosing, 46.4% of the administered TDCP had been 
metabolized and 16% of the phosphate was recovered as BDCP.  By 30 minutes, 82% of the whole-body
radiolabel was present as metabolite and 27% of the administered phosphate was recovered as BDCP.  At
8, 24, and 120 hours after dosing, 55.7, 59, and 63% of the administered phosphate was recovered as 
BDCP, respectively.
A similar study was conducted by Nomeir et al. (1981).  Intravenous injection of 14C-TDCP to male 
Sprague-Dawley rats resulted in initially high concentrations of radioactivity in the lung, liver, kidneys, 
and blood, whereas the lowest concentrations were found in muscle, skin, and adipose tissue.  The
relatively high concentration of radioactivity in the lung was thought to be the product of a first-pass 
effect.  Except for the skin, radioactivity decreased in most tissues by 7 hours after dosing.  By day 10, the
remaining radioactivity was only 1–5% of that measured 15 minutes after dosing.  Tissue fractioning
studies showed that radiolabel derived from the parent compound significantly decreased in most tissues 
within the first 2 hours following apparent exponential decay rates with half-lives of 3–4 hours;
elimination half-lives from the lung and adipose tissues were 1.5 and 5.4 hours, respectively.  One day
after dosing, only 20–30% of the radioactivity remaining in tissues was the parent compound.  The
clearance of the remaining radioactivity followed a single exponential decay with a half-life much longer
than that observed for TDCP.
Morales and Matthews (1980) studied the subcellular distribution of TDCP in male CD-1 mice.  Mice 
received a single intravenous injection of 14C-TDCP and 6 hours later, the covalent binding of
radioactivity to DNA, RNA, and protein from liver, muscle, and kidney was monitored.  The highest
concentration of radioactivity was found in the liver.  In each tissue in which it was measured, the
concentration of TDCP-derived bound radioactivity was highest in low molecular weight RNA followed 
in decreasing concentration by protein, rRNA, and DNA.  
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TnBP. Administration of a single intravenous dose of 5 mg 14C-TnBP/kg into the tail vein of male or
female Sprague-Dawley rats resulted in ≤1% of the applied radioactivity in tissues 168 hours after dosing
(SOCMA 1992).
3.4.3 Metabolism
TDCP. Lynn et al. (1981) studied the metabolism of TDCP in male Sprague-Dawley rats.  Analysis by
high-pressure liquid chromatography (HPLC)/liquid scintillation counting of the urine of rats following
an intraperitoneal dose of 14C-TDCP showed a major component (approximately 69% of the radioactivity)
identified as BDCP.  A second component was identified as the dimethyl derivative of 1,3-dichloro-
2-propyl phosphate.  Analysis without derivatization of chloroform extracts of the urine of rats by gas
chromatography/mass spectrometry (GC/MS) showed that the major component was 1,3-dichloro-
2-propanol.  Analysis over a 5-day period of excreta from rats injected intravenously with 14C-TDCP also 
showed BDCP to be a major component of the urine, feces, and bile.  A metabolic scheme was not
proposed, but Lynn et al. (1981) noted that the formation of the mono- and diester-metabolites was likely
to proceed by either mixed function oxidase reactions, hydrolase reactions, and/or glutathione
S-alkyltransferase reactions.  Similar studies in rats conducted by Nomeir et al. (1981) also showed that
the major metabolite excreted in the urine was BDCP, which accounted for 67.2% of the total
radioactivity in the urine. Approximately 32% of the 14C-TDCP-derived radioactivity in the urine was an 
unidentified polar metabolite, whereas only 0.29% was 1,3-dichloro-2-propyl phosphate and 0.45% was
unchanged parent compound. 
In vitro studies with rat liver fractions showed that TDCP was metabolized by enzymes located in the 
microsomal and soluble fractions, and to a lesser extent, by enzymes in the mitochondrial fraction 
(Nomeir et al. 1981).  It appeared that TDCP was metabolized via oxidative and conjugation reactions.
Experiments using the 10,000 g supernatant in the presence and absence of various cofactors showed that
little metabolism (6.4%) occurred in the absence of cofactors.  In contrast, addition of GSH or NADPH
markedly increased metabolism (28 and 26%, respectively), with the highest rate being observed in the
presence of both cofactors (34.7%).  Metabolism also increased steadily for up to 2 hours.  Experiments
with the isolated microsomal fraction showed that this fraction metabolized TDCP to 1,3-dichloro-
2-propanol, 3-chloro-1,2-propanediol, BDCP, and at least one unidentified metabolite.  In the soluble
fraction, TDCP was metabolized to one metabolite, which was probably a glutathione conjugate formed 
with the intact TDCP molecule. 
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TCEP. HPLC analyses of the cumulative 24-hour urine of male and female Fischer-344 rats and male 
B6C3F1 mice following a gavage dose of 175 mg
14C-TCEP/kg showed the presence of up to six peaks
(Burka et al. 1991).  Although qualitatively similar, the profiles showed quantitative differences between 
rats and mice and between male and female rats.  The major peak in both species accounted for 70% of 
the total radioactivity in urine from male mice, but only 50% in both male and female rats.  In contrast, 
both male and female rat urine contained approximately 2 times more of a peak eluting at 9.7 minutes
than did urine from mice, whereas urine from female rats contained more of a peak eluted at 12.9 minutes
(12%) than either male rats (4%) or male mice (7%).  Characterization of urinary metabolites by nuclear
magnetic resonance and MS showed that the major metabolite in female rat urine was bis(2-chloroethyl)
carboxymethyl phosphate (BCCP).  This metabolite co-chromatographed with the major metabolite found 
in both male rats and mouse urine.  Two additional metabolites that were identified in female rat urine
were bis(2-chloroethyl) hydrogen phosphate (BCHP) and the glucuronide of bis(2-chloroethyl)
2-hydroxyethyl phosphate (BCGP); both BCHP and BCGP also co-chromatographed with metabolites
found in mouse and male rat urine.  Experiments pretreating male rats with inhibitors of the enzyme
aldehyde dehydrogenase showed increased TCEP-induced toxicity, whereas preadministration of SK
525A, a mixed-function oxidase inhibitor, slowed elimination of 14C in urine and inhibited production of
BCCP, but did not increase neurotoxicity.  Burka et al. (1991) took these observations to imply that a
metabolite rather than unmetabolized TCEP produces neurotoxicity.  This, however, seems to conflict
with results of studies of distribution of 14C in brains of rats that reported that at the time of seizures, most
of the TCEP-derived radioactivity present in brain tissue was in the form of parent compound (Herr et al. 
1991).  A metabolic scheme proposed by Burka et al. (1991) is shown in Figure 3-7.
Differences in the metabolism of TCEP between male and female Fischer-344 rats have also been
reported in in vitro studies.  In a study that also included liver preparations from humans, Chapman et al. 
(1991) reported that both liver slices and microsomes from humans and male rats metabolized TCEP to 
bis(2-chloroethyl) hydrogen phosphate, 2-chloroethanol, and three unidentified metabolites.  TCEP was 
metabolized by liver slices from female rats, but liver microsomes from female rats did not appear to 
metabolize TCEP.  Additional experiments suggested that a substantial TCEP-hydrolyzing activity in rat 
liver was localized in the cytosol.  The overall rate of TCEP metabolism by male rat liver slices was 
1.7 times greater than for female rat liver slices.  TCEP was metabolized by rat plasma, without sex 
differences, but not by human plasma or whole blood.  In all studies, the major metabolites were 
bis(2-chloroethyl) hydrogen phosphate and 2-chloroethanol.  Since BCCP and BCGP were produced in 
vivo in rats (Burka et al. 1991), but no significant amounts were produced in vitro, Chapman et al. (1991)
suggested that in vivo α-oxidation of TCEP may occur extrahepatically.  Studies with enzyme inhibitors
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Figure 3-7.  Proposed Scheme for TCEP Metabolism in Rats and Mice
O 
ClCH2CH2OP(OCH2CH2Cl)2 
TCEP 
Hyd Ox 
OHO O CHCH2OP(OCH2CH2Cl)2HOP(OCH2CH2Cl)2 Cl
 
BCHP
 -HCl 
Hyd 
O O 
HOOCCH2OP(OCH2CH2Cl)2 OCHCH2OP(OCH2CH2Cl)2 
Ox 
BCCP 
Red 
O O 
Glu-OCH2CH2OP(OCH2CH2Cl)2 HOCH2CH2OP(OCH2CH2Cl)2 
BCGP 
BCCP = bis(2-chloroethyl) carboxymethyl phosphate; BCGP =bis(2-chloroethyl) 2-hydroxyethyl phosphate;
BCHP = bis(2-chloroethyl) hydrogen phosphate; GT = glucuronyl transferase; Hyd = hydrolysis; Ox = oxidation;
Red = reduction
Source:  Burka et al. 1991
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(male rats only) suggested that cytochrome P-450 was responsible for approximately 38% of the total
microsomal TCEP hydrolytic activity.  The remaining microsomal TCEP hydrolytic activity appeared to 
be associated with a B-esterase.  Chapman et al. (1991) noted that B-esterases are present in rat serum, 
but not human serum, which would be consistent with the finding in their study of hydrolysis of TCEP by
rat serum, but not human plasma.
TnBP. Analyses of urine samples from male Wistar rats administered a single intraperitoneal dose of
250 mg 14C-TnBP revealed 11 phosphorus-containing metabolites (Suzuki et al. 1984a).  The major
metabolites were dibutyl hydrogen phosphate, butyl dihydrogen phosphate, and butyl bis(3-hydroxybutyl)
phosphate; no glucuronide or cysteine conjugates could be detected, which suggested that biotrans-
formation of TnBP in rats is carried out mainly by phase I reactions.  However, in a subsequent study, 
Suzuki et al. (1984b) detected several S-containing metabolites in crude extracts of urine from rats treated 
with TnBP intraperitoneally.  The main metabolites were (3-oxobutyl)- and (3-hydroxybutyl) mercapturic
acids, and traces of (2-oxobutyl)- and (2-hydroxybutyl) mercapturic acids.  The results also suggested that
TnBP undergoes transalkylation of 3-hydroxybutyl or 3-oxobutyl moieties after oxidation of the original
butyl moieties.  Based on these findings, Suzuki et al. (1984b) proposed a metabolic scheme for TnBP
shown in Figure 3-8.
SOCMA (1992) also studied the metabolism of TnBP in male and female Sprague-Dawley rats following
administration of intravenous, dermal, or oral (single or repeated doses of 10 or 350 mg/kg) doses.  Urine, 
feces, and expired air were collected at various times up to 168 hours after dosing (rats sacrificed); blood 
was collected at termination.  Because blood at collection contained <5% of the administered dose, blood 
samples were not chromatographed.  HPLC analyses of urine showed the presence of 10 radioactive 
peaks, and 6 of them contained radioactivity ≥5% of the administered dose.  None of the fecal samples
contained >5% of the administered radioactivity.  In general, the chromatographic profiles of all samples 
were similar, with differences only in the relative concentration of the peaks.  Usually, the majority of the
radioactivity in the urine was contained in the more polar peaks.  Incubation of urine with 
β-glucuronidase produced no changes in the profile, suggesting that phase II metabolism was not a
significant biotransformation route for TnBP.  Differences in chromatographic profiles from rats in the 
various groups appeared greater between individual animals than among treatment groups or between 
male and female rats.  However, profiles from female rats treated with multiple doses or a single high 
dose of TnBP showed higher concentrations of less polar metabolites than profiles from similarly treated 
males.  From the 10 detected radioactive peaks, 18 metabolites were characterized.  The three metabolites 
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Figure 3-8.  Proposed Metabolic Pathway of TnBP in Rats
MFO = mixed function oxidase; GSH = glutathione; GSR = reduced glutathione; TnBP = tributyl phosphate
Source:  Suzuki et al. 1984b
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present in the highest concentrations in most of the samples were butyl 3-hydroxybutyl hydrogen 
phosphate (M8-4 in Figure 3-9), dibutyl hydrogen phosphate (M7), and butyl butanoic acid hydrogen 
phosphate (M8-6).  Other metabolites were phase I metabolites produced by oxidation (acid, keto, 
hydroxylated) or enzymatic hydrolysis of the butyl chains of TnBP.  SOCMA (1992) proposed a scheme
in which the butyl groups of TnBP are oxidized metabolically to alcoholic, ketonic, and acidic groups.  
The oxidized butyl groups are then enzymatically hydrolyzed with sequential loss proceeding from the tri-
substituted to the di-, mono-, and finally to unsubstituted phosphoric acid.  The degree of oxidation or
extent of hydrolysis of the detected metabolites was found to be independent on dosing, treatment, or sex 
of the animal.  The metabolic scheme is presented in Figure 3-9. 
SOCMA et al. (1994) also studied the metabolism of TnBP in Yucatan® minipigs following
administration of 14C-TnBP in a single intravenous injection (5 mg/kg) or after application of chemical
(10 or 350 mg/kg) to the skin for 6 hours, as done in the rat experiments.  Excreta were collected for up to 
168 hours after dosing.  Only urine samples from animals dosed intravenously were analyzed for 
metabolites since fecal samples from pigs treated intravenously or dermally, or urine samples from pigs 
treated dermally contained <5% of the administered dose.  HPLC profiles of urine showed four major
peaks, which were characterized as two diasteromeric pairs of glucuronides of two precursor metabolites, 
a monohydroxy and a dihydroxy dibutyl phosphate.  Neither time of sample collection or gender appeared 
to qualitatively change the distribution or type of the excreted metabolites.  Unchanged TnBP was found 
at ≤0.4% of the administered dose.  Hydrolysis of urine samples with β-glucuronidase followed by
derivatization reactions and GC analysis showed that two peaks with mass spectra corresponding to 
2-hydroxybutyl dibutyl phosphate and dibutyl phosphate.  Based on these results, SOCMA (1994)
proposed a metabolic scheme, shown in Figure 3-10, that involves phase I and phase II reactions.  The
parent chemical is assumed to be oxidized by mixed function oxidases to produce the monohydroxyl and
dihydroxyl species, which are substrates for glucuronide formation.
TPP. Sasaki et al. (1984) provided some information regarding the in vitro metabolism of TPP by a rat
liver preparation.  Rat liver microsomes were able to metabolize TPP in the presence (91% of substrate) 
and absence (66% of substrate) of NADPH.  This suggested that an arylesterase in the microsomes also 
contributed to the metabolism of TPP.  Sasaki et al. (1984) also reported that the soluble fraction from rat
liver also metabolized (15%) TPP.  Experiments to identify metabolites of TPP were not conducted.
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(M10-1) 
[ ] = not observed; DBP = dibutyl phosphate; MBP = monobutyl phosphate; TnBP = tributyl phosphate
Source:  SOCMA 1992
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3.4.4 Elimination and Excretion 
No studies were located regarding elimination and excretion of the selected phosphate ester flame 
retardants or metabolites in humans following any route of exposure.
3.4.4.1 Inhalation Exposure 
No pertinent information was located regarding excretion of phosphate ester flame retardants in animals 
following inhalation exposure.
3.4.4.2 Oral Exposure
Minegishi et al. (1988) compared the excretion of TDCP, TCPP, and TCEP in male Wistar rats during a 
7-day period following gavage administration of a single equimolar dose of 50 μmol/kg of 14C-labeled 
compound.  During the 7-day period, the cumulative excretion of radiolabel in urine followed the order
TCEP > TCPP > TDCP.  Almost all (~90%) of the administered TCEP was excreted in the urine, whereas
~60% of TCPP and ~40% of TDCP were excreted in the urine.  The order of excretion was TDCP
(~40%) > TCPP > TCEP in feces, and TDCP (~18%) > TCPP > TCEP in expired air.  For the three
compounds, recovery within the 7 days was almost 100%.  Experiments in rats with cannulated bile ducts
showed that peak biliary excretion occurred approximately 2 hours after dosing with TCPP and TCEP, 
whereas the peak for TDCP was reached at approximately 6 hours after dosing.  As a percent of the
administered dose, 45% of TCPP, 40% of TDCP, and 25% of TCEP were excreted in the bile in 48 hours.  
Since the biliary/fecal excretion ratios for TCEP and TCPP exceeded 1, it appeared that enterohepatic 
circulation occurred for these two compounds. 
TCEP. Excretion of 14C was studied in female Fischer-344 rats by collecting urine, feces, exhaled 
volatiles, and CO2 over a 3-day period following gavage administration of 175 or 350 mg 
14C-TCEP/kg
(Herr et al. 1991).  The major portion of either dose was excreted in the urine within 24 hours.  Only ≤1%
of the radioactivity was excreted in expired air or as 14C-CO2 in 72 hours.  Less than 10% of the
radiolabel was excreted in feces over 3 days.  Additional experiments were conducted to compare 
excretion between male and female rats over a 24-hour period.  No significant differences were seen 
between males and females administered 175 mg TCEP/kg.  However, females dosed with 350 mg 
TCEP/kg excreted significantly less cumulative 14C in urine than males at the 8- and 24-hour time points. 
Also, high-dose female rats excreted less cumulative 14C in urine than low-dose females at the 4-, 12-, and 
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24-hour time points.  High-dose females also excreted less cumulative 14C in feces over the 24-hour
period than males.
Further studies of the metabolism and excretion of TCEP were conducted by Burka et al. (1991).  In that
study, cumulative 24-hour excretion of 14C-TCEP-derived radioactivity was measured in the urine and 
feces of male and female Fisher-344 rats and male B6C3F1 mice following a gavage dose of 175 mg
TCEP/kg.  In rats, >75% of the administered 14C was eliminated in the urine and <10% was eliminated in 
the feces over 24 hours; no significant differences were seen between males and females.  However, male 
mice eliminated 14C 3 times faster than rats during the first 8 hours.  Administration of nine consecutive
oral doses to rats did not change the elimination rate of 14C in urine.  The elimination of 14C in urine of
female rats followed first-order kinetics with mean half-lives of 6.2, 6.1, and 6.5 hours after one, four, and 
seven doses, respectively.  The corresponding half-lives in male rats were 7.6, 7.8, and 7.1 hours.  The
difference between males and females was statistically significant after one and four doses, but not after
seven doses. 
TnBP. Administration of a single dose of 14 mg 14C-TnBP by gavage to male Wistar rats resulted in 50%
of the 14C recovered in the urine, 10% in exhaled air, and 6% in feces within 1 day (Suzuki et al. 1984a).
This was compared with corresponding values of 70, 7, and 7% after administration of the same dose by
intraperitoneal injection (Suzuki et al. 1984a).  
The excretion of 14C-TnBP-derived radioactivity was also studied in male and female Sprague-Dawley
rats over a 168-hour period following administration by gavage of a single dose of 10 or 350 mg TnBP/kg 
or eight consecutive doses of 10 or 350 mg/kg/day (SOCMA 1992).  Analyses of excreta showed that the
major portions of the administered doses were eliminated within 48 hours in urine and feces.  The ratio of
radioactivity urine/feces ranged from about 4 in single- low-dose males to 14 in repeated-high-dose
females.  Excretion of radioactivity in expired was low ranging from 3.6% in repeated-high-dose females 
to 8.3% in single-high-dose males.
3.4.4.3 Dermal Exposure 
TnBP. SOCMA (1992) studied the excretion of 14C-TnBP-derived radioactivity in Sprague-Dawley rats 
over a 168-hour period after application of 10 or 350 mg TnBP/kg to a 2-cm2 area of the skin for 6 hours
followed by washing with soap and water.  The major portion of the recoverable dose was excreted in the
urine and feces within 48 hours.  In males, over the 168-hour period, approximately 29 and 40% of the
***DRAFT FOR PUBLIC COMMENT***
    
 
    
 
 
 
 
 
 
  
   
    
     
     
 
       
  
   
 
    
 
    
    
       
 
  
 
     
 
     
 
 
 
  
  
  
   
     
 
 
      
   
160PHOSPHATE ESTER FLAME RETARDANTS
3. HEALTH EFFECTS
applied low- and high-dose, respectively, was recovered in urine and 3 and 7% in feces.  In females, 
approximately 32 and 44% of the applied low- and high-dose, respectively, was recovered in urine and 
3 and 7% in feces.  In both the low- and high-dose groups, between 24% (high-dose females) and 43%
(low-dose females) of the applied 14C was recovered in the wash.  Radioactivity in expired air comprised 
≤2% of the applied dose.  No significant differences in excretion were seen between males and females.
Yucatan® minipigs excreted in the urine and feces ≤4% of a dermal dose of 10 or 350 mg of 14C-TnBP/kg
applied to the skin for 6 hours, indicating that dermal absorption of TnBP in this species is about 10 times 
lower than in rats under similar experimental conditions (SOCMA 1992).  
3.4.4.4 Other Routes of Exposure 
TDCP. In male Sprague-Dawley rats administered a single intravenous injection of 14C-TDCP, the
primary route of excretion of radiolabel was the urine with significantly lesser amounts being excreted in 
the feces and in expired CO2 (Lynn et al. 1981).  Approximately 62% of the radiolabel in the composite
urine and 51% in composite feces over a 5-day period was found to be BDCP.  On a molar basis, BDCP
excreted in the urine and feces accounted for approximately 63% of the administered dose of TDCP.  
Only trace amounts of the parent compound were detected in the urine and feces.  Experiments in rats
with cannulated bile ducts showed that approximately one third of the administered radiolabel was
excreted via the bile in 24 hours.  Comparison of rats with cannulated bile ducts with normal rats showed 
that at least 67% of the radiolabel excreted in the bile was reabsorbed.
Similar results were reported by Nomeir et al. (1981) who also administered 14C-TCDP to male Sprague-
Dawley rats intravenously.  In their study, approximately 47 and 21% of the administered radiolabel was 
excreted in the urine and feces, respectively, within 10 days of administration.  The major metabolite
excreted in the urine was BDCP.  Experiments with bile duct-cannulated rats suggested that a portion of
the radioactivity excreted in the bile was reabsorbed from the gastrointestinal tract and excreted in the
urine.  Nomeir et al. (1981) also showed that approximately 20% of an intravenous dose of TDCP was
exhaled as CO2 during the first 24 hours after dosing; the radioactivity was primarily metabolites rather
than parent compound.  
TnBP. Administration of a single intraperitoneal dose of 14 mg 14C-TnBP to male Wistar rats resulted in 
70% of the 14C recovered in the urine, 7% in exhaled air, and 4% in feces within 1 day (Suzuki et al. 
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1984a).  The detection of radiolabel in the feces after an intraperitoneal injection suggested that some 
metabolites were excreted via the bile duct.
SOCMA (1992) studied the excretion of 14C-TnBP-derived radioactivity in Sprague-Dawley rats over a 
168-hour period after a single intravenous injection of 5 mg TnBP/kg into the tail vein.  The major
portion of the recoverable dose was excreted in the urine and feces within 48 hours.  Over the 168-hour
period, approximately 69 and 80% of the injected dose was recovered in urine of males and females, 
respectively; in the same period, 17 and 7% was recovered in feces from males and females, respectively.  
Cumulative recovery of 14C in expired air accounted for 4–6% of the administered dose of TnBP.  Only
≤1% of the administered dose was recovered in tissues.  In total, approximately 90% of the administered 
dose of radioactivity was recovered in excreta. 
SOCMA (1992) also studied the excretion of 14C-TnBP-derived radioactivity in Yucatan® minipigs by
analyzing excreta collected for up to 168 hours after administration of a single intravenous dose of 5 mg
TnBP/kg.  About 82% of the administered dose was excreted in the urine and 2–3% in the feces.  The
majority of the urinary excretion occurred during the first 6 hours after dosing.  There was no difference 
between males and females.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
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route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-11 shows a conceptualized representation of a PBPK model.
If PBPK models for phosphate ester flame retardants exist, the overall results and individual models are 
discussed in this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and 
species extrapolations.
No PBPK models have been developed for the phosphate ester flame retardants discussed in this profile.
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Figure 3-11.  Conceptual Representation of a Physiologically Based
 
Pharmacokinetic (PBPK) Model for a Hypothetical

Chemical Substance
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Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  adapted from Krishnan and Andersen 1994
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3.5 MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms 
Absorption. Studies with TCEP, TDCP, and TnBP in animals showed that these substances are rapidly
and extensively absorbed through the gastrointestinal tract (Herr et al. 1991; Nomeir et al. 1981; SOCMA
1992).  However, the mechanisms involved in the absorption of these compounds have not been studied.  
Given the fast absorption, it seems reasonable to assume that the process occurs through passive 
diffusion.  TDCP was also rapidly absorbed through the skin of rats, but a rate of absorption was not
estimated (Nomeir et al. 1981).  A study with TnBP showed significant differences in dermal absorption 
between rats and minipigs; that rats absorbed about 10 times more of 14C-TnBP-derived radioactivity than 
did minipigs (SOCMA 1992).  No mechanism for dermal absorption was proposed, but a study with 
isolated human skin showed that for a group of alkyl phosphate ester flame retardants, chain length was
an important factor in dermal absorption; the shorter the alkyl chain length, the faster the compound was
absorbed (Marzulli et al. 1965).  It was also observed that substances with benzene/water partition ratios
closest to 1 had the highest penetration rates, and compounds with the lower boiling points penetrated the
skin better than those with the highest boiling points.
Distribution. No specific mechanisms of distribution were apparent for the phosphate ester flame 
retardants for which there are distribution data (i.e., TCEP, TnBP, TDCP, TCPP).  In general, oral studies
with radiolabeled compounds showed no preferential accumulation in tissues.  A study in which three
dose levels of TDCP (0.086, 0.86, or 8.6 mg/kg) were administered to rats showed linear increases in 
distribution to tissues over the dose range tested 24 hours after dosing, indicating independence from dose
size (Nomeir et al. 1981).  That study also provided evidence of distribution independent from the route
of exposure as tissue/blood ratios of radioactivity after dermal exposure to TDCP were similar to ratios 
calculated after intravenous administration of the compound.  A study of distribution of 14C-TCEP-
derived radioactivity to various brain areas from rats also showed almost linear distribution of
radioactivity over the dose range tested 2 hours after dosing (Herr et al. 1991).  That study also showed 
that distribution to the areas monitored was sex-independent.  
Metabolism. The metabolism of TDCP, TCEP, and TnBP has been fairly well studied and involves
both phase I and phase II reactions.  In rats, metabolism was the main form of elimination of TDCP (Lynn 
et al. 1981).  The role that metabolism may play in the toxicity and/or carcinogenicity of TDCP is
unknown.  
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Studies in rats aimed at identifying the chemical entity responsible for the seizure activity and brain 
lesions in rats exposed to TCEP showed quantitative differences in metabolism between rats and mice and 
between female and male rats (Burka et al. 1991).  Pretreatment of the rats with the mixed function 
oxidase inhibitor SK 525A, which should have led to accumulation of parent compound, did not result in 
increased neurotoxicity, which led Burka et al. (1991) to suggest that a metabolite rather than TCEP
produces neurotoxicity.  This, however, seems to be in conflict with the observation that at the time of
seizure activity, only unmetabolized TCEP was detected in extractions of brain cortical tissues from
individual rats.  In addition, further experiments showed some evidence that in pooled tissues, the
unmetabolized TCEP/metabolite ratio was greater for cortical tissues of female rats (the more sensitive 
gender) than male rats (Herr et al. 1991).  In vitro studies with liver preparations from humans and rats
also showed differences in the metabolism of TCEP between species and between male and female rats 
(Chapman et al. 1991).  For example, both liver slices and microsomes from humans and male rats
metabolized TCEP to bis(2-chloroethyl) hydrogen phosphate, 2-chloroethanol, and three unidentified 
metabolites.  However, TCEP was metabolized by liver slices from female rats, but not by liver
microsomes from female rats.  In addition, TCEP was metabolized by rat plasma, without sex differences, 
but not by human plasma or whole blood.  
The metabolism of TnBP has been studied in rats and minipigs.  SOCMA (1992, 1994) conducted studies
in both species and reported that phase II metabolism appeared to be a much more significant
biotransformation route in minipigs than in rats.  In neither species did there appear to be significant
differences in the metabolic profile between males and females.  The role of metabolism of TnBP in the
toxicity of this substance is not known.  Intermediate- and chronic-duration toxicity studies with TnBP in 
rats showed the urinary bladder to be the most sensitive tissue, as it caused urinary bladder hyperplasia, 
which appeared to develop into urinary bladder tumors after chronic-duration exposure (Arnold et al. 
1997; Auletta et al. 1998a; FMC 1985a; Tyl et al. 1997).  The mechanism by which this occurs is not
known, but it has been suggested that it may involve one or more metabolites, particularly dibutyl 
phosphate (Arnold et al. 1997).
Excretion. Studies of elimination of some of the selected phosphate ester flame retardants indicate that
the urine is the main route of elimination and that, for some of them, there are differences between species
and between male and female animals.  For example, a comparative study of TDCP, TCPP, and TCEP
reported that in rats, approximately 90% of the administered TCEP was excreted in the urine, whereas 
60% of TCPP and 40% of TDCP were excreted in the urine (Minegishi et al. (1988).  It also appeared that
enterohepatic circulation occurred for TCEP and TCPP, but not TDCP.  A study with TCEP reported that
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at high doses, female rats excreted less cumulative TCEP-derived radioactivity in urine and feces than 
males over a 24-hour period (Herr et al. 1991).  It was also shown that male mice eliminated TCEP-
derived radioactivity significantly faster than male or female rats during an 8-hour period after a single
gavage dose (Burka et al. 1991).  Studies with TnBP in rats and minipigs applied the same doses of the
chemical onto the skin showed that rats eliminated considerably more TnBP-derived radioactivity in the
urine (up to 40% of the applied dose) than minipigs ( ≤4% of theapplied dose) over the same period of 
time (SOCMA 1992).  This reflected reduced absorption in minipigs compared to rats, since rats and 
minipigs excreted similar percentages of radioactivity in the urine following intravenous administration of
the chemical.  
3.5.2 Mechanisms of Toxicity
Few studies were located that explored possible mechanisms of action of the phosphate ester flame 
retardants flame retardants discussed in this profile.  The rat kidney was a sensitive target for TCEP, as 
chronic treatment resulted in increased incidence of renal tubule hyperplasia (NTP 1991a).  The
mechanism by which this occurred is not known.  However, a recent study suggested that TCEP might
alter the levels of cell cycle regulatory proteins in the kidney (Ren et al. 2008).  The investigators
incubated primary cultured rabbit renal proximal tubule cells with TCEP and reported that TCEP
decreased cell viability, inhibited the expression of some regulatory proteins (CDK4, cyclin D1, CDK2, 
cyclin E), increased the expression of others (p21WAF/Cip1, p27Kip1), and decreased DNA synthesis and cell
numbers.  Whether or not this also occurs in vivo in rats is not known, but further research in this area
would be valuable.
TCEP also induced brain lesions in rats in acute-, intermediate-, and chronic-duration studies; this was
observed mostly in females (NTP 1991a, Tilson et al. 1990).  The lesions occurred mostly in the
hippocampus following acute- and intermediate-duration exposure and in the cerebral cortex and brain 
stem following chronic-duration exposure.  In the acute study, the rats also exhibited seizure activity, and 
rats in the highest dose groups in the intermediate-duration study experienced occasional periods of
hyperactivity after dosing; no clinical signs were reported in the chronic-duration study (NTP 1991a).  
Since in the acute study, the seizure activity and neurohistological damage were attenuated by
pretreatment with atropine or chlordiazepoxide, Tilson et al. (1990) suggested that the morphological
damage was related to the seizures produced by TCEP.  What triggers the seizures is not known for
certain, but a study of the effects of TCEP on ambulatory activity in mice suggested that TCEP may act as 
a GABA antagonist (Umezu et al. 1998). Through the use of various pharmacological manipulations with 
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cholinergic antagonists and GABA agonists, the investigators determined that the TCEP-induced 
increased ambulatory activity was not a result of inhibition of acetylcholinesterase, but of an action as 
GABA antagonist.  It would be useful to try to replicate these results in rats. 
A characteristic effect of TnBP was the induction of urinary bladder hyperplasia in rats in intermediate-
and chronic-duration studies (Arnold et al. 1997; Auletta et al. 1998a; FMC 1985a; Tyl et al. 1991).  The
hyperplasia was the consequence of focal urothelial necrosis.  In one of the intermediate-duration studies, 
it was shown that the effects were reversible upon cessation of treatment and that acidification of the 
urine with ammonium chloride did not prevent, but attenuated, the proliferative changes (Arnold et al. 
1997).  The mechanism by which the urinary bladder changes occur is not known, but scanning electron 
microscopy showed that the epithelial necrosis was not due to the presence of urinary calculi, 
microcrystalluria, or precipitate formation.  Since TnBP is extensively metabolized, Arnold et al. (1997)
speculated that the cytotoxicity may be due to one or more metabolites, possibly dibutyl phosphate.
TPP was one of several triaryl phosphates that were tested for effects on human nuclear receptors 
(Honkakoski et al. 2004).  Nuclear receptors control a wide range of cellular processes and alterations in 
their functions can result in also a wide range of clinical manifestations. Experiments were conducted 
with HEK293 cells transfected with mouse or human nuclear constitutively active receptor (CAR) or 
pregnane X receptor (PXR) and their reported genes; the cells were incubated with vehicle, reference 
substances, or triaryl phosphates.  The results showed TPP to be a weak activator of mouse CAR and 
PXR, but a greater activator of human CAR (5.5-fold) and PXR (3-fold).  Additional experiments with 
COS-1 cells transfected with human glucocorticoid receptor (GR), progesterone receptor (PR), androgen 
receptor (AR), and estrogen receptor (ER) showed TPP to inhibit GR and AR in the absence of any added 
agonist and to inhibit testosterone-induced AR-activity by 30–40%.  The significance of these findings to 
in vivo exposure situations remains to be determined.  The few toxicity studies available with TPP in 
animals did not identify significant health effects.
3.5.3 Animal-to-Human Extrapolations 
An animal model that can be used to predict health effects in humans resulting from exposure to any of
the selected phosphate ester flame retardants has not been identified largely because there is very limited 
information regarding health effects of these substances in humans.  Trying to predict what would happen 
to humans exposed to any of these chemicals based on the results from the available animal studies may
be inappropriate at this time given that several studies identified significant differences in susceptibility
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between species for some toxic effects.  For example, treatment of rats and mice with TCEP resulted in 
brain lesions only in rats, even though mice received higher doses of TCEP (NTP 1991a).  Also, rats were
significantly more sensitive to the effects of TnBP on the urinary bladder than mice (Arnold et al. 1997;
Auletta 1991; Auletta et al. 1998a, 1998b; FMC 1985a; Tyl et al. 1997).  The mechanisms of these
differential susceptibilities have not been elucidated, but may be related to differences in 
pharmacokinetics between species. Some evidence for this was presented by Chapman et al. (1991) in 
studies of the metabolism of TCEP by liver slices and microsomes, and plasma from male and female rats 
and humans. 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
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for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans after exposure to the phosphate ester
flame retardants subject of this profile.  
The information available from studies in animals does not suggest that these substances have endocrine
disrupting properties.  Toxicity studies summarized in Section 3.2.2.2, Systemic Effects, did not find 
alterations in gross or microscopic appearance of endocrine glands.  It should be noted, however, that
none of the studies available examined endocrine gland function as judged, for example, by levels of
hormones in serum (i.e., thyroid hormones, sex hormones).  
TCEP decreased fertility in mice in a continuous breeding protocol study following exposure of the
parental generation to ≥350 mg/kg/day by gavage for approximately 14 weeks (NTP 1991b).  Reduced 
fertility appeared to have been due primarily to alterations in sperm parameters such as concentration,
motility, and abnormal forms, but a specific mechanism was not apparent.  A study by Laham et al. 
(1984b) reported that administration of 411 mg TnBP/kg/day to rats by gavage for 14 days induced 
degenerative changes in the seminiferous tubules in the testes.  However, this was based on the 
examination of only 4 male rats out of 10, and only one presented the lesions.  A study of TDCP in which 
rabbits were administered up to 200 mg TDCP/kg/day by gavage for 12 weeks and then mated with 
untreated females showed no effect on fertility when the females were sacrificed at mid-gestation and 
their uteri were examined (Anonymous 1977).  Examination of sperm from the rabbits showed no 
significant alterations in quantity or quality.
Little information is available regarding tests that evaluate potential endocrine disrupting properties in 
vitro. TCEP, TnBP, and TBEP tested negative for estrogenic activity in a reporter gene expression assay
using yeast cells (Nishihara et al. 2000).  A substance was considered positive when its activity was >10%
of the activity of 10-7 M 17β-estradiol.  TPP was inactive (nonbinder) in a binding assay to the estrogen 
receptor from uteri from ovariectomized Sprague-Dawley rats (Blair et al. 2000).  TPP was characterized 
as a moderate binder to the androgen receptor (AR) in a competitive binding assay that used a
commercially obtained recombinant rat protein expressed in E. coli (Fang et al. 2003).  The relative
binding affinity of TPP was four orders of magnitude lower than that of the standard AR ligand used in 
the assay.  TPP was also shown to inhibit the AR in COS-1 cells transfected with human AR in the
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absence of any added agonist to the incubation medium and also to inhibit testosterone-induced AR-
activity by 30–40% (Honkakoski et al. 2004).  Föllman and Wober (2006) examined the estrogenic or
anti-estrogenic effects of TCEP and TCPP with the recombinant yeast reporter gene assay and in human 
endometrial cancer cells and reported that neither compound showed hormonal activity.  No information 
was located for the remaining phosphate ester flame retardants discussed in this profile.  
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
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and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
No studies were located that described health effects in children following exposure to the phosphate ester
flame retardants discussed in this profile.  Also, no studies were located that compared the health effects 
of these compounds in young and adult animals to ascertain potential age-related differences in 
susceptibility.
A limited number of studies in animals suggest that developmental indices, especially in studies of
gestational exposure alone, are not particularly sensitive to exposure to these compounds.  For example, 
rats exposed to 200 mg TCEP/kg/day on Gd 7–15 showed piloerection, general weakness, and reduced 
food consumption, and 7 out of 30 died (Kawashima et al. 1983a).  However, fetal parameters recorded in 
survivors on Gd 20 were not affected and gestational exposure did not affect neonatal viability monitored
up to week 10.  Pregnant mice dosed with 940 mg TCEP/kg/day on Gd 6–13 suffered a significant
reduction in body weight gain, yet at delivery, there were no significant effects on the number of viable
litters, number of live pups born per litter, percent survival of pups, pup birth weight, or pup weight gain 
(Hardin et al. 1987).  Similar results were reported with TBEP (Monsanto 1985b) and TnBP (Noda et al. 
1994) in rats.  Doses of TBEP that induced frank signs of toxicity in the dams such as ataxia and lethargy, 
and reduced weight gain did not induce embryotoxicity or teratogenicity.  Doses of TnBP that induced a
significant reduction in adjusted weight gain on Gd 0–20 did not produce a significant difference between 
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groups in the number of corpora lutea, implants or living fetuses, incidence of dead or resorbed fetuses, 
sex ratio, or body weight of the living fetuses.  In a study with TDCP, doses that significantly decreased 
weight gain in pregnant rats did not significantly affect fetal viability or mean fetal weight or length 
(Stauffer Chemical Co. 1981b).  No developmental effects were reported in a gestational exposure study
with TCPP (Kawasaki et al. 1982) or in a study with TPP administered to male and female rats in doses of
up to approximately 690 mg/kg/day for 91 days before mating and continuing during gestation (Welsh et
al. 1987). 
In a continuous breeding protocol study conducted by NTP (1991b), treatment of the F0 generation with 
≥350 mg TCEP/kg/day significantly reduced the number of live pups per litter.  In addition, the number
of F2 male pups per litter born to the treated F1 generation was significantly lower than in controls in the
groups dosed with ≥175 mg TCEP/kg/day, the lowest dose level tested; a developmental NOAEL was not
identified in the study.  In the absence of clear signs of parental toxicity, the mechanism of action for
these effects is unknown.  In a 2-generation reproduction study, the only significant developmental effect
was a significant reduction in F1 and F2 pup weight per litter measured 5 times from postnatal days 0 to 
21 at maternal doses of approximately 217 mg/kg/day; the number of pups per litter was comparable
among groups (Tyl et al. 1997).  Significant reductions in maternal body weight also occurred at this
level, which may have contributed to the decrease in pup weight.
No information was located regarding the pharmacokinetics of these compounds in children or regarding
biomarkers of exposure or effect for these compounds in children.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source.  The substance being measured may
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be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to 
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 
phosphate ester flame retardants are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific.  They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by phosphate ester flame retardants are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1	 Biomarkers Used to Identify or Quantify Exposure to Phosphate Ester Flame 
Retardants
There are no specific biomarkers that can be used to identify exposure to the subject phosphate ester
flame retardants flame retardants of this profile other than the chemical themselves.  TDCP was detected 
in adipose tissue from members of the general Canadian population (LeBel and Williams 1986) and also 
in seminal fluid from the U.S. general population (Hudec et al. 1981), indicating that exposure to this
substance had occurred or was ongoing.  
TPP was found to inhibit human blood monocyte carboxylesterase (Saboori et al. 1991), but so did a
variety of organophosphorous compounds.  Thus, reductions in the activity of this enzyme are not specific
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for TPP.  No studies were located of the metabolism of these substances in humans that could have 
provided information regarding metabolic products in urine.  
3.8.2	 Biomarkers Used to Characterize Effects Caused by Phosphate Ester Flame
Retardants
The few studies available of workers exposed to the phosphate ester flame retardants discussed in this 
profile did not identify any specific medical condition related to exposure (Stouffer Chemical Company
1983a).  Sutton et al. (1960) reported that red blood cell cholinesterase activity was significantly reduced 
(18%) in a small group of regular operators in a TPP production plant compared to unexposed subjects.  
However, exposure to other chemicals, particularly organophosphate pesticides, can also reduce the
activity of red blood cell cholinesterase; therefore, a reduction in red blood cell cholinesterase activity
may be used as biomarker for a class of chemicals, but not for any one of the chemicals discussed in this 
profile.
3.9 INTERACTIONS WITH OTHER CHEMICALS
No studies were located regarding interactions of the phosphate ester flame retardants discussed in this
profile with other unrelated chemicals or with other phosphate esters. The mechanisms of action for some
of the most sensitive effects of the selected phosphate ester flame retardants have not been elucidated.  
For example, the mechanisms by which TCEP induces brain damage in rats or TnBP induces urinary
bladder hyperplasia in rats are not known; therefore, it is difficult to anticipate the type of response that 
might occur following simultaneous exposure to any of these chemicals and other substances. In addition
to chemical-specific effects that occurred at low doses, such as those mentioned above, phosphate esters
have also shown common effects.  For instance, TCEP, TnBP, and TDCP induced increases in liver
weight in rodents in long-term studies, but in the absence of information on a possible mechanism of
action, any prediction of what the response would be to exposure to a mixture would be pure speculation. 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to phosphate ester flame retardants 
than will most persons exposed to the same level of phosphate ester flame retardants in the environment.  
Reasons may include genetic makeup, age, health and nutritional status, and exposure to other toxic
substances (e.g., cigarette smoke).  These parameters result in reduced detoxification or excretion of
phosphate ester flame retardants, or compromised function of organs affected by phosphate ester flame
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retardants.  Populations that are at greater risk due to their unusually high exposure to phosphate ester
flame retardants are discussed in Section 6.7, Populations with Potentially High Exposures.
There is no adequate information from studies in humans to determine whether there are populations
unusually susceptible to the selected phosphate ester flame retardants discussed in this profile.  Studies in 
animals have described species and gender differences in susceptibility to some of these chemicals.  For 
example, male rats were more susceptible than females to the liver effects of TBEP (Reyna and Thacke 
1987a); female rats were more susceptible to brain lesions produced by exposure to TCEP than males, 
and rats were more susceptible than mice (NTP 1991a).  However, making inferences into potential
differences in humans based on what has been reported in studies in animals would be purely speculative 
at this time. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to phosphate ester flame retardants.  However, because some of the treatments discussed may be
experimental and unproven, this section should not be used as a guide for treatment of exposures to 
phosphate ester flame retardants.  When specific exposures have occurred, poison control centers and 
medical toxicologists should be consulted for medical advice.  No texts were located that provide specific 
information about treatment following exposures to the subject phosphate ester flame retardants flame 
retardants of this profile.  
3.11.1 Reducing Peak Absorption Following Exposure 
There have been no reports of health effects in humans induced by exposure to phosphate ester flame
retardants other than reports of skin irritation and contact dermatitis in subjects exposed to TnBP, TBEP, 
and TPP (ACGIH 2001; Camarasa and Serra-Baldrich 1992; Carlsen et al. 1986; IPCS 1991a, 1991b).
Skin irritation can be relieved by applying general measures such as removing the contaminated clothing
and washing the exposed area thoroughly with soap and water (HSDB 2009).  If contact with the eyes
occurs, irrigation with copious amounts water at room temperature for at least 15 minutes is 
recommended (HSDB 2009).  In case of ingestion, emesis is not recommended because of the potential
for gastrointestinal irritation.  The use of activated charcoal is of unproven value in patients ingesting
irritant chemicals where it may obscure the endoscopic findings when the procedure is justified (HSDB
2009).  If used, it is recommended that it be administered as slurry (240 mL water per 30 g of charcoal).  
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The usual dose is 25–100 g in adults and adolescents, 25–50 g in children (1–12 years), and 1 g/kg in 
infants <1 year old (HSDB 2009).
3.11.2 Reducing Body Burden
No information was located regarding reducing body burden following exposure to phosphate ester flame
retardants. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The phosphate ester flame retardants discussed in this profile are not potent anticholinesterase agents, but
cases of accidental or intentional acute exposure to high amounts may occur.  If cholinergic signs and 
symptoms develop, appropriate treatment may be warranted.  The following information has been 
extracted from HSDB (2009).  Suction of oral secretions is recommended until atropine can be 
administered.  Atropine should be administered intravenously until atropinization is achieved.  Adults
should receive 2–5 mg every 5–10 minutes, and children should receive 0.05 mg/kg every 10–15 minutes.
This may be necessary for hours or days depending on the severity of the intoxication.  Patients with 
moderate to severe poisoning should be treated with 2-PAM (Pralidoxime) in addition to atropine; 
2-PAM is most effective if given within 48 hours for 24 hours after cholinergic manifestations have 
ceased.  The initial recommended dose is 30 mg/kg followed by an infusion of >8 mg/kg/hour.  
Alternatively, adults may receive 1–2 g 2-PAM in 100 mL of 0.9% saline over 15–30 minutes follow by 
infusion of 500–1,000 mg/hour as a 2.5% solution. The initial dose may be repeated 1 hour and then 
every 3–8 hours if muscle weakness or fasciculations persist.  Children may be treated with 20– 
50 mg/2-PAM/kg infused over a 2-hour period (maximum 2 g) as a 5% solution in 0.9% saline followed 
by a continuous infusion of 10–20 mg/kg/hour.  Alternatively, the initial dose may be repeated in 1 hour
and then every 3–6 hours if muscle weakness or fasciculations persist.
3.12 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of phosphate ester flame retardants is available.  Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology Program
(NTP), is required to assure the initiation of a program of research designed to determine the health 
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effects (and techniques for developing methods to determine such health effects) of phosphate ester flame
retardants.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Phosphate Ester Flame Retardants
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
phosphate ester flame retardants are summarized in Figure 3-12.  The purpose of this figure is to illustrate
the existing information concerning the health effects of phosphate ester flame retardants. The presence
of the acronym in a square indicates that one or more studies provide information associated with that
particular effect for that particular phosphate ester.  The presence of the acronym in the square does not
necessarily imply anything about the quality of the study or studies, nor should missing information in 
this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for
Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic
Substances and Disease Registry 1989), is substance-specific information necessary to conduct
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any
substance-specific information missing from the scientific literature.
As shown in Figure 3-12, there was very limited information on the effects in humans of the phosphate 
ester flame retardants discussed in this profile.  The available information was derived from only a few
occupational studies in which exposure was assumed to have been primarily by inhalation of vapor mists
and dust.  These studies provided information on morbidity and mortality of workers exposed to TDCP
and TPP.  A few studies were also available that provide information on dermal effects of TPP on 
members of the general population.
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Figure 3-12.  Existing Information on Health Effects of Phosphate Ester Flame
Retardants
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Most of the studies available in animals were conducted by the oral route of exposure, although 
information on lethality due to acute high inhalation and dermal exposures was also available.  Sufficient
information on health effects of oral exposure to TCEP, TnBP, TBEP, and TDCP was available to derive 
oral MRLs for these substances, although not for all exposure durations.  In general, information was
available for systemic, neurological, reproductive, developmental effects, genotoxicity, and cancer; less 
data were located for immunological effects.  Limited information was available for TPP and even less 
information was available for TiBP and TCPP.
The information available from animal studies was insufficient to conclusively determine whether or not
the effects of the selected phosphate ester flame retardants are route-dependent; however, the
toxicokinetics data for a few of these chemicals suggested that, other than portal-of-entry effects such as 
skin or gastrointestinal irritation, the toxicity of these substances is probably not route-dependent.  In 
addition, the environmental monitoring data available suggested that the levels of some of these
substances to which the general population might be exposed through contact or use of consumer
products (including food and water), or that are commonly found in environmental media are generally
orders of magnitude lower than those used in studies with experimental animals.
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. No data were located regarding health effects in humans following acute 
exposure by any route to the phosphate ester flame retardants discussed in this profile.  The acute 
inhalation studies in animals provide information mostly on lethal doses and are not adequate for
derivation of acute-duration inhalation MRLs.  The dermal studies available in animals were also 
designed to estimate lethal doses.  However, it would be useful to determine whether dermal exposure to
these substances results in sufficient material being absorbed to be of concern.  The selection of an 
appropriate animal model for human dermal exposure is important; limited data with TnBP indicate that
Yucatan® minipigs absorbed 10 times less TnBP through the skin than rats (SOCMA 1992).  Sufficient
data were available to derive acute-duration oral MRLs for TnBP and TBEP; both studies were
gestational exposure studies in rats (Monsanto Co. 1985b; Noda et al. 1994).  No MRLs were derived for
TCEP, TDCP, TCPP, TiBP, or TPP due to either lack of studies or the studies available did not identify
clear adverse effects.  In general, and this applies also to the subsequent sections, the decision to 
recommend additional studies by any route for any one of phosphate ester flame retardants selected for
this profile should take into account information regarding environmental monitoring, potential routes of
exposure for the population, and information on levels of these substances in biological fluids from a
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representative sample of the population.  While recognizing that it would be useful for health assessors to 
have MRLs for all of these chemicals, this information should help prioritize the need for additional
studies.
Intermediate-Duration Exposure. No specific information was located regarding health effects in 
humans following intermediate-duration exposure to the selected phosphate ester flame retardants, 
although some workers exposed to TDCP or TPP in the studies conducted by Stauffer Chemical Co. 
(1983a) and Sutton et al. (1960) may have been exposed for <1 year.  No intermediate-duration inhalation 
studies in animals were located.  Intermediate-duration dermal studies in rabbits were available for TPP
(Monsanto Co. 1979) and TBEP (Monsanto Co. 1985d).  These studies evaluated systemic toxicity end 
points as well as effects at the application site.  The only effects reported were dermal effects in rabbits 
treated with ≥10 mg TBEP/kg/day.  Intermediate-duration oral studies, adequate for use as the basis for
MRL derivation, were available for TCEP, TnBP, TBEP, and TDCP.  The MRL for TCEP was based on 
necrosis of hippocampal neurons in female rats in a 16-week gavage study (NTP 1991a). That study also 
provided information on a wide range of systemic end points.  In addition, a continuous breeding protocol
study in mice was available (NTP 1991b).  Several intermediate-duration studies in rats exposed to TnBP
in the diet were available (Arnold et al. 1997; FMC 1985a; Laham et al. 1985a; Tyl et al. 1997).  These
studies identified the urinary bladder of rats as a sensitive target for TnBP and the intermediate-duration 
oral MRL for this chemical was based on this end point (Arnold et al. 1997).  Information on reproductive
and neurological effects of TnBP was also available (Arnold et al. 1997; Healy et al. 1995).  The
intermediate-duration oral MRL for TBEP was based on hepatic effects in rats exposed to TBEP in the
diet in the only wide scope study available for this chemical (Reyna and Thacke 1987a). An 
intermediate-duration oral study that evaluated reproductive parameters in male rabbits was available for
TDCP (Anonymous 1977).  The limited scope of this study precluded its use for MRL derivation. 
However, data from the interim assessement of rats after 12 months of treatment in the 24-month bioassay
conducted by Stauffer Chemical Co (1981a) were used to derive an intermediate-duration oral MRL for
TDCP. Intermediate-duration oral studies with TPP provided information regarding organ weights in rats
(Sutton et al. 1960), neurobehavioral effects in rats (Sobotka et al. 1986), reproductive and developmental
effects in rats (Welsch et al. 1987), and immunological effects in rats (Hinton et al. 1996).  However, no 
MRL was derived for TPP based on no clear evidence of toxicity provided in these studies.  Only one
intermediate-duration study that reported effects of unknown toxicological significance in rats was 
located for TiBP (Naylor and Ribelin 199).  No intermediate-duration oral studies were available for 
TCPP.  As indicated above, monitoring data as well as potential for exposure should be considered in the
decision to recommend conducting studies to fill the data gaps for individual triphosphate ester flame
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retardants. Since these chemicals are usually found as mixtures at hazardous waste sites and in 
environmental media, there is a need to conduct toxicity studies for mixtures to determine how these
chemicals interact with each other and how this affects their toxicity.
Chronic-Duration Exposure and Cancer. Studies by Stauffer Chemical Co. (1983a) and Sutton et
al. (1960) provide data on workers exposed chronically to TDCP and TPP, respectively.  Neither study
found significant associations between exposure to these substances and adverse health effects.  In both 
cases, the primary route of exposure is assumed to have been inhalation, but dermal exposure probably 
also occurred.  No information was located regarding health effects in humans following chronic
exposure to the other phosphate ester flame retardants discussed in this profile.  No chronic inhalation or
dermal studies were identified for any of the phosphate ester flame retardants discussed in this profile.  
Chronic data were available for TCEP in an NTP (1991a) bioassay that examined a wide range of end 
points in rats and mice treated with the chemical by gavage.  The most sensitive effects identified in that
study were brain lesions in female rats and renal tubule lesions in male and female rats.  A chronic-
duration oral MRL was derived for TCEP based on the renal lesions in female rats; additional chronic 
studies for this chemical do not seem necessary.  Long-term studies were also available for TnBP in rats 
and mice (Auletta et al. 1998a, 1998b).  The urinary bladder from rats was the target for TnBP toxicity;
treated rats showed an increased incidence of urinary bladder hyperplasia.  Because the incidences were 
lower than those seen in intermediate-duration studies at comparable doses, the intermediate-duration oral
MRL was also adopted as the chronic-duration MRL (a detailed explanation can be found in Section 2.3).
A chronic-duration study in rats treated with TDCP in the diet was available (Stauffer Chemical Co. 
1981a).  Liver and kidneys effects occurred at the lowest dose tested and the latter served as the basis for
derivation of a chronic-duration oral MRL for TDCP.  Additional studies for TDCP do not seem
necessary.  No chronic-duration oral studies were identified for TBEP, TPP, TiBP, or TCPP.  It seems
reasonable that before conducting chronic-duration studies with these chemicals, a more or less complete 
intermediate-duration database be available in which the most sensitive end points have been identified in 
well-conducted studies. As previously mentioned, studies of the toxicity of mixtures of phosphate esters
flame retardants would be valuable since these substances are generally found as mixtures at hazardous 
waste sites and other environmental media.
No associations between exposure to TDCP and cancer were reported in a retrospective cohort study that
examined the mortality experience of workers employed in the manufacture of TDCP (Stauffer Chemical
Co. 1983a).  No further information was located regarding exposure to the selected phosphate ester flame
retardants and cancer in humans.  TCEP, TnBP, and TDCP have been tested for carcinogenicity in long-
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term oral bioassays.  Treatment of rats with TCEP by gavage increased the incidence of renal tubule 
adenoma or carcinoma in males and renal tubule adenomas in females (NTP 1991a).  TCEP also induced 
a nonsignificant increase in the incidence of a rare renal tubule neoplasm in male B6C3F1 mice.  TCEP 
increased, although not significantly, the incidence of tumors of the Harderian gland in female B6C3F1 
mice.  In another study, dietary treatment of mice with TCEP increased the incidences of renal and liver
tumors in male mice and forestomach tumors and leukemia in female mice (Takada et al. 1989).  In 
dermal assays, TCEP showed no significant carcinogenic, initiating, or promoting activity on the skin of
female mice (Sala et al. 1982).  TnBP increased the incidence of urinary bladder cancer in male rats 
(Auletta et al. 1998a) and hepatocellular adenomas in male mice (Auletta et al. 1998b).  TDCP increased 
the incidence of neoplastic nodules in the liver of male and female rats and the incidence of hepatocellular
carcinomas in male rats (Stauffer Chemical Co. 1981a).  TDCP also increased the incidence of renal
cortical tumors in male and female rats, interstitial cell tumors in the testes in male rats, and 
adrenocortical adenomas in female rats.  Additional standard cancer studies for these chemicals seem
unnecessary, but mechanistic studies are lacking.  For example, further research is needed to elucidate the 
mechanism by which TnBP induces urinary bladder cancer in rats, which does not seem to be related to 
changes in urine pH and composition or to physical agents such as calculi, microcrystals, or precipitate 
(Auletta et al. 1998a).  It would be valuable to determine also whether or not urinary bladder hyperplasia
is a precursor of bladder cancer. The mechanisms of carcinogenicity for TCEP or TDCP also are not
known.  Studies of subcellular distribution of radioactivity derived from phosphate ester flame retardants,
such as those conducted by Morales and Matthews (1980) with TDCP can provide information on the
possible formation of adducts with cellular macromolecules that may be involved in carcinogenicity.  No 
information was located regarding cancer effects in animals exposed to TBEP, TPP, TiBP, or TCPP.
Knowing the extent of exposure of the general population to these substances may be a factor to consider
in deciding whether or not to conduct cancer studies with these chemicals.
Genotoxicity. No information was located regarding genotoxic effects of the selected phosphate ester
flame retardants in humans.  All of the selected phosphate ester flame retardants have been tested for 
genotoxic effects in in vitro assays in various strains of S. typhimurium. With a few exceptions, the
results have been mostly negative.  Positive results were reported for TDCP in the presence of metabolic 
activation in two studies (Gold et al. 1978; NTP 1983) and in one study both in the presence and absence
of metabolic activation (Mortelmans et al. 1986).  It is unclear what the value would be of conducting
additional mutagenicity studies in prokaryotic organisms.  In vitro assays in mammalian cells yielded 
negative results for TBEP (Mobil Oil Corp 1991; Monsanto Co. 1985c) and TnBP (Batt et al. 1992).  
Mixed results were reported for TCEP (Föllmann and Wober 2006; Galloway et al. 1987; NTP 1991a;
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Sala et al. 1982), TCPP (Föllmann and Wober 2006), and TDCP (Brusick et al. 1979; Dybing et al. 1983;
Søderlund et al. 1985; Stauffer Chemical Co. 1981b); no studies were located for TPP or TiBP.  It is
difficult to determine whether the different results with a specific test among the phosphate ester flame 
retardants represent true mechanistic differences or reflect methodological differences.  Additional tests 
will probably not resolve the issue.  However, as mentioned above, additional studies of the potential
binding of phosphate ester flame retardants or their metabolites, particularly of those that have shown to 
induce cancer in animals, to cellular macromolecules could provide valuable information regarding
mechanisms of carcinogenicity.  TDCP, TCEP, TiBP, and TnBP yielded negative results in tests for
clastogenicity in vivo (Batt et al. 1992; Brusick et al. 1979; Flowers and Garrett 1992; Sala et al. 1982;
Stauffer Chemical Co. 1981b; Vogel and Nivard 1993).  In vivo studies with TCPP, TBEP, and TPP
would be valuable.  
Reproductive Toxicity. No information was located regarding reproductive effects in human exposed 
to the selected phosphate ester flame retardants. TCEP, TnBP, TPP, and TDCP have been tested for
effects on fertility in oral studies.  TCEP reduced fertility in mice in a continuous breeding protocol study
(NTP 1991b).  Both sexes were adversely affected, but the males appeared to be more sensitive than 
females, as all sperm end points examined (concentration, motility, and percent abnormal) were affected.  
In a 2-generation reproductive toxicity study in rats, TnBP had no significant effect on mating and 
fertility rates, or on gross and microscopic appearance of the reproductive organs in the F0 or
F1 generations (Tyl et al. 1997).  TDCP did not affect fertility in male rabbits treated by gavage for 
12 weeks and then mated with untreated females (Anonymous 1977).  Fertility indices (number pregnant, 
corpora lutea, implantations, implantation efficiency, resorptions) were not affected in male or female rats
dosed with TPP for 91 days before mating (Welsh et al. 1987).  TBEP has not been tested for effects on 
fertility, but acute- and intermediate-duration studies in rats reported no gross or microscopic alterations
in the reproductive organs of males and females (Komsta et al. 1989; Reyna and Thacke 1987a).  
Exposure of rats to TiBP in the diet for 13 weeks also did not result in gross or microscopic alterations in 
the reproductive organs (Naylor and Ribelin 1990).  In the absence of any evidence indicating that the
reproductive organs are sensitive targets for TBEP or TiBP, fertility testing does not appear necessary at
this time.  No relevant data were located for TCPP; acute and intermediate oral studies that might be
conducted with this chemical should include examination of the reproductive organs to determine
potential reproductive effects.  
Developmental Toxicity. No information was located regarding developmental effects in humans
exposed to the phosphate ester flame retardants discussed in this profile.  The developmental effects of
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TCEP (Hardin et al. 1987; Kawashima et al. 1983a), TnBP (Noda et al. 1994), TBEP (Monsanto 1985b), 
TDCP (Stauffer Chemical Co. 1981b), TPP (Welsch et al. 1987), and TCPP (Kawasaki et al. 1982) have
been examined in oral studies that included exposure during gestation.  In general, these studies did not
report fetotoxicity or teratogenicity even at doses that produced maternal toxicity.  However, in a
continuous breeding protocol study in mice exposed to TCEP, there was a decrease in the number of live 
male F2 pups per litter (NTP 1991b).  Also, in a 2-generation reproductive study in mice exposed to 
TnBP, there was reduction in F1 and F2 pup weight per litter during postnatal days 0–21 (Tyl et al. 1997).  
Additional developmental studies for these six phosphate ester flame retardants do not seem necessary at
this time.  However, since no relevant information was located for TiBP, conducting a preliminary test in 
mice, as done for TCEP by Hardin et al. (1987), may be appropriate. 
Immunotoxicity. No studies were located that examined immunological effects in humans following
exposure to the selected phosphate ester flame retardants discussed in this document.  However, there 
have been reports of allergic dermal reactions to products containing TPP (Camarasa and Serra-Baldrich 
1992; Carlsen et al. 1986). Oral toxicity studies conducted with the selected phosphate ester flame
retardants, except TCPP, did not report significant alterations in the gross or microscopic appearance of
lymphoreticular tissues.  However, immunocompetence was examined only in one study in rats exposed 
to TPP (Hinton et al. 1996).  No significant alterations in the humoral response to immunization with 
SRBC were reported.  Since very limited information is available regarding the immunotoxicity of the
remaining phosphate ester flame retardants, studies performing a Tier I battery of tests would help 
evaluate the possibility that exposure to these chemicals might cause subtle alterations in immune
parameters. 
Neurotoxicity. No relevant information was located regarding neurological effects in humans exposed 
to the selected phosphate ester flame retardants.  Studies in animals have provided information regarding
the effects of TCEP, TnBP, TBEP, TDCP, TiBP, and TPP on the nervous system.  No relevant data were 
located for TCPP, but before conducting neurotoxicity studies for this chemical, it may be desirable first
to determine whether there is any indication of neurotoxicity in a general toxicity study.  The nervous
system did not seem to be a particularly sensitive target for this group of chemicals except for TCEP.  
While effects were reported in some studies, they tended to occur at the highest dose levels.  Some of the
data available were limited to reports of lack of clinical signs and histopathological effects in the brain 
and spinal cord of rats in a 24-month study with TDCP (Stauffer Chemical Co. 1981a) or of similar
observations in rats dosed with TiBP for 13 weeks (Naylor and Ribelin 1990).  TPP was evaluated for
neurobehavioral effects in rats in a 4-month dietary study; no significant effects were reported (Sobotka et
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al. 1986).  TnBP reduced nerve conduction velocity and altered the morphology of the nerve in rats
(Laham et al. 1983), but did not significantly alter parameters of a functional observation battery in acute-
or intermediate-duration studies (Healy et al. 1995).  TBEP was also reported to cause a reduction in 
nerve conduction velocity in rats in an intermediate-duration study (Reyna and Thacke 1987b).  TCEP
affected the nervous system in acute-, intermediate-, and chronic-duration studies.  Treatment with TCEP
caused morphological damage to the hippocampus of rats in acute- (Tilson et al. 1990) and intermediate-
duration (NTP 1991a) studies and to the cortex and brain stem in a chronic-duration study (NTP 1991a);
rats were considerably more sensitive than mice, and female rats appeared more sensitive than males.  In 
the acute study, rats suffered seizures 60–90 minutes after dosing and showed mildly impaired learning
behavior 3 weeks after dosing (Tilson et al. 1990).  Pharmacokinetics studies have been conducted that
tried to identify the chemical entity responsible for the physiological and morphological effects of TCEP
as well as provide an explanation for the differential susceptibility between rats and mice and between 
female and male rats (Burka et al. 1991; Herr et al. 1991).  These issues have not been resolved and 
continued research seems necessary.  The mechanism by which TCEP or a metabolite induces seizures in 
rats has not been elucidated, although there is some evidence indicating that it acts as a GABA antagonist
(Umezu et al. 1998).  Further research on this specific issue would also be valuable. 
Epidemiological and Human Dosimetry Studies. Information on health effects in humans
exposed specifically to the selected phosphate ester flame retardants (not to mixtures) was derived from a 
study of workers employed in the manufacture of TDCP (Stauffer Chemical Co. 1983a) and a study of
operators in a TPP production plant (Sutton et al. 1960).  In neither case were there associations found 
between exposure to the phosphate ester flame retardants and any health conditions.  In addition, there are
some reports of allergic dermal reactions to products containing TPP (Camarasa and Serra-Baldrich 1992;
Carlsen et al. 1986).  Follow-up evaluations of individuals who may have been occupationally exposed to 
any of these substances would provide valuable information.  No specific group from the general
population that may have been subjected to unusually high concentrations of these chemicals was
identified.  Studies in animals have identified sensitive targets for some of the phosphate ester flame 
retardants discussed in this profile (i.e., brain areas for TCEP, urinary bladder for TnBP, liver for TBEP).  
Studies have also shown differences in susceptibility between species.  Therefore, there is no basis to 
speculate, based on studies in animals, what health effects might be observed (or what health effects one 
should look for) in subjects who might experience repeated exposure to these compounds. 
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3. HEALTH EFFECTS
Biomarkers of Exposure and Effect.
Exposure.  There are no specific biomarkers that can be used to identify exposure to the phosphate ester
flame retardants flame retardants subject of this profile other than the chemicals themselves.  Studies of
levels of phosphate ester flame retardants in blood and urine of workers who are exposed to higher levels 
of these substances than the general population would be helpful to characterize potential biomarkers, 
which could be the parent compound and/or metabolites.  These biomarkers could then be looked for in 
biological fluids of members of the general population, particularly children, to ascertain the prevalence 
and magnitude of exposure to these chemicals, if the existing analytical methods are sensitive enough to 
do so.  
Effect.  There are no biomarkers of effect specific for the selected phosphate ester flame retardants.  
Exposure to high amounts of some of these chemicals, particularly TPP, may reduce the activity of 
plasma and red blood cell cholinesterase, but this can also occur following exposure to a variety of
chemicals.  Research to identify reliable biomarkers for exposure to these chemicals would be useful.
Absorption, Distribution, Metabolism, and Excretion. There were no data regarding the
toxicokinetics of the selected phosphate ester flame retardants in humans except for a study that
investigated the metabolism of TCEP in human liver preparations in vitro (Chapman et al. 1991) and a
study that investigated the pulmonary retention of TPP in volunteers exposed to an aerosol of this 
chemical (Landahl et al. 1951, 1952).  There are no data regarding the toxicokinetics of these chemicals in 
animals following inhalation exposure, but this information would likely do little to further our
understanding of the pharmacokinetics processes of these substances.  There are studies in animals that
provide information regarding the oral absorption of TCEP (Herr et al. 1991), TDCP (Nomeir et al. 1981), 
and TnBP (SOCMA 1992), and dermal absorption of TDCP (Nomeir et al. 1981) and TnBP (SOCMA
1992).  Tissue distribution data are available for TCPP, TCEP, TDCP, and TnBP following oral exposure
(Herr et al. 1991; Minegishi et al. 1988; SOCMA 1992), for TDCP and TnBP following dermal exposure
(Nomeir et al. 1981; SOCMA 1992), and for TDCP following intravenous administration (Lynn et al. 
1981).  The metabolism of TCEP, TDCP, and TnBP has been well studied (Burka et al. 1991; Chapman 
et al. 1991; Lynn et al. 1981; Nomeir et al. 1981; SOCMA 1992, 1994; Suzuki et al. 1984a, 1984b).
These studies were able to identify and quantify metabolites in excreta and propose metabolic pathways 
for these phosphate ester flame retardants.  The excretion routes for TDCP, TCPP, TCEP, and TnBP
(Burka et al. 1991; Herr et al. 1991; Minegishi et al. 1988; Suzuki et al. 1984a) have been studied in 
animals following oral exposure and for TnBP following dermal exposure (SOCMA 1992).  It would be
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3. HEALTH EFFECTS
useful to have information on the toxicokinetics of TBEP, TPP, and TiBP. Since phosphate ester flame 
retardants are usually found as mixtures in the environment, it would be valuable to have information on 
toxicokinetic interactions among these chemicals and how these interactions can potentially affect their
toxicity. 
Comparative Toxicokinetics. Relevant information is available for TCEP and TnBP.  Herr et al. 
(1991) studied the distribution of radioactivity in the brain of male and female rats following oral
administration of 14C-TCEP and reported no significant differences between the sexes, although there was
suggestive evidence that the parent compound/metabolite ratio in cortical tissues was greater in females 
than in males 2 hours after a single dose of TCEP.  Herr et al. (1991) also reported slower excretion of
metabolic products in females than in males.  Burka et al. (1991) investigated the metabolism and 
excretion of TCEP-derived radioactivity in female and male rats and in male mice.  The results showed 
quantitative differences in metabolic products between rats and mice and between male and female rats 
and slower elimination of radioactivity in the urine in rats than in mice.  A study of the metabolism of
TCEP by in vitro liver preparations and plasma from humans and male and female rats also showed 
differences between the rat sexes and between rats and humans (Chapman et al. 1991).  Studies with 
TnBP showed that rats absorb about 10 times less TnBP through the skin than minipigs and that there are 
also differences in the metabolic disposition of TnBP between rats and minipigs (SOCMA 1992, 1994).  
No comparative data were located for other phosphate ester flame retardants.  If the metabolism of any of 
the selected phosphate ester flame retardants can be elucidated in humans, for example, through the
analysis of blood and urine samples from workers exposed to these compounds, it would be valuable to 
have data in more than one animal species to identify the best possible animal model for human risk
assessment. 
Methods for Reducing Toxic Effects. Acute exposure to high amounts of phosphate ester flame
retardants may inhibit cholinesterase activity to the extent that clinical signs and symptoms indicative of 
cholinergic stimulation may occur.  If such situation arises, there are well-established treatment
procedures.  Since no population has been identified as having been subjected or currently undergoing
exposure to excessive amounts of phosphate ester flame retardants, attempts to propose studies of specific 
methods to reduce possible adverse effects do not appear warranted at this time.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
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3. HEALTH EFFECTS
There are no studies that specifically address exposure to phosphate ester flame retardants in children.  
There have been some case reports of allergic dermatitis in subjects exposed to products containing TPP
(Camarasa and Serra-Baldrich 1992; Carlsen et al. 1986).  It is reasonable to assume that this may also 
occur in children.  There is no information on whether exposure to phosphate ester flame retardants alters 
the developmental process in humans.  Gestational exposure studies have been conducted with six out of
the seven selected phosphate ester flame retardants discussed in this profile, the exception being TiBP.  In 
general, these studies showed that developmental end points are not particularly sensitive.  The possibility
that phosphate ester flame retardants may have endocrine-disrupting ability in mammals has not been 
systematically studied.
There are no data to evaluate whether pharmacokinetics of phosphate ester flame retardants in children 
are different from adults.  There is no information on whether these substances can cross the placenta and 
there are no studies on whether they can be transferred from mother to offspring through maternal milk.  
Cross-fostering studies can provide important information regarding the role of in utero vs. lactation 
exposure to phosphate ester flame retardants in normal development.  
Research into the development of sensitive and specific biomarkers of exposures and effects for 
phosphate ester flame retardants would be valuable for both adults and children.  There are no data on the
interactions of phosphate ester flame retardants with other chemicals in children.  There are no pediatric-
specific methods to reduce peak absorption, reduce body burdens, or to interfere with the mechanisms of
action of these compounds.  Based on the information available, it is reasonable to assume that the
supportive methods recommended for maintaining vital functions in adults will also be applicable to 
children. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
No ongoing studies pertaining to the phosphate ester flame retardants subject of this profile were 
identified in the Federal Research in Progress (FEDRIP 2009) database.
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4. CHEMICAL AND PHYSICAL INFORMATION 
4.1 CHEMICAL IDENTITY 
Phosphate esters are considered derivatives of the tri protic acid, phosphoric acid O=P(OH) 3, with the 
general formula of RxH3-xPO4 where x=1 for mono, x=2 for di, and x=3 for triesters.  Phosphorus has a 
high affinity for oxygen due to the difference in electronegativity (1.4), and consequently, the P=O bond 
possesses more  character than  character. Therefore, the P=O bond, which dominates phosphate 
chemistry, can be more accurately depicted as a coordinate bond, PO, or as P+–O-. These phosphoric 
acid esters are often referred to as organophosphates.  Trialkyl, triaryl, and trihaloalkyl/aryl, and mixed 
phosphate esters possess a central phosphorus atom with an oxidation state of +5 and an approximate 
tetrahedral geometry (Fee 2005; Gard 2005).
A wide array of substituents can occur as esters of phosphates.  In many cases, all of the substituents are 
identical, as is the case for this profile; however, variable, mono-, di-, or tri-substituted as well as mixed 
substituents are common.  The selected compounds, shown above, are trisubstituted, contain identical 
substituents, and fall into the following categories:  alkyl (TnBP, TiBP), alkyl ether (TBEP), chloroalkyl
(TCEP, TCPP, TDCP), and aryl (TPP) phosphate esters.  Although the selected compounds are discrete 
chemicals, commercial formulations of TCPP may contain minor amounts of structural isomers (NAS 
2000).  Table 4-1 lists common synonyms, trade names, and other pertinent information to identify the 
selected phosphate esters for this profile.  
4.2 PHYSICAL AND CHEMICAL PROPERTIES 
Table 4-2 lists important chemical and physical properties of the selected phosphate esters. 
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Selected Phosphate Ester Flame Retardantsa 
Tributoxyethyl 
Characteristic Tributyl phosphate Triisobutyl phosphate phosphate
Synonym(s) TnBP; butyl phosphate; TiBP; isobutyl phosphate; TBEP; tri(2-butoxyethyl) 
phosphoric acid tributyl phosphoric acid; phosphate; tris(2-butoxy-
ester; tri-n-butyl tris(2-methylpropyl) ester ethyl) phosphate; 
phosphate; 2-butoxyethanol, phos-
tributoxyphosphine oxide phate; ethanol, 2-butoxy-, 
phosphate (3:1); phos-
phoric acid, tributoxyethyl 
ester; tributyl cellosolve 
phosphate
Registered trade 	 Disflamoll TB; Celluphos No data Kronitex KP-140; KP 140; 
name(s) 	 4; Phosflex 4b; Skydrol Phosflex T-bep
LD-4b 
Chemical formula C12H27O4P C12H27O4P C18H39O7P 
Chemical structure O 
O P
O O
O 
O 
O O 
Identification numbers: 
CAS registry 126-73-8 126-71-6 78-51-3
RTECSc TC7700000 No data KJ9800000
EPA hazardous waste No data No data No data 
EPA/OPP pesticide No data No data No data
Code 
OHM/TADS No data No data No data
DOT/UN/NA/IMDG No data No data No data
shipping
HSDB 1678 No data 2564
EINECS 204-800-2 204-798-3 201-122-9
NCI No data No data No data
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Selected Phosphate Ester Flame Retardantsa 
Characteristic Triphenyl phosphate Tri-(2-chloroisopropyl) phosphate
Synonym(s) TPP; phosphoric acid, triphenyl ester; TCPP; tris(1-chloro-2-propyl) 
triphenoxyphosphine oxide phosphate; tris(2-chloroisopropyl)
phosphated; phosphoric acid,
tris(2-chloro-1-methyl) ethere 
Registered trade 
name(s) 
Celluflex TPP; Disflamoll TP; Phosflex 
TPP 
Hostaflam OP 820; Amgard TMCP; 
Fyrol PFCd; Antiblaze 80f 
Chemical formula C18H15O4P C9H18Cl3O4P 
Chemical structure O 
P 
OO 
O 
Identification numbers: 
CAS registry 115-86-6 13674-84-5
RTECSc TC8400000 TC9000000
EPA hazardous waste No data No data 
EPA/OPP Pesticide No data No data
Code 
OHM/TADS No data No data
DOT/UN/NA/IMDG IMO 9.0 No data
shipping
HSDB 2536 No data
EINECS 204-112-2 237-158-7
NCI No data No data
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Selected Phosphate Ester Flame Retardantsa 
Tris(1,3-dichloro-2-propyl) 
Characteristic phosphate Tris-(2-chloroethyl)-phosphate 
Synonym(s) TDCP; tris(1,3-dichloroisopropyl) TCEP; trichlorethyl phosphate; phos-
phosphate; tris(1-chloromethyl- phoric acid; tris(2-chloroethyl)ester; 
2-chloroethyl)phosphate; 2-propanol, tri(2-chloroethyl) phosphate; ethanol, 
1,3-dichloro-, phosphate (3:1) 2-chloro-, phosphate (3:1); tris(2-
chloroethyl) orthophosphate  
Registered trade Fyrol FR-2; Antiblaze 195f Antiblaze 100; Celluflex CEF; Disflamoll 
name(s) TCA; Fyrol CEF; Niax 3CF, Tolgard 
TCEP; Genomoll P; Hostaflam UP810; 
Levagard EP 
Chemical formula C9H15Cl6O4P C6H12Cl3O4P 
Chemical structure
Identification numbers: 
CAS registry 13674-87-8 115-96-8
RTECSc No data KK2450000
EPA hazardous waste No data No data 
EPA/OPP Pesticide No data No data
Code 
OHM/TADS No data No data
DOT/UN/NA/IMDG No data UN: 3082g 
shipping
HSDB 4364 2577
EINECS 237-159-2 204-118-5
NCI No data C60128
aAll information obtained from HSDB 2009 and ChemIDplus 2009, except where noted.
bIPCS 1991a, 2000b
cRTECS 2009
dAshford 1994
eLewis 2000
fWeil 2001
gNIOSH 2007
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/Intergovernmental Maritime Dangerous Goods Code; EINECS = European Inventory of Existing Chemical 
Substances;  EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National 
Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; OHM/TADS = Oil and Hazardous 
Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemical Substances 
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Selected Phosphate Ester Flame 

Retardantsa
 
Property
Tributyl phosphate 
(TnBP)
Triisobutyl phosphate 
(TiBP)
Tributoxyethyl phosphate 
(TBEP)
Molecular weight 266.31 266.31d 398.48
Physical 
description
Colorless to pale-yellow
liquid
Clear, colorless, low
viscosity liquidd 
Slightly yellow, oily liquid
Melting point
Boiling point
Density
Odor
-80 °C
289 °C; decomposesb 
0.9727 g/cm3 at 25 °C
Odorless
No data
264 °Cc 
0.9681 g/cm3 at 20 °Cc 
Specific odord 
-70 °C
215–228 °C at 4 mm Hg
1.020 g/cm3 at 20 °C
Sweetish, butyl-like
Solubility:
Water 0.28 g/L at 25 °C Very soluble in waterd; 
0.05% in waterd and 6.3%
water in TnBPd 
1.1 g/L at 25 °C
Organic
solvent(s)
Soluble in diethyl ether,
benzene, carbon disulfide;
miscible with ethanol
Very soluble in benzene,
ether, and ethanolc 
Soluble in most organic
liquids; soluble in mineral
oil; insoluble or limited 
solubility in glycerol, glycols,
certain amines
Other Miscible with most solvents No data No data
and diluents
Log Kow 
Vapor pressure 
Autoignition
temperature
Flashpoint
4.00
1.13x10-3 mm Hg at 25 °C
>482 °Cb 
146 °C
3.60 (estimated)e 
0.0128 mm Hg at 25 °C
(estimated)e 
No data
175 °C (Cleveland)d 
3.75
0.03 mm Hg at 150 °C
No data
223 °C
Flammability
limits in air
Combustible No data Combustible
Conversion 
factors
1 ppm=10.89 mg/m3b No data No data
Explosive limits No data No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Selected Phosphate Ester Flame 

Retardantsa
 
Tri-(2-chloroisopropyl) phosphate 
Property Triphenyl phosphate (TPP) (TCPP)
Molecular weight 326.28 327.57
Physical Colorless, crystalline powder; white Colorless liquidf 
Description platelets, crystals from absolute alcohol­
ligroin, prisms from alcohol, needles from
ether-ligroin
Melting point 49–50 °C -40 °C
Boiling point 245 °C at 11 mm Hg >270 °C; gradually decomposes when
heated over 200°Cf 
Density 1.2055 g/cm3 at 50 °C 1.29 g/cm3 at 25 °Cf 
Odor Slightly aromatic odor resembling phenol Mild odorf 
Solubility:
Water 0.0019 g/L at 25 °C 1.2 g/L at 25 °C
Organic
solvents
Very soluble in carbon tetrachloride;
soluble in alcohol, benzene, ether,
Soluble in most organic solvents; insoluble
in waterf 
chloroform and acetone; insoluble in 
petroleum
Other Soluble in most lacquers, solvents No data
thinners, and oils
Log Kow 4.59 2.59
Vapor pressure 6.28x10-6 mm Hg at 25 °C 2.02x10-5 mm Hg at 25 °C
Autoignition No data No data
temperature
Flashpoint 220 °C No data
Flammability Noncombustible No data
limits in air
Conversion 1 ppm=13.32 mg/m3 No data
factors
Explosive limits No data No data
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Table 4-2.  Physical and Chemical Properties of Selected Phosphate Ester Flame 
Retardantsa 
 
Tris(1,3-dichloro-2-propyl) phosphate 
Property (TDCP) Tris-(2-chloroethyl)-phosphate (TCEP)
Molecular weight 430.88 285.50 
Physical Viscous, clear liquid Clear, transparent, Low viscosity liquid 
Description 
Melting point 27 °C -55 °C 
Boiling point 236–237 °C at 5 mm Hg 330 °C at 1 atm  
Density 1.48 g/cm3 at 25 °C 1.425 g/cm3 at 20 °C 
Odor Mild odor Slight odor 
Solubility:   
 Water 7 mg/L at 24 °C 7.0 g/L (temperature not specified) 
 Organic Soluble in most organic solvents Soluble in most organic solvents; soluble 
solvents in carbon tetrachloride, alcohols, esters, 
ketones, and aromatic hydrocarbons; very 
slightly soluble in aliphatic hydrocarbons; 
insoluble in benzene 
 Other No data No data 
Log Kow 3.65 1.44 
Vapor pressure  5.2 x10-2 mm Hg at 25 °C (estimated)e 6.125x10-2 mm Hg at 25 °C 
Autoignition No data 1,115 °C 
temperature 
Flashpoint 252 °C 216 °C 
Flammability No data Combustible 
limits in air 
Conversion No data 1 ppm=11.65 mg/m3 
factors 
Explosive limits No data No data 
 
aAll information from HSDB 2009 and ChemIDplus 2009, except where noted. 
bNIOSH 2005a 
cLide 2008 
d
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197PHOSPHATE ESTER FLAME RETARDANTS
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
Phosphate esters are a class of anthropogenic organic compounds found in the environment as a result of
release from commercial and industrial products (Watts and Linden 2009).  Phosphate esters, TnBP, 
TiBP, TBEP, and TCEP are produced by chemical synthesis via condensation of phosphorus oxychloride
and an alkyl or aryl alcohol (Davis and Richardson 1980; HSDB 2009; Kelly 2006; Muir 1984) at low
temperatures and pressures to avoid formation of alkyl chlorides (Muir 1984). TPP is made from either
phosphorus pentachloride or phosphorus oxychloride and phenol (HSDB 2009).  TDCP is produced via
the epoxide opening of epichlorohydrin in the presence of phosphorus oxychloride (Weil 2001), and 
TCPP is similarly produced with propylene oxide and sometimes TCEP with ethylene oxide (Muir 1984).  
Worldwide production of flame retardants in 1992 was estimated at 600,000 metric tons with 
102,000 metric tons representing phosphate ester-derived flame retardants.  In 2001, estimates increased 
to 1,217,000 and 186,000 metric tons, respectively (Hartmann et al. 2004).  Use of flame retardants in the
United States totaled an estimated 622,000 metric tons in 2007 (Fink et al. 2008).  This represents an 
increase of 58 thousand metric tons, or 10% over the 2004 level. The value of these products rose from
$844 million in 2004 to $1,126 million in 2007, a 33% increase, (Fink et al. 2008) and U.S. flame
retardant demand is expected to grow at a 2–3% average annual rate through 2012 (Fink et al. 2008) due
to an increase in restrictions for competing polybrominated diphenyl ethers (PDBE) (Hartmann et al. 
2004; Quintana and Reemtsma 2006). 
TnBP production in 1975 was > 908 kg (1 metric ton) (HSDB 2009) and is currently estimated by the
2006 Inventory Update Reporting (IUR) to be in the range of 1–10 million pounds (EPA 2006c).  
TiBP production is not listed with the EPA or other agencies as it appears that this chemical is produced 
predominantly outside of the United States.  
TBEP production is estimated by the 2006 IUR in the range of 1–10 million pounds (EPA 2006c).  
TPP production in 1975 was > 908 kg (1 metric ton) (HSDB 2009) and is currently estimated by the
2006 IUR to be in the range of 10–50 million pounds (EPA 2006c).  
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
TCEP production in 1975 was estimated to be > 908 kg (1 metric ton) (HSDB 2009) and is currently
estimated by the 2006 IUR to be in the range of 500,000–1 million pounds (EPA 2006c). 
TCPP annual worldwide demand exceeded 40,000 metric tons in 1997 (IPCS 1998) and currently is
estimated by the 2006 IUR to be produced in the range of 10–50 million pounds (EPA 2006c).  
TDCP annual worldwide demand was 8,000 metric tons in 1997 (IPCS 1998) and is currently estimated 
by the 2006 IUR to be produced in the range of 10–50 million pounds (EPA 2006c). 
No information is available in the TRI database on facilities that manufacture or process phosphate ester
flame retardants because this chemical is not required to be reported under Section 313 of the Emergency
Planning and Community Right-to-Know Act (Title III of the Superfund Amendments and 
Reauthorization Act of 1986) (EPA 1998).
5.2 IMPORT/EXPORT
Imports of TBEP and TCEP were reported to be negligible in 1972, while all other selected phosphate
esters were not listed as being imported (HSDB 2009).  No export data were available for the selected
phosphate ester compounds discussed in this profile.
5.3 USE 
Trialkyl, triaryl, and trihaloalkyl/aryl, and mixed phosphate esters have been used since the 1940s in 
industrial consumer products (Muir 1984).  Phosphate esters represent an important class of commercial
additives used as flame retardants, plasticizers, hydraulic fluids, solvents, extraction agents, antifoam
agents, adhesives, and coatings for electronic devices (Andresen and Bester 2006; Ashford 1994; Lewis
2007; Lide 2008; Owens et al. 2007; Watts and Linden 2009; Weil 2001; Wolf and Kaul 2005).  A
summary of applications of the selected phosphate ester flame retardants is shown in Table 5-1. 
Flame retardants generally function in the vapor phase, where the enthalpy-generating combustion occurs, 
and serve to slow or hinder the ignition or growth of a fire (Gann and Gilman 2003).  There are five
specific mechanisms by which flame retardancy may occur:  physical dilution, chemical interaction, inert 
gas dilution, thermal quenching, or protective coatings (Mack 2004).  Phosphate ester flame retardation 
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1. Applications of Phosphate Ester Flame Retardants
Floor Lacquer,
Compound Flame Hydraulic finish, paint, Anti-foam Industrial
Name retardant Plasticizer fluid wax glue agent processes
Tributyl X X X X X X
phosphate
(TnBP)
Triisobutyl
phosphatea
X X X
(TiBP)
Tributoxyethyl X X X X X
phosphate
(TBEP)
Triphenyl X X X X
phosphate
(TPP)
Tri-(2-chloro- X X
isopropyl)
phosphate
(TCPP)
Tris(1,3-di- X X X
chloro-2-propyl) 
phosphate
(TDCP)
Tris- X X X X
(2-chloroethyl)­
phosphate
(TCEP)
aTiBP Datasheet, Anderson et al. 2004, 2006
Source: Marklund et al. 2003
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200PHOSPHATE ESTER FLAME RETARDANTS
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
mechanisms vary based on structure and properties, but generally function by suppressing flammability of
pyrolysis products (vapor-phase mechanism) or by chemical interaction through changing the nature of
the decomposition products (Weil 2001).  In general, the effectiveness of a particular phosphorus
compound depends strongly on the nature of the matrix polymer but, for chemically similar compounds, 
the flame-retardant effectiveness often increases with increasing phosphorus content (Granzow 1978).  
Halogens play an important part in contributing to flame retardancy, although this contribution is offset
by the lower phosphorus content.  The halogens reduce vapor pressure and water solubility, thus aiding
retention of these additives (Weil 2001).  
Due to an increased demand for fire safety in commercial products, flame retardant use substantially
increased during the 1960s and 1970s (Muir 1984).  In particular, products made from synthetic polymers
are treated with phosphate esters (Weil 2001).  The chlorinated haloalkyl phosphates, TCPP, TDCP, and 
TCEP, are most commonly used as flame retardants in both rigid and flexible polyurethane foam, and 
some textiles (Anderson et al. 2004).
The nonderivatized alkyl and aryl phosphates, TnBP, TiBP, TBEP, and TPP, all function predominantly
as industrial plasticizers in polymers, rubbers, plastics, and vinyl resins, as well as flame retardants 
(Anderson et al. 2004, 2006).  Phosphate esters are added to flexible plastics such as polyvinyl chloride
(PVC) and polyurethane foams in low part per hundred concentrations (Muir 1984).  Addition of
phosphate esters often effects the flammability of rigid plastics such as PVC by dilution of the highly
flammable chlorinated plasticizers (Green 1992).  Phosphate esters can, however, change polymer
decomposition chemistry when combusted (Gann and Gilman 2003).  Advantages of phosphate esters
over traditional plasticizers include low corrosivity of the combustion gases, lack of effect on polymer
transparency, and suppression of afterglow.  Disadvantages include volatility, sensitivity to hydrolysis, 
and negative effects on the heat distortion temperatures of plastics (Wolf and Kaul 2005).  When used as
flame retardants in polymers, phosphate esters typically represent 1–30% of the composition of the
polymer with an average of 5–15% (Hartmann et al. 2004).
TnBP and TPP are used as hydraulic fluids with flame retardant properties predominantly present as
mixtures of various alkyl- and aryl-substituted phosphate esters (Anderson et al. 2004; Batt et al. 1992).  
They are recognized as replacements to polychlorinated biphenyls (PCBs) (Gomez-Belinchon et al. 1988;
Muir 1984).  Phosphate esters generally have better fire resistance than mineral oils and are less 
hazardous than PCBs.  The lubricating properties are generally good; however, the high temperature
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stability is fair.  Decomposition products, such as phosphoric acid, can be corrosive, deteriorate paints and 
finishes, and cause swelling of many seal materials in hydraulic systems (Denniston 1995).
TnBP is used as a solvent for cellulose esters, lacquers, natural gums, herbicide solutions, and carbonless 
copying systems and as an extractant in the nuclear fuel reprocessing and other metals (Anderson et al.
2004; Thomas and Macaskie 1996).  Some trialkyl phosphates, O=P(OR)3, are outstanding solvents for
nitrates, especially (UO2)(NO3)2, and are therefore important in uranium processing (Fee 2005).  TnBP
forms weak complexes with the neutral metal nitrates, affecting the solubilizing of the actinides in the
organic phase (Godfrey et al. 1996).  TnBP is the most frequently used solvent in liquid-liquid extraction 
for fuel reprocessing via a process known as the PUREX process (Plutonium Uranium Refining by
EXtraction) (Dodi and Verda 2001; Godfrey et al. 1996; Stevens et al. 2007).  This method enables
recycling of extracted uranium and plutonium from an aqueous nitric acid phase (Dodi and Verda 2001)
and is considered the most convenient method to retreat spent fuel (Lamouroux et al. 2000).  Due to the
acidic nature of the process, some decomposition of TnBP to dibutyl phosphate (DBP) and monobutyl
phosphate (MBP) occurs via dealkylation of one or two butoxy groups, respectively (Dodi and Verda
2001).
TiBP is used as a pore size regulator for concrete, while TnBP shows excellent antifoam properties in
concrete (Anderson et al. 2004; Andresen and Bester 2006).  TBEP is also found in some floor polishes.  
TCEP was phased out due to toxicity issues (EPA 2006c).  Electronic equipment can contain various
phosphate esters (Carlsson et al. 2000; Marklund et al. 2003).
5.4 DISPOSAL
No data are available on the disposal of specific phosphate ester flame retardants; however, hydraulic 
fluids containing phosphate esters do have recommended disposal methods.  Used phosphate ester
hydraulic fluids are not listed as hazardous wastes and can be recycled or burned for energy recovery.  In 
general, the newer phosphate ester hydraulic fluids do not contain known chemicals or other materials 
that are listed in 40 CFR 261 (Resource Conservation and Recovery Act [RCRA]).  Recycling of some 
flame retardant-containing products, including some plastics, has been found possible (Lorenz and 
Bahadir 1993; Mayer et al. 1993).
With the exception of TnBP, the selected phosphate ester flame retardants are regulated under the Toxic 
Substances Control Act (TSCA) of 1976, requiring the reporting of record-keeping, testing, and 
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restrictions to the EPA.  The High Production Volume Challenge (HPV) program, administered by the
EPA, challenges companies to report health and environmental effects data publicly for chemicals 
produced or imported in the United States in quantities of 1 million pounds or more per year.  All of the
selected chemicals except TiBP appear on this list.  
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6.1 OVERVIEW
Phosphate ester flame retardants have been identified in at least 8 of the 1,699 hazardous waste sites that
have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, 
the number of sites evaluated for phosphate ester flame retardants is not known.  The frequency of these 
sites can be seen in Figure 6-1. 
Phosphate ester flame retardants are released to the environment through their use in industrial and 
consumer products.  Since their introduction in the 1940s and popularization in the 1970s, these
anthropogenic compounds have been frequently detected in water, soil, and air (Muir 1984). Trialkyl, 
triaryl and trihaloalkyl/aryl, and mixed phosphate esters represent an important class of commercial
additives used as flame retardants, plasticizers, hydraulic fluids, solvents, extraction agents, antifoam
agents, adhesives, and coatings for electronic devices (Ashford 1994; Andresen and Bester 2006; Lide
2008; Lewis 2007; Owens et al. 2007; Watts and Linden 2009; Weil 2001; Wolf and Kaul 2005).  
Water is the most common medium in which phosphate ester flame retardants are detected in the
environment.  Phosphate ester flame retardant presence is widespread in surface water and groundwater
of the United States and other foreign countries, primarily due to landfill leaching of PVC plastics and 
polyurethane foams, effluent from industrial sources, and spills of hydraulic fluids.  Many hydraulic
fluids are composed of mixtures of phosphate esters and are consequently released into the environment
as a mixture as indicated, for example, in the Toxicological Profile for Hydraulic Fliuds (ATSDR 1997).  
Ultimately, these primary contaminated waters are transported to secondary sources, such as drinking
water, by treated sewage, agricultural runoff, and deposition from snow and rain (Andresen et al. 2004;
Fries and Puttmann 2001; Gomez-Belinchon et al. 1988; Ishikawa et al. 1985; Lee and Rasmussen 2006;
Meyer and Bester 2004; Muir 1984; Peterman et al. 1980; Reemtsma et al. 2006; Watts and Liden 2008, 
2009).  Hydrolysis, although slow due to poor solubility and pH dependence, is the most important abiotic
fate process for phosphate esters (Boethling and Cooper 1985).  Biodegradation via hydrolysis from
microbial esterases in river water, lake water, sewage, and sludge takes place in <10 days (Howard and 
Deo 1979; Mayer et al. 1981; Muir et al. 1980; Saeger et al. 1979). 
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In soil and sediment, phosphate ester flame retardants are considered persistent as they have a tendency to 
adsorb strongly, thus limiting the availability of these substances to microorganisms (Boethling and 
Cooper 1985; Muir 1984). Phosphate esters generally have a low water solubility and relatively high 
octanol/water partition coefficient (Kow), which results in high soil adsorption coefficients (Koc).  Muir
(1984) reported Koc values ranging from 151 to 7,850 for several of the selected phosphate esters.  
Reports from soil analyses at military bases and airports have confirmed the presence of some phosphate
esters, particularly TnBP, as it represents a major component in hydraulic fluid Skydrol 500B, Skydrol
LD, and Hyjet IV (Monsanto Co. 1980).  In addition, sediments of rivers and lakes have been shown to 
contain these compounds (Ishikawa et al. 1985; Muir et al. 1989).  Volatilization and biodegradation are 
potential fate processes for phosphate esters adsorbed to soils (Anderson 1993; Muir 1984, 1989).
Diffusion into air from plastics, textiles, adhesives, and electronics accounts for numerous reports of 
phosphate esters in indoor air (Carlsson et al. 2000; Garcia et al. 2007; Hutter et al. 2006; Ingerowski et
al. 2001, 2003; Otake et al. 2004, 2001; Owens et al. 2007; Sjodin et al. 2001).  Outdoor air sampled near
places where hydraulic fluids are used, such as at airports and outside of newly constructed homes and
buildings, have indicated the presence of these phosphate esters (Haraguchi et al. 1985; Monsanto Co. 
1980; Saito et al. 2007).
Ingestion of food or water is the primary exposure pathway that humans have to the phosphate ester flame 
retardants discussed in this profile.  Exposure to phosphate esters via direct or indirect dermal adsorption 
from treated matricies is also possible, but unlikely due to the chemical and physical properties that make
flame retardants useful.  Young children are at an increased exposure risk due to the potential for oral
exposure via dissolution of phosphate esters from repeated sucking on treated materials (NRC 2000).  
Inhalation is also a potential route of exposure primarily in indoor air from PVC plasticizers, floor 
polishes, electronics, and textiles. 
Average daily intakes (ADIs) have been estimated for the U.S. population for TnBP, TPP, TBEP, TCPP,
and TCEP (Gunderson 1988, 1995a, 1995b).  The estimated ADI values are generally in the ng/kg body
weight/day range.  Additional sources of exposure for the general population include inhalation of air and 
ingestion of drinking water containing these phosphate esters.  Occupational exposure may be greater
than exposure to the general population for employees in industries where significant quantities of
phosphate esters are manufactured or used.  
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
   
  
 
  
 
   
 
   
 
 
     
 
  
    
  
    
  
   
   
  
      
   
 
     
 
  
 
 
 
    
   
  
206PHOSPHATE ESTER FLAME RETARDANTS
6.  POTENTIAL FOR HUMAN EXPOSURE
The selected phosphate esters indicated in Table 4-1 have been frequently detected in the environment
due to their commercial production, use, and disposal. However, other compounds that were not selected 
are also reported in the environmental monitoring literature.  Mixtures of several phosphate esters present
in a single monitoring sample are commonplace.  According to the surveyed literature, the most prevalent
phosphate esters in all environmental and dietary samples appear to be TnBP and TPP.  Consequently, a
significant portion of the noted studies pertain to these compounds.  TBEP is also quite prevalent due to 
its presence in floor polishes, while the chlorinated phosphate esters, TCEP, TCPP, and TDCP, all appear
much less frequently in the literature.  TiBP appears the most infrequently in published monitoring
studies of the environment or food.  
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
6.2.1 Air
There is no information on releases of phosphate ester flame retardants to the atmosphere from
manufacturing and processing facilities because these releases are not required to be reported (EPA
1997).
Phosphate ester flame retardants are generally liquids in their pure form at 25 °C and have moderate
Henry’s Law constants (10-4–10-8 atm-m3/mol) and vapor pressures (10-2–10-7 mm Hg); therefore, if 
aerosolized, they should exist in the vapor phase or vapor phase and particulate phase (Muir 1984).
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Halogenated phosphate esters have a reduced vapor pressure and solubility, which generally aid in 
retention of these compounds as additives.  Releases to the air likely occur from industrial sources, such 
as the manufacture, production, and transportation of pure phosphate esters, as well as diffusion from
products containing phosphate esters.
Semi-volatile flame retardant hydraulic fluids could account for aerosolized phosphate esters lost from
seal leakage, plastics, or vinyl car seats (EPA 1979).  Skydrol 500B, a hydraulic fluid, contains 65–75%
TnBP.  In 1979, TnBP was detected in airport air over Vancouver, British Colombia at concentrations of 
0.01–0.3 mg/m3 (Monsanto Co. 1980). 
6.2.2 Water
There is no information on releases of phosphate ester flame retardants to the water from manufacturing
and processing facilities because these releases are not required to be reported (EPA 1997).
Phosphate ester flame retardants are released to environmental surface water and groundwater primarily
from leaching of hydraulic fluid spills and discarded or landfilled PVC, polyurethane foam, electronic
wall coverings, and other flame retardant materials (Muir 1984).
6.2.3 Soil 
There is no information on releases of phosphate ester flame retardants to the soil from manufacturing and
processing facilities because these releases are not required to be reported (EPA 1997).
Phosphate ester flame retardants are released to soil from the use of waste water for irrigation, the 
disposal of flame retardant plastics in landfills, the leakage of hydraulic fluids, or the deposition of
aerosolized phosphate esters (Muir 1984).  
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
Phosphate esters are synthetic compounds that are present in the air, water, and soil due to their use
primarily as flame retardants, hydraulic fluids, and plasticizers. The ability of phosphate esters to enter
the atmosphere as vapors depends greatly upon the vapor pressure of the individual compound.  
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Therefore, phosphate esters can be present in the vapor phase or particulate phase (EPA 1979; Muir
1984).  
Phosphate esters generally have low water solubilities and relatively high Kow values, which result in high 
Koc values.  Muir (1984) reported the Koc values for TPP, TnBP, TBEP, TCEP, and TDCP as 7,850, 
3,592, 2,311, 151, and 2,591, respectively, using data from Kenaga and Goring (1980).  TCEP, as
apparent from the Koc values, is particularly mobile in soil and has the greatest potential to leach into 
groundwater.  Relative to pesticides, the high Koc of the other phosphate esters indicate relatively low
leaching potential.  The fate and distribution of several phosphate esters were studied in laboratory
experiments using river water, pond water, and sediment mesocosms (Muir et al. 1989).  Following
addition of each compound to the water column, rapid partitioning into the sediment was observed in each 
case.  Volatilization of phosphate esters from dry soils is unlikely given the vapor pressures and 
adsorption coefficients; however, volatilization from moist soil is possible given the range of Henry’s
Law constants (10-4–10-8 atm-m3/mol) and vapor pressures (10-2–10-7 mm Hg) (Muir 1984).
TnBP, TPP, TCEP, and TDCP have been reported to have a moderate potential to bioaccumulate in 
aquatic organisms based on their Kow values (Sasaki et al. 1981).  Bioconcentration of phosphate esters
requires assessment by using not only the Kow or water solubility, but also the capacity of absorption and 
metabolic behavior (Sasaki et al. 1981, 1982).  Bioaccumulation ratios in fish (rainbow trout) are reported 
to range from 133 to 2,807 (Muir et al. 1981).  Phosphate esters have been detected in fish, sediment, and
water at or near the site of hydraulic fluid use (Mayer et al. 1981).
Uptake or degradation of TCEP in water was nearly nonexistent, resulting in very low bioaccumulation 
for this compound as analyzed for bioconcentration in kilifish and goldfish using both a static water
system and a continuous flow test system.  Muir et al. (1983a) calculated the bioconcentration factors
(BCFs) for TPP as 573 and 561 for rainbow trout and fathead minnows, respectively, using 14C-labeled 
TPP.  It was found that, in general, the hydrolysis rate of the phosphate ester had a greater effect on 
bioconcentration than the hydrophobicity of the compound (Muir et al. 1983a). 
6.3.2 Transformation and Degradation
6.3.2.1 Air
These compounds are capable of degrading through reaction with hydroxyl radicals, which is the main 
route of atmospheric degradation for most organic substances.  Predicted hydroxyl radical rate constants
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range from 10-12 to 10-11 cm3/molecule-second and corresponding atmospheric half-lives are on the order
of 1–12 hours for the selected phosphate esters assuming a constant atmospheric hydroxyl radical
concentration of 1.5x106 hydroxyl radicals per cm3 (Meylan and Howard 1993).  Particulate-phase 
phosphate esters are subject to wet and dry deposition, while semi-volatile phosphate esters have the 
potential to hydrolyze to diesters, monoesters, and phosphoric acid (Ishikawa et al. 1992).  Phosphate
esters maintain oxidative stability at isothermal or room temperature conditions; however, thermal
decomposition of these substances predominates at high temperature in the presence of air (Shankwalkar
and Placek 1992). 
6.3.2.2 Water
Hydrolysis is the most important abiotic fate process for phosphate esters proceeding stepwise to release 
alkyl and aryl alcohols (Boethling and Cooper 1985).  The rate of hydrolysis is highly dependent on pH, 
temperature, presence of catalytic reagents, and stability of the conjugate acid or base, as well as the 
dielectric constant of the solvent (Katagi 2002).  Phosphate esters are highly pH-dependent and generally
are resistant to hydrolysis in neutral or acidic water (pH 5.0–7.0), but readily degrade in more alkaline
conditions (pH 9.0–9.5) (Howard and Deo 1979; Mayer et al. 1981; Muir 1984).  Half-lives of TPP at pH
8.2, 9.0, and 9.5 were 7.5, 3.0, and 1.3 days, respectively, indicating much faster hydrolysis as alkalinity
increases.  TPP hydrolysis was measured in distilled, lake, and river water.  The results showed that the
pseudo first-order rate constants for distilled water, Lake Ontario water, and Seneca River water were 
0.93, 0.64, and 0.34 days-1, corresponding to half-lives of 0.75, 1.0, and 2.0 days, respectively (Howard 
and Deo 1979).
Comparatively, dialkyl and diaryl phosphate esters have been found to be far less susceptible to 
hydrolysis than the corresponding triesters, likely due to the primary species being an anion.  
Dichloroalkyl phosphate esters such as TDCP are more labile than monochloroalkyl phosphate esters 
such as TCEP and TCPP (Hartley 1959; Muir 1984). Therefore, once the first ester substituent is
hydrolyzed, removal of the second and third ester become much more difficult.  
Aqueous base-catalyzed hydrolysis occurs via an SN2-like nucleophilic attack on the phosphorus atom by
OH- on one of the tetrahedral faces, forming a transient tetracoordinate trigonal bipyramidal intermediate, 
followed by departure of the leaving group to form a phosphate diester.  This mechanism and structure are
evidenced by 18O labeling and crystallographic data, respectively (Davis and Richardson 1980; Katagi
2002; Vernon 1959).  Given this mechanism, electron-withdrawing substituents, such as halogens, 
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increase the electrophilicity of the phosphorus, whereas electron-donating substituents are stabilizing
(Davis and Richardson 1980).  Through coordination, certain metal ions such as Ir, Rh, Co, Cu, Zn, and 
Mn have shown to facilitate phosphate ester hydrolysis.  Low environmental concentrations of dissolved 
transition metals in the aquatic environment do, however, make this an unlikely mechanism.  
Heterogeneous reactions with suspended or sedimentary mineral phases have been shown to hydrolyze 
some phosphate esters (Baldwin et al. 1995).
Nonhalogenated phosphate esters are degraded by microorganisms in activated sludge; however, the 
halogenated phosphate esters are resistant to biodegradation.  Standard biodegradation tests indicated that
both TnBP and TPP are readily biodegradable, but TCPP is not.  TPP achieved 83–94% of its theoretical
biochemical oxygen demand (BOD) and TnBP achieved 89–91% of its theoretical BOD in 28 days using
an activated sludge as inoculum and the modified MITI (OECD 301C) test (IPCS 2004, 2006).  TCPP
achieved 0% of its theoretical BOD in 28 days using the same test (IPCS 2000a) and showed no decrease
in concentration in landfill leachate after 80 days under aerobic conditions (Kawagoshi et al. 2002). 
Biodegradation is generally initiated by hydrolysis of the ester bond by microbial esterases (Yamada
1987).  The hydrolysis product of TnBP, butanol, can be used as a carbon source (Thomas and Macaskie 
1996, 1998).  Consequently, several naturally isolated Pseudomonas cultures were found to substantially
degrade TnBP by metabolizing and growing on minimal TnBP media as the feedstock (Thomas et al. 
1997).  Ninety-six percent of both TnBP and TPP was degraded upon addition of activated sludge (Saeger
et al. 1979).  Takahashi et al. (2008) isolated a mixed bacterial culture capable of degrading previously
nonbiodegradable chlorinated phosphate esters TCEP and TCPP.  A mixed culture primarily composed of
Acidovorax spp., Aquabacterium spp., and Sphingomonas spp. degraded TCEP, while a mixed culture of
Acidovorax spp. and Sphingomonas spp. was found to degrade TCPP.
Efforts to enhance the degradation of halogenated phosphate esters such as TCPP at water treatment
facilities have been investigated (Watts and Linden 2008, 2009).  The addition of ozone and hydrogen 
peroxide to produce photochemically generated hydroxyl radicals in aqueous solution was shown to be an 
effective method of increasing the oxidation of TCEP and TCPP in bench scale experiments.  High initial
levels of hydrogen peroxide are used in conjunction with a powerful ultraviolet light source to initiate the
formation of hydroxyl radicals (Watts and Linden 2009).  
Removal of phosphate esters from waste water can require additional processing.  Halogenated phosphate 
esters, including TCEP, are particularly biorecalcitrant and are emerging as significant contaminants from
waste water pollution into freshwater resources (Watts and Linden 2008).  Ishikawa and Baba (1988)
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recognized the pH dependence of hydrolysis while attempting to hydrolyze phosphate esters with aqueous
chlorine.  Chlorination had little effect on TCEP and TCPP at all pHs and only achieved 50% degradation 
at pH 7 for TnBP and TPP.
6.3.2.3 Sediment and Soil
Muir et al. (1989) studied the fate and degradation of four phosphate esters, including TPP, in 
sediment/water systems and observed rapid degradation of these substances.  The average half-lives of 
TPP in river sediments were 2.8 days at 25 °C, 2.8 days at 10 °C, and 11.9 days at 2 °C; the overall
average half-life was 7.0 days.  Under anaerobic soil conditions, TPP had a half-life of 32 days (Anderson 
1993), while sterile soil produced nearly quantitative recovery of TPP after 101 days.  TCEP soil
attenuation was <33% from waste waters passed through soil columns for 1 month (Watts and Linden 
2008).
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to phosphate ester flame retardants depends in 
part on the reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of phosphate ester flame retardants in unpolluted atmospheres and in pristine surface 
waters are often so low as to be near the limits of current analytical methods.  In reviewing data on
phosphate ester flame retardants levels monitored or estimated in the environment, it should also be noted 
that the amount of chemical identified analytically is not necessarily equivalent to the amount that is
bioavailable.  The analytical methods available for monitoring phosphate ester flame retardants in a 
variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Several phosphate esters were detected in the ambient air of Kitakyushu, Japan and measured by gas 
chromatography-mass spectrometry (GC-MS) at concentrations (μg/m3) of 0.0023 (TnBP), 
0.0053 (TCPP), 0.0047 (TDCP), and 0.0022 (TPP) in 1983 (Haraguchi et al. 1985).  Several phosphate
esters were detected in outdoor air from eight sites in Tokyo, Japan including TnBP (0–1.7 ng/m3), TCPP 
(0–3.1 ng/m3), and TBEP (0–1.1 ng/m3) (Saito et al. 2007).
TnBP is a component of two formulations of hydraulic fluid, Skydrol 500B and Skydrol LD.  
Consequently, TnBP was detected in the air at the CP air test facility at Vancouver International Airport 
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at a concentration of 0.04–0.3 mg/m3 (Monsanto Co. 1980), indicating that phosphate ester hydraulic
fluids may be released during aircraft maintenance operations from equipment using phosphate ester
hydraulic fluids. 
The use of phosphate esters as an additive to flexible plastics, such as PVC and polyurethane foams, and 
their ability to leach from the polymer matrix often leads to their detection in indoor air at low levels.  
Phosphate esters have been found in indoor air from both homes and offices (Carlsson et al. 2000; Garcia
et al. 2007; Hutter et al. 2006; Ingerowski et al. 2001, 2003; Otake et al. 2004, 2001; Owens et al. 2007;
Sjodin et al. 2001).  PVC plasticizers, floor polishes, and flame retardants for electronics and textiles are 
the primary contributors of phosphate esters to indoor air.  PVC-containing plasticizer is a stiff resin but 
softens and expands upon heating and remains this way when cooled due to the molecular changes that
take place (Otake et al. 2001, 2004).  Phosphate esters are not chemically bound to host materials and 
consequently, can be emitted to the surrounding air as vapor or particulates depending on the vapor
pressure of the compound (Carlsson et al. 2000; Garcia et al. 2007).  
Recognition that phosphate esters, particularly TCEP and TCPP, were impacting indoor air took place in 
1993 in Japan.  TCEP was used in wall coverings and television sets in Japan until its carcinogenic 
properties were suspected and it was replaced with TCPP (Saito et al. 2007).  In Tokyo, Japan, several
phosphate esters were detected in indoor air environments.  In 18 houses sampled, concentration ranges
(ng/m3) were 0–30.6 (TnBP), 0–1,260 (TCPP), 0–136 (TCEP), 0–13.7 (TBEP), and 0–0.60 (TDCP).  In 
addition, 14 office buildings had concentration ranges (ng/m3) of 0.46–21.7 (TnBP), 0–0.86 (TPP), 0– 
57.6 (TCPP), 0–42.1 (TCEP), 0–118 (TBEP), and 0–8.7 (TDCP) (Saito et al. 2007).  In a newly
constructed home in Tokyo, Japan, indoor air concentrations (ng/m3) were 36.6 (TnBP), 5.5 (TCPP), 
1.2 (TCEP), 71.0 (TBEP), and 1.3 (TDCP).  TBEP was determined to originate from the floor polishing
agent, while TnBP originated from the polyolefin wall and ceiling coverings (Saito et al. 2007). 
Migration rates of TDCP and TCP were measured as 0.28 and 5.9 μg/m2-hour, respectively, from
computer monitors, and migration rates of TCPP and TCEP were measured as 1.7 and 13.0 μg/m2-hour, 
respectively, from TV sets using an interior surface to solid extraction disk (Saito et al. 2007).  This
indicates that migration from electronic devices to air is occurring at ambient temperatures.  
6.4.2 Water
Phosphate esters are commonly detected in surface water, groundwater, sewage, waste water, and 
drinking water due to their presence in many commercial products and the ability to leach or diffuse from
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their anthropogenic source (Watts and Linden 2009).  These contaminants are widely distributed in the
aquatic environment (Ishikawa et al. 1985; Muir 1984).  In the United States, the presence of phosphate
esters has been reported in waters from the Delaware River, the Great Lakes region, and several Midwest
rivers; phosphate esters have also been detected in water at foreign locations such as Japan, the
Netherlands, Germany, and Canada (Muir 1984).  Conventional treatment of drinking water in the United 
States showed that removal of TnBP, TBEP, TCEP, and TDCP was incomplete (Andresen and Bester
2006). In particular, TCEP is resistant to conventional potable water and waste water treatments (Meyer
and Bester, 2004; Reemtsma et al. 2006; Watts and Liden 2008, 2009). Several studies have measured 
phosphate esters in surface waters from Wisconsin (Peterman et al. 1980), Kansas (Lee and Rasmussen 
2006), and Germany (Andresen et al. 2004; Fries and Puttmann 2001).  Phosphate esters have also been 
detected in coastal waters from Spain (Gomez-Belinchon et al. 1988) and Japan (Ishikawa et al. 1985).  
Pedersen et al. (2005) detected TCEP, TCPP, TBEP, and TDCP flame retardants in agricultural runoff
from fields irrigated with treated effluent in Ventura County, California.  
Waters from waste water treatment facilities (WWTF) discharged into lakes, rivers, streams, and 
tributaries of various watersheds are known to contain phosphate esters.  A number of studies indicate
influent and effluent of WWTF testing positive for phosphate esters (Jackson and Sutton 2008; Marklund
2005b; Pedersen et al. 2005; Reemtsma et al. 2006; Thruston et al. 1991).  Therefore, introduction of
these anthropogenic compounds into the environment is augmented if an effective purification is not
performed to remove or degrade phosphate esters at the WWTF.
Analysis of several streams in Johnson County, Kansas in 2002–2003 revealed the presence of phosphate
ester flame retardants.  On average, concentrations of 0.5 μg/L of TnBP, TPP, TBEP, TCEP, and TDCP
were reported in these streams.  In addition, several water samples collected and analyzed near a WWTF
in the same area contained TBEP and TDCP.  The mean concentrations of TBEP and TCDP in the
effluent were 4.4 and 0.4 μg/L, respectively, and 2.0 and 0.4 μg/L <500 m downstream from the treatment
plant.  Maximum concentrations of 15 and 0.6 μg/L for TBEP and TDCP, respectively, were measured in 
the immediate effluent, and maximum levels of 6.2 and 0.6 μg/L, respectively, were measured <500 m 
downstream (Lee and Rasmussen 2006).  A comprehensive study conducted by the U.S. Geological
Survey from 1999 to 2000 analyzed surface water samples from 139 streams obtained in 30 states across 
the continental United States (Kolpin et al. 2002). TCEP, TDCP, and TPP were detected in 57.6, 12.9, 
and 14.1% of the surface water samples tested over this 2-year period, respectively.  The maximum
concentrations of TCEP, TDCP, and TPP were reported as 0.54, 0.16, and 0.22 μg/L, respectively, with 
median levels of 0.1, 0.1, and 0.04 μg/L, respectively (Kolpin et al. 2002).  
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Municipal waste water effluent collected from a treatment plant leading to the Oder River, Germany, 
contained mean levels of 622, 352, and 2,955 ng/L of TnBP, TCEP, and TBEP, respectively, in 
specimens obtained during a 2002–2003 sampling period (Fries and Puttmann 2003).  Mean levels of
TnBP, TCEP, and TBEP measured in the influent to the plant were 15,404, 986, and 12,835 ng/L, 
respectively.  The concentration of TnBP, TCEP, and TBEP in river water at various sampling points in 
the river downstream from the plant ranged from 69 to 1,044 ng/L (TnBP), from not detected to 
1,036 ng/L (TCEP), and from 121 to 952 ng/L (TBEP).  Groundwater samples obtained from areas 
adjacent to the river contained TnBP, TCEP, and TBEP at ranges from not detected to 1,120, from not
detected to 312, and from 154 to 410 ng/L, respectively.  
Phosphate esters are widely used as incombustible plasticizers in Japan and, as a consequence, have been 
detected in the environment.  Samples collected and analyzed in 1989–1990 from the Yodo River, Osaka
City Rivers, Osaka Bay, and Yamato River in Japan indicated the presence of phosphate ester flame 
retardants.  The most prevalent phosphate ester detected was TCPP at 13.1 µg/L in the Yamato River; 
however, TCEP, TnBP, TDCP, and TPP were also detected at lower concentrations (Fukushima et al.
1992).
Three volcanic lakes located in Central Italy were examined for the presence of phosphate esters
(Bacaloni et al. 2008).  Due to their location, the lakes lack emissaries and tributaries and sewage 
treatment plant inputs.  Therefore, contamination can occur only via local anthropogenic activities or
long-range transport and deposition from rainfall or runoff processes.  The results of this study indicated 
the presence of TCEP, TCPP, TDCP, TPP, TiBP, TnBP, and TBEP in all three of these lakes at the parts
per trillion (ng/L) level, with a noticeable seasonal variation for several of the compounds. For each of
the three lakes, maximum concentrations of the phosphate esters tended to occur during the late summer
to autumn months, which coincide with heavy tourist activity and increased vehicular traffic at all three
locations.  The mean monthly range of concentrations at all three lakes were as follows: TCEP, not
detected to 64 ng/L; TCPP, 2–62 ng/L; TDCP, 2–60 ng/L; TPP 2–21 ng/L; TiBP, 1–380 ng/L; TnBP, 3– 
784 ng/L; and TBEP, 8–127 ng/L.  
Aerosolized phosphate esters are subject to wet deposition. TPP and TnBP were identified, but not
quantified, in rainwater samples obtained from Los Angeles, California (Kawamura and Kaplan 1983), 
and snowfall samples from various areas of Northern Sweden (Marklund 2005a). TnBP was detected in 
the snowfall at an airport in Sweden at levels as high as 23,000 ng/kg, likely as a consequence of its use in 
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aircraft hydraulic fluids.  TnBP, TCEP, and TBEP were detected in rainwater samples collected in 
Bahnbrucke, Germany at levels of 911, 121, and 394 ng/L, respectively (Fries and Puttmann 2003).
TnBP is frequently used as a solvent in liquid-liquid extraction for uranium and plutonium fuel
reprocessing.  Consequently, it has been detected in storage ponds and waste streams at nuclear fuel
reprocessing sites.  TnBP and uranium concentrations in a typical fuel rod storage pond were 300 and 
142 μM, respectively (Thomas and Macaskie 1996).
TCEP, TDCP, and TPP were analyzed in groundwater samples from 47 sites in 18 different states as part
of a national reconnaissance program of water quality in the United States (Barnes et al. 2008).  TCEP
was detected in 29.8% of the samples tested at a maximum concentration of 0.737 μg/L.  TDCP and TPP
were detected in 2.1 and 4.3% of the groundwater samples tested, respectively; however, all detections
were below the reporting level.  Focazio et al. (2008) studied the frequency of detection of phosphate
esters and 96 other compounds in 25 ground- and 49 surface-water sources used for public drinking water
systems from 25 different states and Puerto Rico. TCEP, TDCP, TnBP, and TPP were detected in 20.3, 
12.2, 8.1, and 1.35% of the samples tested, respectively.  The maximum concentration of TnBP was
0.74 μg/L; however, all of the other compounds were detected below the reporting limit of 0.5 μg/L.
TPP was identified, but not quantified, in water samples collected from groundwater and treated water
obtained from 31 wells in the Piedmont and Highlands regions of Northern New Jersey (Stiles et al. 
2008).  In a 1979 survey of treated potable drinking water from 29 municipalities across Canada, the
presence of TnBP, TCEP, TDCP, TPP, and TBEP was frequently observed.  TBEP was the most
commonly detected phosphate ester with levels as high as 560 ng/L (Williams et al. 1981).  Phosphate
esters were detected in untreated surface water from the Ruhr River in Germany; reported concentrations 
of TCPP, TCEP, and TDCP were 50–150, 10–130, and 10–40 ng/L, respectively (Andresen and Bester
2006).  Following treatment of the water, the concentrations were all reduced to 0.3–3 ng/L (Andresen 
and Bester 2006).  
6.4.3 Sediment and Soil
Available literature suggests that halogenated phosphate esters are somewhat persistent organic
compounds when adsorbed to soils and sediments (Boethling and Cooper 1985; Muir 1984).  However, 
Muir et al. (1989) found that nonhalogenated phosphate esters, particularly TPP, are degraded in <3 days.  
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In general, partitioning of phosphate esters provides potential for contact with sediments in lakes, rivers, 
and sea floors.  
A national survey conducted in 1977–1978 in Japan resulted in the detection of TnBP at concentrations of
8–130 ng/g in rivers sediments, 3–24 ng/g in estuary sediments, and 2–240 ng/g in sea sediments 
(Ishikawa et al. 1985).  Phosphate ester levels of 0.1–1 μg/g have been detected in river sediments of
industrial areas contaminated with triaryl-based hydraulic fluids (Ishikawa et al. 1985; Muir et al. 1989).  
Commercial and military use of phosphate ester hydraulic fluid is estimated to result in up to 80% of the
consumption of these to be lost to unrecovered leakage.  Consequently, air force bases have reported 
detection of several phosphate esters, including TPP, in soils (David and Seiber 1999b; Monsanto Co. 
1980).  In Glil-Yam, Israel, Muszkat et al. (1993) reported the presence of TnBP at 25 ppb in effluent
used for crop irrigation.  A national survey in 1977–1978 resulted in the detection of TCEP in sea
sediments at a concentration of 90 ng/g (Ishikawa et al. 1985). 
6.4.4 Other Environmental Media 
In 1982, the Food and Drug Administration (FDA) found detectable levels of phosphate esters present in 
food samples during a portion of the annual Pesticide Screening program.  The presence of these
phosphate esters in foodstuffs presumably arose from the diffusion of these substances through the
wrapping material used to package the food (Daft 1982).  Since 1982, phosphate ester flame retardants are
regularly tested for in various foods by the FDA’s Total Diet Study.  The results obtained are summarized 
in Table 6-1.  No data were available for TiBP or TDCP from this study (FDA 2006).  The most
frequently identified phosphate ester flame retardant was TPP, which also had the highest reported 
content.  TPP was found in caramels and margarine at approximately 0.04 ppm.  In baby foods, turkey
and vegetables contained the highest level of TPP at approximately 0.02 ppm.  TnBP was the second most
frequently detected phosphate ester, but most levels measured were below 0.004 ppm, with baby cereal
(prepared with water) and applesauce being the highest (FDA 2006).
In a study based in the United Kingdom, similar to the U.S. based FDA Total Diet Study, the most 
prevalent of the selected phosphate esters were TnBP and TPP, occurring in meats, cereals, nuts, and 
some vegetables (Gilbert et al. 1986).
House dust has been found to contain phosphate esters such as TCEP and TCPP (Garcia et al. 2007;
Hutter et al. 2006; Ingerowski et al. 2001; Marklund 2003).  TBEP was measured at levels of 4,300–
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
 
 
 
  
   
    
   
   
    
    
     
    
    
   
    
   
   
   
    
   
     
   
   
   
  
   
   
   
    
     
   
  
    
   
    
   
   
   
    
217PHOSPHATE ESTER FLAME RETARDANTS
6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Phosphate Ester Flame Retardant Levels in Food
Food item Level (ppm)
Tributyl phosphate (TnBP)
Rice, white, enriched, cooked 0.00011
Oatmeal, plain, cooked 0.00014
Cream of wheat (farina), enriched, cooked 0.00200
Corn flakes cereal 0.00314
Fruit-flavored cereal, presweetened 0.00018
Shredded wheat cereal 0.00123
Raisin bran cereal 0.00018
Crisped rice cereal 0.00086
Oat ring cereal 0.00034
Apple (red), raw (with peel) 0.00043
Applesauce, bottled 0.00430
Orange juice, frozen concentrate, reconstituted 0.00045
Grapefruit juice, frozen concentrate, reconstituted 0.00091
Prune juice, bottled 0.00089
Dill cucumber pickles 0.00023
Sugar, white, granulated 0.00045
Peach, canned in light/medium syrup 0.00045
Tomato juice, bottled 0.00018
Baby food, cereal, mixed, dry, prepared with water 0.00432
Tributoxyethyl phosphate (TBEP)
Oatmeal, plain, cooked 0.00368
Bread, whole wheat 0.00114
Candy, caramels 0.00075
BF, juice, apple 0.00018
Peach, canned in light/medium syrup 0.00039
Popsicle, fruit-flavored 0.00225
Tri-(2-chloroisopropyl) phosphate (TCPP)
Apple (red), raw (with peel) 0.00082 
Pear, raw (with peel) 0.00009 
Prunes, dried, uncooked 0.00015 
Apple juice, bottled 0.00005 
Tomato catsup 0.00030 
Tomato juice, bottled 0.00032 
Baby food, arrowroot cookies 0.00018 
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Table 6-1.  Phosphate Ester Flame Retardant Levels in Food
Food item Level (ppm)
Triphenyl phosphate (TPP)
Peas, green, frozen, boiled 0.00023
Rolls, white, soft, enriched 0.00075
Bread, whole wheat 0.00036
Tortilla, flour 0.00050
Bread, rye 0.00039
Strawberries, raw/frozen 0.00028
Lemonade, frozen concentrate, reconstituted 0.00041
Sauerkraut, canned 0.00025
Broccoli, fresh/frozen, boiled 0.00023
Asparagus, fresh/frozen, boiled 0.00023
Tomato, raw 0.00341
Mashed potatoes with margarine and milk, prepared from instant 0.0025
Scalloped potatoes, homemade 0.00023
Soup, vegetable beef, canned, condensed prepared with water 0.00068
White sauce homemade 0.00285
Margarine, regular (salted) 0.04068
Butter, regular (salted) 0.00175
Cream substitute, non-dairy, liquid/frozen 0.00102
Candy, caramels 0.04503
Fruit drink, from powder 0.00023
Wine, dry table, red/ white 0.00068
Bread, cracked wheat 0.00057
Crackers, graham 0.00045
Sweet cucumber pickles 0.00025
Beef and vegetable stew, canned  0.00975
Baby food, juice, apple-banana 0.00295
Baby food, zwieback toast 0.00400
Baby food, vegetables and turkey 0.02175
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Table 6-1.  Phosphate Ester Flame Retardant Levels in Food
Food item Level (ppm)
Tris-(2-chloroethyl)-phosphate (TCEP)
Peas, green, frozen, boiled 0.00182
Oatmeal, plain, cooked 0.00002
Cream of wheat (farina), enriched, cooked 0.00259
Rolls, white, soft, enriched 0.00008
Broccoli, fresh/frozen, boiled 0.00014
Green beans, fresh/frozen, boiled 0.00159
Baby food, turkey and rice 0.00048
Baby food, peas 0.00002
Bread, cracked wheat 0.00002
Eggplant, fresh, peeled, boiled 0.00175
Candy, hard, any flavor 0.00002
Sweet cucumber pickles 0.00005
Baby food, teething biscuits 0.00006
Soup, Oriental noodles (ramen noodles), prepared with water 0.00725
Baby food, pears and pineapple 0.00002
Source: FDA Total Diet Study Market Baskets 1991–2003 (FDA 2006)
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7,800 mg/kg in house dust prior to removal of the cleaning polish on the floor.  Once a wet cleaning was
performed, the level of TBEP dropped to 410 mg/kg after 3 months and to 90 mg/kg after 6 months
(Hutter et al. 2006).  Dust samples obtained from different private residences (houses) located in the 
northwest of Spain were found to contain levels of TBEP as high as 18.5 μg/g.  Other phosphate esters
were also detected in the dust samples at average concentrations (μg/g) of 0.21 (TiBP), 0.25 (TnBP), 
1.7 (TCEP), 3.9 (TCPP), 0.35 (TDCP), 2.6 (TPP), and 9.9 (TBEP) (Garcia et al. 2007).  
Phosphate esters were detected in soft polyurethane foam samples at levels of 0.4–0.7 μg/g for TnBP, 
0.8–3.1 μg/g for TCEP, 0.9–3.1 μg/g for TCPP, 4.5–10.2 μg/g for TDCP, 4.7–23.3 μg/g for TPP, and 
1.6 μg/g for TBEP (Nagase et al. 2003).  
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Exposure to phosphate esters can occur through ingestion of food and water containing phosphate esters
or inhalation of vapors or particulates released from flame retardant materials.  Dermal exposure can 
occur through direct contact with flame-retarded textiles occurs; however, these substances are not highly
absorbed through dermal routes.  As fabrics and foams treated with phosphate ester flame retardants wear, 
they can shed small fibers and produce particles that could be injested or inhaled if ≤10 µm (NRC 2000).  
The most significant route of exposure to the general population is via ingestion of food or water
contaminated with phosphate ester flame retardants (Fiserova-Bergerova and Pierce 1990; Hartmann et al. 
2004; Hughes et al. 2001; IPCS 1997).
Data regarding dietary intake of phosphate ester flame retardants in children and adults in the United 
States are available only for select compounds and years.  In 1980 and 1981–1982, ADI values of TCEP
for adults were 0.041 and 0.055 μg/kg, respectively.  In 1981–1982, the ADI for TnBP was found to be
0.025 μg/kg.  This value was determined by measuring of TnBP in meats and fruits, and TCEP in cereals
(Gantrell 1986). The ADI was calculated by Gunderson (1988, 1995a, 1995b) from the reported FDA 
Total Diet Study and these data are summarized in Table 6-2.  Mean daily intakes for male and female 
teenagers aged 14–16 were highest for TPP ranging from 1.6 to 18.2 ng/kg/day.  For male and female 
adults aged 25–30, TPP also had the highest mean daily intakes, ranging from 0.8–18.4 ng/kg/day.  Both 
male and female adults aged 60–65 showed the highest mean daily intake for TBEP, ranging from 0.2 to 
16.8 ng/kg/day.  TPP was also quite prevalent for this age group.  No data were reported for TiBP or
TDCP (Gunderson 1988, 1995a, 1995b). 
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Table 6-2.  Dietary Phosphate Ester Flame Retardant Intake
Mean (ng/kg body weight/day)
Age group 1982–1984a 1984–1986b 1986–1991c 
Tributyl phosphate (TnBP)
6–11 months 38.9 42.5 3.0
2 years 27.7 33.1 2.5
14–16 years, females 3.5 4.5 0.5
14–16 years, males 5.0 6.6 0.7
25–30 years, females 3.3 4.0 0.3
25–30 years, males 2.7 3.1 0.3
60–65 years, males 5.4 6.2 0.4
60–65 years, females 6.2 7.1 0.4
Triphenyl phosphate (TPP)
6–11 months 0.3 1.8 15.7
2 years 4.4 16.0 34.8
14–16 years, females 1.6 5.8 16.3
14–16 years, males 1.2 5.0 18.2
25–30 years, females 0.8 3.3 12.8
25–30 years, males 1.6 5.5 18.4
60–65 years, males 0.5 2.4 11.4
60–65 years, females 0.5 2.4 15.8
Tributoxyethyl phosphate (TBEP)
6–11 months 2.9 0.2 5.2
2 years 14.4 1.5 3.7
14–16 years, females 8.4 0.7 1.2
14–16 years, males 7.7 1.1 1.1
25–30 years, females 12.9 0.4 2.0
25–30 years, males 10.7 0.8 0.9
60–65 years, males 16.8 0.2 3.4
60–65 years, females 13.7 0.2 2.8
Tri-(2-chloroisopropyl) phosphate (TCPP)
6–11 months No data No data 0.1
2 years No data No data 0.2
14–16 years, females No data No data 0.1
14–16 years, males No data No data 0.1
25–30 years, females No data No data 0.1
25–30 years, males No data No data 0.1
60–65 years, males No data No data 0.1
60–65 years, females No data No data
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Table 6-2.  Dietary Phosphate Ester Flame Retardant Intake
Mean (ng/kg body weight/day)
Age group 1982–1984a 1984–1986b 1986–1991c 
Tris-(2-chloroethyl)-phosphate (TCEP)
6–11 months No data 4.9 No data
2 years No data 6.5 No data
14–16 years, females No data 2.1 No data
14–16 years, males No data 1.1 No data
25–30 years, females No data 1.8 No data
25–30 years, males No data 1.3 No data
60–65 years, males No data 3.1 No data
60–65 years, females No data 2.6 No data
aGunderson 1988 (ADI 1982–1984)

bGunderson 1995a (ADI 1984–1986); expressed as µg/kg body weight/day in source.
 
cGunderson 1995b (ADI 1986–1991); expressed as µg/kg body weight/day in source.
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In the United Kingdom, a diet study modeled after the U.S. Total Diet Study determined a total daily
intake of 0.075–0.105 mg/day for trialkyl/aryl phosphates.  The most prevalent of the selected phosphate 
esters were TnBP and TPP, found in meats, cereals, nuts, and some vegetables (Gilbert et al. 1986).
In Canada, TDCP was detected in human adipose tissue by LeBel and Williams (1983, 1986) in 
concentrations that ranged from not detectable (<0.001 μg/kg) to 257 μg/kg.  In later studies, samples
from four out of six cities showed no detectable TDCP; however, two concentrations ranged up to 
32 μg/kg. (LeBel and Williams, 1983, 1986; LeBel et al. 1989).  Using negative chemical ionization mass
spectrometry (LC-MS-NCI) with a limit of detection of 0.01 μg, Hudec et al. (1981) found concentrations
of TDCP in the seminal fluid of 34 out of 123 student donors ranging from 5 to 50 μg/L.
Morgan and Hughes (1981) tested workers manufacturing triaryl phosphate esters, including TPP, for
cholinesterase activity to determine its efficacy as a biomarker for absorption.  The results showed that it
is not adequately sensitive to be used as a biomarker for phosphate ester absorption.
Three primary uses that account for the greatest potential worker exposure include aircraft manufacturing, 
hydraulic system component manufacturing, and commercial airline operations (Batt et al. 1992).  In 
addition, workers in industries that manufacture plastics, floor polishes, wall coverings, and electronics
may have a greater-than-average potential for exposure.
A survey conducted by NIOSH (National Institute for Occupational Safety and Health) from 1981–1983 
collected data on potential occupational exposures to chemical agents.  These data provided estimates that
indicated the number of workers potentially exposed to TPP, TnBP, TBEP, TCEP, and TCPP were 
91,754, 109,402, 257,421, 5,073, and 120 respectively (NIOSH 1990).
6.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
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or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Exposure of children to phosphate ester flame retardants is likely to occur primarily through diet, indoor
air, or by contact with flame retardant-treated plastics or fabrics.  Young children are likely to have an 
increased oral exposure risk.  Children may repeatedly suck on furnishing fabrics, plastics, or polished 
surfaces, presenting potential dissolution of leachable flame retardants.  Effective phosphate ester flame 
retardants are dependant upon retention in the applied matrix, and are therefore likely chosen based upon 
their ability to resist extraction from the matrix (NRC 2000).  Children and infants may be exposed to 
phosphate ester flame retardants through ingestion of dust in homes where plastics, foams, floor polishes, 
or wall covering products containing phosphate esters are used (Hutter et al. 2006).  
In 1980, the ADIs of TnBP for infants and toddlers were 0.051 and 0.132 μg/kg, respectively.  In 
1979 and 1980, TCEP was found to have an ADI of 0.016 and 0.004 μg/kg, respectively, in infants and 
0.009 μg/kg and none detected, respectively, in toddlers.  These were determined by measuring TnBP in
cereals and TCEP in fruits (Gantrell 1985).  Mean daily intakes for 6–11-month-old children were highest
for TnBP between 1982 and 1986, ranging from 38.9 to 42.5 ng/kg//day.  This number dropped 
significantly to 0.3 ng/kg/day in the last study published in 1986–1991.  The next greatest exposure of 6– 
11-month-old children via diet appears to be TPP, with an ADI of 15.7 ng/kg/day in 1986–1991.  The
exposure data indicated that 2-year-old children could have exposures >30 ng/kg/day of TnBP and TPP
(Gunderson 1988, 1995a, 1995b).
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Phosphate esters do not occur naturally in the environment; therefore, potential high exposures are limited 
to occupational or indoor environments.  Occupational exposure to phosphate ester flame retardants may
occur during the manufacture, use, transport, processing, or disposal/recycling of flame retardants.  
Routes of exposure could include inhalation, dermal contact, or ingestion.  Living or working in an 
environment where there is an excess of flame retardant-treated products such as wall coverings, plastics, 
or electronics could contribute to a higher-than-average exposure.  Additionally, living in an area where
phosphate ester-contaminated effluent is used for drinking water or crop irrigation could contribute to a
higher-than-average exposure (Fiserova-Bergerova and Pierce 1990; IPCS 1997).
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6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of phosphate ester flame retardants is available.  Where 
adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of phosphate ester flame retardants. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. Table 4-2 summarizes many of the relevant physical and 
chemical properties of the selected phosphate ester flame retardants.  The only data need is for measured 
Log Kow and vapor pressures for TiBP. 
Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning
and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit
substance release and off-site transfer information to the EPA.  The TRI, which contains this information 
for 2006, became available in February of 2008. This database is updated yearly and should provide a list
of industrial production facilities and emissions.
Current data on the use of each selected phosphate ester flame retardants are available and displayed in 
Table 5-1.  Production, import, and export data are scarce and difficult to find, but estimates are provided 
by the EPA High Production Volume (HPV) Challenge Program or the Hazardous Substance Data Bank
(HSDB) for all selected phosphate ester flame retardants.  No data were available for manufacturers for 
TCPP and TiBP as indicated in Table 5-1 (EPA 2006; HSDB 2009).  A data need exists for release and 
disposal of phosphate ester flame retardants. 
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Environmental Fate. The environmental entry mechanism of phosphate esters, as well as transport
and partitioning, is highly dependent on the specific compound.  The environmental fate mechanisms of
groups within the selected compounds (e.g., halogenated, alkyl, and aryl phosphate esters) are well
understood (Muir 1984).  Hydrolysis and adsorption are the primary forces that influence phosphate ester
environmental fate and are well documented (Howard and Deo 1979; Kenaga and Goring 1980; Mayer et
al. 1981; Muir 1984).  No data needs are identified.
Bioavailability from Environmental Media. A data need exists for bioavailability of phosphate 
ester flame retardants from various media.  Minimal data exist in the form of human monitoring, but
several studies suggest that absorption of phosphate esters can occur via ingestion of foods and water
contaminated with effluent or landfill leachate, inhalation of indoor and some outdoor air near airports
and military installations, or dermal contact with contaminated soils or water (Fiserova-Bergerova and 
Pierce 1990; IPCS 1997; Monsanto Co. 1980; Saito et al. 2007).
Food Chain Bioaccumulation. Sufficient bioaccumulation data are available for TnBP, TPP, TCEP, 
and TDCP (Muir 1980, 1983a; Sasaki et al. 1981, 1982); however, a data need exists for bioaccumulation 
of TiBP, TBEP, and TCPP.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of phosphate 
ester flame retardants in contaminated media at hazardous waste sites are needed so that the information 
obtained on levels of phosphate ester flame retardants in the environment can be used in combination with
the known body burden of phosphate ester flame retardants to assess the potential risk of adverse health 
effects in populations living in the vicinity of hazardous waste sites.
Extensive reports are available regarding quantifiable levels of phosphate ester flame retardants detected 
in the environment.  More specifically, extensive monitoring data exist on phosphate ester flame
retardants in water (Andresen et al. 2004; Fries and Puttmann 2001; Gomez-Belinchon et al. 1988;
Ishikawa et al. 1985; Lee and Rasmussen 2006; Meyer and Bester 2004; Muir 1984; Peterman et a 1980;
Reemtsma et al. 2006; Watts and Liden 2008, 2009) and indoor air (Carlsson et al. 2000; Garcia et al. 
2007; Hutter et al. 2006; Ingerowski 2001, 2003; Otake et al. 2004, 2001; Owens et al. 2007; Sjodin et al. 
2001).  Studies detecting phosphate ester flame retardants in outdoor air are more sparse (Haraguchi et al. 
1985; Monsanto Co. 1980; Saito et al. 2007).  Additional data of phosphate ester flame retardants in soil
and in food, as well as more recent average daily intake data, would be useful for estimating human 
exposure.  In particular, there is a data need for environmental concentrations of TiBP.
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Exposure Levels in Humans. Given that these compounds are considered emerging pollutants in 
some of the literature, there are relatively little data concerning levels of phosphate ester flame retardants 
in humans.  There are, however, studies that reported levels of TDCP in human adipose tissue (Lebel and 
Williams 1983, 1986) and in the seminal fluid of student donors (Hudec et al. 1981).  A data need exists
for additional information regarding levels of these substances in blood, and urine from individuals with 
potentially high exposures such as children and infants. A data need exists for studies adressing
biomarkers as a method for determining exposure to mixtures of phosphate esters.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children are exposed to phosphate ester flame retardants by the same routes 
as adults.  In addition, oral exposure can occur from dissolution of phosphate ester treated materials since
children are more likely to repeadtedly suck on these materials (NRC 2000). A data need exists for levels 
of phosphate esters in blood and urine from children with known environmental exposure, as well as
concentrations present in breast milk or infant formula to better estimate total exposure.  Gantrell (1985)
and Gunderson (1988, 1995a, 1995b) addressed only TnBP, TPP, TCEP, TCPP, and TBEP over a limited 
number of years (1982–1991).  A data need exists for updated exposure in the form of ADI for children
with the aforementioned compounds as well as new data regarding of TiBP and TDCP exposures. 
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for phosphate ester flame retardants were located.  This 
substance is not currently one of the compounds for which a sub-registry has been established in the 
National Exposure Registry.  The substance will be considered in the future when chemical selection is 
made for sub-registries to be established.  The information that is amassed in the National Exposure 
Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be
related to exposure to this substance.
6.8.2 Ongoing Studies 
No ongoing studies pertaining to the environmental fate of phosphate ester flame retardants were 
identified in a search of the Federal Research in Progress database (FEDRIP 2009)
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring phosphate ester flame retardants, their metabolites, and other biomarkers of
exposure and effect to phosphate ester flame retardants.  The intent is not to provide an exhaustive list of
analytical methods.  Rather, the intention is to identify well-established methods that are used as the
standard methods of analysis.  Many of the analytical methods used for environmental samples are the
methods approved by federal agencies and organizations such as EPA and the NIOSH.  Other methods
presented in this chapter are those that are approved by groups such as the Association of Official
Analytical Chemists (AOAC) and the American Public Health Association (APHA).  Additionally, 
analytical methods are included that modify previously used methods to obtain lower detection limits
and/or to improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
Methods for the determination of phosphate ester flame retardants in biological materials are summarized 
in Table 7-1. There is virtually no information regarding the toxicokinetics of these chemicals in humans, 
including information on possible metabolites; consequently, there are no methods for determining
metabolites. Thus far, detection of the parent compound is the only method available for detecting
exposure to phosphate ester flame retardants.
There are very few published articles regarding bioanalytical methods for phosphate ester flame 
retardants, but interest in these compounds as emerging pollutants has stimulated development of a select
few (Shah et al. 2006).  The bioanalytical methods presented are preliminary and are not accepted 
methods of accurately determining phosphate ester flame retardants in biological materials.
Alkyl and aryl phosphate ester flame retardants were measured in blood using a method developed by
Jonsson and Nilsson (2003).  The sample preparation from blood plasma consisted of a hollow fibre-
based XT-tube extractor to perform the liquid-liquid microextraction in hexane/methyl tert-butyl ether
2:1 (v/v).  A top gas chromatograph equipped with a TS-2 nitrogen-phosphorus detector (NPD) was
employed to analyze the phosphate esters. The detection limits were 0.3 ng/mL for TPP and 36 ng/mL
for TBEP.  Recoveries varied between 40 and 80% with a relative standard deviation (RSD) around 4%
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Table 7-1. Analytical Methods for Determining Phosphate Ester Flame
 
Retardants in Biological Materials
 
Sample 
matrix
Preparation
method
Analytical 
method
Sample 
detection limit Analyte
Percent
recovery Reference
Urine MISPE >80%
recovery
LC-ESI-MS 0.025 ng/μL TPP 72–75
RSD: 11–12%
Moller et al.
2004
No data TnBP No data
Blood 
plasma
Liquid-liquid 
microextraction
GC-MS­
NPD
0.3 ng/mL TPP 40–80
RSD: 4%
Jonsson and 
Nilsson 2003
36 ng/mL TnBP 40–80
RSD: 4%
No data TBEP,
TCEP,
TCPP
40–80
RSD: 4%
Blood 
Plasma
Methanol
extraction,
acetonitrile 
precipitation, then 
SPME
GC-ICP-MS 17 ng/L
240 ng/L
24 ng/L
TnBP
TCEP
TPP
43
RSD 11%
49
RSD 7%
66
RSD 14%
Shah et al.
2006
Tissue Extract with 
benzene or
acetone/hexane;
fractionation by
GPC
GC-MS­
NPD
No data TPP,
TnBP,
TBEP,
TDCP,
TCEP
2.5 ng: 78–96
10 ng: 52–100
25 ng: 88–105
LeBel and
Williams 1983
Seminal
fluid
Steam distillation;
continuous liquid-
liquid extraction
LC-MS-NCI 0.01 μg TDCP No data Hudec et al.
1981
ESI = electronspray; GC = gas chromatography; GPC = gel permeation chromatography; ICP = inductively coupled 
plasma; LC = liquid chromatography; MISPE = molecularly imprinted polymer solid-phase extraction; MS = mass 
spectrometry; NCI = negative chemical ionization; NPD = nitrogen-phosphorus detection; RSD = relative standard 
deviation; SPME = solid phase microextraction; TBEP = tributoxyethyl phosphate; TCEP = tris-(2-chloroethyl)­
phosphate; TCPP = tri-(2-chloroisopropyl) phosphate ; TiBP = triisobutyl phosphate; TnBP = tributyl phosphate;
TOF = time of flight; TPP = triphenyl phosphate
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for most compounds.  The method was also able to detect and quantify other phosphate ester flame
retardants such as TnBP, TCEP, and TCPP, although the detection limit was not sufficiently low.
Another analytical method to determine phosphorus-specific compounds in human plasma was published 
by Shah et al. (2006).  This technique uses solid-phase microextraction (SPME) followed by gas 
chromatography (GC) inductively coupled plasma (ICP) mass spectrometry (MS) and high resolution GC
time of flight (TOF) MS.  The detection limits from blood plasma were 17 ng/L for TnBP, 240 ng/L for
TCEP, and 24 ng/L for TPP.
In urine, Moller et al. (2004) detected and quantified TnBP and TPP hydrolysis products.  The method is
capable of extracting the corresponding diesters of TnBP and TPP via molecularly imprinted polymer
solid-phase extraction (MISPE) and liquid chromatography (LC) electrospray (ESI) MS method using a
Hypercarb LC column with a graphitized carbon stationary phase.  The detection limit was 0.025 ng/µL 
for diphenyl phosphate, the hydrolysis product of TPP.
In Canada, TDCP was detected in human adipose tissue by LeBel and Williams (1983, 1986) in 
concentrations that ranged from not detectable (<0.001 μg/kg) to 257 μg/kg.  In later studies, samples
from four out of six cities showed no detectable TDCP; however, two concentrations ranged up to 
32 μg/kg (LeBel and Williams 1983, 1986; LeBel et al. 1989).  Using LC negative chemical ionization 
(NCI) MS with a limit of detection of 0.01 μg, Hudec et al. (1981) found TDCP in the seminal fluid of
34 out of 123 student donors.  The TDCP concentrations ranged from 5 to 50 μg/L.
7.2 ENVIRONMENTAL SAMPLES 
Methods for the determination of phosphate ester flame retardants in environmental samples are 
summarized in Table 7-2.
Standard environmental analysis methods are available for several of the selected phosphate ester flame 
retardants from the U.S. Geological Survey (USGS) and NIOSH (NIOSH 1994a, 1994b; USGS 2001).  
All standardized methods, as well as literature methods available, utilize either liquid- or gas-based 
chromatography with predominantly GC flame photometric detection (FPD) being employed.  Methods
for analyzing phosphate ester flame retardants in air, water, soil, and other environmental media are 
prevalent throughout the literature.
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Table 7-2. Analytical Methods for Determining Phosphate Ester Flame Retardants in
 
Environmental Samples
 
Sample 
matrix
Preparation
method
Analytical 
method
Sample 
detection limit
Percent
recovery Analyte(s) Reference
Air (indoor) Collection on filter,
extract with ethyl
ether, filter
NIOSH 5034
GC-FPD
2 μg/sample No data TnBP NIOSH 
1994a
Air (indoor) Absorbed on a 
filter, extracted 
with
GC-MS 3 ng/mL or
13 ng/m3 
92–109 TnBP, TiBP,
TPP
Solbu et al.
2007
dichloromethane
Air (outdoor) Trap with glycerol-
Florisil column,
elute with 
GC-FPD 1 ng/m3 No data Trialkyl/aryl 
phosphates
ICPS 1991b
(EHC-111)
MeOH/water,
extract with
hexane
Water, 
sediments,
solid wastes,
sludges
Collection on filter,
extract with ethyl
ether, filter
NIOSH 5038
GC-FPD
10 μg/sample No data TPP NIOSH 
1994b
Filtered 
waste water
and water
Filtered, extracted 
with an SPE
cartridge 
containing a
polystyrene 
divinylbenzene
phase, dried,
rinsed with
DCM/ether, and 
concentrated
USGS­
NWQL
O-1433-01
GC-MS
TnBP 0.1 μg/L TnBP: 110a ,
5.97% RSD
TBEP 0.2 μg/L TBEP: 103.4a , 
12.52% RSD
TPP 0.06 μg/L TPP: 90a , 
4.5% RSD
TDCP: 0.08 μg/L TDCP: 96.4a , 
5.29% RSD
TCEP: 0.08 μg/L TCEP: 100a , 
5.04% RSD
TnBP,
TBEP, TPP,
TDCP,
TCEP
USGS 2001
Water
(drinking)
Adsorb resin,
elute
GC-NPD 1 ng/L No data Trialkyl/aryl 
phosphates
LeBel et al.
1979
Sediments
(sea or river)
Extract with MeCN
or acetone, Florisil
column
GC-FPD TnBP:  2 ng/g
TCPP: 5 ng/g
TCEP: 5 ng/g
TPP:    5 ng/g
83–98 TnBP,
TCEP, TPP,
TCPP
Ishikawa et
al. 1985
aPercent recovery and relative standard deviation were reported by NEMI (2009).
DCM =  dichloromethane; FPD = flame photometric detection; GC = gas chromatography; MS = mass spectrometry;
NIOSH = National Institute for Occupational Safety and Health; NPD = nitrogen-phosphorus detection; RSD = relative 
standard deviation; SPE = solid phase extraction; TBEP = tributoxyethyl phosphate; TCEP = tris-(2-chloroethyl)­
phosphate; TCPP = tri-(2-chloroisopropyl) phosphate; TiBP = triisobutyl phosphate; TnBP = tributyl phosphate;
TPP = triphenyl phosphate; USGS = U.S. Geological Survey
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Drinking water has been analyzed for TPP using a modified version of EPA method 525.5 using
C-18 bonded solid phase extraction columns (Stiles et al. 2008) and also using GC-MS with NPD (LeBel
et al. 1979).  TPP adsorbed to sediments and soils can also be analyzed using a method developed by
Degeus et al. (1994) using thermionic detection (TID) with supercritical fluid chromatography (SFC).
An alternative method for testing for phosphate ester flame retardants was developed by Lombardo and 
Egry (1979) based on an AOAC method developed for analysis of pesticide residues in fatty foods.  The
method extracted the hydraulic fluid from contaminated fish samples and analyzed them by gas-liquid 
chromatography (GLC) with phosphorus selective detection.  The analysis yielded concentrations of TPP
concentrations of 0.06 and 0.12 ppm in carp and 0.15 ppm in goldfish collected from Waukegan Harbor, 
Illinois.
Several other methods were developed for detection of phosphate esters in various types of media. 
Lamouroux et al. (2000) report an LC-MS method for determining degradation products of TnBP used in 
nuclear fuel processing.  The TnBP content affects the performance of the extracting solvent; therefore,
determining the diester and monoester content is desired.
Nagase et al. (2003) used GC-FPD to detect phosphate ester flame retardants in polyurethane foam
cushions.  The detection limits were 0.3–0.9 μg/g.  The recoveries from a 0.05 g sample of soft
polyurethane foam were 80–90%, when the spiked amounts were 0.25–1 μg.  The compounds were
detected from soft polyurethane foam at the level of 0.4–23.3 μg/g.
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of phosphate ester flame retardants is available.  Where 
adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of phosphate ester flame retardants. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
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that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure. In vitro analytical methods have shown to detect TnBP, TPP, TCEP, TCPP, and TBEP in 
bodily fluids using GC-MS (Moller et al. 2004; Jonsson and Nilsson 2003).  It is not documented whether
these methods could be applied to analysis of TiBP or TDCP in bodily fluids.  TDCP is the only analyte
of the selected phosphate esters reported to be analyzed in human tissue and seminal fluid (Hudec et al. 
1981; Lebel and Williams 1983, 1986). There are no specific biomarkers of exposure other than the
phosphate esters themselves.  A data need exists for additional bioanalytical methods for TiBP and 
TDCP.  As information becomes available regarding the metabolism of these chemicals in humans, 
appropriate methods need to be developed for the detection and quantification of metabolites in tissues
and biological fluids.
Effect. No significant health effects have been reported in humans exposed to the phosphate ester flame
retardants discussed in this profile in the limited studies available of workers exposed to TDCP or TPP
(Stauffer Chem Co. 1983; Sutton et al. 1960).  Consequently, no associations have been established 
between body burdens of phosphate esters and health effects.  More information is needed regarding the 
toxicity and toxicokinetics of these substances to determine whether the existing analytical methods
reported in Table 7-1 are adequate in selectivity and sensitivity to measure phosphate esters in biological
materials at levels associated with adverse health effects.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. GC coupled with various detection methods (MS, FPD, or NPD) provide sufficiently accurate,
precise, and repeatable methods for determining phosphate ester concentrations in the environment
(Ishikawa et al. 1985; LeBel et al. 1979; NIOSH 1994a, 1994b; Solbu et al. 2007; USGS 2001; IPCS
1991a, 1991b). These analytical methods can adequately measure phosphate esters in air, water, soil, and 
sediments at concentrations in the ng/L or ng/m3 range.
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7.3.2 Ongoing Studies 
No ongoing studies pertaining to analytical methods for phosphate ester flame retardants were identified 
in a search of the Federal Research Progress database (FEDRIP 2009).
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MRLs are substance specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
The international and national regulations, advisories, and guidelines regarding phosphate ester flame
retardants in air, water, and other media are summarized in Table 8-1.  
ATSDR has derived an intermediate-duration oral MRL of 0.6 mg/kg/day for TCEP based on an 
increased incidence of brain lesions in female Fischer-344 rats dosed by gavage 5 days/week for 16 weeks 
(NTP 1991a).  The MRL was derived using benchmark modeling of incidence data for brain lesions in
female rats. The predicted dose associated with a 10% extra risk (BMD10) for brain lesions was
143.41 mg/kg/day; the lower 95% confidence limit on this dose (BMDL10) was 85.07 mg/kg/day.  An 
uncertainty factor of 100 was used (10 for animal to human extrapolation and 10 for human variability).
ATSDR has derived a chronic-duration oral MRL of 0.3 mg/kg/day for TCEP based on an increased 
incidence of renal tubule epithelial hyperplasia in female Fischer-344 rats dosed by gavage 5 days/week
for 2 years (NTP 1991a).  The MRL was derived using benchmark modeling of incidence data for renal
lesions in female rats.  The BMD10 for renal lesions was 53.09 mg/kg/day; the BMDL10 was 
36.09 mg/kg/day.  An uncertainty factor of 100 was used (10 for animal to human extrapolation and 
10 for human variability).
ATSDR has derived an acute-duration oral MRL of 1.1 mg/kg/day for TnBP based on decreased body
weight gain in Wistar rats during pregnancy (Noda et al. 1994).  The MRL was derived using benchmark 
modeling of the decrease in body weight gain.  The BMD1SD was 130.32 mg/kg/day; the corresponding
BMDL1SD was 111.47 mg/kg/day.  An uncertainty factor of 100 was used (10 for animal to human 
extrapolation and 10 for human variability).
ATSDR has derived an intermediate-duration oral MRL of 0.02 mg/kg/day for TnBP based on an 
increased incidence of urinary bladder hyperplasia in male Sprague-Dawley rats dosed via the diet for 
10 weeks (Arnold et al. 1997).  The MRL was derived using benchmark modeling of incidence data for 
urinary bladder lesions in male rats.  The BMD10 for urinary bladder lesions was 3.30 mg/kg/day; the
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Table 8-1.  Regulations and Guidelines Applicable to Phosphate Ester Flame 

Retardants
 
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification Group 3a IARC 2009
Tris-(2-chloroethyl)-phosphate
WHO Air quality guidelines No WHO 2000
Drinking water quality guidelines No WHO 2006
NATIONAL
Regulations and 
Guidelines:
a.  Air
ACGIH TLV (8-hour TWA)
Tributyl phosphate
Triphenyl phosphate
2.5 mg/m3 (0.19 ppm)
3.0 mg/m3 (0.22 ppm)
ACGIH 2008
TLV Basis
Tributyl phosphate Nausea, headache,
eye and upper
respiratory irritation
Triphenyl phosphate Cholinesterase 
inhibitor
AIHA ERPG values No AIHA 2008
EPA AEGL values No EPA 2009a
Hazardous air pollutant No EPA 2009b
42 USC 7412
NIOSH REL (10-hour TWA)
Tributyl phosphate
Triphenyl phosphate
2.5 mg/m3 (0.19 ppm)
3.0 mg/m3 (0.22 ppm)
NIOSH 2005b
IDLH
Tributyl phosphate
Triphenyl phosphate
327 mg/m3 (30 ppm)
1,000 mg/m3 (75 ppm)
Target organs
Tributyl phosphate Eyes, skin, and 
respiratory system
Triphenyl phosphate Blood and peripheral
nervous system
OSHA PEL (8-hour TWA) for general industry
Tributyl phosphate
Triphenyl phosphate
5.0 mg/m3 (0.46 ppm)
3.0 mg/m3 (0.22 ppm)
OSHA 2009
29 CFR 1910.1000,
Table Z-1
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Table 8-1.  Regulations and Guidelines Applicable to Phosphate Ester Flame 

Retardants
 
Agency Description Information Reference
NATIONAL (cont.)
b.  Water
EPA Drinking water standards and health 
advisories
No EPA 2006a
National primary drinking water
standards
No EPA 2003
National recommended water quality
criteria
No EPA 2006b
c.  Food
FDA EAFUSb No FDA 2008
d.  Other
ACGIH Carcinogenicity classification ACGIH 2008
Tributyl phosphate No
Triphenyl phosphate A4c 
EPA Inert ingredients are permitted for use in 
nonfood use pesticide products
EPA 2009c
Tributyl phosphate, tributoxyethyl
phosphate, and triphenyl phosphate
Yes
Carcinogenicity classification No IRIS 2009
RfC No
RfD No
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous
substance
No EPA 2009d
40 CFR 302.4
Effective date of toxic chemical
release reporting
No EPA 2009e
40 CFR 372.65
TSCA chemical lists and reporting 
periods
Tributyl phosphate, triisobutyl
phosphate, and tributoxyethyl
phosphate
EPA 2009f
40 CFR 712.30
Effective date 10/29/1990
Reporting date 12/27/1990
TSCA health and safety data reporting
Tributyl phosphate
EPA 2009g
40 CFR 716.120
Effective date 06/18/1986
Sunset date 06/18/1996
Triisobutyl phosphate
Effective date 10/29/1990
Sunset date 11/09/1993
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations and Guidelines Applicable to Phosphate Ester Flame 

Retardants
 
Agency Description Information Reference
NATIONAL (cont.)
EPA Tributoxyethyl phosphate
Effective date 10/29/1990
Sunset date 12/19/1995
Triphenyl phosphate
Effective date 10/04/1982
Sunset date 10/04/1992
TSCA chemical lists and reporting EPA 2009f
periods 40 CFR 712.30
Tri-(2-chloroisopropyl) phosphate
and tris-(2-chloroethyl)-phosphate
Effective date 12/16/1988
Sunset date 11/09/1993
Tris(1,3-dichloro-2-propyl) phosphate
Effective date 12/16/1988
Sunset date 12/19/1995
NTP Carcinogenicity classification No data NTP 2005
aGroup 3:  not classifiable as to carcinogenicity to humans

bThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 

additives or listed or affirmed as GRAS.
 
cA4:  not classifiable as a human carcinogen
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,
 
Compensation, and Liability Act; CFR = Code of Federal Regulations; EAFUS = Everything Added to Food in the 

United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines;
 
FDA = Food and Drug Administration; GRAS = Generally Recognized As Safe; IARC = International Agency for
 
Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System;
 
NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program;
 
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 

exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values;
 
TSCA = Toxic Substances Control Act; TWA = time-weighted average; USC = United States Code; WHO = World
 
Health Organization
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
BMDL10 was 1.96 mg/kg/day.  An uncertainty factor of 100 was used (10 for animal to human 
extrapolation and 10 for human variability). 
ATSDR has adopted the intermediate-duration oral MRL of 0.02 mg/kg/day for TnBP also as the chronic-
duration oral MRL for TnBP.  A detailed explanation can be found in Section 2.3.
ATSDR has derived an acute-duration oral MRL of 4.8 mg/kg/day for TBEP based on decreased body
weight gain in CD rats during gestation days 6–15 (Monsanto Co. 1985b). The MRL was derived using
benchmark modeling of the decrease in body weight gain.  The BMD1SD was 824.97 mg/kg/day; the
corresponding BMDL1SD was 477.25 mg/kg/day.  An uncertainty factor of 100 was used (10 for animal to 
human extrapolation and 10 for human variability).
ATSDR has derived an intermediate-duration oral MRL of 0.2 mg/kg/day for TBEP based on an 
increased incidence of periportal hepatocyte hypertrophy in male Sprague-Dawley rats dosed via the diet 
for 18 weeks (Reyna and Thacke 1987a).  The MRL was derived using benchmark modeling of incidence
data for hepatocyte vacuolation in male rats.  The BMD10 for hepatocyte hypertrophy was 
80.62 mg/kg/day; the BMDL10 was 21.92 mg/kg/day.  An uncertainty factor of 100 was used (10 for 
animal to human extrapolation and 10 for human variability).
ATSDR has derived an intermediate-duration oral MRL of 0.05 mg/kg/day for TDCP based on increased 
absolute kidney weight in male Sprague-Dawley rats dosed via the diet for 12 months (Stauffer Chemical
Co. 1981a).  The MRL was derived using benchmark modeling of the increase in kidney weight.  The
BMD1SD was 13.36 mg/kg/day; the corresponding BMDL1SD was 4.69 mg/kg/day.  An uncertainty factor
of 100 was used (10 for animal to human extrapolation and 10 for human variability).
ATSDR has derived a chronic-duration oral MRL of 0.02 mg/kg/day for TDCP based on an increased 
incidence of renal tubular epithelial hyperplasia in male Sprague-Dawley rats dosed via the diet for
2 years (Stauffer Chemical Co. 1981a).  The MRL was derived using benchmark modeling of incidence 
data for renal lesions in male rats.  The BMD10 for renal tubular hyperplasia was 2.60 mg/kg/day; the
lower 95% confidence limit on this dose (BMDL10) was 1.94 mg/kg/day.  An uncertainty factor of
100 was used (10 for animal to human extrapolation and 10 for human variability).
EPA (IRIS 2009) has not established an oral reference dose (RfD) or inhalation reference concentration 
(RfC) for phosphate ester flame retardants.
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The International Agency for Research on Cancer (IARC) has classified TCEP as a Group 3 carcinogen 
(not classifiable as to carcinogenicity to humans) (IARC 2009).  The American Conference of
Governmental Industrial Hygienists (ACGIH) has classified TPP as an A4 carcinogen (not classifiable as
a human carcinogen) (ACGIH 2008).  Neither the National Toxicology Program (NTP) nor the EPA has
classified the phosphate ester flame retardants discussed in this profile for human carcinogenicity (IRIS 
2009; NTP 2005).
OSHA has required employers of workers who are occupationally exposed to TnBP and TPP to institute
engineering controls and work practices to reduce and maintain employee exposure at or below
permissible exposure limits (PELs) (OSHA 2009).  The employer must use engineering and work practice 
controls to reduce exposures to not exceed 5 and 3 mg/m3 at any time for TnBP and TPP, respectively
(OSHA 2009).
Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), TnBP, TBPE, and TPP are
permitted for use in nonfood pesticide products (EPA 2009c).
All of the phosphate ester flame retardants subject of this profile are required under Section 4(a) of the
Toxic Substances Control Act (TSCA) to submit copies of health and safety studies (EPA 2009f).  TnBP, 
TiBP, and TBEP are required to report production, use, and exposure-related information on chemical
substances listed under TSCA (EPA 2009g).
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.  
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
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Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
  
  
 
 
 
 
   
 
 
    
 
 
   
 
  
 
     
 
 
    
 
 
    
  
 
    
 
 
   
  
 
 
  
 
 
 
 
 
 
 
 
 
    
   
  
 
 
 
273PHOSPHATE ESTER FLAME RETARDANTS
10.  GLOSSARY
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors.  The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
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Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
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10.  GLOSSARY
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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A-1PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
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APPENDIX A
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-62, Atlanta, Georgia 30333.
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tris(2-chloroethyl) phosphate (TCEP)
CAS Numbers: 115-96-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 23
Species: Rat
Minimal Risk Level: 0.6 [X] mg/kg/day   [ ] ppm
Reference:  NTP.  1991a.  NTP toxicology and carcinogenesis studies of tris(2-chloroethyl) phosphate
(CAS No. 115-96-8) in F344/N rats and B6C3F1 mice (gavage studies).  Program NT.  TR 391.  
http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr391.pdf. May 6, 2009.
Experimental design:  Groups of Fischer-344 rats (10/sex/dose) were administered 0, 22, 44, 88, 175, or
350 mg TCEP by gavage in corn oil 5 days/week for 16 weeks (females) or 18 weeks (males).  End points 
examined included clinical signs, body weight, serum cholinesterase activity, organ weight, gross
necropsy, and histopathology of tissues and organs (control and highest dose group).  The brain and 
kidneys of mid-dose (88 mg/kg/day) females were also examined microscopically.
Effect noted in study and corresponding doses: Two females in each the 175 and 350 mg/kg/day groups
died on week 4 due to overdosing that week; others in these groups showed ataxia, convulsions, excessive
salivation, and gasping.  Females receiving 175 and 350 mg/kg/day experienced occasional periods of
hyperactivity after dosing.  High-dose females showed periodic convulsions during week 12.  At
termination, serum cholinesterase was reduced by 25 and 41% in females treated with 175 and 
350 mg/kg/day, respectively; serum cholinesterase activity in males was comparable among groups.  
Final absolute and relative (to body weight or brain weight) weight of the liver and kidney of treated 
males and females were increased relative to controls (>10% at 175 mg/kg/day).  At termination, serum
cholinesterase was reduced by 25 and 41% in females treated with 175 and 350 mg/kg/day, respectively; 
cholinesterase in males was comparable among groups.  There were no gross lesions due to treatment.  
However, necrosis of neurons of the hippocampus was seen in 10/10 females and in 2/10 males treated 
with 350 mg/kg/day, and in 8/10 females treated with 175 mg/kg/day.  The affected neurons were mainly
in the dorsomedial portion of the pyramidal row of the hippocampus.  The more severe lesions showed 
mineral deposits in the affected areas.  High-dose females also showed neuronal necrosis in the thalamus.  
The dose of 88 mg TCEP/kg/day is a NOAEL for brain lesions in female rats.
Dose and end point used for MRL derivation:  BMDL10 of 85.07 mg/kg/day for brain lesions in female
rats.
[ ] NOAEL   [ ] LOAEL  [X] BMDL10 
Uncertainty Factors used in MRL derivation:
[ ]  10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
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APPENDIX A
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Yes, the test chemical was 
administered 5 days/week; therefore, the BMDL10 of 85.07 mg/kg/day was adjusted for continuous
exposure by multiplying by 5 and dividing by 7 yielding a duration-adjusted BMDL10 of
60.76 mg/kg/day.
Other additional studies or pertinent information that lend support to this MRL: Only three studies were 
available for review.  NTP (1991a) also conducted studies in B6C3F1 mice and reported that no brain 
lesions were observed in mice treated with up to 700 mg TCEP/kg/day for 16 weeks.  Similar doses were 
tested in CD-1 mice in a reproductive study that used a continuous breeding protocol, and no brain lesions
were reported in that study (NTP 1991b).  In the reproductive study, the lowest dose tested, 175 mg
TCEP/kg/day, caused a significant reduction in the number of live F2 male pups per litter.  In a 90-day 
study in male and female Sprague-Dawley rats administered up to 586 mg TCEP/kg/day via the diet, no 
brain lesions were reported (Anonymous 1977).  However, it is unclear in the report available whether the
brain was examined microscopically.  No adverse effects were reported in that study, including
hematology and clinical chemistry parameters, and histopathology of organs and tissues. 
Modeling of the changes in absolute kidney weight in female rats proved unsuccessful as an adequate fit
could not be obtained with any model.  However, if the changes in absolute kidney weight in female rats
in the NTP (1991a) study had been used as basis for MRL derivation using a NOAEL/LOAEL approach, 
the NOAEL would have been 88 mg TCEP/kg/day (<10% increase in kidney weight).  The next highest
dose, 175 mg/kg/day induced a 16% increase in absolute kidney weight.  Applying an uncertainty factor
of 100 (10 for animal to human extrapolation and 10 for human variability) to the duration-adjusted 
NOAEL of 62.86 mg/kg/day (88 mg/kg/day x 5/7) would have resulted in an MRL of 0.6 mg/kg/day for
TCEP, which supports the MRL derived using the BMD approach using the data set for brain lesions.
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
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APPENDIX A
BENCHMARK MODELING OF BRAIN LESIONS IN FEMALE RATS
Incidence data for brain lesions in female rats exposed to TCEP (NTP 1991a) were analyzed using the
BMD approach for MRL derivation (Table A-1).  Models in the EPA Benchmark Dose Software (BMDS
version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull models)
were fit to the brain lesions data to determine a potential point of departure for the MRL.  Adequate
model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-response curve, 
and scaled residual at the data point (except the control) closest to the predefined BMR.  Among all the
models providing adequate fit to the data, the lowest BMDL is selected as the point of departure when 
differences between the BMDLs estimated from these models are more than 3-fold; otherwise, the BMDL
from the model with the lowest AIC is chosen.  In accordance with EPA (2000) guidance, BMDs and 
BMDLs associated with an extra risk of 10% are calculated for all models.  Based on these criteria, a
Log-logistic model provided the best fit to the data (Table A-2).
Table A-1.  Incidence of Hippocampal Necrosis in Female Rats Exposed to
Tris(2-chloroethyl) Phosphate for 16 Weeks
Dose (mg/kg/day) Total number of rats Number of rats with lesions
0 10 0
22 10 0
44 10 0
88 10 0
175 10 8
350 10 10
Source:  NTP 1991a
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APPENDIX A
Table A-2.  Model Predictions for Necrosis of Hippocampal Neurons in Female
Rats
Model
Gammab 
χ2 Goodness of
fit p-valuea 
1.00
AIC
12.52
BMD10 
(mg/kg/day)
106.78
BMDL10 
(mg/kg/day)
80.41
Logistic 1.00 14.01 160.02 88.23
LogLogistic 1.00 12.01 143.41 85.07
LogProbit
Multistagec (2-degree 
polynomial)
1.00
0.41
14.01
20.35
140.11
56.58
84.26
41.38
Probit 1.00 14.01 147.06 85.11
Weibullb 1.00 14.01 149.30 84.03
Quantal-Linear 0.02 33.31 22.12 14.85
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; SD = standard 
deviation
Source:  NTP 1991a
From this model, the predicted doses associated with a 10% extra risk (BMD10) for brain lesions in female
rats was 143.41 mg/kg/day; the lower 95% confidence limit on this dose (BMDL10) was 85.07 mg/kg/day 
(Figure A-1).  Modeling the decrease in the number of live F2 male pups per litter reported in the NTP
(1991b) study resulted in the Linear (constant variance) model providing the best fit with a BMD10 and 
BMDL10 of 242.19 and 167.83 mg/kg/day, respectively, considerably higher than the values obtained in 
the analysis of the brain lesions in female rats.
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Figure A-1.  Predicted and Observed Incidence of Brain Lesions in Female Rats 
Exposed to Tris(2-chloroethyl) Phosphate for 16 Weeks
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tris(2-chloroethyl) phosphate (TCEP)
CAS Numbers: 115-96-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [ ] Intermediate   [X] Chronic
Graph Key: 34
Species: Rat
Minimal Risk Level:  0.3 [X] mg/kg/day   [ ] ppm
Reference:  NTP.  1991a.  NTP toxicology and carcinogenesis studies of tris(2-chloroethyl) phosphate
(CAS No. 115-96-8) in F344/N rats and B6C3F1 mice (gavage studies).  Program NT.  TR 391.  
http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr391.pdf. May 6, 2009.
Experimental design:  Groups of Fischer-344 rats (60 rats/sex/dose) were administered 0, 44, or 88 mg
TCEP/kg/day by gavage in corn oil 5 days/week for 104 weeks.  End points examined included clinical
signs, body weight, organ weight, gross necropsy, and histopathology of all major tissues and organs at
interim sacrifice (week 66, 10 rats/sex/group) and at termination.  Hematology and clinical chemistry tests
were conducted at interim sacrifice.  
Effect noted in study and corresponding doses: There were no clinical signs attributable to administration 
of TCEP or effects on body weight.  Survival was reduced in high-dose males and females.  Females that
died early frequently had brain lesions, males did not.  There were no chemical-related alterations in 
clinical chemistry and hematology parameters at week 66.  Interim necropsy revealed a significant
increase in absolute and relative liver and kidney weights in high-dose males.  At termination, one of the
principal nonneoplastic alterations attributed to administration of TCEP was a significant increase in renal
tubule epithelial hyperplasia in the convoluted tubules of the cortex in high-dose males and females.  The 
lesions were focal or multifocal and were characterized by stratification of the epithelial cells with partial
to complete obliteration of the tubule lumens.  In addition to the kidneys lesions, high-dose female rats 
showed degenerative lesions in the brain.  The degenerative lesions were located in the cerebral cortex 
and brain stem, involved both the gray and white matter, and were focally distributed.  Specifically, the
lesions were in the thalamus, hypothalamus, basal ganglia, and frontal and parietal cortex.  Other affected 
structures included the cingulate cortex, olfactory cortex, superior colliculus, hippocampus, geniculate
body, globus pallidus, ventral pallidum, and amygdaloid nuclear region. The lesions varied in severity
from minimal to marked, and often involved extensive areas.  Active lesions were characterized by
degeneration and necrosis with hemorrhage, while resolving lesions exhibited loss of neurons and 
neuropil, proliferation of glial cells, capillary hyperplasia, hypertrophy of the tunica media of small
vessels, and hemosiderin-laden macrophages.  Brain lesions were already observed at the 66-month 
interim sacrifice.  Incidences of lesions in specific areas ranged from 24 to 38%.  However, the reporting
of the data (no individual animal data) in the NTP (1991a) report does not allow the determination of
whether individual animals had more than one lesion type.  The lesion with the highest incidence was
cerebrum gliosis with an incidence of 19/50 (38%); the incidences in the control and low-dose groups
were 0/50 and 0/49, respectively.  A NOAEL of 44 mg/kg/day was defined for renal tubule epithelial
hyperplasia in male and female rats and for cerebrum gliosis in female rats.
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Dose and end point used for MRL derivation:  BMDL10 of 36.09 mg/kg/day for renal tubule epithelial 
hyperplasia in female rats.
[ ] NOAEL   [ ] LOAEL  [X] BMDL10 
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Yes, the test chemical was 
administered 5 days/week; therefore, the BMDL10 of 36.09 mg/kg/day was adjusted for continuous
exposure by multiplying by 5 and dividing by 7 yielding a duration-adjusted BMDL10 of
25.78 mg/kg/day.
Other additional studies or pertinent information that lend support to this MRL: The NTP (1991a) study
was the only chronic-duration oral study available for TCEP.  The BMDL10 for cerebrum gliosis in female
rats was somewhat higher (59.86 mg/kg/day) than that obtained for the renal tubular hyperplasia in both 
male and female rats; therefore, the MRL derived based on renal lesion is protective of brain lesions.
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
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APPENDIX A
BENCHMARK MODELING OF RENAL TUBULE HYPERPLASIA IN FEMALE RATS
Incidence data for renal tubule epithelial hyperplasia in female rats exposed to TCEP (NTP 1991a) were
analyzed using the BMD approach for MRL derivation (Table A-3).  Models in the EPA BMDS
(version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull
models) were fit to the brain lesions data to determine a potential point of departure for the MRL.  
Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.  
Among all the models providing adequate fit to the data, the lowest BMDL is selected as the point of
departure when differences between the BMDLs estimated from these models are more than 3-fold;
otherwise, the BMDL from the model with the lowest AIC is chosen.  In accordance with EPA (2000)
guidance, BMDs and BMDLs associated with an extra risk of 10% are calculated for all models.  Based 
on these criteria, a Gamma model provided the best fit to the data (Table A-4).
Table A-3.  Incidence of Renal Tubule Epithelial Hyperplasia in Rats Exposed to
Tris(2-chloroethyl) Phosphate for 2 Years
Dose (mg/kg/day) Total number of rats Males with lesions Females with lesions
0 50 0 0
44 50 2 3
88 50 24 16
Source:  NTP 1991a
Table A-4. Model Predictions for Incidence of Renal Tubule Epithelial
Hyperplasia in Female Rats
Model
Gammab 
χ2 Goodness of
fit p-valuea 
1.00
AIC
89.38
BMD10 
(mg/kg/day)
53.09
BMDL10 
(mg/kg/day)
36.09
Logistic 0.52 90.06 60.16 49.51
LogLogistic 1.00 89.38 53.33 36.29
LogProbit
Multistagec (1-degree 
polynomial)
Probit
1.00
0.16
0.66
89.38
91.51
89.71
52.37
32.13
57.32
37.59
22.50
46.59
Weibullb 1.00 89.38 53.83 35.90
Quantal-Linear 0.16 91.51 32.13 22.50
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; NA
SD = standard deviation
Source:  NTP 1991a
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A-11PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
From this model, the predicted doses associated with a 10% extra risk (BMD10) for renal tubule
hyperplasia in female rats was 53.09 mg/kg/day; the lower 95% confidence limit on this dose (BMDL10) 
was 36.09 mg/kg/day (Figure A-2).  Modeling the data set for renal tubule hyperplasia in male rats
resulted in the Log logistic model providing the best fit with a BMD10 and BMDL10 of 54.80 and 
43.58 mg/kg/day, respectively, only slightly higher than the values obtained in the analysis of the lesions
in female rats.  Modeling the data set for cerebrum gliosis in female rats resulted in the Log logistic model
providing the best fit with a BMD10 and BMDL10 of 80.04 and 59.86 mg/kg/day, respectively.  Therefore, 
the MRL based on renal lesions is protective of brain lesions.
Figure A-2.  Predicted and Observed Incidence of Renal Tubule Hyperplasia in 
Female Rats Exposed to Tris(2-chloroethyl) Phosphate for 2 Years
Gamma Multi-Hit Model with 0.95 Confidence Level 
0.5 
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0.3 
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A-12PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tributyl phosphate (TnBP)
CAS Numbers: 126-76-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate  [ ] Chronic
Graph Key: 13
Species: Rat
Minimal Risk Level: 1.1 [X] mg/kg/day  [  ] ppm
Reference:  Noda T, Yamano T, Shimizu M, et al.  1994.  Effects of TRI-n-butyl phosphate on pregnancy
in rats.  Food Chem Toxicol 32(11):1031-1036.  
Experimental design:  Groups of Wistar rats (20 rats/sex/dose level) were administered 0, 62.5, 125, 250, 
or 500 mg TnBP/kg/day by gavage in corn oil on Gd 7–17.  Clinical signs, body weight, and food 
consumption were monitored.  Sacrifices were conducted on Gd 20.  The gravid uterus, the position and 
number of living and dead fetuses in the uterus, including resorbed fetuses in the uterus, the number of
corpora lutea, and maternal liver, kidneys, and spleen weights were recorded.  The living fetuses were 
examined for their sex and external malformation, and then weighed.  Skeletal abnormalities were 
evaluated in half of the fetuses, whereas the other half was evaluated for visceral abnormalities.  
Effect noted in study and corresponding doses:  Rats exposed to 500 mg TnBP/kg/day showed 
piloerection, wetting of abdominal hair with urine, and salivation during treatment, but these signs
disappeared after the last treatment.  Final maternal weight was reduced 6–9% in the two highest dose
groups.  Adjusted body weight gain (weight gain from Gd 0 to 20 minus gravid uterus weight) was 
reduced 13% at 125 mg/kg/day, 39% at 250 mg/kg/day, and 63% at 500 mg/kg/day.  Absolute liver and 
kidney weight in treated rats was not affected (<10% change relative to controls).  Spleen weight was
reduced 11% at 500 mg/kg/day.  Gravid uterus weight was not affected by treatment.  All pregnant rats 
had fetuses on Gd 20.  There were no significant differences between the groups in any of the 
developmental parameters evaluated.  There was only one malformation occurring in the 125 mg/kg/day 
dose group and consisted of conjoined twins.  No visceral anomalies were reported.  Based on a
significant reduction in maternal body weight gain at ≥125 mg/kg/day, a maternal NOAEL and LOAEL
of 62.5 and 125 mg/kg/day, respectively, were defined in this study; the highest dose tested, 
500 mg/kg/day was a developmental NOAEL.
Dose and end point used for MRL derivation:  BMDL of 111.47 mg/kg/day for decrease weight gain in 
pregnant rats on Gd 0–20.
[ ] NOAEL   [ ] LOAEL  [X] BMDL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
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APPENDIX A
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Only one additional
study was a potential source of data for MRL derivation.  In that study, groups of Sprague-Dawley rats 
(10/sex/group) were administered 0, 137, or 411 mg TnBP/kg/day by gavage on 14 consecutive days 
(Laham et al. 1984b).  End points examined included clinical signs, body weight, hematological and
clinical chemistry tests, and histological examinations of the brain, heart, kidneys, liver, lungs, spleen, 
ovaries, and testes.  Significant findings in high-dose rats included decreased hemoglobin in females, 
increased absolute and relative liver weight in males and females, increased serum potassium in females, 
decreased absolute and relative spleen weight, and degenerative changes in the testes.  A study of limited 
scope reported decreased nerve conduction velocity accompanied by morphological alterations in the
sciatic nerve of rats dosed with 411 mg TnBP/kg/day for 14 days; the NOAEL was 274 mg TnBP/kg/day 
(Laham et al. 1983).  
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
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APPENDIX A
BENCHMARK MODELING OF REDUCED WEIGHT GAIN IN PREGNANT RATS
Data from Noda et al. (1994) were analyzed using the BMD approach for MRL derivation.  BMD models
in the EPA BMDS (version 2.1) (linear, polynomial, power, and Hill models) were fit to the maternal
body weight gain data (Table A-5) to determine potential points of departure for the MRL. 
Table A-5.  Data for the Change in Adjusted Body Weight Gain in Pregnant Rats
on Gestation Days 0–20
Dose (mg/kg/day) Number of animals tested Body weight gain (g) Standard deviation
0 20 38.0 7.46
62.5 20 37.2 8.27
125 20 33.2 8.98
250 20 23.0 6.51
500 20 9.4 8.56
Source:  Noda et al. 1994
Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.  
Among all the models providing adequate fit to the data, the lowest BMDL is selected as the point of
departure when differences between the BMDLs estimated from these models are more than 3-fold;
otherwise, the BMDL from the model with the lowest AIC is chosen.  In the absence of a clear criteria as 
to what level of change in weight gain during pregnancy should be considered adverse, the BMR was 
defined as a change in mean body weight gain equal to one standard deviation from the control mean 
(EPA 2000).  Based on the criteria for model selection, the Linear model provided the best fit (Table A-
6 and Figure A-3).  
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A-15PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
Table A-6.  Model Predictions for Tributyl Phosphate, Change in Body Weight
Gain on Gestation Days 0–20
Model Variance Means BMD1SD BMDL1SD 
(constant variance) p-valuea p-valuea AIC (mg/kg/day) (mg/kg/day)
Hill 0.65 0.86 520.89 162.91 113.67
Linearb 0.65 0.46 519.44 130.32 111.47
Polynomial (2-degree 
polynomial) c 0.65 0.28 521.43 133.85 111.53
Polynomial (3-degree 
polynomial)c 0.65 0.28 521.43 133.85 111.53
Power 0.65 0.31 521.19 145.15 112.27
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bCoefficients restricted to be negative
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; SD = standard 
deviation 
Source:  Noda et al. 1994
Figure A-3.  Fit of Linear Model (Constant Variance) to Data on Body Weight Gain 
on Gestation Days 0–20
Linear Model with 0.95 Confidence Level 
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tributyl phosphate (TnBP)
CAS Numbers: 126-76-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [X] Intermediate  [ ] Chronic
Graph Key: 22
Species: Rat
Minimal Risk Level:  0.02 [X] mg/kg/day  [  ] ppm
Reference:  Arnold LL, Christenson WR, Cano M, et al.  1997. Tributyl phosphate effects on urine and 
bladder epithelium in male Sprague-Dawley rats.  Fundam Appl Toxicol 40(2):247-255. 
Experimental design:  Groups of male Sprague-Dawley rats (20 in the control and high-dose group, 10 in 
the low- and mid-dose groups) were fed a diet containing 0, 200, 700, or 3,000 ppm TnBP for 10 weeks.  
This corresponds to doses of approximately 0, 9, 33, or 143 mg TnBP/kg/day based on a similar study in 
male Sprague-Dawley rats exposed to the same dietary concentrations of TnBP (Auletta et al. 1998a).  
End points examined included clinical signs, body weight, food consumption, urinalysis, and histological
examination (10 rats per group at termination) of the stomach, kidneys, and urinary bladder. To evaluate
the effect of urine acidification, an additional group of rats received 3,000 ppm TnBP plus 12,300 ppm
ammonium chloride.  Yet another group received ammonium chloride alone.  Reversibility of the effects
of TnBP was examined in a group of 10 rats kept on a control diet for 10 weeks after the 10-week
treatment period.  
Effect noted in study and corresponding doses: There were no clinical signs attributable to TnBP.  Mean 
final weight of the high-dose group was reduced >10% relative to controls; food consumption was not
significantly affected.  During the recovery period, body weight of the high-dose recovered to control
levels.  Urinary parameters on week 11 among treated groups were comparable to controls except for
osmolality and creatinine, which were significantly lower in the high-dose group than in controls, 
indicating a dilutional effect.  Urinary pH in the groups receiving ammonium chloride was 6.0 compared 
to ≥ 7.5 in the other groups.  There was no evidence of an amorphous precipitate, abnormal microcrystals, 
or calculi in the urine from individual rats.  Crystals were present in the control and TnBP-treated rats.  
Treatment with TnBP caused urinary bladder hyperplasia in mid-and high-dose rats, with severity that
was dose-related, reversible, and less severe in the rats dosed also with ammonium chloride.  Incidences 
were 0/10, 0/10, 8/10, and 10/10 with increasing doses (see also Table A-7 below).  There were no 
histological alterations in the stomach or kidneys.  A NOAEL of 9 mg TnBP/kg/day for urothelial
hyperplasia was defined in this study; the LOAEL was 33 mg/kg/day.
Dose and end point used for MRL derivation:  BMDL10 of 1.96 mg/kg/day for urinary bladder hyperplasia
in male rats dosed in the diet for 10 weeks.
[ ] NOAEL   [ ] LOAEL  [X] BMDL10 
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APPENDIX A
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes, doses were 
estimated based on a similar study in male Sprague-Dawley rats exposed to the same dietary
concentrations of TnBP (Auletta et al. 1998a).  
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: The urinary bladder was
also the most sensitive tissue in two additional intermediate-duration studies.  Increased incidence of 
urinary bladder hyperplasia was reported in male and female rats in a 3-month dietary study (FMC
1985a); the NOAEL was 13.8 mg TnBP/kg/day and the LOAEL was 68.1 mg TnBP/kg/day.  Tyl et al. 
(1997) reported similar results in F0 and F1 male and female rats dosed with approximately 51 mg
TnBP/kg/day in a 2-generation reproductive study; the NOAEL was 15 mg TnBP/kg/day (see Table A-7, 
below).  
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D.
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
  
 
    
    
  
   
  
      
    
 
   
  
 
     
  
        
        
  
        
        
   
        
        
        
   
        
        
        
 
 
 
 
  
  
   
     
    
 
 
      
        
      
  
 

 

 
A-18PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
BENCHMARK MODELING OF URINARY BLADDER HYPERPLASIA IN RATS
Incidence data for urothelial hyperplasia in male rats from the Arnold et al. (1997) study, for urothelial
hyperplasia in F0 males and females from the Tyl et al. (1997) study, and for urothelial hyperplasia in 
males from the FMC 1985a) study were analyzed using the BMD approach for MRL derivation.   
Incidences are shown in Table A-7.  The data set from Tyl et al. (1997) corresponds to incidences in the
parental generation (F0).  Incidences in F1 females were virtually the same as in F0 females, whereas 
incidences in mid-dose F1 males were slightly lower than in F0 males.  Also included in Table A-6 is the
data set from the 2-year study of Auletta et al. (1998a).
Table A-7.  Incidence of Urinary Bladder Hyperplasia Induced by Tributyl
Phosphate in Four Studies in Rats
NOAEL LOAEL BMDL10 
Arnold et al. (1997)–10 weeks
Dose (mg/kg/day) 0 9 33 143 1.96
Incidence 0/10 0/10 8/10 10/10
FMC (1985a)–13 weeks
Dose (mg/kg/day) 0.12 0.6 2.8 13.8 68.1 360
Males 0/10 0/10 0/10 0/10 10/10 10/10 2.60
Tyl et al. (1997)–10 weeks
Dose (mg/kg/day) 0 15 51 217
Males 0/30 1/29 22/29 30/30 13.77
Females 0/30 2/29 21/30 30/30 4.16
Auletta et al. (1998a)–2 years
Dose (mg/kg/day) 0 9 33 143
Males 3/50 3/50 12/49 17/49 23.51
Females 1/50 1/50 5/49 29/49 19.85
BMDL10 = The 95% lower confidence limit on the dose associated with a 10% extra risk; LOAEL = lowest-observed­
adverse-effect level; NOAEL = no-observed-adverse-effect level
Models in the EPA BMDS (version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, 
quantal linear, Weibull models) were fit to urothelial hyperplasia data to determine potential points of
departure for the MRL.  Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual
inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to 
the predefined BMR.  Among all the models providing adequate fit to the data, the lowest BMDL is
selected as the point of departure when differences between the BMDLs estimated from these models are 
more than 3-fold; otherwise, the BMDL from the model with the lowest AIC is chosen.  In accordance
with EPA (2000) guidance, BMDs and BMDLs associated with an extra risk of 10% are calculated for all
models.  Using these criteria, the Multistage model fit of the Arnold et al. (1997) data set was selected for
MRL derivation. Table A-8 shows model prediction for the data set from Arnold et al. (1997), as this
data set was the one selected for MRL derivation.  The fit of the data by the Multistage model is shown in 
Figure A-4.
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APPENDIX A
Table A-8.  Model Predictions for Incidence of Urinary Bladder Hyperplasia in
Male Rats
χ2 Goodness of fit BMD10 BMDL10 
Model p-valuea AIC (mg/kg/day) (mg/kg/day)
Gammab 1.00 12.01 19.74 8.03
Logistic 1.00 14.01 28.80 10.49
LogLogistic 1.00 14.01 26.21 8.27
LogProbit 1.00 14.01 21.67 8.24
Multistagec 0.22 19.03 3.30 1.96
Probit 1.00 14.01 25.25 9.61
Weibullb 1.00 14.01 23.96 7.89
Quantal-Linear 0.22 19.03 3.30 1.96
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial 
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC
Source:  Arnold et al. 1997 
A BMD10 and BMDL10 of 3.30 and 1.96 mg/kg/day, respectively, were derived for the incidence data 
reported by Arnold et al. (1997).  Analysis of the urinary hyperplasia data in F0 males in the Tyl et al. 
(1997) study yielded a BMD10 and BMDL10 of 20.29 and 13.77 mg TnBP/kg/day, respectively; the
corresponding values from the analysis of incidences in F0 female rats were 5.58 and 4.16 mg
TnBP/kg/day.  Analysis of the incidence in males in the FMC (1985a) study yielded a BMD10 and
BMDL10 of 4.49 and 2.60 mg TnBP/kg/day, respectively.  In order to be health protective, the lowest
BMDL10 of 1.96 mg TnBP/kg/day from Arnold et al. (1997) is selected as the point of departure for the 
MRL.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability) to the BMDL10 of 1.96 mg TnBP/kg/day yields an intermediate-duration oral MRL of
0.02 mg/kg/day for TnBP.
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Figure A-4.  Fit of Multistage Model to Data on Incidence of Urinary Bladder
Hyperplasia in Male Sprague-Dawley Rats  
Multistage Model with 0.95 Confidence Level 
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Source:  Arnold et al. 1997
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tributyl phosphate (TnBP)
CAS Numbers: 126-76-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [ ] Intermediate   [X] Chronic
Species: Rat
Minimal Risk Level:  0.02 [X] mg/kg/day  [ ] ppm
Reference:  Arnold LL, Christenson WR, Cano M, et al.  1997. Tributyl phosphate effects on urine and 
bladder epithelium in male Sprague-Dawley rats.  Fundam Appl Toxicol 40(2):247-255.  
It is recommended that the intermediate-duration oral MRL of 0.02 mg/kg/day for TnBP also be adopted 
as chronic-duration oral MRL, as explained below.
Only two chronic-duration oral studies were located for TnBP, one in rats (Auletta et al. 1998a) and one
in mice (Auletta et al. 1998b).  As in the intermediate-duration studies, the urinary bladder from rats was
the most sensitive target for TnBP toxicity.  Rats were dosed via the diet for 2 years, whereas mice were 
treated for 18 months.  Male rats received doses of 0, 9, 33, or 143 mg TnBP/kg/day, whereas females 
received doses of 0, 12, 42, or 182 mg TnBP/kg/day.  The doses for male and female mice were 0, 28.9, 
169, or 585 mg/kg/day and 0, 24.1, 206, or 711 mg/kg/day, respectively.  At termination, the incidences
of trace to severe urinary bladder hyperplasia in male rats were 3/50, 3/50, 12/49, and 17/49 with 
increasing doses (see Table A-7 in the derivation of the intermediate-duration oral MRL).  The
corresponding incidences in female rats were 1/50, 1/50, 5/49, and 29/49.  Urinary bladder hyperplasia
was not observed in mice.  Based on these findings, the increased incidence of urothelial hyperplasia in 
rats was used to determine a point of departure for derivation of a chronic-duration oral MRL for TnBP. 
Incidence data for urinary bladder hyperplasia in male and female rats exposed to TnBP (Auletta et al. 
1998a) were analyzed using the BMD approach for MRL derivation.  Models in the EPA BMDS 
(version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull
models) were fit to the urinary bladder lesion data to determine potential points of departure for the MRL.  
Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.  
Among all the models providing adequate fit to the data, the lowest BMDL is selected as the point of 
departure when differences between the BMDLs estimated from these models are more than 3-fold;
otherwise, the BMDL from the model with the lowest AIC is chosen.  In accordance with EPA (2000)
guidance, BMDs and BMDLs associated with an extra risk of 10% are calculated for all models.
Comparing across models using these criteria showed that the Gamma model provided the best for the
incidence data in male rats, whereas the Multistage 1-degree polynomial provided the best fit for the
incidence data in female rats.  This analysis yielded respective BMDL10 values of 23.51 and 19.85 mg
TnBP/kg/day (Tables A-9 and A-10).
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Table A-9.  Model Predictions for Tributyl Phosphate, Incidence of Urinary
Bladder Hyperplasia in Male Rats
χ2 Goodness of fit BMDL10 
Model p-valuea AIC BMD10 (mg/kg/day) (mg/kg/day)
Gammab 0.13 171.02 35.41 23.51
Logistic 0.03 173.60 64.45 50.10
LogLogistic 0.00 190.72 2.17x1012 NA
LogProbit 0.00 188.72 4.25x109 NA
Multistagec 0.13 171.02 35.41 23.51
Probit 0.04 173.30 60.52 46.60
Weibullb 0.13 171.02 35.41 23.51
Quantal-Linear 0.13 171.02 35.41 23.51
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC;
NA = Benchmark dose computation failed (lower limit includes zero)
Source:  Auletta et al. 1998a
Table A-10.  Model Predictions for Tributyl Phosphate, Incidence of Urinary
Bladder Hyperplasia in Female Ratsa
χ2 Goodness of Fit BMD10 
Model p-valueb AIC (mg/kg/day) BMDL10 (mg/kg/day)
Gammac 0.74 124.28 47.67 28.56
Logistic 0.49 123.59 73.30 59.41
LogLogistic 0.76 124.27 47.03 28.66
LogProbit 0.91 124.18 45.90 33.21
Multistaged 0.14 126.67 26.26 19.85
Probit 0.62 123.14 65.64 53.59
Weibullc 0.68 124.34 48.48 28.42
Quantal-Linear 0.14 126.67 26.26 19.85
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC
aAuletta et al. 1998a 
bValues <0.10 fail to meet conventional goodness-of-fit criteria
cPower restricted to ≥1
dBetas restricted to ≥0; 1-degree polynomial
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As seen in Tables A-9 and A-10, and also in Table A-7, these values are higher than the BMDL10 values 
obtained in the analyses of the incidences of urinary bladder hyperplasia reported in the intermediate-
duration studies (Arnold et al. 1997; Tyl et al. 1997).  As the data show, the incidences of urinary bladder
hyperplasia at comparable high doses are higher in the intermediate-duration studies than in the chronic-
duration study.  A likely explanation for this phenomenon is provided in the chronic study by the
observation that rats with malignant bladder tumors usually did not have any remaining uninvolved 
epithelium to evaluate for the presence or absence of hyperplasia (Auletta et al. 1998a).  Whether urinary
bladder hyperplasia is a potential precursor of urinary bladder tumors is not known for certain, but the
data are suggestive.  The lower incidence of hyperplasia at the higher dose levels in the chronic-duration 
study may just be the result of the hyperplasia transforming into neoplasia.  As shown in Table A-7, dose
levels that did not increase the incidence of urothelial hyperplasia in the intermediate-duration studies
(NOAELs ranged from 9 to 15 mg/kg/day) also did not increase the incidence of urinary bladder
hyperplasia in the chronic-duration study (NOAEL was 9 mg/kg/day) and did not increase the incidence
of neoplastic lesions; thus, the NOAEL from intermediate-duration studies would also be protective for
chronic exposure.  Therefore, the intermediate-duration oral MRL of 0.02 mg/kg/day based on a BMDL10 
of 1.96 mg/kg/day is adopted also as chronic-duration oral MRL for TnBP.  
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
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A-24PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tris(2-butoxyethyl) phosphate (TBEP)
CAS Numbers: 78-51-3
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate  [ ] Chronic
Graph Key: 3
Species: Rat
Minimal Risk Level:  4.8 [X] mg/kg/day   [ ] ppm
Reference: Monsanto Co.  1985b. Tributoxyethyl phosphate: Teratology study in rats with attachments
and cover letter dated 083085.  Submitted to the U.S. Environmental Protection Agency under TSCA
Section 8D.  EPA96-910000298.  OTS0528528.  
Experimental design:  Groups of female Sprague-Dawley rats (25/dose group) were administered 0, 250, 
500, or 1500 mg TBEP/kg/day by gavage in corn oil on Gd 6–15.  End points monitored included 
mortality, clinical signs, and body weight.  Sacrifices were conducted on Gd 20.  Immediately after
sacrifice, the uterus and ovaries were exposed and the number and location of viable and nonviable
fetuses, early and late resorptions, and number of total implantations and corpora lutea were recorded.  
Fetuses were weighed, sexed, and examined for external malformations and variations.  Fetuses were then 
prepared for visceral and skeletal examinations.  
Effect noted in study and corresponding doses: There was one early death in the high-dose group, but the
cause of death could not be determined.  Chemical-related clinical signs included wet haircoat matting or
staining with urine, brown material or blood on the face, neck, thorax, and/or anogenital area; this was
observed in approximately half of the high-dose rats.  Following dosing on Gd 6, two high-dose rats were 
ataxic, had reduced righting reflex, and/or were lethargic.  Terminal body weight of the dams (unadjusted 
for uterine content) was significantly reduced, but only 6% relative to controls.  Weight gain in high-dose
rats was significantly reduced from Gd 6 on; during treatment (Gd 6–15), weight gain in this group was
reduced 35%.  Fetal body weight and sex ratios were not affected and neither were other developmental
parameters.  Treatment with TBEP did not affect the incidence of external, visceral, or skeletal anomalies.  
A maternal NOAEL and LOAEL of 500 and 1500 mg TBEP/kg/day, respectively, were defined in this 
study.  The highest dose tested, 1500 mg/kg/day, was a developmental NOAEL based on no evidence of
fetotoxicity or teratogenicity.
Dose and end point used for MRL derivation:  BMDL of 477.25 mg/kg/day for decrease weight gain in 
pregnant rats on Gd 6–15.
[ ] NOAEL   [ ] LOAEL  [X] BMDL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
 
 
   
 
      
   
  
 
  
 
  
  
      
   
 
   
 
 
  
 
A-25PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Only one additional 
study was a potential source of data for MRL derivation.  In that study, Sprague-Dawley rats (10/sex/dose 
level) were treated with up to 100 mg TBEP/kg/day by gavage in corn oil for 14 days (Komsta et al. 
1989).  End points monitored included clinical signs, body weight, hematology and clinical chemistry at
termination, organ weights (brain, heart, liver, kidney, and spleen), microsomal liver enzyme activities, 
and gross and microscopic morphology of all major tissues and organs.  The results did not show any
significant differences between the treated and control groups for any of the parameters evaluated.  
However, because no adverse effects were reported, the Komsta et al. (1989) study was not considered a
suitable basis for an MRL.  An additional study that used considerably higher doses reported that 1 week 
after administration of a single gavage dose of ≥1,750 mg TBEP/kg, female rats showed slight tremors
and piloerection, whereas those treated with 3,200 mg/kg exhibited tremors and abnormal gait; males
appeared to be somewhat less sensitive.  Examination of the sciatic nerve showed nerve degeneration in 
females dosed with ≥2,000 mg/kg.  The NOAEL for males and females was 3,200 and 1,500 mg/kg, 
respectively.   
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
  
 
  
   
    
  
 
  
 
    
  
  
 
 
   
  
 
      
    
    
    
    
 
 
 
 
   
   
      
    
  




A-26PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
BENCHMARK MODELING OF REDUCED WEIGHT GAIN IN PREGNANT RATS
Data from Monsanto Co. (1985b) were analyzed using the BMD approach for MRL derivation.  BMD
models in the EPA BMDS (version 2.1) (linear, polynomial, power, and Hill models) were fit to the
maternal body weight gain data to determine potential points of departure for the MRL (Table A-11).  
Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.  
Among all the models providing adequate fit to the data, the lowest BMDL is selected as the point of
departure when differences between the BMDLs estimated from these models are more than 3-fold;
otherwise, the BMDL from the model with the lowest AIC is chosen.  In the absence of a clear criteria as
to what level of change in weight gain during pregnancy should be considered adverse, the BMR was 
defined as a change in mean body weight gain equal to one standard deviation from the control mean 
(EPA 2000).  
Table A-11.  Data for the Change in Body Weight Gain in Pregnant Rats on 
Gestation Days 6–15
Dose (mg/kg/day) Number of animals tested Body weight gain (g) Standard deviation
0 25 55 5.5
250 25 53 8.4
500 25 52 7.6
1,500 25 36 11.1
Source:  Monsanto Co. 1985b
As seen in Table A-12, using the criteria for model selection mentioned above, the Multistage 3-degree 
polynomial model provided the best fit.  The corresponding BMD1SD was 824.97 mg/kg/day; the
corresponding benchmark dose limit (BMDL1SD) was 477.25 mg/kg/day.  Applying an uncertainty factor
of 100 (10 for animal to human extrapolation and 10 for human variability) to the BMDL1SD of
477.25 mg/kg/day results in an acute-duration oral MRL of 4.8 mg/kg/day for TBEP.  The model fit is
shown in Figure A-5.
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APPENDIX A
Table A-12.  Model Predictions for Change in Maternal Body Weight Gain on 
Gestation Days 6–15
Variance Means BMD1SD BMDL1SD 
Model p-valuea p-valuea AIC (mg/kg/day) (mg/kg/day)
Linear—constant 0.007 0.27 530.012 635.60 521.84
Hill—nonconstant 0.18 NA 525.61 766.47 NA
Linearb—nonconstant 0.18 0.27 523.40 533.99 418.71
Polynomial (2-degree 
polynomial)b—nonconstant
0.18 0.42 523.41 776.36 469.34
Polynomial (3-degree 
polynomial)b—nonconstant
0.18 0.50 523.23 824.97 477.25
Power—nonconstant 0.18 0.36 523.60 766.71 461.90
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bCoefficients restricted to be negative 
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; NA = p-value 
not determined; SD = standard deviation
Source:  Monsanto Co. 1985b
***DRAFT FOR PUBLIC COMMENT***
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APPENDIX A
Figure A-5.  Fit of Polynomial Model (Nonconstant Variance) to Data on Body
Weight Gain on Gestation Days 6–15
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APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tris(2-butoxyethyl) phosphate (TBEP)
CAS Numbers: 78-51-3
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [X] Intermediate  [ ] Chronic
Graph Key: 9
Species: Rat
Minimal Risk Level:  0.2 [X] mg/kg/day   [ ] ppm
Reference:  Reyna MS, Thake DG.  1987a.  Eighteen week feeding study of tributoxyethyl phosphate
(TBEP) administered to Sprague-Dawley rats.  Monsanto Agricultural Company.  Submitted to the U.S. 
Environmental Protection Agency under TSCA Section 8D.  OTS0530087.
Experimental design:  Groups of Sprague-Dawley rats (20/sex/group) were fed a diet containing 0, 300,
3,000, or 10,000 ppm TBEP for approximately 18 weeks (Reyna and Thacke 1987a).  This corresponds to 
doses of approximately 0, 17.3, 173, or 578 mg/kg/day for males and 0, 21, 209, or 698 mg/kg/day for
females using food intake and body weight data from the study.  End points monitored included clinical
signs, body weight, food consumption, clinical chemistry and hematology (weeks 9 and 18), organ 
weights (brain, liver, kidneys, testes with epididymides), and gross and microscopic examination of all
the major organs and tissues of controls and high-dose rats plus target tissues defined by the high-dose
group and gross lesions from all necropsied animals. 
Effect noted in study and corresponding doses: There were no treatment-related mortalities or adverse 
clinical signs.  Body weight was not significantly affected by treatment with the test material.  Food 
consumption was lower in high-dose males and females and mid-dose males during the first week of the
study, but was comparable to controls the remainder of the study.  Ophthalmological examinations at
termination were unremarkable.  Statistically significant hematological changes included decreased 
leukocyte (lymphocyte) in high-dose males on week 9, and increased platelet counts in high-dose males 
and females on week 9 and 18 and in mid-dose males on week 9.  Significant clinical chemistry changes 
consisted of increased serum cholesterol in high-dose males on week 18 and on mid- and high-dose
females on week 9, increased serum GGT activity in high-dose males on week 9 and 18 and in high-dose
females on week 9, decreased serum cholinesterase in high-dose males and females on weeks 9 and 18,
and decreased erythrocyte cholinesterase in all treated females only on week 9; brain cholinesterase 
activity was not affected.  Absolute and relative liver weights were increased in high-dose males and 
females, but not significantly.  Histopathology was restricted to the liver of males and consisted of
increased incidence of periportal hepatocellular hypertrophy (0/10, 0/10, 3/10, 7/10) and periportal
vacuolization (1/10, 2/10, 6/10, 7/10).
Dose and end point used for MRL derivation:  BMDL10 of 21.92 mg/kg/day for hepatocyte hypertrophy in 
male rats dosed in the diet for 18 weeks.
[ ] NOAEL   [ ] LOAEL  [X] BMDL10 
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APPENDIX A
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes, ppm in food 
were converted to doses using mean food intake and body weight from the study.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: The study by Reyna and 
Thacke (1987a) was the only intermediate-duration oral study that examined a wide range of end points
available for review.  In the same study, although presented separately, the investigators measured tail
nerve conduction velocity at the end of the treatment period (Reyna and Thacke 1987b).  Following these
measurements, the sciatic, tibial, and plantar nerves were processed for light microscopy.  A significant
reduction in nerve conduction velocity was measured only in high-dose females.  Since both the absolute 
and relative refractory periods were decreased (the opposite of what would be expected in the case of a 
reduction in conduction velocity), the effect was not seen in males, and morphology of the nerves was 
unremarkable, the decrease in conduction velocity in females appeared questionable.
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D.
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A-31PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
BENCHMARK MODELING OF HEPATOCYTE HYPERTROPHY AND VACUOLIZATION IN 
MALE RATS
Incidence data for periportal hepatocyte hypertrophy and vacuolization in male rats exposed to TBEP
(Reyna and Thacke 1987a) were analyzed using the BMD approach for MRL derivation (Tables A-13 and 
A-14).  
Table A-13. Incidence of Periportal Hepatocyte Hypertrophy in Male Rats 
Exposed to Tris(2-butoxyethyl) Phosphate for 18 Weeks
Dose (mg/kg/day) Total number of rats Number of rats with lesions
0 10 0
17.3 10 0
173 10 3
578 10 7
Source:  Reyna and Thacke 1987a
Table A-14.  Incidence of Periportal Hepatocyte Vacuolization in Male Rats 
Exposed to Tris(2-butoxyethyl) Phosphate for 18 Weeks
Dose (mg/kg/day) Total number of rats Number of rats with lesions
0 10 1
17.3 10 2
173 10 6
578 10 7
Source:  Reyna and Thacke 1987a
Models in the EPA BMDS (version 2.1) (gamma, logistic, log-logistic, multi-stage, probit, log-probit, 
quantal linear, Weibull models) were fit to the hepatocyte hypertrophy and hepatocyte vacuolation 
reported in male rats to determine a point of departure for the MRL.  Adequate model fit is judged by
three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-response curve, and scaled residual at
the data point (except the control) closest to the predefined BMR.  Among all the models providing
adequate fit to the data, the lowest BMDL is selected as the point of departure when differences between 
the BMDLs estimated from these models are more than 3-fold; otherwise, the BMDL from the model
with the lowest AIC is chosen.  In accordance with EPA (2000) guidance, BMDs and BMDLs associated 
with an extra risk of 10% are calculated for all models. 
Based on the criteria for model selection, comparing across models (Tables A-15 and A-16), the best fit
for the hepatocyte hypertrophy data was provided by the Log logistic model; the BMD10 and BMDL10 
were 80.62 and 21.92 mg TBEP/kg/day, respectively.  The best fit for the incidence of hepatocyte 
vacuolization was provided by the Log logistic model, which estimated a BMD10 and BMDL10 of 22.02 
and 8.88 mg TBEP/kg/day, respectively.  Since hypertrophy is a more valid physiological end point than 
vacuolization, the BMDL10 of 21.92 mg/kg/day is selected as the point of departure for the intermediate-
duration MRL.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for
human variability) to the BMDL10 results in an intermediate-duration oral MRL of 0.2 mg/kg/day for
TBEP.  The model fit for hepatocyte hypertrophy is shown in Figure A-6.
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A-32PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
Table A-15.  Model Predictions for Incidence of Hepatocyte Hypertrophy in Male 
Rats
χ2 Goodness of fit
Model p-valuea AIC BMD10 (mg/kg/day) BMDL10 (mg/kg/day)
Gammab 0.87 28.85 78.52 32.71
Logistic 0.22 32.18 168.20 104.90
LogLogistic 0.93 28.68 80.62 21.92
LogProbit 0.99 26.54 88.23 54.34
Multistagec 0.95 27.14 52.73 31.87
Probit 0.26 31.71 156.18 100.50
Weibullb 0.86 28.92 74.28 32.50
Quantal-Linear 0.95 27.14 52.73 31.87
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial
Source:  Reyna and Thacke 1987a
Table A-16.  Model Predictions for Incidence of Hepatocyte Vacuolization in Male
Rats
χ2 Goodness of fit BMD10 BMDL10 
Model p-valuea AIC (mg/kg/day) (mg/kg/day)
Gammab 0.42 47.89 43.84 24.80
Logistic 0.18 49.64 95.80 60.25
LogLogistic 0.76 46.73 22.02 8.88
LogProbit 0.32 48.40 73.86 40.22
Multistagec 0.42 47.89 43.84 24.80
Probit 0.19 49.59 93.91 62.31
Weibullb 0.42 47.89 43.84 24.80
Quantal-Linear 0.42 47.89 43.84 24.80
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; NA = not 
applicable; SD = standard deviation
Source:  Reyna and Thacke 1987a
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APPENDIX A
Figure A-6.  Fit of Log Logistic Model to Data on the Incidence of Periportal
Hepatocyte Hypertrophy in Male Rats
Log-Logistic Model with 0.95 Confidence Level 
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A-34PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tris(1,3-dichloro-2-propyl) phosphate (TDCP)
CAS Numbers: 13674-87-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [X ] Intermediate  [ ] Chronic
Graph Key: 4
Species: Rat
Minimal Risk Level: 0.05 [X] mg/kg/day  [  ] ppm
Reference: Stauffer Chemical Co.  1981a.  A two year oral toxicity/carcinogenicity study of fyrol FR-2 in 
rats.  In:  A two-year oral toxicity/carcinogenicity study of fyrol FR-2 in rats (volume I-IV) (final reports) 
with attachments, cover sheets and letter dated 093081.  Stauffer Chemical Company.  Submitted to the
U.S. Environmental Protection Agency under TSCA Section 8E.  EPA88-8100282.  OTS0204911.
Experimental design:  Groups of Sprague-Dawley rats (60/sex/dose level) were fed a diet that provided 0, 
5, 20, or 80 mg/kg/day of TDCP for 24 months.  End points monitored included lethality, clinical signs, 
body weight, food consumption, hematology, clinical chemistry and urinalysis (at 3, 6, 12, 18, and 
24 months, 9–10 rats/sex/sampling), gross necropsy, and histopathology at termination and at 12 months
(10 rats/sex/dose).  
Effect noted in study and corresponding doses: Mortality was comparable among groups during the first
year of the study.  Clinical signs were comparable among groups.  Body weights were reduced in males 
and females 5–7% relative to controls at the 3- and 6-month time points.  At week 50, mean body weight
of males was 12% lower than controls, whereas mean body weight of females was 8% lower than 
controls.  Hematology tests showed significant reductions in hemoglobin and hematocrit in high-dose
males both at 3 and 6 months and of hemoglobin in females at 6 months.  High-dose males also showed a 
reduction in red blood cell count at 6 months.  The differences in mean hematological parameters between 
treated and control rats seen at 3 and 6 months were ≤5%.  At 12 months, there were significant
reductions in hemoglobin in high-dose males (10.6%) and females (7.5%) and in red cell counts in high-
dose males (10.7%).  None of these alterations were observed after 24 months of treatment with TDCP.  
Prothrombin times and partial thromboplastin times showed considerable variability from interval to
interval and no consistent pattern of differences between treated and control rats were apparent during the
study.  Serum alkaline phosphatase levels were lower than controls in high-dose rats both at the 3- and 
6-month intervals.  BUN values in treated rats were not significantly different than in controls.  Other
clinical chemistry tests showed no consistent dose-related differences between controls and treated rats 
that could be attributed to treatment with TDCP.  The most significant observations at 12 months were
dose-related increases in absolute kidney and liver weights which achieved significance at the highest
dose level; these changes in organs weight were not accompanied by histological alterations. Changes in 
kidney weight were more marked than those in liver weight, 48% increase in high-dose males and 39%
increase in high-dose females relative to controls.  At the lowest dose, kidney weight was increased 12%
in males relative to controls.  In mid-dose males, absolute thyroid and liver weight were increased by
14 and 12%, respectively; the corresponding increases in high-dose males were 25 and 26%.  Since the
kidney was the most sensitive end point in rats exposed to TDCP for 24 months in the same study, it
would appear that the increase in kidney weight observed at 12 months is on the continuum of the same 
spectrum of health effects used to derive the chronic-duration MRL and may, in fact, be a precursor to the
renal tubule hyperplasia seen in rats exposed to TDCP for 24 months.  Since the hematological changes
observed during the first year of the study are of questionable toxicological significance, it is appropriate 
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APPENDIX A
to use the changes in absolute kidney weight at the 12-month time point as basis for derivation of an 
intermediate-duration oral MRL for TDCP. Changes in absolute kidney weight in male and female rats 
were analyzed using the BMD approach for MRL derivation as detailed below. 
Dose and end point used for MRL derivation:  BMDL1SD of 4.49 mg/kg/day for increase absolute kidney
weight in male rats.
[ ] NOAEL   [ ] LOAEL  [X] BMDL1SD 
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Only one addition 
intermediate-duration study is available for TDCP (Anonymous 1977).  In that study, male rabbits were
administered doses of 0, 2, 20, or 200 mg TDC/kg/day by gavage for 12 weeks.  During the last week of
treatment, male fertility was tested by mating the males with untreated females.  Fertility was assessed by
sacrificing the females at mid-gestation and evaluating their uteri.  After the mating period, the males
were sacrificed and sperm from the cauda epididymides were analyzed for motility, morphology, and 
concentration.  Blood was also collected for hematology and clinical chemistry tests.  The pituitary, liver, 
kidneys, and reproductive tract were processed for microscopic examination. The treatment-related 
effects appeared to be a significant increase in relative liver weight (23%) and in absolute kidney weight
(14%) at 200 mg/kg/day.  Neither gross necropsy nor microscopic examinations revealed significant
alterations in the organs examined.    
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
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APPENDIX A
BENCHMARK MODELING OF CHANGES IN KIDNEY WEIGHT IN RATS
Data from Stauffer Chem Co. (1981a) were analyzed using the BMD approach for MRL derivation.  
BMD models in the EPA BMDS (version 2.1) (linear, polynomial, power, and Hill models) were fit to the 	
absolute kidney weight male and female datasets (Tables A-17 and A-18) to determine potential points of 	
departure for the MRL. 
Table A-17.  Data for the Change in Absolute Kidney Weight in Male rats
Dose (mg/kg/day) Number of animals tested Kidney weight (g) Standard deviation
0 9 3.185 0.488
5 10 3.571 0.311
20 10 3.736 0.654
80 10 4.703 0.853
Source: Stauffer Chem Co.  1981a
Table A-18.  Data for the Change in Absolute Kidney Weight in Female rats
Dose (mg/kg/day) Number of animals tested Kidney weight (g) Standard deviation
0 10 2.031 0.193
5 10 2.179 0.198
20 10 2.271 0.269
80 10 2.836 0.443
Source: Stauffer Chem Co.  1981a
Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.  
Among all the models providing adequate fit to the data, the lowest BMDL is selected as the point of
departure when differences between the BMDLs estimated from these models are more than 3-fold;
otherwise, the BMDL from the model with the lowest AIC is chosen.  In the absence of a clear criteria as 
to what level of change in kidney weight should be considered adverse, the BMR was defined as a change 
in mean kidney weight equal to one standard deviation from the control mean (EPA 2000).  Based on the 
criteria for model selection, the Hill model provided the best fit for the male data set, whereas the Linear
model provided the best fit for the female data set (Tables A-19 and A-20).  In order to be health 
protective, the male BMDL1SD of 4.69 mg/kg/day is preferred as point of departure over the female
BMDL1SD of 13.49 mg/kg/day.  The model fit of the male data set is shown in Figure A-7. 
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APPENDIX A
Table A-19.  Model predictions for TDCP, changes in absolute kidney weight in 
male rats
Variance Means BMD1SD BMDL1SD 
Model p-valuea p-valuea AIC (mg/kg-day) (mg/kg-day)
Constant variance
Linearb 0.02 0.52 3.98 34.6 25.79
Nonconstant variance
Hill 0.11 0.48 1.70 13.36 4.69
Linearb 0.11 0.48 0.67 24.86 16.31
Polynomial (2-degree 
polynomial)b 0.11 0.48 0.67 24.86 16.31
Polynomial (3-degree 
polynomial)b 0.11 0.48 0.67 24.86 16.31
Power 0.11 0.48 0.67 24.86 16.31
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; SD = standard 
deviation
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bCoefficients restricted to be positive
Source: Stauffer Chem Co. 1981a
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Table A-20.  Model predictions for TDCP, changes in absolute kidney weight in 
female rats
Variance Means BMD1SD BMDL1SD 
Model p-valuea p-valuea AIC (mg/kg-day) (mg/kg-day)
Constant variance
Linearb 0.02 0.72 -55.58 29.59 22.67
Nonconstant variance
Hill 0.83 0.35 -60.81 14.80 5.79
Linearb 0.83 0.56 -62.53 19.73 13.49
Polynomial (2-degree 
polynomial)b 0.83 0.56 -62.53 19.73 13.49
Polynomial (3-degree 
polynomial)b 0.83 0.56 -62.53 19.73 13.49
Power 0.83 0.56 -62.53 19.73 13.49
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; SD = standard 
deviation
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bCoefficients restricted to be positive
Source: Stauffer Chem Co. 1981a
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Figure A-7.  Fit of Hill model (non-constant variance) to data on TDCP, changes in 
absolute kidney weight in male rats
Hill Model with 0.95 Confidence Level 
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Source:  Stauffer Chemical Co. 1981a
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Tris(1,3-dichloro-2-propyl) phosphate (TDCP)
CAS Numbers: 13674-87-8
Date: September 2009
Profile Status: Draft 3, Pre-public
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic
Graph Key: 10
Species: Rat
Minimal Risk Level:  0.02 [X] mg/kg/day  [ ] ppm
Reference:  Stauffer Chemical Co.  1981a.  A two year oral toxicity/carcinogenicity study of fyrol FR-2 in 
rats.  In:  A two-year oral toxicity/carcinogenicity study of fyrol FR-2 in rats (volume I-IV) (final reports) 
with attachments, cover sheets and letter dated 093081.  Stauffer Chemical Company.  Submitted to the
U.S. Environmental Protection Agency under TSCA Section 8E.  EPA88-8100282.  OTS0204911.
Experimental design:  Groups of Sprague-Dawley rats (60/sex/dose level) were fed a diet that provided 0, 
5, 20, or 80 mg/kg/day of TDCP for 24 months.  End points monitored included lethality, clinical signs, 
body weight, food consumption, hematology, clinical chemistry and urinalysis (periodically throughout
the study), gross necropsy, and histopathology at termination and at 12 months (10 rats/sex/dose). 
Effect noted in study and corresponding doses: Mortality was comparable among groups during the first
year of the study, but increased in high-dose males during the second year and was significantly higher
than controls at termination.  Clinical signs were comparable among groups.  Ophthalmological
examinations at 18 and 24 months suggested that treatment with TDCP may have accelerated the
development of sacculations along the course of the retinal arterioles in high-dose rats.  In general, body
weights of mid- and high-dose rats were lower than controls throughout the study.  At termination, final
body weights of high-dose males and females were 24 and 21% lower than controls, respectively.  At
week 50, body weights of mid-dose males and females were 12 and 8% lower than controls, respectively.  
There was no consistent pattern of differences among groups over time regarding food consumption.  
Hemoglobin, hematocrit, and total erythrocyte values were often significantly lower than controls in high-
dose rats and the differences were usually more pronounced in males.  This was observed throughout the
study.  At 24 months, prothrombin times and partial thromboplastin times were significantly elevated in 
high-dose males.  Serum alkaline phosphatase values were lower than controls in high-dose males 
throughout the study; the biological significance of this is unclear.  BUN was markedly elevated in a few
mid- and high-dose rats at 18 and 24 months, which was consistent with microscopic evidence of renal
pathology.  Other clinical chemistry parameters were not consistently altered by treatment.  Plasma 
cholinesterase was lower in high-dose females at 18 months (34%, significant) and 24 months (30%, not
significant); changes at other times or in red blood cell cholinesterase were inconsistent.  Urinalyses were 
unremarkable.  Significant changes in organ weight consisted of increase absolute and relative liver, 
kidney, and thyroid weights in high-dose males and females at 12 and 24 months.  At termination, gross
observations revealed masses, nodules, and raised areas in the liver of high-dose rats; enlargement of the 
kidney in mid- and high-dose males and high-dose females plus higher incidence of discolorations, 
surface irregularities, masses, nodules, and cysts in treated rats than in controls; higher incidence of small
seminal vesicles and testicular enlargement, masses, nodules, flaccidity, and discolorations in mid- and 
high-dose males.  Nonneoplastic lesions that were significantly increased in treated rats were foci/areas of 
hepatocellular alterations (high-dose males and females), dilation of liver sinusoids (high-dose males and 
females), hyperplasia of convoluted tubular epithelium of the kidney (high-dose males and females, mid-
dose males), and chronic nephropathy (high-dose males and females).  None of these alterations were 
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seen at the 12-month interim sacrifice.  Hyperplasia of the renal convoluted tubular epithelium was the
most sensitive effect and occurred with incidences of 2/45, 10/49, 28/48, and 24/46 in males as the doses 
increased; the corresponding incidences in females were 0/49, 1/48, 3/48, and 22/50.  A NOAEL and 
LOAEL of 5 and 20 mg TDCP/kg/day, respectively, for renal epithelial hyperplasia in male rats was 
defined in this study.  
Dose and end point used for MRL derivation:  BMDL10 of 1.94 mg/kg/day for renal tubular epithelial
hyperplasia in male rats dosed in the diet for 2 years.
[ ] NOAEL   [ ] LOAEL  [X] BMDL10 
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes, ppm in food 
were converted to doses by the investigators.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: The study by Stauffer 
Chemical Co. (1981a) was the only chronic-duration oral study available for review.  
Agency Contacts (Chemical Managers): G. Daniel Todd, Ph.D.
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BENCHMARK MODELING OF RENAL TUBULE HYPERPLASIA IN RATS
Incidence data for renal tubule epithelial hyperplasia in male rats exposed to TDCP (Stauffer Chemical
Co. 1981a) were analyzed using the BMD approach for MRL derivation (Table A-21).
Table A-21.  Incidence of Renal Tubule Epithelial Hyperplasia in Rats Exposed to
Tris(1,3-dichloro-2-propyl) phosphate for 2 Years
Dose Total number of Males with Total number of Females with 
(mg/kg/day) males lesions females lesions
0 45 2 49 0
5 49 10 48 1
20 48 28 48 3
80 46 24 50 22
Source:  Stauffer Chemical Co. 1981a
A glance at these incidences shows that males were clearly more sensitive than females.  Therefore, the
data set for hyperplasia of the renal convoluted tubular epithelium in males served as the basis for
determining a point of departure for MRL derivation.  Models in the EPA BMDS (version 2.1) (gamma, 
logistic, log-logistic, multi-stage, probit, log-probit, quantal linear, Weibull models) were fit to the renal
tubular epithelial hyperplasia data in male rats to determine potential points of departure for the MRL
(Table A-22).  
Table A-22.  Model Predictions Incidence of Renal Tubular Epithelial Hyperplasia 
in Male Rats (Highest Dose Dropped)
χ2 Goodness of BMD10 BMDL10 
Model fit p-valuea AIC (mg/kg/day) (mg/kg/day)
Gammab NA 137.16 3.04 1.95
Logistic 0.18 137.11 6.07 4.86
LogLogistic NA 137.16 3.22 1.46
LogProbit 0.43 135.78 4.40 3.35
Multistagec (1-degree
polynomial)
0.78 135.23 2.60 1.94
Probit 0.22 136.74 5.59 4.53
Weibullb NA 137.16 3.02 1.95
Quantal-Linear 0.78 135.23 2.60 1.94
aValues <0.10 fail to meet conventional goodness-of-fit criteria
bPower restricted to ≥1
cBetas restricted to ≥0; 1-degree polynomial
AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated 
with the selected benchmark response; BMDL/BMCL = 95% lower confidence limit on the BMD/BMC; NA = not 
applicable
Source:  Stauffer Chemical Co. 1981a
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Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.  
Among all the models providing adequate fit to the data, the lowest BMDL is selected as the point of
departure when differences between the BMDLs estimated from these models are more than 3-fold;
otherwise, the BMDL from the model with the lowest AIC is chosen.  In accordance with EPA (2000)
guidance, BMDs and BMDLs associated with an extra risk of 10% are calculated for all models.  Since an
adequate fit to the data set could not be obtained with any of the models, the high-dose was dropped, in 
accordance with EPA (2000) guidance.  Comparing across models (Table A-22) using the selection 
criteria mentioned above shows that the Multistage (1-degree polynomial) model provided the best fit to 
the renal epithelial hyperplasia.  From this model, the predicted dose associated with a 10% extra risk
(BMD10) was 2.60 mg TDCP/kg/day; the lower 95% confidence limit on this dose was (BMDL10) was
1.94 mg TDCP/kg/day.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 
10 for human variability) to the BMDL10 of 1.94 mg/kg/day yields a chronic-duration oral MRL of
0.02 mg/kg/day for TDCP.  The model fit is shown in Figure A-8.
Figure A-8.  Fit of Multistage (1-Degree Polynomial) Model to Data on 
TDCP, Incidence of Renal Tubular Epithelia Hyperplasia in Male Rats
Multistage Model with 0.95 Confidence Level 
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Source:  Stauffer Chemical Co. 1981a
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APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in nontechnical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1. 	 What effects are known to occur in humans?
2. 	 What effects observed in animals are likely to be of concern to humans?
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.  
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not
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meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2,
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgment, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgment or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
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LEGEND
See Sample LSE Table 3-1 (page B-6)
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2) 	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) 	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5) 	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6) 	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) 	 System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) 	 NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
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which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9) 	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10) 	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) 	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12) 	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) 	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) 	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table.
(15) 	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) 	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number
18 corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) 	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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(18) 	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19) 	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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SAMPLE
Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
→
→
Exposure 
Key to frequency/
figurea Species duration
INTERMEDIATE EXPOSURE
5 6
Systemic ↓ ↓
NOAEL
System (ppm)
7 8
↓ ↓
LOAEL (effect)
Less serious 
(ppm)
9
↓
Serious (ppm)
Reference
10
↓
→
→
18 Rat 13 wk Resp 3b 10 (hyperplasia)
5 d/wk Nitschke et al. 1981
6 hr/d
CHRONIC EXPOSURE
Cancer 11
↓
38 Rat 18 mo 20 (CEL, multiple Wong et al. 1982
5 d/wk organs)
7 hr/d
39 Rat 89–104 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk nasal tumors)
6 hr/d
40 Mouse 79–103 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk hemangiosarcomas)
6 hr/d
a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
  
  
  
   
           
   
  
  
  
  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
   
  
    
  
  
  
  
  
  
  
   
  
   
  
  
  
  
  
  
  
C-2PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX C
DOE
DOL
DOT
DOT/UN/
NA/IMDG
DWEL
ECD
ECG/EKG
EEG
EEGL
EPA
F
F1 
FAO
FDA
FEMA
FIFRA
FPD
fpm
FR
FSH
g
GC
gd
GLC
GPC
HPLC
HRGC
HSDB
IARC
IDLH
ILO
IRIS
Kd
kg
kkg
Koc 
Kow 
L
LC
LC50 
LCLo 
LD50 
LDLo 
LDH
LH
LOAEL
LSE
LT50 
m
Department of Energy
Department of Labor
Department of Transportation
Department of Transportation/United Nations/
North America/Intergovernmental Maritime Dangerous Goods Code
drinking water exposure level
electron capture detection
electrocardiogram
electroencephalogram
Emergency Exposure Guidance Level
Environmental Protection Agency
Fahrenheit
first-filial generation
Food and Agricultural Organization of the United Nations
Food and Drug Administration
Federal Emergency Management Agency
Federal Insecticide, Fungicide, and Rodenticide Act
flame photometric detection
feet per minute
Federal Register
follicle stimulating hormone
gram
gas chromatography
gestational day
gas liquid chromatography
gel permeation chromatography
high-performance liquid chromatography
high resolution gas chromatography
Hazardous Substance Data Bank
International Agency for Research on Cancer
immediately dangerous to life and health
International Labor Organization
Integrated Risk Information System
adsorption ratio
kilogram
metric ton
organic carbon partition coefficient
octanol-water partition coefficient
liter
liquid chromatography
lethal concentration, 50% kill
lethal concentration, low
lethal dose, 50% kill
lethal dose, low
lactic dehydrogenase
luteinizing hormone
lowest-observed-adverse-effect level
Levels of Significant Exposure
lethal time, 50% kill
meter
***DRAFT FOR PUBLIC COMMENT***
    
 
  
 
 
 
 
 
 
  
  
  
  
  
   
  
  
  
  
  
  
  
   
  
  
  
  
   
   
  
   
  
  
  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
C-3PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX C
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
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C-4PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX C
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
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C-5PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX C
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
> greater than
≥ greater than or equal to
= equal to
< less than
≤ less than or equal to
% percent
α alpha
β beta
γ gamma
δ delta
μm micrometer
μg microgram
q1
* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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D-1PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX D.  INDEX
absorbed dose............................................................................................................................................ 173 	
acetylcholinesterase .......................................................................................................................... 117, 167 	
adenocarcinoma ........................................................................................................................................ 124 	
adipose tissue ............................................................................................ 144, 147, 149, 173, 223, 227, 231 	
adrenal gland................................................................................................................................................. 5 	
adrenals ............................................................................................................................................... 34, 111 	
adsorbed .................................................................................................................................... 205, 215, 233 	
adsorption.................................................................................................................................. 205, 208, 226 	
aerobic....................................................................................................................................................... 210 	
alanine aminotransferase (see ALT) ......................................................................................................... 108 	
ALT (see alanine aminotransferase) ......................................................................................................... 108 	
ambient air ................................................................................................................................................ 211 	
anaerobic ................................................................................................................................................... 211 	
androgen receptor.............................................................................................................................. 167, 169 	
aspartate aminotransferase (see AST)......................................................................................................... 41 	
AST (see aspartate aminotransferase)......................................................................................................... 41 	
atropine ............................................................................................................................................. 166, 176 	
bioaccumulation........................................................................................................................ 147, 208, 226 	
bioavailability ........................................................................................................................................... 226 	
bioconcentration factor ............................................................................................................................. 208 	
biodegradation............................................................................................................................... 2, 205, 210 	
biomarker .................................................................................. 172, 173, 174, 186, 188, 223, 227, 229, 234 	
blood cell count............................................................................................................................. 30, 41, 106 	
body weight effects ........................................................................................................................... 112, 135 	
breast milk..................................................................................................................................... 6, 223, 227 	
cancer .................................................................................................. 5, 17, 37, 43, 170, 171, 179, 181, 183 	
carcinogen................................................................................................................................. 137, 240, 242 	
carcinogenic ................................................................................................ 5, 15, 16, 35, 123, 124, 182, 212 	
carcinogenicity.......................................................................... 5, 15, 16, 124, 137, 164, 181, 183, 240, 242 	
carcinoma............................................................................................................................ 15, 123, 124, 182 	
carcinomas .................................................................................................................. 15, 123, 124, 125, 182 	
cardiovascular ..................................................................................................................................... 17, 104 	
cardiovascular effects.................................................................................................................. 41, 104, 126 	
cholinesterase.......................................................................... 13, 17, 42, 117, 118, 136, 174, 186, 187, 223 	
chromosomal aberrations .................................................................................................................. 142, 143 	
clearance ................................................................................................................................................... 149 	
death.................................................................................................................................... 12, 17, 18, 35, 37 	
delayed neurotoxicity.................................................................................................................................. 13 	
dermal effects.............................................................................................................. 42, 112, 134, 177, 180 	
developmental effects ............................................. 15, 18, 42, 121, 122, 123, 137, 172, 179, 180, 183, 187 	
elimination rate ......................................................................................................................................... 159 	
endocrine........................................................................................................................... 111, 168, 169, 188 	
endocrine effects ............................................................................................................................... 111, 134 	
erythema.................................................................................................................................................... 135 	
estrogen receptor............................................................................................................................... 167, 169 	
estrogenic .................................................................................................................................................. 169 	
fetus....................................................................................................................................................... 6, 170 	
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D-2PHOSPHATE ESTER FLAME RETARDANTS
APPENDIX D
gastrointestinal effects ...................................................................................................................... 104, 126 	
general population..................................... 4, 6, 7, 11, 36, 144, 147, 173, 177, 179, 182, 185, 186, 205, 220 	
genotoxic..................................................................................................................................... 35, 142, 182 	
genotoxicity............................................................................................................................... 137, 143, 179 	
groundwater ........................................................................................................ 11, 203, 207, 208, 212, 215 	
half-life.............................................................................................................. 145, 146, 148, 149, 173, 211 	
hematological effects ............................................................................................................ 33, 41, 105, 134 	
hepatic effects ..................................................................................................................... 41, 107, 134, 180 	
hydrolysis.......................................................................... 152, 153, 155, 200, 203, 208, 209, 210, 211, 231 	
hydroxyl radical ................................................................................................................................ 208, 210 	
immune system ........................................................................................................................................... 15 	
immunological ................................................................................ 12, 35, 42, 115, 116, 136, 179, 180, 184 	
immunological effects......................................................................................................... 12, 179, 180, 184 	
Kow .................................................................................................................... 193, 194, 195, 205, 208, 225 	
LD50..................................................................................................................... 18, 33, 34, 43, 44, 125, 126 	
leukemia.......................................................................................................................... 5, 15, 123, 124, 182 	
lymphoreticular ........................................................................................................... 42, 115, 116, 136, 184 	
metabolic effects ............................................................................................................................... 113, 136 	
milk ................................................................................................................................................... 188, 218 	
musculoskeletal effects ..................................................................................................................... 107, 134 	
neonatal ............................................................................................................................................. 119, 171 	
neoplasm ............................................................................................................................................. 15, 182 	
neoplastic .............................................................................................................. 15, 26, 123, 124, 125, 182 	
neurobehavioral................................................................................................................... 18, 169, 180, 184 	
neurological effects....................................................................................... 18, 42, 116, 119, 136, 180, 184 	
nuclear................................................................................................. 21, 110, 117, 151, 167, 201, 215, 233 	
ocular effects............................................................................................................................. 112, 126, 135 	
pharmacodynamic ..................................................................................................................................... 161 	
pharmacokinetic........................................................................ 144, 161, 168, 162, 163, 170, 172, 186, 188 	
placenta ................................................................................................................................................. 6, 188 	
rate constant ...................................................................................................................................... 208, 209 	
renal effects................................................................................................................................. 41, 109, 134 	
reproductive effects....................................................................................... 14, 42, 119, 120, 121, 137, 183 	
respiratory effects........................................................................................................................ 38, 104, 126 	
retention ............................................................................................................................ 186, 200, 207, 224 	
salivation..................................................................................................... 22, 24, 29, 43, 44, 117, 118, 121 	
solubility ........................................................................................................... 193, 200, 203, 205, 207, 208 	
systemic effects........................................................................................................... 38, 104, 114, 126, 169 	
thyroid......................................................................................................................... 31, 111, 123, 134, 169 	
toxicokinetic................................................................................................ 35, 143, 179, 186, 187, 229, 234 	
tremors .................................................................................................................................... 13, 27, 44, 118 	
tumors ........................................................................... 5, 13, 15, 16, 26, 115, 123, 124, 125, 137, 165, 182 	
vapor phase ............................................................................................................................... 198, 206, 208 	
vapor pressure ................................................................................................... 200, 206, 207, 208, 212, 225 	
volatility .................................................................................................................................................... 200 	
volatilization ....................................................................................................................................... 11, 208 	
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